U.S. patent application number 15/676316 was filed with the patent office on 2018-03-22 for novel benzodiazepine derivatives.
This patent application is currently assigned to IMMUNOGEN, INC.. The applicant listed for this patent is IMMUNOGEN, INC.. Invention is credited to Ravi V.J. Chari, Nathan Elliott Fishkin, Wei Li, Michael Louis Miller, Robert Yongxin Zhao.
Application Number | 20180079823 15/676316 |
Document ID | / |
Family ID | 42540587 |
Filed Date | 2018-03-22 |
United States Patent
Application |
20180079823 |
Kind Code |
A1 |
Li; Wei ; et al. |
March 22, 2018 |
NOVEL BENZODIAZEPINE DERIVATIVES
Abstract
The invention relates to novel benzodiazepine derivatives with
antiproliferative activity and more specifically to novel
benzodiazepines of formula (I) and (II), in which the diazepine
ring (B) is fused with a heterocyclic ring (CD), wherein the
heterocyclic ring is bicyclic or a compound of formula (III), in
which the diazepine ring (B) is fused with a heterocyclic ring (C),
wherein the heterocyclic ring is monocyclic. The invention provides
cytotoxic dimers of these compounds. The invention also provides
conjugates of the monomers and the dimers. The invention further
provides compositions and methods useful for inhibiting abnormal
cell growth or treating a proliferative disorder in a mammal using
the compounds or conjugates of the invention. The invention further
relates to methods of using the compounds or conjugates for in
vitro, in situ, and in vivo diagnosis or treatment of mammalian
cells, or associated pathological conditions.
Inventors: |
Li; Wei; (Acton, MA)
; Fishkin; Nathan Elliott; (Weymouth, MA) ; Zhao;
Robert Yongxin; (Lexington, MA) ; Miller; Michael
Louis; (Framingham, MA) ; Chari; Ravi V.J.;
(Newton, MA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
IMMUNOGEN, INC. |
Waltham |
MA |
US |
|
|
Assignee: |
IMMUNOGEN, INC.
Waltham
MA
|
Family ID: |
42540587 |
Appl. No.: |
15/676316 |
Filed: |
August 14, 2017 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15371738 |
Dec 7, 2016 |
|
|
|
15676316 |
|
|
|
|
14990569 |
Jan 7, 2016 |
9550787 |
|
|
15371738 |
|
|
|
|
14316105 |
Jun 26, 2014 |
9265841 |
|
|
14990569 |
|
|
|
|
13774059 |
Feb 22, 2013 |
8809320 |
|
|
14316105 |
|
|
|
|
12700131 |
Feb 4, 2010 |
8426402 |
|
|
13774059 |
|
|
|
|
61150201 |
Feb 5, 2009 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 47/6835 20170801;
A61K 38/07 20130101; A61K 47/60 20170801; C07D 487/04 20130101;
A61K 47/6849 20170801; C07K 5/1008 20130101; C07K 5/0202 20130101;
C07K 16/2803 20130101; A61K 45/06 20130101; C07D 519/00 20130101;
C07D 498/04 20130101; C07K 16/46 20130101; C07K 19/00 20130101;
A61K 47/6863 20170801; A61P 35/00 20180101; C07K 16/2896 20130101;
A61K 31/5517 20130101 |
International
Class: |
C07K 16/28 20060101
C07K016/28; C07K 19/00 20060101 C07K019/00; C07K 5/103 20060101
C07K005/103; C07K 5/02 20060101 C07K005/02; C07D 519/00 20060101
C07D519/00; C07D 498/04 20060101 C07D498/04; C07D 487/04 20060101
C07D487/04; A61K 45/06 20060101 A61K045/06; A61K 38/07 20060101
A61K038/07; A61K 31/5517 20060101 A61K031/5517; C07K 16/46 20060101
C07K016/46 |
Claims
1-31. (canceled)
32. A compound having formula (XII): ##STR00261## or a
pharmaceutically acceptable salt thereof, wherein: the double line
between N and C represents a single bond or a double bond, provided
that when it is a double bond X is absent and Y is --H, and when it
is a single bond, X is --H; Y is selected from the group consisting
of --OH, --OR, --NR'R'', --SO.sub.3, and --OSO.sub.3, wherein R, R'
and R'' are a linear, branched or cyclic alkyl, alkenyl or alkynyl
having from 1 to 10 carbon atoms; one of R.sub.2, R.sub.3, R.sub.2'
and R.sub.3' is the linking group and the others are --H or
--NO.sub.2; R.sub.6 is --OR; Z is CH.sub.2; A is O or NR.sub.15;
and R.sub.15 is H, linear, branched or cyclic alkyl having from 1
to 10 carbon atoms, a polyethylene glycol unit
(--OCH.sub.2CH.sub.3).sub.n, wherein n is an integer from 1 to
2000.
33. The compound of claim 32, having formula (XIV): ##STR00262## or
a pharmaceutically acceptable salt thereof, wherein Y is selected
from the group consisting of --OH, --OR, --SO.sub.3, and
--OSO.sub.3, wherein R is a linear, branched or cyclic alkyl,
alkenyl or alkynyl having from 1 to 10 carbon atoms; nn is 0 or an
integer from 1 to 5; and one of R.sub.2, R.sub.3, R.sub.2' and
R.sub.3' is the linking group and the others are --H or
--NO.sub.2.
34. The compound of claim 32, wherein one of R.sub.2, R.sub.3,
R.sub.2', or R.sub.3' is selected from the group consisting of:
--NR.sub.33(C.dbd.O).sub.p''(CR.sub.20R.sub.21).sub.m(CR.sub.22R.sub.23).-
sub.n(OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.24R.su-
b.25).sub.q(CO).sub.tX'',
--NR.sub.33(C.dbd.O).sub.p''(CR.sub.20R.sub.21).sub.m(CR.sub.26.dbd.CR.su-
b.27).sub.m'(CR.sub.22R.sub.23).sub.n(OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.-
sub.41).sub.p''Y''(CR.sub.24R.sub.25).sub.q(CO).sub.tX'',
--NR.sub.33(C.dbd.O).sub.p''(CR.sub.20R.sub.21).sub.m(alkynyl).sub.n'(CR.-
sub.22R.sub.23).sub.n(OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y-
'(CR.sub.24R.sub.25).sub.q(CO).sub.tX'',
--NR.sub.33(C.dbd.O).sub.p''(CR.sub.20R.sub.21).sub.m(piperazino).sub.t'(-
CR.sub.22R.sub.23).sub.n(OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p-
''Y''(CR.sub.24R.sub.25).sub.q(CO).sub.tX'',
--NR.sub.33(C.dbd.O).sub.p''(CR.sub.20R.sub.21).sub.m(pyrrolo).sub.t'(CR.-
sub.22R.sub.23).sub.n(OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y-
''(CR.sub.24R.sub.25).sub.q(CO).sub.tX'', and
--NR.sub.33(C.dbd.O).sub.p''(CR.sub.20R.sub.21).sub.mA''.sub.m''(CR.sub.2-
2R.sub.23).sub.n(OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR-
.sub.24R.sub.25).sub.q(CO).sub.tX'', wherein: m, n, p, q, m', n',
t' are integer from 1 to 10, or are optionally 0; m'', n'' and p''
are 0 or 1; X'' is covalently linked to the CBA, and when Y'' is
not S--S and t=0, X'' is ##STR00263## --CH.sub.2--CO--, or --S--;
and when t=1, X'' is --NH--; Y'' is absent or is selected from O,
S, S--S or NR.sub.32, wherein R.sub.32 has the same definition as
given above for R; A'' is an amino acid selected from glycine,
alanine, leucine, valine, lysine, citrulline, glutamate, or a
polypeptide containing between 2 to 20 amino acid units; R.sub.20,
R.sub.21, R.sub.22, R.sub.23, R.sub.24, and R.sub.25 are the same
or different and are --H or a linear or branched alkyl having from
1 to 5 carbon atoms; and one of R.sub.40 and R.sub.41 is optionally
a negatively or positively charged functional group and the other
is --H or an alkyl, alkenyl, alkynyl having 1 to 4 carbon
atoms.
35. The compound of claim 32, wherein the compound is selected
from: ##STR00264##
36. A conjugate comprising a compound of claim 32 linked to a cell
binding agent.
37. The conjugate of claim 36, wherein the compound is selected
from the group consisting of: ##STR00265## wherein the wavy line
represents a linkage to the cell-binding agent.
38. The conjugate of claim 36, wherein the cell-binding agent binds
to target cells selected from tumor cells, virus infected cells,
microorganism infected cells, parasite infected cells, autoimmune
cells, activated cells, myeloid cells, activated T-cells, B cells,
or melanocytes; cells expressing the CD4, CD6, CD19, CD20, CD22,
CD30, CD33, CD37, CD38, CD40, CD44, CD56, EpCAM, CanAg, CALLA, or
Her-2 antigens; Her-3 antigens or cells expressing insulin growth
factor receptor, epidermal growth factor receptor, and folate
receptor.
39. The conjugate of claim 38, wherein the tumor cells are selected
from breast cancer cells, prostate cancer cells, ovarian cancer
cells, colorectal cancer cells, gastric cancer cells, squamous
cancer cells, small-cell lung cancer cells, and testicular cancer
cells.
40. The conjugate of claim 36, wherein the cell-binding agent is an
antibody, a single chain antibody, an antibody fragment that
specifically binds to the target cell, a monoclonal antibody, a
single chain monoclonal antibody, or a monoclonal antibody fragment
that specifically binds the a target cell, a chimeric antibody, a
chimeric antibody fragment that specifically binds to the target
cell, a domain antibody, a domain antibody fragment that
specifically binds to the target cell, a lymphokine, a hormone, a
vitamin, a growth factor, a colony stimulating factor, or a
nutrient-transport molecule.
41. The conjugate of claim 40, wherein the antibody is a resurfaced
antibody, a resurfaced single chain antibody, or a resurfaced
antibody fragment; a monoclonal antibody, a single chain monoclonal
antibody, or a monoclonal antibody fragment thereof; a chimeric
antibody fragment, a domain antibody, or a domain antibody
fragment; a humanized antibody, a humanized single chain antibody,
or a humanized antibody fragment.
42. A pharmaceutical composition comprising the compound of claim
32, or a pharmaceutically acceptable salt thereof, and a
pharmaceutically acceptable carrier.
43. The pharmaceutical composition of claim 42, further comprising
a second compound, which is a chemotherapeutic agent.
44. A method of treating a cancer in a mammal, comprising
administering to said mammal a therapeutically effective amount of
the compound of claim 32, or a pharmaceutically acceptable salt
thereof.
45. The method of claim 44, further comprising administering to
said mammal a second compound, which is a chemotherapeutic
agent.
46. The method of claim 45, wherein said chemotherapeutic agent is
administered to said mammal sequentially.
Description
REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation application of U.S.
patent application Ser. No. 15/371,738, filed Jul. 12, 2016; which
is a continuation application of U.S. patent application Ser. No.
14/990,569, filed Jan. 7, 2016 and now U.S. Pat. No. 9,550,787;
which is a continuation application of U.S. patent application Ser.
No. 14/316,105, filed Jun. 26, 2014 and now U.S. Pat. No.
9,265,841; which is a divisional application of U.S. patent
application Ser. No. 13/774,059, filed Feb. 22, 2013 and now U.S.
Pat. No. 8,809,320; which is a divisional application of U.S.
patent application Ser. No. 12/700,131, filed Feb. 4, 2010 and now
U.S. Pat. No. 8,426,402; which claims the benefit of the filing
date, under 35 U.S.C. .sctn. 119(e), of U.S. Provisional
Application No. 61/150,201, filed Feb. 5, 2009. The entire contents
of each of the above-referenced applications are incorporated
herein by reference.
FIELD OF THE INVENTION
[0002] The present invention relates to novel cytotoxic compounds
and cytotoxic conjugates comprising these cytotoxic compounds and
cell-binding agents. More specifically, this invention relates to
novel benzodiazepine compounds (e.g., indolinobenzodiazepines or
oxazolidinobenzodiazepines), derivatives thereof, intermediates
thereof, conjugates thereof, and pharmaceutically acceptable salts
thereof, which are useful as medicaments, in particular as
antiproliferative agents.
BACKGROUND OF THE INVENTION
[0003] Benzodiazepine derivatives are useful compounds for treating
various disorders, and include medicaments such as, antiepileptics
(imidazo [2,1-b][1,3,5]benzothiadiazepines, U.S. Pat. No.
4,444,688; U.S. Pat. No. 4,062,852), antibacterials
(pyrimido[1,2-c][1,3,5]benzothiadiazepines, GB 1476684), diuretics
and hypotensives (pyrrolo(1,2-b)[1,2,5]benzothiadiazepine 5,5
dioxide, U.S. Pat. No. 3,506,646), hypolipidemics (WO 03091232),
anti-depressants (U.S. Pat. No. 3,453,266); osteoporosis (JP
2138272).
[0004] Recently, it has been shown in animal tumor models that
benzodiazepine derivatives, such as pyrrolobenzodiazepines (PBDs),
act as anti-tumor agents (N-2-imidazolyl alkyl substituted
1,2,5-benzothiadiazepine-1,1-dioxide, U.S. Pat. No. 6,156,746),
benzo-pyrido or dipyrido thiadiazepine (WO 2004/069843), pyrrolo
[1,2-b] [1,2,5] benzothiadiazepines and pirrole [1,2-b][1,2,5]
benzodiazepine derivatives (WO2007/015280), tomaymycin derivatives
(e.g., pyrrolo[1,4]benzodiazepines), such as those described in WO
00/12508, WO2005/085260, WO2007/085930, and EP 2019104.
Benzodiazepines are also known to affect cell growth and
differentiation (Kamal A., et al., Bioorg Med Chem. 2008 Aug. 15;
16(16):7804-10 (and references cited therein); Kumar R, Mini Rev
Med Chem. 2003 June; 3(4):323-39 (and references cited therein);
Bednarski J J, et al., 2004; Sutter A. P, et al., 2002; Blatt N B,
et al., 2002), Kamal A. et al., Current Med. Chem., 2002; 2;
215-254, Wang J-J., J. Med. Chem., 2206; 49:1442-1449, Alley M. C.
et al., Cancer Res. 2004; 64:6700-6706, Pepper C. J., Cancer Res
2004; 74:6750-6755, Thurston D. E. and Bose D. S., Chem Rev 1994;
94:433-465; and Tozuka, Z., et al., Journal of Antibiotics, (1983)
36; 1699-1708. General structure of PBDs is described in US
Publication Number 20070072846. The PBDs differ in the number, type
and position of substituents, in both their aromatic A rings and
pyrrolo C rings, and in the degree of saturation of the C ring.
Their ability to form an adduct in the minor groove enables them to
interfere with DNA processing, hence their potential for use as
antiproliferative agents.
[0005] There still exists a need for novel benzodiazepine
derivatives as effective and safe therapeutics for treating a
variety of proliferative disease states, such as cancer.
SUMMARY OF THE INVENTION
[0006] One object of the invention is to provide novel
benzodiazepines of formula (I) and (II), in which the diazepine
ring (B) is fused with a heterocyclic ring (CD), wherein the
heterocyclic ring is bicyclic,
##STR00001##
wherein: the double line between N and C represents a single bond
or a double bond, provided that when it is a double bond X is
absent and Y is H, and when it is a single bond, X is H, or an
amine protecting moiety that converts the compound into a prodrug
that can be transformed into the free amine in vitro or in vivo; Y
is selected from --OR, an ester represented by --OCOR', a carbonate
represented by --OCOOR', a carbamate represented by --OCONR'R'', an
amine or a hydroxyl amine represented by NR'R'', amide represented
by --NRCOR', a peptide represented by NRCOP, wherein P is an amino
acid or a polypeptide containing between 2 to 20 amino acid units,
a thioether represented by SR', a sulfoxide represented by SOR', a
sulfone represented by --SO.sub.2R', a sulfite --SO.sub.3, a
bisulfite --OSO.sub.3, a halogen, cyano, an azido, or a thiol,
wherein R, R' and R'' are same or different and are selected from
H, substituted or unsubstituted linear, branched or cyclic alkyl,
alkenyl or alkynyl having from 1 to 20 carbon atoms a polyethylene
glycol unit (--OCH.sub.2CH.sub.2).sub.n, wherein n is an integer
from 1 to 2000, a 5- or 6-membered heteroaryl ring containing one
or more heteroatoms independently selected from nitrogen, oxygen,
and sulfur, a 5 to 18 membered fused ring system, wherein at least
one of the rings is aromatic, containing one or more heteroatoms
independently selected from nitrogen, oxygen, and sulfur, aryl
having from 6 to 18 carbon atoms, a 3 to 18-membered heterocyclic
ring having 1 to 6 heteroatoms selected from O, S, N and P wherein
the substituent is selected from halogen, OR.sub.7,
NR.sub.8R.sub.9, NO.sub.2, NRCOR', SR.sub.10, a sulfoxide
represented by SOR', a sulfone represented by --SO.sub.2R', a
sulfite --SO.sub.3, a bisulfite --OSO.sub.3, a sulfonamide
represented by SO.sub.2NRR', cyano, an azido, --COR.sub.11,
OCOR.sub.11 or OCONR.sub.11R.sub.12, wherein R.sub.7, R.sub.8,
R.sub.9, R.sub.10, R.sub.11 and R.sub.12 are each independently
selected from H, linear, branched or cyclic alkyl, alkenyl or
alkynyl having from 1 to 10 carbon atoms, a polyethylene glycol
unit (--OCH.sub.2CH.sub.2).sub.n, wherein n is an integer from 1 to
2000, a 5- or 6-membered heteroaryl ring containing one or more
heteroatoms independently selected from nitrogen, oxygen, and
sulfur. a 5 to 18 membered fused ring system, wherein at least one
of the rings is aromatic. containing one or more heteroatoms
independently selected from nitrogen, oxygen, and sulfur, aryl
having from 6 to 18 carbon atoms 3 to 18-membered heterocyclic ring
having 1 to 6 heteroatoms selected from O, S, N and P and R.sub.10
optionally is SR.sub.13 or COR.sub.13, wherein R.sub.13 is selected
from linear, branched or cyclic alkyl, alkenyl or alkynyl having
from 1 to 10 carbon atoms, a polyethylene glycol unit
(--OCH.sub.2CH.sub.2).sub.n, wherein n is an integer from 1 to
2000, a 5- or 6-membered heteroaryl ring containing one or more
heteroatoms independently selected from nitrogen, oxygen, and
sulfur, a 5 to 18 membered fused ring system, wherein at least one
of the rings is aromatic, containing one or more heteroatoms
independently selected from nitrogen, oxygen, and sulfur, 3 to
18-membered heterocyclic ring having 1 to 6 heteroatoms selected
from O, S, N and P and R.sub.11 can also be OR.sub.14, wherein
R.sub.14 is H or has the same definition as R, optionally, R'' is
an OH; W is C.dbd.O, C.dbd.S, CH.sub.2, BH (B=Boron), SO or
SO.sub.2; R.sub.1, R.sub.2, R.sub.3, R.sub.4, are each
independently selected from H, substituted or unsubstituted linear,
branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10
carbon atoms, a polyethylene glycol unit
(--OCH.sub.2CH.sub.2).sub.n, wherein n is an integer from 1 to
2000, or a substituent selected from a halogen, OR.sub.7,
NR.sub.8R.sub.9, NO.sub.2, NRCOR', SR.sub.10, a sulfoxide
represented by SOR', a sulfone represented by --SO.sub.2R', a
sulfite --SO.sub.3, a bisulfite --OSO.sub.3, a sulfonamide
represented by SO.sub.2NRR', cyano, an azido, guanidinium
[--NH(C.dbd.NH)NH.sub.2], --COR.sub.11, --OCOR.sub.11 or
--OCONR.sub.11R.sub.12 wherein R.sub.7, R.sub.8, R.sub.9, R.sub.10,
R.sub.11 and R.sub.12 have the same definitions as given above,
optionally, any one of R.sub.1, R.sub.2, R.sub.3, R.sub.4 is a
linking group that enables linkage to a cell binding agent via a
covalent bond or is selected from a polypyrrolo, poly-indolyl,
poly-imidazolyl, polypyrollo-imidazolyl, poly-pyrollo-indolyl or
polyimidazolo-indolyl unit optionally bearing a linking group that
enables linkage to a cell binding agent; R.sub.5 is selected from
OR.sub.15, CRR'OH, SH, CRR'SH, NHR.sub.15 or CRR'NHR.sub.15,
wherein R.sub.15 has the same definition as R., R and R' have the
same definition as given above; optionally, R.sub.5 is a linking
group that enables linkage to a cell binding agent via a covalent
bond or is selected from a polypyrrolo, poly-indolyl,
poly-imidazolyl, polypyrollo-imidazolyl, poly-pyrollo-indolyl or
polyimidazolo-indolyl unit optionally bearing a linking group that
enables linkage to a cell binding agent; R.sub.6 is OR, SR, NRR',
wherein R and R' have the same definition as given above, or
optionally R.sub.6 is a linking group; Z is selected from
(CH.sub.2).sub.n, wherein n is 1, 2 or 3, CR.sub.15R.sub.16,
NR.sub.17, O or S, wherein R.sub.15, R.sub.16 and R.sub.17 are each
independently selected from H, linear, branched or cyclic alkyl
having from 1 to 10 carbon atoms, a polyethylene glycol unit
(--OCH.sub.2CH.sub.2).sub.n, wherein n is an integer from 1 to
2000; or their pharmaceutically acceptable solvates, salts,
hydrates or hydrated salts, their optical isomers, racemates,
diastereomers, enantiomers of these compounds. provided that the
compound has no more than one linking group that enables linkage to
a cell binding agent via a covalent bond.
[0007] A second object of the invention is to provide novel
benzodiazepines of formula (III), in which the diazepine ring (B)
is fused with a heterocyclic ring (C), wherein the heterocyclic
ring is monocyclic,
##STR00002##
wherein: the double line between N and C represents a single bond
or a double bond, provided that when it is a double bond X is
absent and Y is H, and when it is a single bond, X is H or an amine
protecting moiety that converts the compound into a prodrug; Y is
selected from --OR, an ester represented by --OCOR', a carbonate
represented by --OCOOR', a carbamate represented by --OCONR'R'', an
amine or a hydroxyl amine represented by NR'R'', amide represented
by --NRCOR', a peptide represented by NRCOP, wherein P is an amino
acid or a polypeptide containing between 2 to 20 amino acid units,
a thioether represented by SR', a sulfoxide represented by SOR', a
sulfone represented by --SO.sub.2R', a sulfite --SO.sub.3, a
bisulfite --OSO.sub.3, a halogen, cyano, an azido, or a thiol,
wherein R, R' and R'' are same or different and selected from H,
substituted or unsubstituted linear, branched or cyclic alkyl,
alkenyl or alkynyl having from 1 to 10 carbon atoms, a polyethylene
glycol unit (--OCH.sub.2CH.sub.2).sub.n, wherein n is an integer
from 1 to 2000, a 5- or 6-membered heteroaryl ring containing one
or more heteroatoms independently selected from nitrogen, oxygen,
and sulfur, a 5 to 18 membered fused ring system, wherein at least
one of the rings is aromatic, containing one or more heteroatoms
independently selected from nitrogen, oxygen, and sulfur, aryl
having from 6 to 18 carbon atoms 3 to 18-membered heterocyclic ring
having 1 to 6 heteroatoms selected from O, S, N and P, wherein the
substituent is selected from halogen, OR.sub.7, NR.sub.8R.sub.9,
NO.sub.2, NRCOR', SR.sub.10, a sulfoxide represented by SOR', a
sulfone represented by --SO.sub.2R', a sulfite --SO.sub.3, a
bisulfite --OSO.sub.3, a sulfonamide represented by SO.sub.2NRR',
cyano, an azido, --COR.sub.11, OCOR.sub.11 or OCONR.sub.11R.sub.12,
wherein R.sub.7, R.sub.8, R.sub.9, R.sub.10, R.sub.11 and R.sub.12
are each independently selected from H, linear, branched or cyclic
alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, a
polyethylene glycol unit (--OCH.sub.2CH.sub.2).sub.n, wherein n is
an integer from 1 to 2000, a 5- or 6-membered heteroaryl ring
containing one or more heteroatoms independently selected from
nitrogen, oxygen, and sulfur, a 5 to 18 membered fused ring system,
wherein at least one of the rings is aromatic, containing one or
more heteroatoms independently selected from nitrogen, oxygen, and
sulfur, aryl having from 6 to 18 carbon atoms 3 to 18-membered
heterocyclic ring having 1 to 6 heteroatoms selected from O, S, N
and P and R.sub.10 optionally is SR.sub.13 or COR.sub.13, herein
R.sub.13 is selected from linear, branched or cyclic alkyl, alkenyl
or alkynyl having from 1 to 10 carbon atoms, a polyethylene glycol
unit (--OCH.sub.2CH.sub.2).sub.n, wherein n is an integer from 1 to
2000, a 5- or 6-membered heteroaryl ring containing one or more
heteroatoms independently selected from nitrogen, oxygen, and
sulfur, a 5 to 18 membered fused ring system, wherein at least one
of the rings is aromatic, containing one or more heteroatoms
independently selected from nitrogen, oxygen, and sulfur, aryl
having from 6 to 18 carbon atoms, 3 to 18-membered heterocyclic
ring having 1 to 6 heteroatoms selected from O, S, N and P and
R.sub.11 can also be OR.sub.14, wherein R.sub.14 is H or has the
same definition as R, optionally R'' is OH; W is C.dbd.O, C.dbd.S,
CH.sub.2, BH, SO or SO.sub.2; R.sub.5 is selected from OR.sub.15,
CRR'OH, SH, CRR'SH, NHR.sub.15 or CRR'NHR.sub.15, wherein R.sub.15
has the same definition as R. or is a linking group that enables
linkage to a cell binding agent via a covalent bond or is selected
from a polypyrrolo, poly-indolyl, poly-imidazolyl,
polypyrollo-imidazolyl, poly-pyrollo-indolyl or
polyimidazolo-indolyl unit optionally bearing a linking group that
enables linkage to a cell binding agent; R.sub.6 is OR, SR or NRR',
wherein R and R' have the same definition as given above,
optionally R.sub.6 is a linking group; X' is CH.sub.2, NR, CO, BH,
SO or SO.sub.2;
Y' is O, CH.sub.2, NR or S;
[0008] Z' is CH.sub.2 or (CH.sub.2).sub.n, wherein n is 2, 3 or 4;
or their pharmaceutically acceptable solvates, salts, hydrates or
hydrated salts, their optical isomers, racemates, diastereomers,
enantiomers or the polymorphic crystalline structures of these
compounds; provided that the compound has no more than one linking
group that enables linkage to a cell binding agent via a covalent
bond.
[0009] A third object of the invention is to provide cytotoxic
dimers (IV), (V) and (VI)
##STR00003##
of the benzodiazepine monomers of formulas (I) and (II) and (III),
respectively, in which the dimer compounds optionally bear a
linking group that allows for linkage to cell binding agents,
wherein: the double line between N and C represents a single bond
or a double bond, provided that when it is a double bond X is
absent and Y is H, and when it is a single bond, X is H or an amine
protecting moiety that converts the compound into a prodrug; Y is
selected from --OR, an ester represented by --OCOR', a carbonate
represented by --OCOOR', a carbamate represented by --OCONR'R'', an
amine or a hydroxyl amine represented by NR'R'', amide represented
by --NRCOR', a peptide represented by NRCOP, wherein P is an amino
acid or a polypeptide containing between 2 to 20 amino acid units,
a thioether represented by SR', a sulfoxide represented by SOR', a
sulfone represented by --SO.sub.2R', a sulfite --SO.sub.3, a
bisulfite --OSO.sub.3, a halogen, cyano, an azido, or a thiol,
wherein R, R' and R'' are same or different and are selected from
H, substituted or unsubstituted linear, branched or cyclic alkyl,
alkenyl or alkynyl having from 1 to 10 carbon atoms, a polyethylene
glycol unit (--OCH.sub.2CH.sub.2).sub.n, wherein n is an integer
from 1 to 2000, a 5- or 6-membered heteroaryl ring containing one
or more heteroatoms independently selected from nitrogen, oxygen,
and sulfur, a 5 to 18 membered fused ring system, wherein at least
one of the rings is aromatic, containing one or more heteroatoms
independently selected from nitrogen, oxygen, and sulfur, aryl
having from 6 to 18 carbon atoms, 3 to 18-membered heterocyclic
ring having 1 to 6 heteroatoms selected from O, S, N and P wherein
the substituent is selected from halogen, OR.sub.7,
NR.sub.8R.sub.9, NO.sub.2, NRCOR', SR.sub.10, a sulfoxide
represented by SOR', a sulfone represented by --SO.sub.2R', a
sulfite --SO.sub.3, a bisulfite --OSO.sub.3, a sulfonamide
represented by SO.sub.2NRR', cyano, an azido, --COR.sub.11,
OCOR.sub.11 or OCONR.sub.11R.sub.12, wherein of R.sub.7, R.sub.8,
R.sub.9, R.sub.10, R.sub.11 and R.sub.12 are each independently
selected from H, linear, branched or cyclic alkyl, alkenyl or
alkynyl having from 1 to 10 carbon atoms, a polyethylene glycol
unit (--OCH.sub.2CH.sub.2).sub.n, wherein n is an integer from 1 to
2000, a 5- or 6-membered heteroaryl ring containing one or more
heteroatoms independently selected from nitrogen, oxygen, and
sulfur, a 5 to 18 membered fused ring system, wherein at least one
of the rings is aromatic, containing one or more heteroatoms
independently selected from nitrogen, oxygen, and sulfur, aryl
having from 6 to 18 carbon atoms, 3 to 10-membered heterocyclic
ring having 3 to 18-membered heterocyclic ring having 1 to 6
heteroatoms selected from O, S, N and P and R.sub.10 is optionally
SR.sub.13 or COR.sub.3, wherein R.sub.13 is selected from linear,
branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10
carbon atoms, a 5- or 6-membered heteroaryl ring containing one or
more heteroatoms independently selected from nitrogen, oxygen, and
sulfur, a 5 to 18 membered fused ring system, wherein at least one
of the rings is aromatic, containing one or more heteroatoms
independently selected from nitrogen, oxygen, and sulfur, aryl
having from 6 to 18 carbon atoms, 3 to 18-membered heterocyclic
ring having 1 to 6 heteroatoms selected from O, S, N and P,
optionally R.sub.11 is OR.sub.14, wherein R.sub.14 has the same
definition as R, optionally R'' is OH; W is C.dbd.O, C.dbd.S,
CH.sub.2, BH, SO or SO.sub.2; R.sub.1, R.sub.2, R.sub.3, R.sub.4,
R.sub.1', R.sub.2', R.sub.3' and R.sub.4' are each independently
selected from H, substituted or unsubstituted linear, branched or
cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms,
a polyethylene glycol unit (--OCH.sub.2CH.sub.2).sub.n, wherein n
is an integer from 1 to 2000, or a substituent selected from a
halogen, guanidinium [--NH(C.dbd.NH)NH.sub.2], OR.sub.7,
NR.sub.8R.sub.9, NO.sub.2, NRCOR', SR.sub.10, a sulfoxide
represented by SOR', a sulfone represented by --SO.sub.2R', a
sulfite --SO.sub.3, a bisulfite --OSO.sub.3, a sulfonamide
represented by SO.sub.2NRR', cyano, an azido, --COR.sub.1,
OCOR.sub.11 or OCONR.sub.11R.sub.12 wherein R.sub.7, R.sub.8,
R.sub.9, R.sub.10, R.sub.11 and R.sub.12 are as defined above
optionally, any one of R.sub.1, R.sub.2, R.sub.3, R.sub.4,
R.sub.1', R.sub.2', R.sub.3', or R.sub.4' is a linking group that
enables linkage to a cell binding agent via a covalent bond or is
selected from a polypyrrolo, poly-indolyl, poly-imidazolyl,
polypyrollo-imidazolyl, poly-pyrollo-indolyl or
polyimidazolo-indolyl unit optionally bearing a linking group that
enables linkage to a cell binding agent, Z is selected from
(CH.sub.2).sub.n, wherein n is 1, 2 or 3, CR.sub.15R.sub.16,
NR.sub.17, O or S, wherein R.sub.15, R.sub.16 and R.sub.17 are each
independently selected from H, linear, branched or cyclic alkyl
having from 1 to 10 carbon atoms, a polyethylene glycol unit
(--OCH.sub.2CH.sub.2).sub.n, wherein n is an integer from 1 to
2000; R.sub.6 is OR, SR or NRR', wherein R and R' have the same
definition as given above, optionally R.sub.6 is a linking group;
X' is selected from CH.sub.2, NR, CO, BH, SO or SO.sub.2 wherein R
has the same definition as given above; Y' is O, CH.sub.2, NR or S,
wherein R has the same definition as given above; Z' is CH.sub.2 or
(CH.sub.2).sub.n, wherein n is 2, 3 or 4, provided that X', Y' and
Z' are not all CH.sub.2 at the same time; A and A' are the same or
different and are selected from O, --CRR'O, S, --CRR'S, --NR.sub.15
or CRR'NHR.sub.15, wherein R and R' have the same definition as
given above and wherein R.sub.15 has the same definition as R. D
and D' are same or different and independently selected from
linear, branched or cyclic alkyl, alkenyl or alkynyl having 1 to 10
carbon atoms, optionally substituted with any one of halogen,
OR.sub.7, NR.sub.8R.sub.9, NO.sub.2, NRCOR', SR.sub.10, a sulfoxide
represented by SOR', a sulfone represented by --SO.sub.2R', a
sulfite --SO.sub.3, a bisulfite --OSO.sub.3, a sulfonamide
represented by SO.sub.2NRR', cyano, an azido, --COR.sub.11,
OCOR.sub.11 or OCONR.sub.11R.sub.12, wherein the definitions of
R.sub.7, R.sub.8, R.sub.9, R.sub.10, R.sub.11 and R.sub.12 are as
defined above, or a polyethylene glycol unit
(--OCH.sub.2CH.sub.2).sub.n, wherein n is an integer from 1 to
2000; L is an optional phenyl group or 3 to 18-membered
heterocyclic ring having 1 to 6 heteroatoms selected from O, S, N
and P that is optionally substituted, wherein the substituent is a
linking group that enables linkage to a cell binding agent via a
covalent bond, or is selected from linear, branched or cyclic
alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms,
optionally substituted with any one of halogen, OR.sub.7,
NR.sub.8R.sub.9, NO.sub.2, NRCOR', SR.sub.10, a sulfoxide
represented by SOR', a sulfone represented by --SO.sub.2R', a
sulfite --SO.sub.3, a bisulfite --OSO.sub.3, a sulfonamide
represented by SO.sub.2NRR', cyano, an azido, --COR.sub.11,
OCOR.sub.11 or OCONR.sub.11R.sub.12, wherein R.sub.7, R.sub.8,
R.sub.9, R.sub.10, R.sub.11 and R.sub.12 have the same definitions
as given above, a polyethylene glycol unit
(--OCH.sub.2CH.sub.2).sub.n, wherein n is an integer from 1 to
2000; optionally, L itself is a linking group that enables linkage
to a cell binding agent via a covalent bond; or their
pharmaceutically acceptable solvates, salts, hydrates or hydrated
salts, their optical isomers, racemates, diastereomers, enantiomers
or the polymorphic crystalline structures of these compounds;
provided that the compound has no more than one linking group that
enables linkage to a cell binding agent via a covalent bond.
[0010] A fourth object of the invention is to provide conjugates of
cell binding agents with the novel benzodiazepine compounds or
derivatives thereof of the present invention. These conjugates are
useful as therapeutic agents, which are delivered specifically to
target cells and are cytotoxic.
[0011] The present invention includes a composition (e.g., a
pharmaceutical composition) comprising novel benzodiazepine
compounds, derivatives thereof, or conjugates thereof, (and/or
solvates, hydrates and/or salts thereof) and a carrier (a
pharmaceutically acceptable carrier). The present invention also
includes a composition (e.g., a pharmaceutical composition)
comprising novel benzodiazepine compounds, derivatives thereof, or
conjugates thereof, (and/or solvates, hydrates and/or salts
thereof) and a carrier (a pharmaceutically acceptable carrier),
further comprising a second therapeutic agent. The present
compositions are useful for inhibiting abnormal cell growth or
treating a proliferative disorder in a mammal (e.g., human). The
present compositions are also useful for treating depression,
anxiety, stress, phobias, panic, dysphoria, psychiatric disorders,
pain, and inflammatory diseases in a mammal (e.g., human).
[0012] The present invention includes a method of inhibiting
abnormal cell growth or treating a proliferative disorder in a
mammal (e.g., human) comprising administering to said mammal a
therapeutically effective amount of novel benzodiazepine compounds,
derivatives thereof, or conjugates thereof, (and/or solvates and
salts thereof) or a composition thereof, alone or in combination
with a second therapeutic agent.
[0013] The present invention includes a method of synthesizing and
using novel benzodiazepine compounds, derivatives thereof, and
conjugates thereof for in vitro, in situ, and in vivo diagnosis or
treatment of mammalian cells, organisms, or associated pathological
conditions.
[0014] The compounds of this invention, derivatives thereof, or
conjugates thereof, and compositions comprising them, are useful
for treating or lessening the severity of disorders, such as,
characterized by abnormal growth of cells (e.g., cancer). Other
applications for compounds and conjugates of this invention
include, but are not limited to, treating osteoporosis, depression,
anxiety, stress, phobias, panic, dysphoria, psychiatric disorders,
and pain or as antiepileptics, antibacterials, diuretics and
hypotensives, hypolipidemics, and anti-depressants.
BRIEF DESCRIPTION OF THE FIGURES
[0015] FIGS. 1-10 show the schemes for the synthesis of
indolinobenzodiazepine and oxazolidinobenzodiazepine monomers, the
representative linkers and the dimers in the present invention.
[0016] FIG. 11 shows the scheme for the synthesis of the
representative B-ring modified indolinobenzodiazepine monomer.
[0017] FIG. 12 shows the scheme for the synthesis of the
representative isoindolinobenzodiazepine monomer.
[0018] FIG. 13 shows the scheme for the synthesis of the
representative dimer with the linker directly attached on the
indolinobenzodiazepine moiety in the present invention.
[0019] FIGS. 14 and 15 show the schemes for the synthesis of the
representative dimers containing (PEG).sub.n moieties on the
linkers.
[0020] FIG. 16 shows the schemes for the synthesis of the
representative mixed imine-amine and imine-amide
indolinobenzodiazepine dimers.
[0021] FIG. 17 shows the scheme for the synthesis of the
representative IBD-poly(N-methylpyrrole-imidazole) conjugates.
[0022] FIGS. 18-19 show the synthetic scheme for the preparation of
polypyrrolo and polypyrrolo-imidazolo derivatives of the
monomers.
[0023] FIG. 20 shows a scheme for the synthesis of
piperidinylbenzodiazepines bearing a hydrazone linker.
[0024] FIGS. 21-26 show the dose dependent in vitro
antiproliferative activity of muB38.1-IGN-03, huN901-IGN-03,
huN901-IGN-07, and muB38.1-IGN-10 conjugates on antigen positive
and antigen negative cancer cell lines.
[0025] FIG. 27 shows in vivo efficacy of huN901-IGN-07 conjugate in
mice bearing Molp-8 tumors.
[0026] FIGS. 28-30 show data that demonstrate that IGN-01, IGN-02,
and IGN-09 bind and covalently adduct to double stranded DNA
containing guanine residues on opposite strands.
[0027] FIG. 31 contains TABLE 1, which shows the IC.sub.50 values
for in vitro antiproliferative activity of indolinobenzodiazepine
dimers and oxazolidinobenzodiazepine dimer on several cancer cell
lines.
[0028] FIG. 32 contains TABLE 2, which shows the comparison of the
IC.sub.50 values for in vitro antiproliferative activity of
indolinobenzodiazepine dimers with and without linkers.
[0029] FIGS. 33-36, 39, 42, 43, 44, 48, 49 and 50 show synthetic
schemes for the preparation of compounds of the present
invention.
[0030] FIGS. 37, 38, 40 and 41, 45, 46, and 47 show synthetic
schemes for the preparation of linkable compounds of the present
invention.
[0031] FIG. 51 shows the in vitro cytotoxicity of compounds of the
present invention.
[0032] FIGS. 52, 54, 56, 57 and 58 show the in vitro cytotoxicity
and specificity of chB38.1 conjugates.
[0033] FIGS. 53 and 55 show the in vitro cytotoxicity and
specificity of huMy9-6 conjugates.
[0034] FIG. 59 shows the in vivo anti-tumor activity of chB38.1
conjugate
DETAILED DESCRIPTION OF THE INVENTION
[0035] Reference will now be made in detail to certain embodiments
of the invention, examples of which are illustrated in the
accompanying structures and formulas. While the invention will be
described in conjunction with the enumerated embodiments, it will
be understood that they are not intended to limit the invention to
those embodiments. On the contrary, the invention is intended to
cover all alternatives, modifications, and equivalents which may be
included within the scope of the present invention as defined by
the claims. One skilled in the art will recognize many methods and
materials similar or equivalent to those described herein, which
could be used in the practice of the present invention.
Definitions
[0036] "Linear or branched alkyl" as used herein refers to a
saturated linear or branched-chain monovalent hydrocarbon radical
of one to twenty carbon atoms. Examples of alkyl include, but are
not limited to, methyl, ethyl, 1-propyl, 2-propyl, 1-butyl,
2-methyl-1-propyl, --CH.sub.2CH(CH.sub.3).sub.2), 2-butyl,
2-methyl-2-propyl, 1-pentyl, 2-pentyl 3-pentyl, 2-methyl-2-butyl,
3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, 1-hexyl),
2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl,
4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl,
2,3-dimethyl-2-butyl, 3,3-dimethyl-2-butyl, 1-heptyl, 1-octyl, and
the like.
[0037] "Linear or branched alkenyl" refers to linear or
branched-chain monovalent hydrocarbon radical of two to twenty
carbon atoms with at least one site of unsaturation, i.e., a
carbon-carbon, double bond, wherein the alkenyl radical includes
radicals having "cis" and "trans" orientations, or alternatively,
"E" and "Z" orientations. Examples include, but are not limited to,
ethylenyl or vinyl (--CH.dbd.CH.sub.2), allyl
(--CH.sub.2CH.dbd.CH.sub.2), and the like.
[0038] "Linear or branched alkynyl" refers to a linear or branched
monovalent hydrocarbon radical of two to twenty carbon atoms with
at least one site of unsaturation, i.e., a carbon-carbon, triple
bond. Examples include, but are not limited to, ethynyl, propynyl,
1-butynyl, 2-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, hexynyl,
and the like.
[0039] The terms "cyclic alkyl", "cyclic alkenyl", "cyclic
alkynyl", "carbocycle", "carbocyclyl", "carbocyclic ring" and
"cycloalkyl" refer to a monovalent non-aromatic, saturated or
partially unsaturated ring having 3 to 12 carbon atoms as a
monocyclic ring or 7 to 12 carbon atoms as a bicyclic ring.
Bicyclic carbocycles having 7 to 12 atoms can be arranged, for
example, as a bicyclo[4,5], [5,5], [5,6] or [6,6] system, and
bicyclic carbocycles having 9 or 10 ring atoms can be arranged as a
bicyclo [5,6] or [6,6] system, or as bridged systems such as
bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane and
bicyclo[3.2.2]nonane. Examples of monocyclic carbocycles include,
but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl,
1-cyclopent-1-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl,
cyclohexyl, 1-cyclohex-1-enyl, 1-cyclohex-2-enyl,
1-cyclohex-3-enyl, cyclohexadienyl, cycloheptyl, cyclooctyl,
cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, and the
like.
[0040] "Aryl" means a monovalent aromatic hydrocarbon radical of
6-18 carbon atoms derived by the removal of one hydrogen atom from
a single carbon atom of a parent aromatic ring system. Some aryl
groups are represented in the exemplary structures as "Ar". Aryl
includes bicyclic radicals comprising an aromatic ring fused to a
saturated, partially unsaturated ring, or aromatic carbocyclic or
heterocyclic ring. Typical aryl groups include, but are not limited
to, radicals derived from benzene (phenyl), substituted benzenes,
naphthalene, anthracene, indenyl, indanyl, 1,2-dihydronapthalene,
1,2,3,4-tetrahydronapthyl, and the like.
[0041] The terms "heterocycle," "heterocyclyl" and "heterocyclic
ring" are used interchangeably herein and refer to a saturated or a
partially unsaturated (i.e., having one or more double and/or
triple bonds within the ring) carbocyclic radical of 3 to 18 ring
atoms in which at least one ring atom is a heteroatom selected from
nitrogen, oxygen, phosphorus, and sulfur, the remaining ring atoms
being C, where one or more ring atoms is optionally substituted
independently with one or more substituents described below. A
heterocycle may be a monocycle having 3 to 7 ring members (2 to 6
carbon atoms and 1 to 4 heteroatoms selected from N, O, P, and S)
or a bicycle having 7 to 10 ring members (4 to 9 carbon atoms and 1
to 6 heteroatoms selected from N, O, P, and S), for example: a
bicyclo [4,5], [5,5], [5,6], or [6,6] system. Heterocycles are
described in Paquette, Leo A.; "Principles of Modern Heterocyclic
Chemistry" (W. A. Benjamin, New York, 1968), particularly Chapters
1, 3, 4, 6, 7, and 9; "The Chemistry of Heterocyclic Compounds, A
series of Monographs" (John Wiley & Sons, New York, 1950 to
present), in particular Volumes 13, 14, 16, 19, and 28; and J. Am.
Chem. Soc. (1960) 82:5566. "Heterocyclyl" also includes radicals
where heterocycle radicals are fused with a saturated, partially
unsaturated ring, or aromatic carbocyclic or heterocyclic ring.
Examples of heterocyclic rings include, but are not limited to,
pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl,
tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl,
piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl,
homopiperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl,
oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl,
2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl,
dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dithianyl, dithiolanyl,
dihydropyranyl, dihydrothienyl, dihydrofuranyl,
pyrazolidinylimidazolinyl, imidazolidinyl,
3-azabicyco[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl, and
azabicyclo[2.2.2]hexanyl. Spiro moieties are also included within
the scope of this definition. Examples of a heterocyclic group
wherein ring atoms are substituted with oxo (.dbd.O) moieties are
pyrimidinonyl and 1,1-dioxo-thiomorpholinyl.
[0042] The term "heteroaryl" refers to a monovalent aromatic
radical of 5- or 6-membered rings, and includes fused ring systems
(at least one of which is aromatic) of 5-18 atoms, containing one
or more heteroatoms independently selected from nitrogen, oxygen,
and sulfur. Examples of heteroaryl groups are pyridinyl (including,
for example, 2-hydroxypyridinyl), imidazolyl, imidazopyridinyl,
pyrimidinyl (including, for example, 4-hydroxypyrimidinyl),
pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl,
isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl,
quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl,
cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl,
triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, triazolyl,
thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl,
benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl,
naphthyridinyl, and furopyridinyl.
[0043] The heterocycle or heteroaryl groups may be carbon
(carbon-linked) or nitrogen (nitrogen-linked) attached where such
is possible. By way of example and not limitation, carbon bonded
heterocycles or heteroaryls are bonded at position 2, 3, 4, 5, or 6
of a pyridine, position 3, 4, 5, or 6 of a pyridazine, position 2,
4, 5, or 6 of a pyrimidine, position 2, 3, 5, or 6 of a pyrazine,
position 2, 3, 4, or 5 of a furan, tetrahydrofuran, thiofuran,
thiophene, pyrrole or tetrahydropyrrole, position 2, 4, or 5 of an
oxazole, imidazole or thiazole, position 3, 4, or 5 of an
isoxazole, pyrazole, or isothiazole, position 2 or 3 of an
aziridine, position 2, 3, or 4 of an azetidine, position 2, 3, 4,
5, 6, 7, or 8 of a quinoline or position 1, 3, 4, 5, 6, 7, or 8 of
an isoquinoline.
[0044] By way of example and not limitation, nitrogen bonded
heterocycles or heteroaryls are bonded at position 1 of an
aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline,
3-pyrroline, imidazole, imidazolidine, 2-imidazoline,
3-imidazoline, pyrazole, pyrazoline, 2-pyrazoline, 3-pyrazoline,
piperidine, piperazine, indole, indoline, 1H-indazole, position 2
of a isoindole, or isoindoline, position 4 of a morpholine, and
position 9 of a carbazole, or O-carboline.
[0045] The heteroatoms present in heteroaryl or heterocyclcyl
include the oxidized forms such as NO, SO, and SO.sub.2.
[0046] The term "halo" or "halogen" refers to F, Cl, Br or I.
[0047] The term "compound" or "cytotoxic compound" or "cytotoxic
agent" as used herein is intended to include compounds for which a
structure or formula or any derivative thereof has been disclosed
in the present invention or a structure or formula or any
derivative thereof that has been incorporated by reference. The
term also includes, stereoisomers, geometric isomers, tautomers,
solvates, metabolites, salts (e.g., pharmaceutically acceptable
salts) and prodrugs, and prodrug salts of a compound of all the
formulae disclosed in the present invention. The term also includes
any solvates, hydrates, and polymorphs of any of the foregoing. The
specific recitation of "stereoisomers", "geometric isomers",
"tautomers", "solvates", "metabolites", "salt" "prodrug," "prodrug
salt," "conjugates," "conjugates salt," "solvate," "hydrate," or
"polymorph" in certain aspects of the invention described in this
application shall not be interpreted as an intended omission of
these forms in other aspects of the invention where the term
"compound" is used without recitation of these other forms.
[0048] The term "conjugate" as used herein refers to a compound or
a derivative thereof that is linked to a cell binding agent and is
defined by a generic formula: C-L-CBA, wherein C=compound,
L=linker, and CBA=cell binding agent.
[0049] The term "linkable to a cell binding agent" as used herein
refers to the novel benzodiazepine compounds (e.g.,
indolinobenzodiazepine or oxazolidinobenzodiazepine), derivates
thereof or dimers thereof comprising at least one linking group or
a precursor thereof suitable to bond these compounds, derivatives
thereof or dimers thereof to a cell binding agent.
[0050] The term "precursor" of a given group refers to any group
which may lead to that group by any deprotection, a chemical
modification, or a coupling reaction.
[0051] The term "linked to a cell binding agent" refers to a
conjugate molecule comprising at least one the novel benzodiazepine
compounds (e.g., indolinobenzodiazepine or
oxazolidinobenzodiazepine), derivates thereof or dimers thereof
bound to a cell binding agent via a suitable linking group or a
precursor thereof.
[0052] The term "chiral" refers to molecules which have the
property of non-superimposability of the mirror image partner,
while the term "achiral" refers to molecules which are
superimposable on their mirror image partner.
[0053] The term "stereoisomer" refers to compounds which have
identical chemical constitution and connectivity, but different
orientations of their atoms in space that cannot be interconverted
by rotation about single bonds.
[0054] "Diastereomer" refers to a stereoisomer with two or more
centers of chirality and whose molecules are not mirror images of
one another. Diastereomers have different physical properties, e.g.
melting points, boiling points, spectral properties, and
reactivities. Mixtures of diastereomers may separate under high
resolution analytical procedures such as crystallization,
electrophoresis and chromatography.
[0055] "Enantiomers" refer to two stereoisomers of a compound which
are non-superimposable mirror images of one another.
[0056] Stereochemical definitions and conventions used herein
generally follow S. P. Parker, Ed., McGraw-Hill Dictionary of
Chemical Terms (1984) McGraw-Hill Book Company, New York; and
Eliel, E. and Wilen, S., "Stereochemistry of Organic Compounds",
John Wiley & Sons, Inc., New York, 1994. The compounds of the
invention may contain asymmetric or chiral centers, and therefore
exist in different stereoisomeric forms. It is intended that all
stereoisomeric forms of the compounds of the invention, including
but not limited to, diastereomers, enantiomers and atropisomers, as
well as mixtures thereof such as racemic mixtures, form part of the
present invention. Many organic compounds exist in optically active
forms, i.e., they have the ability to rotate the plane of
plane-polarized light. In describing an optically active compound,
the prefixes D and L, or R and S, are used to denote the absolute
configuration of the molecule about its chiral center(s). The
prefixes d and I or (+) and (-) are employed to designate the sign
of rotation of plane-polarized light by the compound, with (-) or 1
meaning that the compound is levorotatory. A compound prefixed with
(+) or d is dextrorotatory. For a given chemical structure, these
stereoisomers are identical except that they are mirror images of
one another. A specific stereoisomer may also be referred to as an
enantiomer, and a mixture of such isomers is often called an
enantiomeric mixture. A 50:50 mixture of enantiomers is referred to
as a racemic mixture or a racemate, which may occur where there has
been no stereoselection or stereospecificity in a chemical reaction
or process. The terms "racemic mixture" and "racemate" refer to an
equimolar mixture of two enantiomeric species, devoid of optical
activity.
[0057] The term "tautomer" or "tautomeric form" refers to
structural isomers of different energies which are interconvertible
via a low energy barrier. For example, proton tautomers (also known
as prototropic tautomers) include interconversions via migration of
a proton, such as keto-enol and imine-enamine isomerizations.
Valence tautomers include interconversions by reorganization of
some of the bonding electrons.
[0058] A substituent is "substitutable" if it comprises at least
one carbon, sulfur, oxygen or nitrogen atom that is bonded to one
or more hydrogen atoms. Thus, for example, hydrogen, halogen, and
cyano do not fall within this definition.
[0059] If a substituent is described as being "substituted," a
non-hydrogen substituent is in the place of a hydrogen substituent
on a carbon, oxygen, sulfur or nitrogen of the substituent. Thus,
for example, a substituted alkyl substituent is an alkyl
substituent wherein at least one non-hydrogen substituent is in the
place of a hydrogen substituent on the alkyl substituent. To
illustrate, monofluoroalkyl is alkyl substituted with a fluoro
substituent, and difluoroalkyl is alkyl substituted with two fluoro
substituents. It should be recognized that if there is more than
one substitution on a substituent, each non-hydrogen substituent
may be identical or different (unless otherwise stated).
[0060] If a substituent is described as being "optionally
substituted," the substituent may be either (1) not substituted, or
(2) substituted. If a carbon of a substituent is described as being
optionally substituted with one or more of a list of substituents,
one or more of the hydrogens on the carbon (to the extent there are
any) may separately and/or together be replaced with an
independently selected optional substituent. If a nitrogen of a
substituent is described as being optionally substituted with one
or more of a list of substituents, one or more of the hydrogens on
the nitrogen (to the extent there are any) may each be replaced
with an independently selected optional substituent. One exemplary
substituent may be depicted as --NR'R'', wherein R' and R''
together with the nitrogen atom to which they are attached, may
form a heterocyclic ring. The heterocyclic ring formed from R' and
R'' together with the nitrogen atom to which they are attached may
be partially or fully saturated. In one embodiment, the
heterocyclic ring consists of 3 to 7 atoms. In another embodiment,
the heterocyclic ring is selected from the group consisting of
pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, isoxazolyl,
pyridyl and thiazolyl.
[0061] This specification uses the terms "substituent," "radical,"
and "group" interchangeably.
[0062] If a group of substituents are collectively described as
being optionally substituted by one or more of a list of
substituents, the group may include: (1) unsubstitutable
substituents, (2) substitutable substituents that are not
substituted by the optional substituents, and/or (3) substitutable
substituents that are substituted by one or more of the optional
substituents.
[0063] If a substituent is described as being optionally
substituted with up to a particular number of non-hydrogen
substituents, that substituent may be either (1) not substituted;
or (2) substituted by up to that particular number of non-hydrogen
substituents or by up to the maximum number of substitutable
positions on the substituent, whichever is less. Thus, for example,
if a substituent is described as a heteroaryl optionally
substituted with up to 3 non-hydrogen substituents, then any
heteroaryl with less than 3 substitutable positions would be
optionally substituted by up to only as many non-hydrogen
substituents as the heteroaryl has substitutable positions. Such
substituents, in non-limiting examples, can be selected from a
linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1
to 10 carbon atoms, halogen, guanidinium [--NH(C.dbd.NH)NH.sub.2],
OR.sub.7, NR.sub.8R.sub.9, NO.sub.2, NRCOR', SR10, a sulfoxide
represented by SOR', a sulfone represented by --SO.sub.2R', a
sulfite --SO.sub.3, a bisulfite --OSO.sub.3, a sulfonamide
represented by SO.sub.2NRR', cyano, an azido, --COR.sub.11,
OCOR.sub.11 or OCONR.sub.11R.sub.12 wherein R.sub.7, R.sub.8,
R.sub.9, R.sub.10, R.sub.11 and R.sub.12 are each independently
selected from H, linear, branched or cyclic alkyl, alkenyl or
alkynyl having from 1 to 10 carbon atoms, a polyethylene glycol
unit (--OCH.sub.2CH.sub.2).sub.n, wherein n is an integer from 1 to
2000, aryl having from 6 to 10 carbon atoms, heterocyclic ring
having from 3 to 10 carbon atoms.
[0064] The term "prodrug" as used in this application refers to a
precursor or derivative form of a compound of the invention that is
capable of being enzymatically or hydrolytically activated or
converted into the more active parent form. See, e.g., Wilman,
"Prodrugs in Cancer Chemotherapy" Biochemical Society Transactions,
14, pp. 375-382, 615th Meeting Belfast (1986) and Stella et al.,
"Prodrugs: A Chemical Approach to Targeted Drug Delivery," Directed
Drug Delivery, Borchardt et al., (ed.), pp. 247-267, Humana Press
(1985). The prodrugs of this invention include, but are not limited
to, ester-containing prodrugs, phosphate-containing prodrugs,
thiophosphate-containing prodrugs, sulfate-containing prodrugs,
peptide-containing prodrugs, D-amino acid-modified prodrugs,
glycosylated prodrugs, .beta.-lactam-containing prodrugs,
optionally substituted phenoxyacetamide-containing prodrugs,
optionally substituted phenylacetamide-containing prodrugs,
5-fluorocytosine and other 5-fluorouridine prodrugs which can be
converted into the more active cytotoxic free drug. Examples of
cytotoxic drugs that can be derivatized into a prodrug form for use
in this invention include, but are not limited to, compounds of the
invention and chemotherapeutic agents such as described above.
[0065] The term "prodrug" is also meant to include a derivative of
a compound that can hydrolyze, oxidize, or otherwise react under
biological conditions (in vitro or in vivo) to provide a compound
of this invention. Prodrugs may only become active upon such
reaction under biological conditions, or they may have activity in
their unreacted forms. Examples of prodrugs contemplated in this
invention include, but are not limited to, analogs or derivatives
of compounds of any one of the formulae disclosed herein that
comprise biohydrolyzable moieties such as biohydrolyzable amides,
biohydrolyzable esters, biohydrolyzable carbamates, biohydrolyzable
carbonates, biohydrolyzable ureides, and biohydrolyzable phosphate
analogues. Other examples of prodrugs include derivatives of
compounds of any one of the formulae disclosed herein that comprise
--NO, --NO.sub.2, --ONO, or --ONO.sub.2 moieties. Prodrugs can
typically be prepared using well-known methods, such as those
described by Burger's Medicinal Chemistry and Drug Discovery (1995)
172-178, 949-982 (Manfred E. Wolff ed., 5th ed); see also Goodman
and Gilman's, The Pharmacological basis of Therapeutics, 8th ed.,
McGraw-Hill, Int. Ed. 1992, "Biotransformation of Drugs".
[0066] As used herein and unless otherwise indicated, the terms
"biohydrolyzable amide", "biohydrolyzable ester", "biohydrolyzable
carbamate", "biohydrolyzable carbonate", "biohydrolyzable ureide"
and "biohydrolyzable phosphate analogue" mean an amide, ester,
carbamate, carbonate, ureide, or phosphate analogue, respectively,
that either: 1) does not destroy the biological activity of the
compound and confers upon that compound advantageous properties in
vivo, such as uptake, duration of action, or onset of action; or 2)
is itself biologically inactive but is converted in vivo to a
biologically active compound. Examples of biohydrolyzable amides
include, but are not limited to, lower alkyl amides, .alpha.-amino
acid amides, alkoxyacyl amides, and alkylaminoalkylcarbonyl amides.
Examples of biohydrolyzable esters include, but are not limited to,
lower alkyl esters, alkoxyacyloxy esters, alkyl acylamino alkyl
esters, and choline esters. Examples of biohydrolyzable carbamates
include, but are not limited to, lower alkylamines, substituted
ethylenediamines, amino acids, hydroxyalkylamines, heterocyclic and
heteroaromatic amines, and polyether amines. Particularly favored
prodrugs and prodrug salts are those that increase the
bioavailability of the compounds of this invention when such
compounds are administered to a mammal.
[0067] The phrase "pharmaceutically acceptable salt" as used
herein, refers to pharmaceutically acceptable organic or inorganic
salts of a compound of the invention. Exemplary salts include, but
are not limited, to sulfate, citrate, acetate, oxalate, chloride,
bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate,
isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate,
tannate, pantothenate, bitartrate, ascorbate, succinate, maleate,
gentisinate, fumarate, gluconate, glucuronate, saccharate, formate,
benzoate, glutamate, methanesulfonate "mesylate", ethanesulfonate,
benzenesulfonate, p-toluenesulfonate, pamoate (i.e.,
1,1'-methylene-bis-(2-hydroxy-3-naphthoate)) salts, alkali metal
(e.g., sodium and potassium) salts, alkaline earth metal (e.g.,
magnesium) salts, and ammonium salts. A pharmaceutically acceptable
salt may involve the inclusion of another molecule such as an
acetate ion, a succinate ion or other counter ion. The counter ion
may be any organic or inorganic moiety that stabilizes the charge
on the parent compound. Furthermore, a pharmaceutically acceptable
salt may have more than one charged atom in its structure.
Instances where multiple charged atoms are part of the
pharmaceutically acceptable salt can have multiple counter ions.
Hence, a pharmaceutically acceptable salt can have one or more
charged atoms and/or one or more counter ion.
[0068] If the compound of the invention is a base, the desired
pharmaceutically acceptable salt may be prepared by any suitable
method available in the art, for example, treatment of the free
base with an inorganic acid, such as hydrochloric acid, hydrobromic
acid, sulfuric acid, nitric acid, methanesulfonic acid, phosphoric
acid and the like, or with an organic acid, such as acetic acid,
maleic acid, succinic acid, mandelic acid, fumaric acid, malonic
acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, a
pyranosidyl acid, such as glucuronic acid or galacturonic acid, an
alpha hydroxy acid, such as citric acid or tartaric acid, an amino
acid, such as aspartic acid or glutamic acid, an aromatic acid,
such as benzoic acid or cinnamic acid, a sulfonic acid, such as
p-toluenesulfonic acid or ethanesulfonic acid, or the like.
[0069] If the compound of the invention is an acid, the desired
pharmaceutically acceptable salt may be prepared by any suitable
method, for example, treatment of the free acid with an inorganic
or organic base, such as an amine (primary, secondary or tertiary),
an alkali metal hydroxide or alkaline earth metal hydroxide, or the
like. Illustrative examples of suitable salts include, but are not
limited to, organic salts derived from amino acids, such as glycine
and arginine, ammonia, primary, secondary, and tertiary amines, and
cyclic amines, such as piperidine, morpholine and piperazine, and
inorganic salts derived from sodium, calcium, potassium, magnesium,
manganese, iron, copper, zinc, aluminum and lithium.
[0070] As used herein, the term "solvate" means a compound which
further includes a stoichiometric or non-stoichiometric amount of
solvent such as water, isopropanol, acetone, ethanol, methanol,
DMSO, ethyl acetate, acetic acid, and ethanolamine dichloromethane,
2-propanol, or the like, bound by non-covalent intermolecular
forces. Solvates or hydrates of the compounds are readily prepared
by addition of at least one molar equivalent of a hydroxylic
solvent such as methanol, ethanol, 1-propanol, 2-propanol or water
to the compound to result in solvation or hydration of the imine
moiety.
[0071] The terms "abnormal cell growth" and "proliferative
disorder" are used interchangeably in this application. "Abnormal
cell growth", as used herein, unless otherwise indicated, refers to
cell growth that is independent of normal regulatory mechanisms
(e.g., loss of contact inhibition). This includes, for example, the
abnormal growth of: (1) tumor cells (tumors) that proliferate by
expressing a mutated tyrosine kinase or overexpression of a
receptor tyrosine kinase; (2) benign and malignant cells of other
proliferative diseases in which aberrant tyrosine kinase activation
occurs; (3) any tumors that proliferate by receptor tyrosine
kinases; (4) any tumors that proliferate by aberrant
serine/threonine kinase activation; and (5) benign and malignant
cells of other proliferative diseases in which aberrant
serine/threonine kinase activation occurs.
[0072] The terms "cancer" and "cancerous" refer to or describe the
physiological condition in mammals that is typically characterized
by unregulated cell growth. A "tumor" comprises one or more
cancerous cells. Examples of cancer include, but are not limited
to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia or
lymphoid malignancies. More particular examples of such cancers
include squamous cell cancer (e.g., epithelial squamous cell
cancer), lung cancer including small-cell lung cancer, non-small
cell lung cancer ("NSCLC"), adenocarcinoma of the lung and squamous
carcinoma of the lung, cancer of the peritoneum, hepatocellular
cancer, gastric or stomach cancer including gastrointestinal
cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian
cancer, liver cancer, bladder cancer, hepatoma, breast cancer,
colon cancer, rectal cancer, colorectal cancer, endometrial or
uterine carcinoma, salivary gland carcinoma, kidney or renal
cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic
carcinoma, anal carcinoma, penile carcinoma, acute leukemia, as
well as head/brain and neck cancer.
[0073] A "therapeutic agent" encompasses both a biological agent
such as an antibody, a peptide, a protein, an enzyme or a
chemotherapeutic agent. A"chemotherapeutic agent" is a chemical
compound useful in the treatment of cancer. Examples of
chemotherapeutic agents include Erlotinib (TARCEVA.RTM.,
Genentech/OSI Pharm.), Bortezomib (VELCADE.RTM., Millennium
Pharm.), Fulvestrant (FASLODEX.RTM., AstraZeneca), Sutent (SU11248,
Pfizer), Letrozole (FEMARA.RTM., Novartis), Imatinib mesylate
(GLEEVEC.RTM., Novartis), PTK787/ZK 222584 (Novartis), Oxaliplatin
(Eloxatin.RTM., Sanofi), 5-FU (5-fluorouracil), Leucovorin,
Rapamycin (Sirolimus, RAPAMUNE.RTM., Wyeth), Lapatinib
(TYKERB.RTM., GSK572016, Glaxo Smith Kline), Lonafarnib (SCH
66336), Sorafenib (BAY43-9006, Bayer Labs), and Gefitinib
(IRESSA.RTM., AstraZeneca), AG1478, AG1571 (SU 5271; Sugen),
alkylating agents such as thiotepa and CYTOXAN.RTM.
cyclosphosphamide; alkyl sulfonates such as busulfan, improsulfan
and piposulfan; aziridines such as benzodopa, carboquone,
meturedopa, and uredopa; ethylenimines and methylamelamines
including altretamine, triethylenemelamine,
triethylenephosphoramide, triethylenethiophosphoramide and
trimethylomelamine; acetogenins (especially bullatacin and
bullatacinone); a camptothecin (including the synthetic analog
topotecan); bryostatin; callystatin; CC-1065 (including its
adozelesin, carzelesin and bizelesin synthetic analogs);
cryptophycins (particularly cryptophycin 1 and cryptophycin 8);
dolastatin; duocarmycin (including the synthetic analogs, KW-2189
and CB1-TM1); eleutherobin; pancratistatin; a sarcodictyin;
spongistatin; nitrogen mustards such as chlorambucil,
chlornaphazine, chlorophosphamide, estramustine, ifosfamide,
mechlorethamine, mechlorethamine oxide hydrochloride, melphalan,
novembichin, phenesterine, prednimustine, trofosfamide, uracil
mustard; nitrosureas such as carmustine, chlorozotocin,
fotemustine, lomustine, nimustine, and ranimnustine; antibiotics
such as the enediyne antibiotics (e.g., calicheamicin, especially
calicheamicin gammall and calicheamicin omegall (Angew Chem. Intl.
Ed. Engl. (1994) 33:183-186); dynemicin, including dynemicin A;
bisphosphonates, such as clodronate; an esperamicin; as well as
neocarzinostatin chromophore and related chromoprotein enediyne
antibiotic chromophores), aclacinomysins, actinomycin, authramycin,
azaserine, bleomycins, cactinomycin, carabicin, caminomycin,
carzinophilin, chromomycinis, dactinomycin, daunorubicin,
detorubicin, 6-diazo-5-oxo-L-norleucine, ADRIAMYCIN.RTM.
(doxorubicin), morpholino-doxorubicin, cyanomorpholino-doxorubicin,
2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin,
esorubicin, idarubicin, marcellomycin, mitomycins such as mitomycin
C, mycophenolic acid, nogalamycin, olivomycins, peplomycin,
porfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin,
streptozocin, tubercidin, ubenimex, zinostatin, zorubicin;
anti-metabolites such as methotrexate and 5-fluorouracil (5-FU);
folic acid analogs such as denopterin, methotrexate, pteropterin,
trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine,
thiamniprine, thioguanine; pyrimidine analogs such as ancitabine,
azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine,
doxifluridine, enocitabine, floxuridine; androgens such as
calusterone, dromostanolone propionate, epitiostanol, mepitiostane,
testolactone; anti-adrenals such as aminoglutethimide, mitotane,
trilostane; folic acid replenisher such as frolinic acid;
aceglatone; aldophosphamide glycoside; aminolevulinic acid;
eniluracil; amsacrine; bestrabucil; bisantrene; edatraxate;
defofamine; demecolcine; diaziquone; elformithine; elliptinium
acetate; an epothilone; etoglucid; gallium nitrate; hydroxyurea;
lentinan; lonidainine; maytansinoids such as maytansine and
ansamitocins; mitoguazone; mitoxantrone; mopidanmol; nitraerine;
pentostatin; phenamet; pirarubicin; losoxantrone; podophyllinic
acid; 2-ethylhydrazide; procarbazine; PSK.RTM. polysaccharide
complex (JHS Natural Products, Eugene, Oreg.); razoxane; rhizoxin;
sizofuran; spirogermanium; tenuazonic acid; triaziquone;
2,2',2''-trichlorotriethylamine; trichothecenes (especially T-2
toxin, verracurin A, roridin A and anguidine); urethan; vindesine;
dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman;
gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiotepa;
taxoids, e.g., TAXOL.RTM. (paclitaxel; Bristol-Myers Squibb
Oncology, Princeton, N.J.), ABRAXANE.RTM. (Cremophor-free),
albumin-engineered nanoparticle formulations of paclitaxel
(American Pharmaceutical Partners, Schaumberg, Ill.), and
TAXOTERE.RTM. (doxetaxel; Rhone-Poulenc Rorer, Antony, France);
chloranmbucil; GEMZAR.RTM. (gemcitabine); 6-thioguanine;
mercaptopurine; methotrexate; platinum analogs such as cisplatin
and carboplatin; vinblastine; etoposide (VP-16); ifosfamide;
mitoxantrone; vincristine; NAVELBINE.RTM. (vinorelbine);
novantrone; teniposide; edatrexate; daunomycin; aminopterin;
capecitabine (XELODA.RTM.); ibandronate; CPT-11; topoisomerase
inhibitor RFS 2000; difluoromethylomithine (DMFO); retinoids such
as retinoic acid; and pharmaceutically acceptable salts, acids and
derivatives of any of the above.
[0074] Also included in the definition of "chemotherapeutic agent"
are: (i) anti-hormonal agents that act to regulate or inhibit
hormone action on tumors such as anti-estrogens and selective
estrogen receptor modulators (SERMs), including, for example,
tamoxifen (including NOLVADEX.RTM.; tamoxifen citrate), raloxifene,
droloxifene, 4-hydroxytamoxifen, trioxifene, keoxifene, LY 117018,
onapristone, and FARESTON.RTM. (toremifine citrate); (ii) aromatase
inhibitors that inhibit the enzyme aromatase, which regulates
estrogen production in the adrenal glands, such as, for example,
4(5)-imidazoles, aminoglutethimide, MEGASE.RTM. (megestrol
acetate), AROMASIN.RTM. (exemestane; Pfizer), formestanie,
fadrozole, RIVISOR.RTM. (vorozole), FEMARA.RTM. (letrozole;
Novartis), and ARIMIDEX.RTM. (anastrozole; AstraZeneca); (iii)
anti-androgens such as flutamide, nilutamide, bicalutamide,
leuprolide, and goserelin; as well as troxacitabine (a
1,3-dioxolane nucleoside cytosine analog); (iv) protein kinase
inhibitors; (v) lipid kinase inhibitors; (vi) antisense
oligonucleotides, particularly those which inhibit expression of
genes in signaling pathways implicated in aberrant cell
proliferation, such as, for example, PKC-alpha, Ralf and H-Ras;
(vii) ribozymes such as VEGF expression inhibitors (e.g.,
ANGIOZYME.RTM.) and HER2 expression inhibitors; (viii) vaccines
such as gene therapy vaccines, for example, ALLOVECTIN.RTM.,
LEUVECTIN.RTM., and VAXID.RTM.; PROLEUKIN.RTM. rIL-2; a
topoisomerase 1 inhibitor such as LURTOTECAN.RTM.; ABARELIX.RTM.
rmRH; (ix) anti-angiogenic agents such as bevacizumab
(AVASTIN.RTM., Genentech); and (x) pharmaceutically acceptable
salts, acids and derivatives of any of the above. Other
anti-angiogenic agents include MMP-2 (matrix-metalloproteinase 2)
inhibitors, MMP-9 (matrix-metalloproteinase 9) inhibitors, COX-II
(cyclooxygenase II) inhibitors, and VEGF receptor tyrosine kinase
inhibitors. Examples of such useful matrix metalloproteinase
inhibitors that can be used in combination with the present
compounds/compositions are described in WO 96/33172, WO 96/27583,
EP 818442, EP 1004578, WO 98/07697, WO 98/03516, WO 98/34918, WO
98/34915, WO 98/33768, WO 98/30566, EP 606,046, EP 931,788, WO
90/05719, WO 99/52910, WO 99/52889, WO 99/29667, WO 99/07675, EP
945864, U.S. Pat. No. 5,863,949, U.S. Pat. No. 5,861,510, and EP
780,386, all of which are incorporated herein in their entireties
by reference. Examples of VEGF receptor tyrosine kinase inhibitors
include
4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)qu-
inazoline (ZD6474; Example 2 within WO 01/32651),
4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)-
-quinazoline (AZD2171; Example 240 within WO 00/47212), vatalanib
(PTK787; WO 98/35985) and SU11248 (sunitinib; WO 01/60814), and
compounds such as those disclosed in PCT Publication Nos. WO
97/22596, WO 97/30035, WO 97/32856, and WO 98/13354).
[0075] Other examples of chemotherapeutic agents that can be used
in combination with the present compounds include inhibitors of
PI3K (phosphoinositide-3 kinase), such as those reported in Yaguchi
et al (2006) Jour. of the Nat. Cancer Inst. 98(8):545-556; U.S.
Pat. No. 7,173,029; U.S. Pat. No. 7,037,915; U.S. Pat. No.
6,608,056; U.S. Pat. No. 6,608,053; U.S. Pat. No. 6,838,457; U.S.
Pat. No. 6,770,641; U.S. Pat. No. 6,653,320; U.S. Pat. No.
6,403,588; WO 2006/046031; WO 2006/046035; WO 2006/046040; WO
2007/042806; WO 2007/042810; WO 2004/017950; US 2004/092561; WO
2004/007491; WO 2004/006916; WO 2003/037886; US 2003/149074; WO
2003/035618; WO 2003/034997; US 2003/158212; EP 1417976; US
2004/053946; JP 2001247477; JP 08175990; JP 08176070; U.S. Pat. No.
6,703,414; and WO 97/15658, all of which are incorporated herein in
their entireties by reference. Specific examples of such PI3K
inhibitors include SF-1126 (PI3K inhibitor, Semafore
Pharmaceuticals), BEZ-235 (PI3K inhibitor, Novartis), XL-147 (PI3K
inhibitor, Exelixis, Inc.).
[0076] A "metabolite" is a product produced through metabolism in
the body of a specified compound, a derivative thereof, or a
conjugate thereof, or salt thereof. Metabolites of a compound, a
derivative thereof, or a conjugate thereof, may be identified using
routine techniques known in the art and their activities determined
using tests such as those described herein. Such products may
result for example from the oxidation, hydroxylation, reduction,
hydrolysis, amidation, deamidation, esterification,
deesterification, enzymatic cleavage, and the like, of the
administered compound. Accordingly, the invention includes
metabolites of compounds, a derivative thereof, or a conjugate
thereof, of the invention, including compounds, a derivative
thereof, or a conjugate thereof, produced by a process comprising
contacting a compound, a derivative thereof, or a conjugate
thereof, of this invention with a mammal for a period of time
sufficient to yield a metabolic product thereof.
[0077] The phrase "pharmaceutically acceptable" indicates that the
substance or composition must be compatible chemically and/or
toxicologically, with the other ingredients comprising a
formulation, and/or the mammal being treated therewith.
[0078] The term "protecting group" or "protecting moiety" refers to
a substituent that is commonly employed to block or protect a
particular functionality while reacting other functional groups on
the compound, a derivative thereof, or a conjugate thereof. For
example, an "amino-protecting group" or an "amino-protecting
moiety" is a substituent attached to an amino group that blocks or
protects the amino functionality in the compound. Suitable
amino-protecting groups include acetyl, trifluoroacetyl,
t-butoxycarbonyl (BOC), benzyloxycarbonyl (CBZ) and
9-fluorenylmethylenoxycarbonyl (Fmoc). Similarly, a
"hydroxy-protecting group" refers to a substituent of a hydroxy
group that blocks or protects the hydroxy functionality. Suitable
protecting groups include acetyl and silyl. A "carboxy-protecting
group" refers to a substituent of the carboxy group that blocks or
protects the carboxy functionality. Common carboxy-protecting
groups include phenylsulfonylethyl, cyanoethyl,
2-(trimethylsilyl)ethyl, 2-(trimethylsilyl)ethoxymethyl,
2-(p-toluenesulfonyl)ethyl, 2-(p-nitrophenylsulfenyl)ethyl,
2-(diphenylphosphino)-ethyl, nitroethyl and the like. Common
thiol-protecting groups include those that convert the thiol into a
thioester, such as acetyl, benzoyl or trifluoroacetyl, into a
thioether, such as benzyl, t-butyl, triphenylmethyl,
9-fluorenylmetyl, methoxymethyl, 2-tetrahydropyranyl or silyl, into
a disulfide, such as methyl, benzyl, t-butyl, pyridyl,
nitropyridyl, phenyl, nitrophenyl or dinitrophenyl, into a
thiocarbonate, such as t-butoxycarbonyl, into a thiocarbamate, such
as N-ethyl. For a general description of protecting groups and
their use, see P. G. M. Wuts & T. W. Greene, Protective Groups
in Organic Synthesis, John Wiley & Sons, New York, 2007.
[0079] For novel benzodiazepines of formula (I) and (II),
##STR00004##
wherein: the double line between N and C represents a single bond
or a double bond, provided that when it is a double bond X is
absent and Y is H, and when it is a single bond, X is H, or an
amine protecting moiety that converts the compound into a prodrug
that can be transformed into the free amine in vitro or in vivo; Y
is selected from --OR, an ester represented by --OCOR', a carbonate
represented by --OCOOR', a carbamate represented by --OCONR'R'', an
amine or a hydroxyl amine represented by NR'R'', amide represented
by --NRCOR', a peptide represented by NRCOP, wherein P is an amino
acid or a polypeptide containing between 2 to 20 amino acid units,
a thioether represented by SR', a sulfoxide represented by SOR', a
sulfone represented by --SO.sub.2R', a sulfite --SO.sub.3, a
bisulfite --OSO.sub.3, a halogen, cyano, an azido, or a thiol,
wherein R, R' and R'' are same or different and are selected from
H, substituted or unsubstituted linear, branched or cyclic alkyl,
alkenyl or alkynyl having from 1 to 20 carbon atoms a polyethylene
glycol unit (--OCH.sub.2CH.sub.2).sub.n, wherein n is an integer
from 1 to 2000, a 5- or 6-membered heteroaryl ring containing one
or more heteroatoms independently selected from nitrogen, oxygen,
and sulfur, a 5 to 18 membered fused ring system, wherein at least
one of the rings is aromatic, containing one or more heteroatoms
independently selected from nitrogen, oxygen, and sulfur, aryl
having from 6 to 18 carbon atoms, a 3 to 18-membered heterocyclic
ring having 1 to 6 heteroatoms selected from O, S, N and P wherein
the substituent is selected from halogen, OR.sub.7,
NR.sub.8R.sub.9, NO.sub.2, NRCOR', SR.sub.10, a sulfoxide
represented by SOR', a sulfone represented by --SO.sub.2R', a
sulfite --SO.sub.3, a bisulfite --OSO.sub.3, a sulfonamide
represented by SO.sub.2NRR', cyano, an azido, --COR.sub.11,
OCOR.sub.11 or OCONR.sub.11R.sub.12, wherein R.sub.7, R.sub.8,
R.sub.9, R.sub.10, R.sub.11 and R.sub.12 are each independently
selected from H, linear, branched or cyclic alkyl, alkenyl or
alkynyl having from 1 to 10 carbon atoms, a polyethylene glycol
unit (--OCH.sub.2CH.sub.2).sub.n, wherein n is an integer from 1 to
2000, a 5- or 6-membered heteroaryl ring containing one or more
heteroatoms independently selected from nitrogen, oxygen, and
sulfur. a 5 to 18 membered fused ring system, wherein at least one
of the rings is aromatic. containing one or more heteroatoms
independently selected from nitrogen, oxygen, and sulfur, aryl
having from 6 to 18 carbon atoms 3 to 18-membered heterocyclic ring
having 1 to 6 heteroatoms selected from O, S, N and P and R.sub.10
optionally is SR.sub.13 or COR.sub.13, wherein R.sub.13 is selected
from linear, branched or cyclic alkyl, alkenyl or alkynyl having
from 1 to 10 carbon atoms, a polyethylene glycol unit
(--OCH.sub.2CH.sub.2).sub.n, wherein n is an integer from 1 to
2000, a 5- or 6-membered heteroaryl ring containing one or more
heteroatoms independently selected from nitrogen, oxygen, and
sulfur, a 5 to 18 membered fused ring system, wherein at least one
of the rings is aromatic, containing one or more heteroatoms
independently selected from nitrogen, oxygen, and sulfur, 3 to
18-membered heterocyclic ring having 1 to 6 heteroatoms selected
from O, S, N and P and R.sub.11 can also be OR.sub.14, wherein
R.sub.14 is H or has the same definition as R, optionally, R'' is
an OH; W is C.dbd.O, C.dbd.S, CH.sub.2, BH (B=Boron), SO or
SO.sub.2; R.sub.1, R.sub.2, R.sub.3, R.sub.4, are each
independently selected from H, substituted or unsubstituted linear,
branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10
carbon atoms, a polyethylene glycol unit
(--OCH.sub.2CH.sub.2).sub.n, wherein n is an integer from 1 to
2000, or a substituent selected from a halogen, OR.sub.7,
NR.sub.8R.sub.9, NO.sub.2, NRCOR', SR.sub.10, a sulfoxide
represented by SOR', a sulfone represented by --SO.sub.2R', a
sulfite --SO.sub.3, a bisulfite --OSO.sub.3, a sulfonamide
represented by SO.sub.2NRR', cyano, an azido, guanidinium
[--NH(C.dbd.NH)NH.sub.2], --COR.sub.11, --OCOR.sub.11 or
--OCONR.sub.11R.sub.12 wherein R.sub.7, R.sub.8, R.sub.9, R.sub.10,
R.sub.11 and R.sub.12 are as defined above, optionally, any one of
R.sub.1, R.sub.2, R.sub.3, R.sub.4 is a linking group that enables
linkage to a cell binding agent via a covalent bond or is selected
from a polypyrrolo, poly-indolyl, poly-imidazolyl,
polypyrollo-imidazolyl, poly-pyrollo-indolyl or
polyimidazolo-indolyl unit optionally bearing a linking group that
enables linkage to a cell binding agent; R.sub.5 is selected from
OR.sub.15, CRR'OH, SH, CRR'SH, NHR.sub.15 or CRR'NHR.sub.15,
wherein R.sub.15 has the same definition as R., R and R' have the
same definition as given above; optionally, R.sub.5 is a linking
group that enables linkage to a cell binding agent via a covalent
bond or is selected from a polypyrrolo, poly-indolyl,
poly-imidazolyl, polypyrollo-imidazolyl, poly-pyrollo-indolyl or
polyimidazolo-indolyl unit optionally bearing a linking group that
enables linkage to a cell binding agent; R.sub.6 is OR, SR, NRR',
wherein R and R' have the same definition as given above, or
optionally R.sub.6 is a linking group; Z is selected from
(CH.sub.2).sub.n, wherein n is 1, 2 or 3, CR.sub.15R.sub.16,
NR.sub.17, O or S, wherein R.sub.15, R.sub.16 and R.sub.17 are each
independently selected from H, linear, branched or cyclic alkyl
having from 1 to 10 carbon atoms, a polyethylene glycol unit
(--OCH.sub.2CH.sub.2).sub.n, wherein n is an integer from 1 to
2000; or their pharmaceutically acceptable solvates, salts,
hydrates or hydrated salts, their optical isomers, racemates,
diastereomers, enantiomers of these compounds. provided that the
compound has no more than one linking group that enables linkage to
a cell binding agent via a covalent bond.
[0080] In one preferred embodiment, the double line between N and C
represents a double bond and X is absent and Y is H, or the double
line between N and C represents a single bond wherein X is H and Y
is selected from --OR, a sulfite --SO.sub.3, or an amine protecting
moiety that converts the compound into a prodrug;
W is C.dbd.O, CH.sub.2, or SO.sub.2; R.sub.1, R.sub.2, R.sub.3,
R.sub.4, are each H; optionally, independently, any one of R.sub.1,
R.sub.2, R.sub.3 and R.sub.4 can be a linking group that enables
linkage to a cell binding agent via a covalent bond; R.sub.5 is
selected from OR.sub.15, CRR'OH, SH, CRR'SH, NHR.sub.15 or
CRR'NHR.sub.15, wherein R.sub.15 is H or has the same definition as
given above for R, or is selected from a polypyrrolo, poly-indolyl,
poly-imidazolyl, polypyrollo-imidazolyl, poly-pyrollo-indolyl or
polyimidazolo-indolyl unit optionally bearing a linking group that
enables linkage to a cell binding agent, R and R' have the same
definition as given above; R.sub.6 is OCH.sub.3; Z is selected from
(CH.sub.2).sub.n, wherein n is 1 or 2, NH, NCH.sub.3 or S; or their
pharmaceutically acceptable solvates, salts, hydrates or hydrated
salts, their optical isomers, racemates, diastereomers, enantiomers
or the polymorphic crystalline structures of these compounds.
[0081] In a preferred embodiment, compounds of formula (I) and (II)
are compounds of formulae (VII), (VIII) or (IX):
##STR00005##
wherein the substituents are described as above; or their
pharmaceutically acceptable solvates, salts, hydrates or hydrated
salts, their optical isomers, racemates, diastereomers, enantiomers
or the polymorphic crystalline structures of these compounds.
[0082] For the novel benzodiazepines of formula (III), in which the
diazepine ring (B) is fused with a heterocyclic ring (C), wherein
the heterocyclic ring is monocyclic,
##STR00006##
wherein the double line between N and C represents a single bond or
a double bond, provided that when it is a double bond X is absent
and Y is H, and when it is a single bond, X is H or an amine
protecting moiety that converts the compound into a prodrug; Y is
selected from --OR, an ester represented by --OCOR', a carbonate
represented by --OCOOR', a carbamate represented by --OCONR'R'', an
amine or a hydroxyl amine represented by NR'R'', amide represented
by --NRCOR', a peptide represented by NRCOP, wherein P is an amino
acid or a polypeptide containing between 2 to 20 amino acid units,
a thioether represented by SR', a sulfoxide represented by SOR', a
sulfone represented by --SO.sub.2R', a sulfite --SO.sub.3, a
bisulfite --OSO.sub.3, a halogen, cyano, an azido, or a thiol,
wherein R, R' and R'' are same or different and selected from H,
substituted or unsubstituted linear, branched or cyclic alkyl,
alkenyl or alkynyl having from 1 to 10 carbon atoms, a polyethylene
glycol unit (--OCH.sub.2CH.sub.2).sub.n, wherein n is an integer
from 1 to 2000, a 5- or 6-membered heteroaryl ring containing one
or more heteroatoms independently selected from nitrogen, oxygen,
and sulfur, a 5 to 18 membered fused ring system, wherein at least
one of the rings is aromatic, containing one or more heteroatoms
independently selected from nitrogen, oxygen, and sulfurheteroaryl
comprising of 5- or 6-membered rings, including fused ring systems
(at least one of which is aromatic) of 5-18 atoms, containing one
or more heteroatoms independently selected from nitrogen, oxygen,
and sulfur, aryl having from 6 to 18 carbon atoms 3 to 18-membered
heterocyclic ring having 1 to 6 heteroatoms selected from O, S, N
and P, wherein the substituent is selected from halogen, OR.sub.7,
NR.sub.8R.sub.9, NO.sub.2, NRCOR', SR.sub.10, a sulfoxide
represented by SOR', a sulfone represented by --SO.sub.2R', a
sulfite --SO.sub.3, a bisulfite --OSO.sub.3, a sulfonamide
represented by SO.sub.2NRR', cyano, an azido, --COR.sub.11,
OCOR.sub.11 or OCONR.sub.11R.sub.12, wherein R.sub.7, R.sub.8,
R.sub.9, R.sub.10, R.sub.11 and R.sub.12 are each independently
selected from H, linear, branched or cyclic alkyl, alkenyl or
alkynyl having from 1 to 10 carbon atoms, a polyethylene glycol
unit (--OCH.sub.2CH.sub.2).sub.n, wherein n is an integer from 1 to
2000, a 5- or 6-membered heteroaryl ring containing one or more
heteroatoms independently selected from nitrogen, oxygen, and
sulfur, a 5 to 18 membered fused ring system, wherein at least one
of the rings is aromatic, containing one or more heteroatoms
independently selected from nitrogen, oxygen, and sulfurheteroaryl
comprising of 5- or 6-membered rings, including fused ring systems
(at least one of which is aromatic) of 5-18 atoms, containing one
or more heteroatoms independently selected from nitrogen, oxygen,
and sulfur, aryl having from 6 to 18 carbon atoms 3 to 18-membered
heterocyclic ring having 1 to 6 heteroatoms selected from O, S, N
and P and R.sub.10 optionally is SR.sub.13 or COR.sub.13, wherein
R.sub.13 is selected from linear, branched or cyclic alkyl, alkenyl
or alkynyl having from 1 to 10 carbon atoms, a polyethylene glycol
unit (--OCH.sub.2CH.sub.2).sub.n, wherein n is an integer from 1 to
2000, a 5- or 6-membered heteroaryl ring containing one or more
heteroatoms independently selected from nitrogen, oxygen, and
sulfur, a 5 to 18 membered fused ring system, wherein at least one
of the rings is aromatic, containing one or more heteroatoms
independently selected from nitrogen, oxygen, and sulfurheteroaryl
comprising of 5- or 6-membered rings, including fused ring systems
(at least one of which is aromatic) of 5-18 atoms, containing one
or more heteroatoms independently selected from nitrogen, oxygen,
and sulfur, aryl having from 6 to 18 carbon atoms, 3 to 18-membered
heterocyclic ring having 1 to 6 heteroatoms selected from O, S, N
and P and R.sub.11 can also be OR.sub.14, wherein R.sub.14 is H or
has the same definition as R, optionally R'' is OH; W is C.dbd.O,
C.dbd.S, CH.sub.2, BH, SO or SO.sub.2; R.sub.5 is selected from
OR.sub.15, CRR'OH, SH, CRR'SH, NHR.sub.15 or CRR'NHR.sub.15,
wherein R.sub.15 is H or has the same definition as R. or is a
linking group that enables linkage to a cell binding agent via a
covalent bond or is selected from a polypyrrolo, poly-indolyl,
poly-imidazolyl, polypyrollo-imidazolyl, poly-pyrollo-indolyl or
polyimidazolo-indolyl unit optionally bearing a linking group that
enables linkage to a cell binding agent; is selected from a
poly-pyrrolo, poly-indolyl, poly-imidazolyl,
polypyrollo-imidazolyl, poly-pyrollo-indolyl or
polyimidazolo-indolyl unit optionally bearing a linking group that
enables linkage to a cell binding agent, optionally, R.sub.5 is a
linking group that enables linkage to a cell binding agent via a
covalent bond; R.sub.6 is OR, SR or NRR', wherein R and R' have the
same definition as given above, optionally R.sub.6 is a linking
group; X' is CH.sub.2, NR, CO, BH, SO or SO.sub.2;
Y' is O, CH.sub.2, NR or S;
[0083] Z' is CH.sub.2 or (CH.sub.2).sub.n, wherein n is 2, 3 or 4;
or their pharmaceutically acceptable solvates, salts, hydrates or
hydrated salts, their optical isomers, racemates, diastereomers,
enantiomers or the polymorphic crystalline structures of these
compounds; provided that the compound has no more than one linking
group that enables linkage to a cell binding agent via a covalent
bond.
[0084] In one preferred embodiment, the double line between N and C
represents a double bond and X is absent and Y=H, or the double
line between N and C represents a single bond wherein X is H and Y
is selected from --OR, a sulfite --SO.sub.3, or an amine protecting
moiety that converts the compound into a prodrug;
W is C.dbd.O, CH.sub.2, or SO.sub.2; R.sub.5 is selected from
OR.sub.15, CRR'OH, SH, CRR'SH, NHR.sub.15 or CRR'NHR.sub.15,
wherein R.sub.15 is H or has the same definition as given above for
R, or is selected from a polypyrrolo, poly-indolyl,
poly-imidazolyl, polypyrollo-imidazolyl, poly-pyrolloindolyl or
polyimidazoloindolyl unit optionally bearing a linking group that
enables linkage to a cell binding agent; R.sub.6 is OCH.sub.3; X'
is selected from CH.sub.2, or C.dbd.O;
Y' is O, CH.sub.2, NR or S;
[0085] Z' is (CH.sub.2).sub.n, wherein n is 1 or 2, provided that
X', Y' and Z' are not all CH.sub.2 at the same time; or their
pharmaceutically acceptable solvates, salts, hydrates or hydrated
salts, their optical isomers, racemates, diastereomers, enantiomers
or the polymorphic crystalline structures of these compounds.
[0086] In a preferred embodiment, compound of formula III is
represented by a compound of formula (X) or (XI),
##STR00007##
wherein the substituents are described as above; or their
pharmaceutically acceptable solvates, salts, hydrates or hydrated
salts, their optical isomers, racemates, diastereomers, enantiomers
or the polymorphic crystalline structures of these compounds.
[0087] For the cytotoxic dimers represented by formulas (IV), (V)
and (VI)
##STR00008##
the double line between N and C represents a single bond or a
double bond, provided that when it is a double bond X is absent and
Y is H, and when it is a single bond, X is H or an amine protecting
moiety that converts the compound into a prodrug; Y is selected
from --OR, an ester represented by --OCOR', a carbonate represented
by --OCOOR', a carbamate represented by --OCONR'R'', an amine or a
hydroxyl amine represented by NR'R'', amide represented by
--NRCOR', a peptide represented by NRCOP, wherein P is an amino
acid or a polypeptide containing between 2 to 20 amino acid units,
a thioether represented by SR', a sulfoxide represented by SOR', a
sulfone represented by --SO.sub.2R', a sulfite --SO.sub.3, a
bisulfite --OSO.sub.3, a halogen, cyano, an azido, or a thiol,
wherein R, R' and R'' are same or different and are selected from
H, substituted or unsubstituted linear, branched or cyclic alkyl,
alkenyl or alkynyl having from 1 to 10 carbon atoms, a polyethylene
glycol unit (--OCH.sub.2CH.sub.2).sub.n, wherein n is an integer
from 1 to 2000, a 5- or 6-membered heteroaryl ring containing one
or more heteroatoms independently selected from nitrogen, oxygen,
and sulfur, a 5 to 18 membered fused ring system, wherein at least
one of the rings is aromatic, containing one or more heteroatoms
independently selected from nitrogen, oxygen, and sulfur, aryl
having from 6 to 18 carbon atoms, 3 to 18-membered heterocyclic
ring having 1 to 6 heteroatoms selected from O, S, N and P wherein
the substituent is selected from halogen, OR.sub.7,
NR.sub.8R.sub.9, NO.sub.2, NRCOR', SR.sub.10, a sulfoxide
represented by SOR', a sulfone represented by --SO.sub.2R', a
sulfite --SO.sub.3, a bisulfite --OSO.sub.3, a sulfonamide
represented by SO.sub.2NRR', cyano, an azido, --COR.sub.11,
OCOR.sub.11 or OCONR.sub.11R.sub.12, wherein R.sub.7, R.sub.8,
R.sub.9, R.sub.10, R.sub.11 and R.sub.12 are each independently
selected from H, linear, branched or cyclic alkyl, alkenyl or
alkynyl having from 1 to 10 carbon atoms, a polyethylene glycol
unit (--OCH.sub.2CH.sub.2).sub.n, wherein n is an integer from 1 to
2000, a 5- or 6-membered heteroaryl ring containing one or more
heteroatoms independently selected from nitrogen, oxygen, and
sulfur, a 5 to 18 membered fused ring system, wherein at least one
of the rings is aromatic, containing one or more heteroatoms
independently selected from nitrogen, oxygen, and sulfur, aryl
having from 6 to 18 carbon atoms, 3 to 10-membered heterocyclic
ring having 3 to 18-membered heterocyclic ring having 1 to 6
heteroatoms selected from O, S, N and P and R.sub.10 is optionally
SR.sub.13 or COR.sub.13, wherein R.sub.13 is selected from linear,
branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10
carbon atoms, a 5- or 6-membered heteroaryl ring containing one or
more heteroatoms independently selected from nitrogen, oxygen, and
sulfur, a 5 to 18 membered fused ring system, wherein at least one
of the rings is aromatic, containing one or more heteroatoms
independently selected from nitrogen, oxygen, and sulfur, aryl
having from 6 to 18 carbon atoms, 3 to 18-membered heterocyclic
ring having 1 to 6 heteroatoms selected from O, S, N and P,
optionally R.sub.11 is OR.sub.14, wherein R.sub.14 has the same
definition as R, optionally R'' is OH; W is C.dbd.O, C.dbd.S,
CH.sub.2, BH, SO or SO.sub.2; R.sub.1, R.sub.2, R.sub.3, R.sub.4,
R.sub.1', R.sub.2', R.sub.3' and R.sub.4' are each independently
selected from H, substituted or unsubstituted linear, branched or
cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms,
a polyethylene glycol unit (--OCH.sub.2CH.sub.2).sub.n, wherein n
is an integer from 1 to 2000, or a substituent selected from a
halogen, guanidinium [--NH(C.dbd.NH)NH.sub.2], OR.sub.7,
NR.sub.8R.sub.9, NO.sub.2, NRCOR', SR.sub.10, a sulfoxide
represented by SOR', a sulfone represented by --SO.sub.2R', a
sulfite --SO.sub.3, a bisulfite --OSO.sub.3, a sulfonamide
represented by SO.sub.2NRR', cyano, an azido, --COR.sub.11,
OCOR.sub.11 or OCONR.sub.11R.sub.12 wherein R.sub.7, R.sub.8,
R.sub.9, R.sub.10, R.sub.11 and R.sub.12 are as defined above,
optionally, any one of R.sub.1, R.sub.2, R.sub.3, R.sub.4,
R.sub.1', R.sub.2', R.sub.3', or R.sub.4' is a linking group that
enables linkage to a cell binding agent via a covalent bond or is
selected from a polypyrrolo, poly-indolyl, poly-imidazolyl,
polypyrollo-imidazolyl, poly-pyrollo-indolyl or
polyimidazolo-indolyl unit optionally bearing a linking group that
enables linkage to a cell binding agent, Z is selected from
(CH.sub.2).sub.n, wherein n is 1, 2 or 3, CR.sub.15R.sub.16,
NR.sub.17, O or S, wherein R.sub.15, R.sub.16 and R.sub.17 are each
independently selected from H, linear, branched or cyclic alkyl
having from 1 to 10 carbon atoms, a polyethylene glycol unit
(--OCH.sub.2CH.sub.2).sub.n, wherein n is an integer from 1 to
2000; R.sub.6 is OR, SR or NRR', wherein R and R' have the same
definition as given above, optionally R.sub.6 is a linking group;
X' is selected from CH.sub.2, NR, CO, BH, SO or SO.sub.2 wherein R
has the same definition as given above; Y' is O, CH.sub.2, NR or S,
wherein R has the same definition as given above; Z' is CH.sub.2 or
(CH.sub.2).sub.n, wherein n is 2, 3 or 4, provided that X', Y' and
Z' are not all CH.sub.2 at the same time; A and A' are the same or
different and are selected from O, --CRR'O, S, --CRR'S, --NR.sub.15
or CRR'NHR.sub.15, wherein R and R' have the same definition as
given above and wherein R.sub.15 has the same definition as R. D
and D' are same or different and independently selected from
linear, branched or cyclic alkyl, alkenyl or alkynyl having 1 to 10
carbon atoms, optionally substituted with any one of halogen,
OR.sub.7, NR.sub.8R.sub.9, NO.sub.2, NRCOR', SR.sub.10, a sulfoxide
represented by SOR', a sulfone represented by --SO.sub.2R', a
sulfite --SO.sub.3, a bisulfite --OSO.sub.3, a sulfonamide
represented by SO.sub.2NRR', cyano, an azido, --COR.sub.11,
OCOR.sub.11 or OCONR.sub.11R.sub.12, wherein the definitions of
R.sub.7, R.sub.8, R.sub.9, R.sub.10, R.sub.11 and R.sub.12 are as
defined above, or a polyethylene glycol unit
(--OCH.sub.2CH.sub.2).sub.n, wherein n is an integer from 1 to
2000; L is an optional phenyl group or 3 to 18-membered
heterocyclic ring having 1 to 6 heteroatoms selected from O, S, N
and P that is optionally substituted, wherein the substituent is a
linking group that enables linkage to a cell binding agent via a
covalent bond, or is selected from linear, branched or cyclic
alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms,
optionally substituted with any one of halogen, OR.sub.7,
NR.sub.8R.sub.9, NO.sub.2, NRCOR', SR.sub.10, a sulfoxide
represented by SOR', a sulfone represented by --SO.sub.2R', a
sulfite --SO.sub.3, a bisulfite --OSO.sub.3, a sulfonamide
represented by SO.sub.2NRR', cyano, an azido, --COR.sub.11,
OCOR.sub.11 or OCONR.sub.11R.sub.12, wherein the definitions of
R.sub.7, R.sub.8, R.sub.9, R.sub.10, R.sub.11 and R.sub.12 are as
defined above, a polyethylene glycol unit
(--OCH.sub.2CH.sub.2).sub.n, wherein n is an integer from 1 to
2000; optionally, L itself is a linking group that enables linkage
to a cell binding agent via a covalent bond; or their
pharmaceutically acceptable solvates, salts, hydrates or hydrated
salts, their optical isomers, racemates, diastereomers, enantiomers
or the polymorphic crystalline structures of these compounds;
provided that the compound has no more than one linking group that
enables linkage to a cell binding agent via a covalent bond.
[0088] In one preferred embodiment, the double line between N and C
represents a single bond or a double bond, provided that when it is
a double bond X is absent and Y is H, and when it is a single bond,
X is H or an amine protecting group that converts the compound into
a prodrug;
Y is selected from --OR, NR'R'', a sulfite --SO.sub.3, or a
bisulfite --OSO.sub.3, wherein R is selected from H, linear,
branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10
carbon atoms, a polyethylene glycol unit
(--OCH.sub.2CH.sub.2).sub.n, wherein n is an integer from 1 to
2000, aryl having from 6 to 10 carbon atoms, heterocyclic ring
having from 3 to 10 carbon atoms; W is C.dbd.O, CH.sub.2 or
SO.sub.2; R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.1'. R.sub.2'.
R.sub.3' and R.sub.4' are each independently selected from H,
NO.sub.2 or a linking group that enables linkage to a cell binding
agent via a covalent bond; R.sub.6 is OR.sub.18, wherein R.sub.18
has the same definition as R; Z is selected from (CH.sub.2).sub.n,
wherein n is 1, 2 or 3, CR.sub.15R.sub.16, NR.sub.17, O or S,
wherein R.sub.15, R.sub.16 and R.sub.17 are each independently
selected from H, linear, branched or cyclic alkyl having from 1 to
10 carbon atoms, a polyethylene glycol unit
(--OCH.sub.2CH.sub.2).sub.n, wherein n is an integer from 1 to
2000; X' is selected from CH.sub.2, or C.dbd.O; Y' is O, NR, or S,
wherein R is defined as above; Z' is CH.sub.2 or (CH.sub.2).sub.2;
A and A' are each O; D and D' are same or different and
independently selected from linear, branched or cyclic alkyl,
alkenyl or alkynyl having from 1 to 10 carbon atoms; L is an
optional phenyl group or a heterocycle ring having from 3 to 10
carbon atoms that is optionally substituted, wherein the
substituent is a linking group that enables linkage to a cell
binding agent via a covalent bond, or is selected from linear,
branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10
carbon atoms, optionally substituted with any one of halogen,
OR.sub.7, NR.sub.8R.sub.9, NO.sub.2, NRCOR', SR.sub.10, a sulfoxide
represented by SOR', a sulfone represented by --SO.sub.2R', a
sulfite --SO.sub.3, a bisulfite --OSO.sub.3, a sulfonamide
represented by SO.sub.2NRR', cyano, an azido, --COR.sub.11,
OCOR.sub.11 or OCONR.sub.11R.sub.12, a polyethylene glycol unit
(--OCH.sub.2CH.sub.2).sub.n, wherein n is an integer from 1 to
2000; optionally, L itself is a linking group that enables linkage
to a cell binding agent via a covalent bond; or their
pharmaceutically acceptable solvates, salts, hydrates or hydrated
salts, their optical isomers, racemates, diastereomers, enantiomers
or the polymorphic crystalline structures of these compounds.
[0089] In another preferred embodiment, the compound of formula
(IV), (V) or (VI) is represented by compounds of formulae (XII) and
(XIII):
##STR00009##
wherein the double line between N and C represents a single bond or
a double bond, provided that when it is a double bond X is absent
and Y is H, and when it is a single bond, X is H or an amine
protecting group that converts the compound into a prodrug; Y is
selected from OH, an ether represented by --OR, NR'R'', a sulfite
--SO.sub.3, or a bisulfite --OSO.sub.3, wherein R, R' and R'' are
selected from linear, branched or cyclic alkyl, alkenyl or alkynyl
having from 1 to 10 carbon atoms; one of R.sub.2, R.sub.3, R.sub.2'
and R.sub.3' is a linking group that enables linkage to a cell
binding agent via a covalent bond and the others are H, NRCOR' or
NO.sub.2; R.sub.6 is OR, wherein R has the same definition as
above; Z is CH.sub.2 or NR, wherein R has the same definition as
above;
A is O or NR.sub.15;
[0090] L is (CH.sub.2).sub.nn, wherein nn is 0 or an integer
between 1 and 5, or a substituted or unsubstituted alkyl or alkenyl
having from 2 to 4 carbon atoms, wherein the substituent is
selected from halogen, OR.sub.7, NR.sub.8R.sub.9, NO.sub.2, NRCOR',
SR.sub.10, a sulfoxide represented by SOR', a sulfone represented
by --SO.sub.2R', a sulfite --SO.sub.3, a bisulfite --OSO.sub.3, a
sulfonamide represented by SO.sub.2NRR', cyano, an azido,
--COR.sub.11, OCOR.sub.11 or OCONR.sub.11R.sub.12, wherein R.sub.7,
R.sub.8, R.sub.9, R.sub.10, R.sub.11, R.sub.12 and R.sub.15 has the
same definition as given above, optionally, L itself is a linking
group that enables linkage to a cell binding agent via a covalent
bond; one of L', L'' or L''' is a linking group that enables
linkage to a cell binding agent, while the others are H; preferably
L' is the linking group; and G is CH or N or their pharmaceutically
acceptable solvates, salts, hydrates or hydrated salts, their
optical isomers, racemates, diastereomers, enantiomers or the
polymorphic crystalline structures of these compounds.
[0091] In yet another preferred embodiment, the compound of formula
(IV), (V) or (VI) is represented by compounds of formulae from
formulae (XIV) and (XV):
##STR00010##
wherein the double line between N and C represents a single bond or
a double bond, provided that when it is a double bond X is absent
and Y is H, and when it is a single bond, X is H or an amine
protecting group that converts the compound into a prodrug; Y is
selected from OH, an ether represented by --OR, a sulfite
--SO.sub.3, or a bisulfite --OSO.sub.3, wherein R is selected from
linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1
to 10 carbon atoms; nn is 0 or an integer from 1 to 5; One of
R.sub.2, R.sub.3, R.sub.2' and R.sub.3' is a linking group that
enables linkage to a cell binding agent via a covalent bond and the
others are H, NRCOR', or NO.sub.2; one of L', L'' or L''' is a
linking group that enables linkage to a cell binding agent,
provided that when one of L', L'' or L''' is a linking group others
are H (e.g., if L' is a linker, then L'' and L''' are H) G is CH or
N or their pharmaceutically acceptable solvates, salts, hydrates or
hydrated salts, their optical isomers, racemates, diastereomers,
enantiomers or the polymorphic crystalline structures of these
compounds.
[0092] In order to link the cytotoxic compounds (e.g.,
indolinobenzodiazepine or oxazolidinobenzodiazepine), derivatives
thereof, or dimers thereof of the present invention to the
cell-binding agent, the cytotoxic compound comprises a linking
moiety. While a linker that connects two moieties is bifunctional,
one end of the linker moiety can be first reacted with the
cytotoxic compound to provide the compound bearing a monofunctional
linking group, which can then react with a cell binding agent.
Alternatively, one end of the linker moiety can be first reacted
with the cell binding agent to provide the cell binding agent
bearing a monofunctional linking group, which can then react with a
cytotoxic compound. The linking moiety contains a chemical bond
that allows for the release of the cytotoxic moiety at a particular
site. Suitable chemical bonds are well known in the art and include
disulfide bonds, thioether bonds, acid labile bonds, photolabile
bonds, peptidase labile bonds and esterase labile bonds (see for
example U.S. Pat. Nos. 5,208,020; 5,475,092; 6,441,163; 6,716,821;
6,913,748; 7,276,497; 7,276,499; 7,368,565; 7,388,026 and
7,414,073). Preferred are disulfide bonds, thioether and peptidase
labile bonds. Other linkers that can be used in the present
invention include non-cleavable linkers, such as those described in
are described in detail in U.S. publication number 20050169933, or
charged linkers or hydrophilic linkers and are described in
provisional patent applications, 61/049,291, filed Apr. 30, 2008,
61/147,966, filed Jan. 28, 2009, and 61/049,289, filed Apr. 30,
2008, each of which is expressly incorporated herein by
reference.
[0093] The compounds of formula (1), (II), and (III) (i.e.,
monomers) can be linked through R.sub.1, R.sub.2, R.sub.3, R.sub.4
or R.sub.5. Of these, preferred linkable groups are R.sub.2,
R.sub.3, and R.sub.5, and the most preferred linkable group is
R.sub.5. Examples of suitable substituents at R.sub.1, R.sub.2,
R.sub.3, R.sub.4 and R.sub.5 for compounds of formula (I), (II) and
(III) include, but are not limited to:
--OH,
[0094]
--O(CR.sub.20R.sub.21).sub.m(CR.sub.22R.sub.23).sub.n(OCH.sub.2CH.s-
ub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.24R.sub.25).sub.q(CO).sub-
.tX'',
--O(CR.sub.20R.sub.21).sub.m(CR.sub.26.dbd.CR.sub.27).sub.m'(CR.sub-
.22R.sub.23).sub.n(OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(-
CR.sub.24R.sub.25).sub.q(CO).sub.tX'',
--O(CR.sub.20R.sub.21).sub.m(alkynyl).sub.n'(CR.sub.22R.sub.23).sub.n(OCH-
.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.24R.sub.25).sub-
.q(CO).sub.tX'',
--O(CR.sub.20R.sub.21).sub.m(indolo).sub.p'(CR.sub.22R.sub.23).sub.n(OCH.-
sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.24R.sub.25).sub.-
q(CO).sub.tX'',
--O(CR.sub.20R.sub.21).sub.m(pyrrolo).sub.q'(CR.sub.22R.sub.23).sub.n(OCH-
.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.24R.sub.25).sub-
.q(CO).sub.tX'',
--O(CR.sub.20R.sub.21).sub.m(pyrrolo).sub.q'(imidazolo).sub.q''(CR.sub.22-
R.sub.23).sub.n(OCCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR-
.sub.24R.sub.25).sub.q(CO).sub.tX'',
--O(CR.sub.20R.sub.21).sub.m(imidazolo).sub.q''(CR.sub.22R.sub.23).sub.n(-
OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.24R.sub.25).-
sub.q(CO).sub.tX'',
--O(CR.sub.20R.sub.21).sub.m(pyrrolo).sub.q'(indolo).sub.q''(CR.sub.22R.s-
ub.23).sub.n(OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub-
.24R.sub.25).sub.q(CO).sub.tX'',
--O(CR.sub.20R.sub.21).sub.m(indolo).sub.q'(imidazolo).sub.q''(CR.sub.22R-
.sub.23).sub.n(OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.s-
ub.24R.sub.25).sub.q(CO).sub.tX'',
--O(CR.sub.20R.sub.21).sub.m(piperazino).sub.t'(CR.sub.22R.sub.23).sub.n(-
OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.24R.sub.25).-
sub.q(CO).sub.tX'',
--O(CR.sub.20R.sub.21).sub.mA''.sub.m''(CR.sub.22R.sub.23).sub.n(OCH.sub.-
2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.24R.sub.25).sub.q(CO-
).sub.tX'',
--SH,
[0095]
--S(CR.sub.20R.sub.21).sub.m(CR.sub.22R.sub.23).sub.n(OCH.sub.2CH.s-
ub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.24R.sub.25).sub.q(CO).sub-
.tX'',
--S(CR.sub.20R.sub.21).sub.m(CR.sub.26.dbd.CR.sub.27).sub.m'(CR.sub-
.22R.sub.23).sub.n(OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(-
CR.sub.24R.sub.25).sub.q(CO).sub.tX'',
--S(CR.sub.20R.sub.21).sub.m(alkynyl).sub.n'(CR.sub.22R.sub.23).sub.n(OCH-
.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.24R.sub.25).sub-
.q(CO).sub.tX'',
--S(CR.sub.20R.sub.21).sub.m(indolo).sub.p'(CR.sub.22R.sub.23).sub.n(OCH.-
sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.24R.sub.25).sub.-
q(CO).sub.tX'',
--S(CR.sub.20R.sub.21).sub.m(pyrrolo).sub.q'(CR.sub.22R.sub.23).sub.n(OCH-
.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.24R.sub.25).sub-
.q(CO).sub.tX'',
--S(CR.sub.20R.sub.21).sub.m(imidazolo).sub.q''(CR.sub.22R.sub.23).sub.n(-
OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.24R.sub.25).-
sub.q(CO).sub.tX'',
--S(CR.sub.20R.sub.21).sub.m(pyrrolo).sub.q'(imidazolo).sub.q''(CR.sub.22-
R.sub.23).sub.n(OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.-
sub.24R.sub.25).sub.q(CO).sub.tX'',
--S(CR.sub.20R.sub.21).sub.m(pyrrolo).sub.q'(indolo).sub.q''(CR.sub.22R.s-
ub.23).sub.n(OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub-
.24R.sub.25).sub.q(CO).sub.tX'',
--S(CR.sub.20R.sub.21).sub.m(indolo).sub.q'(imidazolo).sub.q''(CR.sub.22R-
.sub.23).sub.n(OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.s-
ub.24R.sub.25).sub.q(CO).sub.tX'',
--S(CR.sub.20R.sub.21).sub.m(piperazino).sub.t'(CR.sub.22R.sub.23).sub.n(-
OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.24R.sub.25).-
sub.q(CO).sub.tX'',
--S(CR.sub.20R.sub.21).sub.mA''.sub.m''(CR.sub.22R.sub.23).sub.n(OCH.sub.-
2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.24R.sub.25).sub.q(CO-
).sub.tX'',
--NH.sub.2,
[0096]
--NR.sub.28(CR.sub.20R.sub.21).sub.m(CR.sub.22R.sub.23).sub.n(OCH.s-
ub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.24R.sub.25).sub.q-
(CO).sub.tX'',
--NR.sub.28(CR.sub.20R.sub.21).sub.m(CR.sub.26.dbd.CR.sub.27).sub.m'(CR.s-
ub.22R.sub.23).sub.n(OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y'-
'(CR.sub.24R.sub.25).sub.q(CO).sub.tX'',
--NR.sub.28(CR.sub.20R.sub.21).sub.m(alkynyl).sub.n'(CR.sub.22R.sub.23).s-
ub.n(OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.24R.sub-
.25).sub.q(CO).sub.tX'',
--NR.sub.28(CR.sub.20R.sub.21).sub.m(indolo).sub.p'(CR.sub.22R.sub.23).su-
b.n(OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.24R.sub.-
25).sub.q(CO).sub.tX'',
--NR.sub.28(CR.sub.20R.sub.21).sub.m(pyrrolo).sub.q'(CR.sub.22R.sub.23).s-
ub.n(OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.24R.sub-
.25).sub.q(CO).sub.tX'',
--NR.sub.28(CR.sub.20R.sub.21).sub.m(imidazole).sub.q''(CR.sub.22R.sub.23-
).sub.n(OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.24R.-
sub.25).sub.q(CO).sub.tX'',
--NR.sub.28(CR.sub.20R.sub.21).sub.m(pyrrolo).sub.q'(imidazolo).sub.q''(C-
R.sub.22R.sub.23).sub.n(OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p'-
'Y''--(CR.sub.24R.sub.25).sub.q(CO).sub.tX'',
--NR.sub.28(CR.sub.20R.sub.21).sub.m(pyrrolo).sub.q'(indolo).sub.q'(CR.su-
b.22R.sub.23).sub.n(OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''-
--(CR.sub.24R.sub.25).sub.q(CO).sub.tX'',
--NR.sub.28(CR.sub.20R.sub.21).sub.m(indolo).sub.q'(imidazolo).sub.q'(CR.-
sub.22R.sub.23).sub.n(OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y-
''--(CR.sub.24R.sub.25).sub.q(CO).sub.tX'',
--NR.sub.28(CR.sub.20R.sub.21).sub.m(piperazino).sub.t'(CR.sub.22R.sub.23-
).sub.n(OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.24R.-
sub.25).sub.q(CO).sub.tX'',
--NR.sub.28(CR.sub.20R.sub.21).sub.mA''.sub.m''(CR.sub.22R.sub.23).sub.n(-
OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.24R.sub.25).-
sub.q(CO).sub.tX'',
--(CR.sub.20R.sub.21).sub.m(CR.sub.22R.sub.23).sub.n(OCH.sub.2CH.sub.2).s-
ub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.24R.sub.25).sub.q(CO).sub.tX'',
--(CR.sub.20R.sub.21).sub.m(CR.sub.26.dbd.CR.sub.27).sub.m'(CR.sub.22R.su-
b.23).sub.n(OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.-
24R.sub.25).sub.q(CO).sub.tX'',
--(CR.sub.20R.sub.21).sub.m(alkynyl).sub.n'(CR.sub.22R.sub.23).sub.n(OCH.-
sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.24R.sub.25).sub.-
q(CO).sub.tX'',
--(CR.sub.20R.sub.21).sub.m(indolo).sub.p'(CR.sub.22R.sub.23).sub.n(OCH.s-
ub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.24R.sub.25).sub.q-
(CO).sub.tX'',
--(CR.sub.20R.sub.21).sub.m(pyrrolo).sub.q'(CR.sub.22R.sub.23).sub.n(OCH.-
sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.24R.sub.25).sub.-
q(CO).sub.tX'',
--(CR.sub.20R.sub.21).sub.m(piperazino).sub.t'(CR.sub.22R.sub.23).sub.n(O-
CH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.24R.sub.25).s-
ub.q(CO).sub.tX'',
--(CR.sub.20R.sub.21).sub.m(pyrrolo).sub.q'(indolo).sub.q''(CR.sub.22R.su-
b.23).sub.n(OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''--(CR.su-
b.24R.sub.25).sub.q(CO).sub.tX'',
(CR.sub.20R.sub.21).sub.m(imidazolo).sub.q'(CR.sub.22R.sub.23).sub.n(OCH.-
sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''--(CR.sub.24R.sub.25).su-
b.q(CO).sub.tX'',
(CR.sub.20R.sub.21).sub.m(pyrrolo).sub.q'(imidazolo).sub.q''(CR.sub.22R.s-
ub.23).sub.n(OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub-
.24R.sub.25).sub.q(CO).sub.tX'',
(CR.sub.20R.sub.21).sub.m(imidazolo).sub.q'(indolo).sub.q''(CR.sub.22R.su-
b.23).sub.n(OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.-
24R.sub.25).sub.q(CO).sub.tX'',
(CR.sub.20R.sub.21).sub.mA''.sub.m''(CR.sub.22R.sub.23).sub.n(OCH.sub.2CH-
.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.24R.sub.25).sub.q(CO).s-
ub.tX'',
--(CR.sub.20R.sub.21).sub.m(CR.sub.29.dbd.N--NR.sub.30).sub.n''(C-
R.sub.22R.sub.23).sub.n(OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p'-
'Y''(CR.sub.24R.sub.25).sub.q(CO).sub.tX'',
--(CR.sub.20R.sub.21).sub.m(CR.sub.29.dbd.N--NR.sub.30).sub.n''(CR.sub.26-
.dbd.CR.sub.27).sub.m'(CR.sub.22R.sub.23).sub.n(OCH.sub.2CH.sub.2).sub.p(C-
R.sub.40R.sub.41).sub.p''Y''(CR.sub.24R.sub.25).sub.q(CO).sub.tX'',
--(CR.sub.20R.sub.21).sub.m(CR.sub.29.dbd.N--NR.sub.30).sub.n''(alkynyl).-
sub.n'(CR.sub.22R.sub.23).sub.n(OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41-
).sub.p''Y''(CR.sub.24R.sub.25).sub.q(CO).sub.tX'',
--(CR.sub.20R.sub.21).sub.m(CR.sub.29.dbd.N--NR.sub.30).sub.n''A''.sub.m'-
'(CR.sub.22R.sub.23).sub.n(OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub-
.p''Y''(CR.sub.24R.sub.25).sub.q(CO).sub.tX'', wherein: m, n, p, q,
m', n', p', q', q'', are integer from 1 to 10 and can be 0; t, m'',
n'' and p'' are 0 or 1; X'' is selected from OR.sub.36, SR.sub.37,
NR.sub.38R.sub.39, wherein R.sub.36, R.sub.37, R.sub.38, R.sub.39
are H, or linear, branched or cyclic alkyl, alkenyl or alkynyl
having from 1 to 20 carbon atoms and, or, a polyethylene glycol
unit --(OCH.sub.2CH.sub.2).sub.n, optionally R.sub.37 is a thiol
protecting group, or when t=1, COX'' forms a reactive ester
selected from N-hydroxysuccinimide esters, N-hydroxyphthalimide
esters, N-hydroxy sulfo-succinimide esters, para-nitrophenyl
esters, dinitrophenyl esters, pentafluorophenyl esters and their
derivatives, wherein said derivatives facilitate amide formation;
Y'' is absent or is selected from O, S, S--S or NR.sub.32, wherein
R.sub.32 has the same definition as given above for R, or when Y''
is not S--S and t=0, X'' is selected from a maleimido group, a
haloacetyl group or SR.sub.37, wherein R.sub.37 has the same
definition as above; A'' is an amino acid selected from glycine,
alanine, leucine, valine, lysine, citrulline and glutamate or a
polypeptide containing between 2 to 20 amino acid units; R.sub.20,
R.sub.21, R.sub.22, R.sub.23, R.sub.24, R.sub.25, R.sub.26,
R.sub.27 are the same or different and are H or a linear or
branched alkyl having from 1 to 5 carbon atoms; R.sub.28 is H or
alkyl; R.sub.29 and R.sub.30 are the same or different and are H or
alkyl from 1 to 5 carbon atoms; optionally, one of R.sub.40 and
R.sub.41 is a negatively or positively charged functional group
.sup.- and the other is H or alkyl, alkenyl, alkynyl having 1 to 4
carbon atoms.
[0097] The compounds of formula (IV), (V), (VI), (VII), (XII) and
(XIII) (i.e., dimers) can be linked through R.sub.1, R.sub.2,
R.sub.3, R.sub.4, R.sub.1', R.sub.2', R.sub.3', R.sub.4', L', L'',
L'''. Of these, preferred linkable groups are R.sub.2', R.sub.3',
R.sub.4', L', L'', L''' and most preferred linkable groups are
R.sub.2', R.sub.3` and L`. Examples of linking groups for compounds
of formula (IV), (V), (VI), (VII), (XII) and (XIII) include, but
are not limited to:
--O(CR.sub.20R.sub.21).sub.m(CR.sub.22R.sub.23).sub.n(OCH.sub.2CH.sub.2).-
sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.24R.sub.25).sub.q(CO).sub.tX'',
--O(CR.sub.20R.sub.21).sub.m(CR.sub.26.dbd.CR.sub.27).sub.m'(CR.sub.22R.s-
ub.23).sub.n(OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub-
.24R.sub.25).sub.q(CO).sub.tX'',
--O(CR.sub.20R.sub.21).sub.m(alkynyl).sub.n'(CR.sub.22R.sub.23).sub.n(OCH-
.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.24R.sub.25).sub-
.q(CO).sub.tX'',
--O(CR.sub.20R.sub.21).sub.m(piperazino).sub.t'(CR.sub.22R.sub.23).sub.n(-
OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.24R.sub.25).-
sub.q(CO).sub.tX'',
--O(CR.sub.20R.sub.21).sub.m(pyrrolo).sub.t'(CR.sub.22R.sub.23).sub.n(OCH-
.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.24R.sub.25).sub-
.q(CO).sub.tX'',
--O(CR.sub.20R.sub.21).sub.mA''.sub.m''(CR.sub.22R.sub.23).sub.n(OCH.sub.-
2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.24R.sub.25).sub.q(CO-
).sub.tX'',
--S(CR.sub.20R.sub.21).sub.m(CR.sub.22R.sub.23).sub.n(OCH.sub.2CH.sub.2).-
sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.24R.sub.25).sub.q(CO).sub.tX'',
--S(CR.sub.20R.sub.21).sub.m(CR.sub.26.dbd.CR.sub.27).sub.m'(CR.sub.22R.s-
ub.23).sub.n(OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub-
.24R.sub.25).sub.q(CO).sub.tX'',
--S(CR.sub.20R.sub.21).sub.m(alkynyl).sub.n'(CR.sub.22R.sub.23).sub.n(OCH-
.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.24R.sub.25).sub-
.q(CO).sub.tX'',
--S(CR.sub.20R.sub.21).sub.m(piperazino).sub.t'(CR.sub.22R.sub.23).sub.n(-
OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.24R.sub.25).-
sub.q(CO).sub.tX'',
--S(CR.sub.20R.sub.21).sub.m(pyrrolo).sub.t'(CR.sub.22R.sub.23).sub.n(OCH-
.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.24R.sub.25).sub-
.q(CO).sub.tX'',
--S(CR.sub.20R.sub.21).sub.mA''.sub.m''(CR.sub.22R.sub.23).sub.n(OCH.sub.-
2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.24R.sub.25).sub.q(CO-
).sub.tX'',
--NR.sub.33(C.dbd.O).sub.p''(CR.sub.20R.sub.21).sub.m(CR.sub.22R.sub.23).-
sub.n(OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.24R.su-
b.25).sub.q(CO).sub.tX'',
--NR.sub.33(C.dbd.O).sub.p''(CR.sub.20R.sub.21).sub.m(CR.sub.26.dbd.CR.su-
b.27).sub.m'(CR.sub.22R.sub.23).sub.n(OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.-
sub.41).sub.p''Y''(CR.sub.24R.sub.25).sub.q(CO).sub.tX'',
--NR.sub.33(C.dbd.O).sub.p''(CR.sub.20R.sub.21).sub.m(alkynyl).sub.n'(CR.-
sub.22R.sub.23).sub.n(OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y-
''(CR.sub.24R.sub.25).sub.q(CO).sub.tX'',
--NR.sub.33(C.dbd.O).sub.p''(CR.sub.20R.sub.21).sub.m(piperazino).sub.t'(-
CR.sub.22R.sub.23).sub.n(OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p-
''Y''(CR.sub.24R.sub.25).sub.q(CO).sub.tX'',
--NR.sub.33(C.dbd.O).sub.p''(CR.sub.20R.sub.21).sub.m(pyrrolo).sub.t'(CR.-
sub.22R.sub.23).sub.n(OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y-
''(CR.sub.24R.sub.25).sub.q(CO).sub.tX'',
--NR.sub.33(C.dbd.O).sub.p''(CR.sub.20R.sub.21).sub.mA''.sub.m''(CR.sub.2-
2R.sub.23).sub.n(OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR-
.sub.24R.sub.25).sub.q(CO).sub.tX'',
--(CR.sub.20R.sub.21).sub.m(CR.sub.22R.sub.23).sub.n(OCH.sub.2CH.sub.2).s-
ub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.24R.sub.25).sub.q(CO).sub.tX'',
--(CR.sub.20R.sub.21).sub.m(CR.sub.26.dbd.CR.sub.27).sub.m'(CR.sub.22R.su-
b.23).sub.n(OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.-
24R.sub.25).sub.q(CO).sub.tX'',
--(CR.sub.20R.sub.21).sub.m(alkynyl).sub.n'(CR.sub.22R.sub.23).sub.n(OCH.-
sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.24R.sub.25).sub.-
q(CO).sub.tX'',
--(CR.sub.20R.sub.21).sub.m(piperazino).sub.t(CR.sub.22R.sub.23).sub.n(OC-
H.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.24R.sub.25).su-
b.q(CO).sub.tX'',
--(CR.sub.20R.sub.21).sub.mA''.sub.m''(CR.sub.22R.sub.23).sub.n(OCH.sub.2-
CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.p''Y''(CR.sub.24R.sub.25).sub.q(CO)-
.sub.tX'',
--(CR.sub.20R.sub.21).sub.m(CR.sub.29.dbd.N--NR.sub.30).sub.n''-
(CR.sub.22R.sub.23).sub.n(OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub.-
p''Y''(CR.sub.24R.sub.25).sub.q(CO).sub.tX'',
--(CR.sub.20R.sub.21).sub.m(CR.sub.29.dbd.N--NR.sub.30).sub.n''(CR.sub.26-
.dbd.CR.sub.27).sub.m'(CR.sub.22R.sub.23).sub.n(OCH.sub.2CH.sub.2).sub.p(C-
R.sub.40R.sub.41).sub.p''Y''(CR.sub.24R.sub.25).sub.q(CO).sub.tX'',
--(CR.sub.20R.sub.21).sub.m(CR.sub.29.dbd.N--NR.sub.30).sub.n''(alkynyl).-
sub.n'(CR.sub.22R.sub.23).sub.n(OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41-
).sub.p''Y''(CR.sub.24R.sub.25).sub.q(CO).sub.tX'',
--(CR.sub.20R.sub.21).sub.m(CR.sub.29.dbd.N--NR.sub.30).sub.n''A''.sub.m'-
'(CR.sub.22R.sub.23).sub.n(OCH.sub.2CH.sub.2).sub.p(CR.sub.40R.sub.41).sub-
.p''Y''(CR.sub.24R.sub.25).sub.q(CO).sub.tX'', wherein: m, n, p, q,
m', n', t' are integer from 1 to 10, or are optionally 0; t, m'',
n'' and p'' are 0 or 1; X'' is selected from OR.sub.36, SR.sub.37,
NR.sub.38R.sub.39, wherein R.sub.36, R.sub.37, R.sub.38, R.sub.39
are H, or linear, branched or cyclic alkyl, alkenyl or alkynyl
having from 1 to 20 carbon atoms and, or, a polyethylene glycol
unit --(OCH.sub.2CH.sub.2).sub.n, R.sub.37, optionally, is a thiol
protecting group when t=1, COX'' forms a reactive ester selected
from N-hydroxysuccinimide esters, N-hydroxyphthalimide esters,
N-hydroxy sulfo-succinimide esters, para-nitrophenyl esters,
dinitrophenyl esters, pentafluorophenyl esters and their
derivatives, wherein said derivatives facilitate amide bond
formation; Y'' is absent or is selected from O, S, S--S or
NR.sub.32, wherein R.sub.32 has the same definition as given above
for R, or when Y'' is not S--S and t=0, X'' is selected from a
maleimido group, a haloacetyl group or SR.sub.37, wherein R.sub.37
has the same definition as above; A'' is an amino acid selected
from glycine, alanine, leucine, valine, lysine, citrulline and
glutamate or a polypeptide containing between 2 to 20 amino acid
units; R.sub.20, R.sub.21, R.sub.22, R.sub.23, R.sub.24, R.sub.25,
R.sub.26, and R.sub.27 are the same or different and are H or a
linear or branched alkyl having from 1 to 5 carbon atoms; R.sub.29
and R.sub.30 are the same or different and are H or alkyl from 1 to
5 carbon atoms; R.sub.33 is H or linear, branched or cyclic alkyl,
alkenyl or alkynyl having from 1 to 12 carbon atoms, a polyethylene
glycol unit --(OCH.sub.2CH.sub.2).sub.n, or R.sub.33 is
--COR.sub.34, --CSR.sub.34, --SOR.sub.34, or --SO.sub.2R.sub.34,
wherein R.sub.34 is H or linear, branched or cyclic alkyl, alkenyl
or alkynyl having from 1 to 20 carbon atoms or, a polyethylene
glycol unit --(OCH.sub.2CH.sub.2).sub.n; and one of R.sub.40 and
R.sub.41 is optionally a negatively or positively charged
functional group and the other is H or alkyl, alkenyl, alkynyl
having 1 to 4 carbon atoms.
[0098] Further, while the synthesis of cytotoxic compounds (e.g.,
indolinobenzodiazepine or oxazolidinobenzodiazepine), derivatives
thereof, or dimers thereof bearing a linking moiety is described
below in terms of an amide, thioether or disulfide bond containing
linking moieties at the L' (in the compound of formula XIII) or
R.sub.3 (in the compound of formula XII) positions, one of skill in
the art will understand that linking moieties at other positions
and with other chemical bonds, as described above, can also be used
with the present invention.
[0099] The structures of representative compounds, representative
conjugates and claimed compounds in the examples of the present
invention are shown in Tables 3-9:
TABLE-US-00001 TABLE 3 Structures of representative compounds of
the present invention. ##STR00011## ##STR00012## ##STR00013##
##STR00014## ##STR00015## ##STR00016## ##STR00017## ##STR00018##
##STR00019## ##STR00020## ##STR00021## ##STR00022## ##STR00023##
##STR00024## ##STR00025## ##STR00026## ##STR00027## ##STR00028##
NOTE: Z'' = H, SMe, SPy, SPy-NO.sub.2, Ac; X''' = NHS;
TABLE-US-00002 TABLE 4 Structures of representative compounds of
the present invention (Continued). ##STR00029## ##STR00030##
##STR00031## ##STR00032## ##STR00033## ##STR00034## ##STR00035##
##STR00036## ##STR00037## ##STR00038## ##STR00039## ##STR00040##
##STR00041## ##STR00042## ##STR00043## ##STR00044## ##STR00045##
##STR00046## NOTE: Z'' = H, SMe, SPy, SPy-NO.sub.2, Ac; X''' =
NHS;
TABLE-US-00003 TABLE 5 Structures of representative compounds of
the present invention (Continued). ##STR00047## ##STR00048##
##STR00049## ##STR00050## ##STR00051## ##STR00052## ##STR00053##
##STR00054## ##STR00055## ##STR00056## ##STR00057## ##STR00058##
##STR00059## ##STR00060## ##STR00061## ##STR00062##
##STR00063##
TABLE-US-00004 TABLE 6 Structures of representative conjugates of
the prsent invention. ##STR00064## ##STR00065## ##STR00066##
##STR00067## ##STR00068## ##STR00069## ##STR00070## ##STR00071##
##STR00072## ##STR00073## ##STR00074## ##STR00075##
TABLE-US-00005 TABLE 7 Structures of compounds from the examples of
the present invention. Structure Compound No. Example No.
##STR00076## 6 1 ##STR00077## 7 1 ##STR00078## 8 1 ##STR00079## 12
2 ##STR00080## 13 2 ##STR00081## 14 2 ##STR00082## 15 3
##STR00083## 18 4 ##STR00084## 19 5 ##STR00085## 34 6
TABLE-US-00006 TABLE 8 Structures of compounds from the examples of
the present invention (Continued). Structure Compound No. Example
No. ##STR00086## 35 6 ##STR00087## 36 6 ##STR00088## 39 6
##STR00089## 40 6 ##STR00090## 41 7 ##STR00091## 42 7 ##STR00092##
43 7 ##STR00093## 44 7 ##STR00094## 45 7
TABLE-US-00007 TABLE 9 Structures of compounds from the examples of
the present invention (Continued). Structure Compound No. Example
No. ##STR00095## 46 7 ##STR00096## 48 8 ##STR00097## 49 8
##STR00098## 51 9 ##STR00099## 125 10 ##STR00100## 126 10
##STR00101## 127 10
Synthesis of Cytotoxic Compounds
[0100] The process of preparation of a representative monomer
compound of the present invention, exemplified by
indolinobenzodiazepine compound 8, is shown in FIG. 1. Starting
from commercially available indoline-2-carboxylic acid 1, its
methyl ester 2 was prepared in quantitative yield by reaction with
thionyl chloride in methanol. Methyl indoline-2-carboxylate 2 was
coupled with the acid chloride 4, or directly with acid 3, to
furnish the amide 5, which was further reduced with
diisobutylaluminum hydride (DIBAL) to the aldehyde 6. While, many
methods can be used to reduce the nitro functional group of formula
5 to the corresponding amino group, in this example sodium
dithionite was used to conveniently convert to aldehyde 6 to the
ring closed compound 7 after further treatment with methanol under
acidic conditions. The benzyl protecting group was removed to
furnish monomer 8.
[0101] The process of preparation of the oxazolidinobenzodiazepine
monomer compound of formula 14 of the invention is shown in FIG. 2.
Starting from commercially available compound 9, its methyl ester
10 was prepared in quantitative yield by treatment with thionyl
chloride in methanol. Compound 10 was deprotected followed by
coupling with the acetyl chloride 4 or directly with acid 3 to
furnish the amide 11, which was further converted to the aldehyde
12. Reduction of the nitro group was accomplished by treatment with
sodium dithionite followed by efficient conversion to the ring
closed compound 13 after further treatment with methanol under
acidic conditions. The benzyl protecting group was removed to
furnish monomer 14.
[0102] The process of preparation of representative dimer compounds
of the present invention is shown in FIGS. 3-5 and 7. The dimers
were prepared by reacting of the monomers of formula 8 or formula
14 with compounds which possesses two leaving groups such as Br, I,
triflate, mesylate or tosylate.
[0103] Dimers which possess linkers that can react with antibodies
are prepared by converting the methyl esters to the corresponding
reactive esters of a leaving group such as, but not limited to,
N-hydroxysuccinimide esters, N-hydroxyphtalimide esters, N-hydroxy
sulfo-succinimide esters, para-nitrophenyl esters, dinitrophenyl
esters, pentafluorophenyl esters. Representative examples for the
synthesis of the linkable dimers are shown in FIG. 8. Synthesis of
dimers that bear a thiol or disulfide moiety to enable linkage to
cell binding agents via reducible or non-reducible bonds is shown
in FIGS. 9 and 10. The B ring modified monomer 58 devoid of a
carbonyl group is achieved from the benzyl alcohol compound 52 by
the steps shown in FIG. 11. The isoindolino monomer 66 can be
prepared from isoindole 59 as outlined in FIG. 12. The linker can
also be attached directly to the indolino moiety. Methyl
indolino-2-carboxylate can be converted into the linkable dimer 82
via the synthetic steps shown in FIG. 13. The synthesis of linkable
dimers bearing a PEG moiety is shown in FIGS. 14 and 15.
[0104] Thus in one aspect, the invention provides a process for the
preparation of the indolinobenzodiazepine (IBD) monomer of formula
(I) (FIG. 1), the process comprising the steps of:
a) coupling compound of formula (1) and compound of formula (2) to
give compound of formula (3); b) converting compound of formula (3)
into aldehyde of formula (4); and c) converting compound of formula
(4) into compound of formula (I),
##STR00102##
wherein LG is a leaving group; W' is COOR or CH.sub.2OW'', wherein
R has the same definition as above and W'' is a protecting group;
R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, W, Z, X, Y
and have the same definition as described above.
[0105] Another aspect of the invention provides a process for the
preparation of compound of formula (II) comprising the steps
of:
a) coupling compound of formula (1) and compound of formula (5) to
give compound of formula (6); b) converting compound of formula (6)
into aldehyde of formula (7); and c) converting compound of formula
(7) into compound of formula (II),
##STR00103##
wherein LG is a leaving group; W' is COOR or CH.sub.2OW'', wherein
R has the same definition as above and W'' is a protecting group;
R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, W, X, Y and
have the same definition as above.
[0106] Another aspect of the invention provides a process for the
preparation of compound of formula (III) comprising steps of:
a) coupling compound of formula (1) and compound of formula (8) to
give compound of formula (9); b) converting compound of formula (9)
into aldehyde of formula (10); and c) converting compound of
formula (10) into compound of formula (II),
##STR00104##
wherein LG is a leaving group; W' is COOR or CH.sub.2OW'', wherein
R has the same definition as above and W'' is a protecting group;
R.sub.5, R.sub.6, W, X, Y, X', Y', Z' and have the same definition
as above.
[0107] Another aspect of the invention provides a process for the
preparation of compound of formula (Another aspect of the invention
provides a process for the preparation of compound of formula (IV)
comprising the steps of:
coupling compound of formula (11), compound of formula (11)' and
compound of formula (12) to give compound of formula (IV),
##STR00105##
wherein LG is a leaving group; R.sub.1, R.sub.2, R.sub.3, R.sub.4,
R.sub.1', R.sub.2', R.sub.3', R.sub.4', R.sub.6, W, X, Y, Z, A, A',
D, D', L and have the same definition as above.
[0108] Another aspect of the invention provides an alternative
process for the preparation of compound of formula (IV) of the
present invention comprising steps of:
a) converting compound of formula (15) into aldehyde of formula
(16); and b) converting compound of formula (16) into compound of
formula (IV),
##STR00106##
wherein W' is COOR or CH.sub.2OW'', wherein R has the same
definition as above and W'' is a protecting group; R.sub.1,
R.sub.2, R.sub.3, R.sub.4, R.sub.1', R.sub.2', R.sub.3', R.sub.4',
R.sub.6, W, X, Y, Z, A, A', D, D', L and have the same definition
as above.
[0109] Another aspect of the invention provides a process for the
preparation of compound of formula (V) comprising the step of
coupling compound of formula (13), compound of formula (13)' and
compound of formula (12) to give compound of formula (V),
##STR00107##
wherein LG is a leaving group; R.sub.1, R.sub.2, R.sub.3, R.sub.4,
R.sub.1', R.sub.2', R.sub.3', R.sub.4', R.sub.6, W, X, Y, A, A', D,
D', L and have the same definition as above.
[0110] Another aspect of the invention provides an alternative
process for the preparation of compound of formula (V) of the
invention comprising the steps of:
a) converting compound of formula (17) into aldehyde of formula
(18); and b) converting compound of formula (18) into compound of
formula (V),
##STR00108##
wherein W' is COOR or CH.sub.2OW'', wherein R has the same
definition as above and W'' is a protecting group; R, R.sub.2,
R.sub.3, R.sub.4, R.sub.1', R.sub.2', R.sub.3', R.sub.4', R.sub.6,
W, X, Y, A, A', D, D', L and have the same definition as above.
[0111] Another aspect of the invention provides a process for the
preparation of compound of formula (VI) of the invention comprising
the step of coupling compound of formula (14), compound of formula
(14)' and compound of formula (12) to give compound of formula
(VI),
##STR00109##
wherein LG is a leaving group; R.sub.6, W, X, Y, X', Y', Z' A, A',
D, D', L and have the same definition as above.
[0112] Another aspect of the invention provides a process for the
preparation of compound of formula (VI) of the invention comprising
the steps of:
a) converting compound of formula (19) into aldehyde of formula
(20); and b) converting compound of formula (20) into compound of
formula (VI),
##STR00110##
wherein W' is COOR or CH.sub.2OW'', wherein R has the same
definition as above and W'' is a protecting group; R.sub.6, W, X,
Y, X', Y', Z' A, A', D, D', L and have the same definition as
above.
In Vitro Cytotoxicity of Compounds
[0113] The in vitro cytotoxicity of the cytotoxic compounds (e.g.,
indolinobenzodiazepine or oxazolidinobenzodiazepine), derivatives
thereof, dimers thereof or conjugates thereof of the present
invention can be evaluated for their ability to suppress
proliferation of various cancerous cell lines in vitro (Tables 1, 2
in FIGS. 31, 32.). For example, cell lines such as the human breast
carcinoma line SK-Br-3, or the human epidermoid carcinoma cell line
KB, can be used for the assessment of cytotoxicity of these new
compounds. Cells to be evaluated can be exposed to the compounds
for 72 hours and the surviving fractions of cells measured in
direct assays by known methods. IC.sub.50 values can then be
calculated from the results of the assays.
[0114] Examples of in vitro cytotoxicity of compounds of the
present invention that were tested on a panel of cancer cell lines
and their data is shown in Table 1. All the indolinobenzodiazepine
dimer compounds tested were highly potent with IC.sub.50 values in
the low picomolar range. IGN-09 retained most of its potency on
multi-drug resistant cell lines such as COL0205-MDR (only 4-fold
higher IC.sub.50 than COL0205). Compounds of the invention are 1000
to 10,000-fold more cytotoxic than other DNA interacting drugs used
in cancer treatment, such as doxorubicin, melphalan and cis-platin.
In a direct comparison, the potency of the non-linker bearing
compounds IGN1 (compound 18) and IGN09 (compound 15) was compared
to the linker-bearing compounds IGN03 (compound 34) and IGN05
(compound 36) was tested towards a representative cell line Ramos.
As shown in Table 2, all four compounds are highly potent with
IC.sub.50 values less than 1 picomolar, demonstrating that the
incorporation of linker does not affect potency.
Cell-Binding Agents
[0115] The effectiveness of the compounds (e.g.,
indolinobenzodiazepine or oxazolidinobenzodiazepine), derivatives
thereof, dimers thereof or conjugates thereof of the invention as
therapeutic agents depends on the careful selection of an
appropriate cell-binding agent. Cell-binding agents may be of any
kind presently known, or that become known and includes peptides
and non-peptides. Generally, these can be antibodies (especially
monoclonal antibodies), lymphokines, hormones, growth factors,
vitamins, nutrient-transport molecules (such as transferrin), or
any other cell-binding molecule or substance.
[0116] More specific examples of cell-binding agents that can be
used include:
[0117] polyclonal antibodies;
[0118] monoclonal antibodies;
[0119] fragments of antibodies such as Fab, Fab', and F(ab').sub.2,
Fv (Parham, J. Immunol. 131:2895-2902 (1983); Spring et al. J.
Immunol. 113:470-478 (1974); Nisonoff et al. Arch. Biochem.
Biophys. 89:230-244 (1960));
[0120] interferons (e.g. .alpha., .beta., .gamma.);
[0121] lymphokines such as IL-2, IL-3, IL-4, IL-6;
[0122] hormones such as insulin, TRH (thyrotropin releasing
hormone), MSH (melanocyte-stimulating hormone), steroid hormones,
such as androgens and estrogens;
[0123] growth factors and colony-stimulating factors such as EGF,
TGF-alpha, FGF, VEGF, G-CSF, M-CSF and GM-CSF (Burgess, Immunology
Today 5:155-158 (1984));
[0124] transferrin (O'Keefe et al. J. Biol. Chem. 260:932-937
(1985)); and
[0125] vitamins, such as folate.
[0126] Monoclonal antibody techniques allow for the production of
extremely specific cell-binding agents in the form of specific
monoclonal antibodies. Particularly well known in the art are
techniques for creating monoclonal antibodies produced by
immunizing mice, rats, hamsters or any other mammal with the
antigen of interest such as the intact target cell, antigens
isolated from the target cell, whole virus, attenuated whole virus,
and viral proteins such as viral coat proteins. Sensitized human
cells can also be used. Another method of creating monoclonal
antibodies is the use of phage libraries of scFv (single chain
variable region), specifically human scFv (see e.g., Griffiths et
al., U.S. Pat. Nos. 5,885,793 and 5,969,108; McCafferty et al., WO
92/01047; Liming et al., WO 99/06587). In addition, resurfaced
antibodies disclosed in U.S. Pat. No. 5,639,641 may also be used,
as may chimeric antibodies and humanized antibodies. Selection of
the appropriate cell-binding agent is a matter of choice that
depends upon the particular cell population that is to be targeted,
but in general human monoclonal antibodies are preferred if an
appropriate one is available.
[0127] For example, the monoclonal antibody MY9 is a murine
IgG.sub.1 antibody that binds specifically to the CD33 Antigen {J.
D. Griffin et al 8 Leukemia Res., 521 (1984)} and can be used if
the target cells express CD33 as in the disease of acute
myelogenous leukemia (AML). Similarly, the monoclonal antibody
anti-B4 is a murine IgG.sub.1, that binds to the CD19 antigen on B
cells {Nadler et al, 131 J. Immunol. 244-250 (1983)} and can be
used if the target cells are B cells or diseased cells that express
this antigen such as in non-Hodgkin's lymphoma or chronic
lymphoblastic leukemia HuB4 is a resurfaced antibody derived from
the murine anti-B4 antibody (Roguska et al., 1994, Proc. Natl.
Acad. Sci., 91, pg 969-973). HuN901 is a humanized antibody that
binds to the CD56 antigen expressed on small cell lung cancer,
multiple myeloma, ovarian cancer and other solid tumors including
neuroendocrine cancers (Roguska et al., 1994, Proc. Natl. Acad.
Sci., 91, pg 969-973). B38.1 is a chimeric antibody targeting
EpCAM. Fully human antibodies such as panitumumab targeting the EGF
receptor expressed on several solid tumors may also be used (Van
Cutsem et al., J Clin Oncol. 2007; 25(13):1658-1664). The
cell-binding agent that comprises the conjugates and the modified
cell-binding agents of the present invention may be of any kind
presently known, or that become known, and includes peptides and
non-peptides. The cell-binding agent may be any compound that can
bind a cell, either in a specific or non-specific manner.
Generally, these can be antibodies (especially monoclonal
antibodies and antibody fragments), interferons, lymphokines,
hormones, growth factors, vitamins, nutrient-transport molecules
(such as transferrin), or any other cell-binding molecule or
substance.
[0128] Where the cell-binding agent is an antibody, it binds to an
antigen that is a polypeptide and may be a transmembrane molecule
(e.g. receptor) or a ligand such as a growth factor. Exemplary
antigens include molecules such as renin; a growth hormone,
including human growth hormone and bovine growth hormone; growth
hormone releasing factor; parathyroid hormone; thyroid stimulating
hormone; lipoproteins; alpha-1-antitrypsin; insulin A-chain;
insulin B-chain; proinsulin; follicle stimulating hormone;
calcitonin; luteinizing hormone; glucagon; clotting factors such as
factor vmc, factor IX, tissue factor (TF), and von Willebrands
factor; anti-clotting factors such as Protein C; atrial natriuretic
factor; lung surfactant; a plasminogen activator, such as urokinase
or human urine or tissue-type plasminogen activator (t-PA);
bombesin; thrombin; hemopoietic growth factor; tumor necrosis
factor-alpha and -beta; enkephalinase; RANTES (regulated on
activation normally T-cell expressed and secreted); human
macrophage inflammatory protein (MIP-1-alpha); a serum albumin,
such as human serum albumin; Muellerian-inhibiting substance;
relaxin A-chain; relaxin B-chain; prorelaxin; mouse
gonadotropin-associated peptide; a microbial protein, such as
beta-lactamase; DNase; IgE; a cytotoxic T-lymphocyte associated
antigen (CTLA), such as CTLA-4; inhibin; activin; vascular
endothelial growth factor (VEGF); receptors for hormones or growth
factors; protein A or D; rheumatoid factors; a neurotrophic factor
such as bone-derived neurotrophic factor (BDNF), neurotrophin-3,
-4, -5, or -6 (NT-3, NT4, NT-5, or NT-6), or a nerve growth factor
such as NGF-J; platelet-derived growth factor (PDGF); fibroblast
growth factor such as aFGF and bFGF; epidermal growth factor (EGF);
transforming growth factor (TGF) such as TGF-alpha and TGF-beta,
including TGF-.beta.1, TGF-.beta.2, TGF-.beta.3, TGF-.beta.4, or
TGF-.beta.5; insulin-like growth factor-I and -II (IGF-I and
IGF-II); des(1-3)-IGF-I (brain IGF-I), insulin-like growth factor
binding proteins, EpCAM, GD3, FLT3, PSMA, PSCA, MUC1, MUC16, STEAP,
CEA, TENB2, EphA receptors, EphB receptors, folate receptor, FOLR1,
mesothelin, cripto, alpha.sub.vbeta.sub.6, integrins, VEGF, VEGFR,
tamsferrin receptor, IRTA1, IRTA2, IRTA3, IRTA4, IRTA5; CD proteins
such as CD2, CD3, CD4, CD5, CD6, CD8, CD11, CD14, CD19, CD20, CD21,
CD22, CD25, CD26, CD28, CD30, CD33, CD36, CD37, CD38, CD40, CD44,
CD52, CD55, CD56, CD59, CD70, CD79, CD80. CD81, CD103, CD105,
CD134, CD137, CD138, CD152 or an antibody which binds to one or
more tumor-associated antigens or cell-surface receptors disclosed
in US Publication No. 20080171040 or US Publication No. 20080305044
and are incorporated in their entirety by reference;
erythropoietin; osteoinductive factors; immunotoxins; a bone
morphogenetic protein (BMP); an interferon, such as
interferon-alpha, -beta, and -gamma; colony stimulating factors
(CSFs), e.g., M-CSF, GM-CSF, and G-CSF; interleukins (ILs), e.g.,
IL-1 to IL-10; superoxide dismutase; T-cell receptors; surface
membrane proteins; decay accelerating factor; viral antigen such
as, for example, a portion of the HIV envelope; transport proteins;
homing receptors; addressins; regulatory proteins; integrins, such
as CD11a, CD11b, CD11c, CD18, an ICAM, VLA-4 and VCAM; a tumor
associated antigen such as HER2, HER3 or HER4 receptor; and
fragments of any of the above-listed polypeptides.
[0129] Additionally, GM-CSF, which binds to myeloid cells can be
used as a cell-binding agent to diseased cells from acute
myelogenous leukemia. IL-2 which binds to activated T-cells can be
used for prevention of transplant graft rejection, for therapy and
prevention of graft-versus-host disease, and for treatment of acute
T-cell leukemia. MSH, which binds to melanocytes, can be used for
the treatment of melanoma. Folic acid can be used to target the
folate receptor expressed on ovarian and other tumors. Epidermal
growth factor can be used to target squamous cancers such as lung
and head and neck. Somatostatin can be used to target
neuroblastomas and other tumor types.
[0130] Cancers of the breast and testes can be successfully
targeted with estrogen (or estrogen analogues) or androgen (or
androgen analogues) respectively as cell-binding agents.
Production of Cytotoxic Conjugates
[0131] The present invention also provides cytotoxic
compound-cell-binding agent conjugates comprising a cell binding
agent linked to one or more cytotoxic compounds via a variety of
linkers, including, but not limited to, disulfide linkers,
thioether linkers, amide bonded linkers, peptidase-labile linkers,
acid-labile linkers, esterase-labile linkers. Representational
cytotoxic conjugates of the invention are antibody/cytotoxic
compound, antibody fragment/cytotoxic compound, epidermal growth
factor (EGF)/cytotoxic compound, melanocyte stimulating hormone
(MSH)/cytotoxic compound, thyroid stimulating hormone
(TSH)/cytotoxic compound, somatostatin/cytotoxic compound,
folate/cytotoxic compound, estrogen/cytotoxic compound, estrogen
analogue/cytotoxic compound, androgen/cytotoxic compound, and
androgen analogue/cytotoxic compound.
[0132] In a preferred embodiment, the present invention provides an
indolinobenzodiazepine dimer-cell-binding agent conjugate
comprising the cytotoxic agent and the cell binding agent linked
through a covalent bond. The linker can be cleaved at the site of
the tumor/unwanted proliferating cells to deliver the cytotoxic
agent to its target in a number of ways. The linker can be cleaved,
for example, by low pH (hydrazone), reductive environment
(disulfide), proteolysis (amide/peptide link), or through an
enzymatic reaction (esterase/glycosidase).
[0133] In a preferred aspect, representative cytotoxic conjugates
of the invention are antibody/indolinobenzodiazepine dimer,
antibody fragment/indolinobenzodiazepine dimer, epidermal growth
factor (EGF)/indolinobenzodiazepine dimer, melanocyte stimulating
hormone (MSH)/indolinobenzodiazepine dimer, thyroid stimulating
hormone (TSH)/indolinobenzodiazepine dimer,
somatostatin/indolinobenzodiazepine dimer,
folate/indolinobenzodiazepine dimer,
estrogen/indolinobenzodiazepine dimer, estrogen
analogue/indolinobenzodiazepine dimer, prostate specific membrane
antigen (PSMA) inhibitor/indolinobenzodiazepine dimer, matriptase
inhibitor/indolinobenzodiazepine dimer, designed ankyrin repeat
proteins (DARPins)/indolinobenzodiazepine dimer,
androgen/indolinobenzodiazepine dimer, and androgen
analogue/indolinobenzodiazepine dimer.
[0134] Disulfide containing cytotoxic conjugates can be made by
reacting a thiol-containing cytotoxic agent such as 49 with an
appropriately modified cell-binding agent. These conjugates may be
purified to remove non-linked cytotoxic agent by using
gel-filtration, ion exchange chromatography, ceramic
hydroxyappetite (CHT) chromatography, hydrophobic interaction
chromatography (CHT), tangential flow filtration (TFF), or by
HPLC.
[0135] A solution of an antibody in aqueous buffer may be incubated
with a molar excess of an antibody modifying agent such as
N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP) or with
N-succinimidyl-4-(2-pyridyldithio)butanoate (SPDB) to introduce
dithiopyridyl groups. The modified antibody is then reacted with
the thiol-containing cytotoxic agent such as compound 49 to produce
a disulfide-linked antibody-indolinobenzodiazepine dimer conjugate.
The cytotoxic-cell binding conjugate may then be purified using any
of the above mentioned methods.
[0136] Alternatively, the antibody may be incubated with a molar
excess of an antibody modifying agent such as 2-iminothiolane,
L-homocysteine thiolactone (or derivatives), or
N-Succinimidyl-S-acetylthioacetate (SATA) to introduce sulfhydryl
groups. The modified antibody is then reacted with the appropriate
disulfide-containing cytotoxic agent, such as, compound 51 to
produce a disulfide-linked antibody-cytotoxic agent conjugate. The
antibody-cytotoxic agent conjugate may then be purified by
gel-filtration or other methods mentioned above.
[0137] The number of cytotoxic molecules bound per antibody
molecule can be determined spectrophotometrically by measuring the
ratio of the absorbance at 280 nm and 330 nm. An average of 1-10
cytotoxic molecules/antibody molecule(s) can be linked by this
method. The preferred average number of linked cytotoxic molecules
per antibody molecule is 2-5, and the most preferred is 3-4.5.
[0138] Alternatively, a solution of an antibody in aqueous buffer
may be incubated with a molar excess of an antibody-modifying agent
such as
N-succinimidyl-4-(N-maleimidomethyl)-cyclohexane-1-carboxylate to
introduce maleimido groups, or with
N-succinimidyl-4-(iodoacetyl)-aminobenzoate (SIAB) to introduce
iodoacetyl groups. The modified antibody is then reacted with the
thiol-containing cytotoxic agent to produce a thioether-linked
antibody-cytotoxic conjugate. The antibody-cytotoxic conjugate may
then be purified by gel-filtration or other methods mentioned above
or by methods known to one of skill in the art.
[0139] Cytotoxic agents containing linkers terminating in an
N-Hydroxy succinimidyl (NHS) ester, such as compounds 43, 44, and
46, can be reacted with the antibody to produce direct amide linked
conjugates such as huN901-IGN-03 and huN901-IGN-07. The
antibody-cytotoxic agent conjugate may then be purified by
gel-filtration or other methods mentioned above.
[0140] The following cell-binding agent/cytotoxic agent conjugates
can be prepared using the appropriate linkers. Dimer 1 and 2 with
peptide cleavable linkers can be prepared from the corresponding
NHS esters, Dimer 3 can be made by reacting the appropriate
thiol-containing cytotoxic agent with SMCC modified cell binding
agent, and acid-labile hydrazone Dimer 4 can be prepared through
condensation of a cytotoxic agent containing an alkyl, aryl ketone
with a hydrazide modified cell binding agent.
##STR00111##
[0141] Asymmetric indolinobenzodiazepine dimer conjugates such as
Dimers 5-8 can also be prepared using similar methods to those
described above.
##STR00112##
[0142] Conjugates of cell-binding agents with cytotoxic agents of
the invention can be evaluated for their ability to suppress
proliferation of various unwanted cell lines in vitro. For example,
cell lines such as the human colon carcinoma line COLO 205, the
rhabdomyosarcoma cell line RH-30, and the multiple myeloma cell
line MOLP-8 can be used for the assessment of cytotoxicity of these
conjugates. Cells to be evaluated can be exposed to the compounds
for 1-5 days and the surviving fractions of cells measured in
direct assays by known methods. IC.sub.50 values can then be
calculated from the results of the assays.
[0143] Examples of in vitro potency and target specificity of
antibody-cytotoxic agent conjugates of the present invention are
shown in FIG. 21-26. All of the conjugates with cytotoxic
agent/antibody ratios of 1-3 are extremely cytotoxic on the antigen
positive cancer cells with an IC.sub.50 in the low picomolar range.
Antigen negative cell lines remained viable when exposed to the
same conjugates. The target specificity of conjugates of the
indolinobenzodiazepine dimers are >1000 with the antibodies
huN901 (anti-CD56) and muB38.1 (anti-EpCAM). For example, the
B38.1-IGN-3 conjugate killed antigen positive COLO 205 cells with
an IC.sub.50 value of 1.86 pM, while the antigen negative Namalwa
cell line was about 200-fold less sensitive with an IC.sub.50 value
of 336.3 pM, demonstrating antigen specificity. In addition, the
conjugate is also highly potent towards the multidrug resistant
COLO 205 MDR cell line with an IC.sub.50 value of 16 pM. Similarly,
the huN901-IGN3 conjugate was highly potent, with an IC.sub.50
value of 15 pM for antigen positive RH30 cells (FIG. 22). Addition
of an excess of unconjugated huN901 antibody abolished this
cytotoxic effect (IC.sub.50>3 nM), demonstrating
antigen-specificity. Another huN901-IGN conjugate (huN901-IGN-07)
also showed high potency towards antigen expressing RH-30 cells,
with drug load dependent cytotoxicity and IC.sub.50 values of 16
pm, 3 pM and 2 pM respectively for conjugates bearing 1.2, 2.0 and
3.0 linked drugs per antibody molecule (FIG. 23). Similar results
were obtained with huN901-IGN07 and huN901-IGN03 towards
antigen-positive Molp-8 cells. Hu901-IGN07 gave IC.sub.50 values of
5 pM, 3 pM and 2 pM respectively for IGN07 loads of 1.2, 2.0 and
3.0 (FIG. 24). The huN901-IGN07 and IGN03 conjugates were much less
potent towards antigen negative Namalwa cells with IC.sub.50 values
ranging from 1000 pM to >3000 pM (FIG. 25). The B38.1-IGN10
conjugate was also specifically potent killing antigen positive
COLO 205 cells, with an IC.sub.50 of 17 pM, and less potent (170
pM) for antigen-negative Ramos cells (FIG. 26).
[0144] In one example, in vivo efficacy of a cell binding
agent/cytotoxic agent conjugate was measured. Nude mice bearing
human MOLP-8 tumors were treated with huN901-IGN-07 conjugate and
significant tumor regression was observed compared while untreated
mice tumors grew rapidly (FIG. 27).
[0145] The indolinobenzodiazepine dimers of the present invention
bind and alkylate double-stranded DNA (dsDNA) containing guanine
residues on opposite strands spaced 4 base pairs apart. FIGS. 28-30
present data from reverse-phase ion pair chromatography assays
showing rate of IGN-01, IGN-02, and IGN-09 binding and crosslinking
to dsDNA. The indolino group (IGN-01) is preferred to the oxazole
group (IGN-02) for rapid DNA binding and interstrand crosslinking
(ICL). Initial rate of IGN1-DNA adduct formation is dependent on
DNA sequence. IGN1 binds faster to DNA containing an internal GATC
motif than DNA with a GTAC sequence. DNA probe substituted with
deoxyInosine (I) (containing no C-2 amino group) in place of
guanine (G) showed no reaction with IGN-1 (FIG. 29).
[0146] The IC.sub.50 values of various compounds of the present
invention towards a panel of cell lines is listed in FIG. 31.
Comparative in vitro potency of linkable and non-linkable compounds
of the present invention are shown in FIG. 32. Incorporation of a
linker does not significantly affect potency of the parent
compounds.
Compositions and Methods of Use
[0147] The present invention includes a composition (e.g., a
pharmaceutical composition) comprising novel benzodiazepine
compounds (e.g., indolinobenzodiazepine or
oxazolidinobenzodiazepine), derivatives thereof, or conjugates
thereof, (and/or solvates, hydrates and/or salts thereof) and a
carrier (a pharmaceutically acceptable carrier). The present
invention also includes a composition (e.g., a pharmaceutical
composition) comprising novel benzodiazepine compounds, derivatives
thereof, or conjugates thereof, (and/or solvates, hydrates and/or
salts thereof) and a carrier (a pharmaceutically acceptable
carrier), further comprising a second therapeutic agent. The
present compositions are useful for inhibiting abnormal cell growth
or treating a proliferative disorder in a mammal (e.g., human). The
present compositions are also useful for treating depression,
anxiety, stress, phobias, panic, dysphoria, psychiatric disorders,
pain, and inflammatory diseases in a mammal (e.g., human).
[0148] The present invention includes a method of inhibiting
abnormal cell growth or treating a proliferative disorder in a
mammal (e.g., human) comprising administering to said mammal a
therapeutically effective amount of novel benzodiazepine compounds
(e.g., indolinobenzodiazepine or oxazolidinobenzodiazepine),
derivatives thereof, or conjugates thereof, (and/or solvates and
salts thereof) or a composition thereof, alone or in combination
with a second therapeutic agent.
[0149] The present invention also provides methods of treatment
comprising administering to a subject in need of treatment an
effective amount of any of the conjugates described above.
[0150] Similarly, the present invention provides a method for
inducing cell death in selected cell populations comprising
contacting target cells or tissue containing target cells with an
effective amount of a cytotoxic agent comprising any of the
cytotoxic compound-cell-binding agents (e.g.,
indolinobenzodiazepine or oxazolidinobenzodiazepine dimer linked to
a cell binding agent) of the present invention, a salt or solvate
thereof. The target cells are cells to which the cell-binding agent
can bind.
[0151] If desired, other active agents, such as other anti-tumor
agents, may be administered along with the conjugate.
[0152] Suitable pharmaceutically acceptable carriers, diluents, and
excipients are well known and can be determined by those of
ordinary skill in the art as the clinical situation warrants.
[0153] Examples of suitable carriers, diluents and/or excipients
include: (1) Dulbecco's phosphate buffered saline, pH about 7.4,
containing or not containing about 1 mg/ml to 25 mg/ml human serum
albumin, (2) 0.9% saline (0.9% w/v NaCl), and (3) 5% (w/v)
dextrose; and may also contain an antioxidant such as tryptamine
and a stabilizing agent such as Tween 20.
[0154] The method for inducing cell death in selected cell
populations can be practiced in vitro, in vivo, or ex vivo.
[0155] Examples of in vitro uses include treatments of autologous
bone marrow prior to their transplant into the same patient in
order to kill diseased or malignant cells: treatments of bone
marrow prior to their transplantation in order to kill competent T
cells and prevent graft-versus-host-disease (GVHD); treatments of
cell cultures in order to kill all cells except for desired
variants that do not express the target antigen; or to kill
variants that express undesired antigen.
[0156] The conditions of non-clinical in vitro use are readily
determined by one of ordinary skill in the art.
[0157] Examples of clinical ex vivo use are to remove tumor cells
or lymphoid cells from bone marrow prior to autologous
transplantation in cancer treatment or in treatment of autoimmune
disease, or to remove T cells and other lymphoid cells from
autologous or allogenic bone marrow or tissue prior to transplant
in order to prevent GVHD. Treatment can be carried out as follows.
Bone marrow is harvested from the patient or other individual and
then incubated in medium containing serum to which is added the
cytotoxic agent of the invention, concentrations range from about
10 .mu.M to 1 pM, for about 30 minutes to about 48 hours at about
37.degree. C. The exact conditions of concentration and time of
incubation, i.e., the dose, are readily determined by one of
ordinary skill in the art. After incubation the bone marrow cells
are washed with medium containing serum and returned to the patient
intravenously according to known methods. In circumstances where
the patient receives other treatment such as a course of ablative
chemotherapy or total-body irradiation between the time of harvest
of the marrow and reinfusion of the treated cells, the treated
marrow cells are stored frozen in liquid nitrogen using standard
medical equipment.
[0158] For clinical in vivo use, the cytotoxic agent of the
invention will be supplied as a solution or a lyophilized powder
that are tested for sterility and for endotoxin levels. Examples of
suitable protocols of conjugate administration are as follows.
Conjugates are given weekly for 4 weeks as an intravenous bolus
each week. Bolus doses are given in 50 to 1000 ml of normal saline
to which 5 to 10 ml of human serum albumin can be added. Dosages
will be 10 .mu.g to 2000 mg per administration, intravenously
(range of 100 ng to 20 mg/kg per day). After four weeks of
treatment, the patient can continue to receive treatment on a
weekly basis. Specific clinical protocols with regard to route of
administration, excipients, diluents, dosages, times, etc., can be
determined by one of ordinary skill in the art as the clinical
situation warrants.
[0159] Examples of medical conditions that can be treated according
to the in vivo or ex vivo methods of inducing cell death in
selected cell populations include malignancy of any type including,
for example, cancer of the lung, breast, colon, prostate, kidney,
pancreas, ovary, and lymphatic organs; autoimmune diseases, such as
systemic lupus, rheumatoid arthritis, and multiple sclerosis; graft
rejections, such as renal transplant rejection, liver transplant
rejection, lung transplant rejection, cardiac transplant rejection,
and bone marrow transplant rejection; graft versus host disease;
viral infections, such as CMV infection, HIV infection, AIDS, etc.;
and parasite infections, such as giardiasis, amoebiasis,
schistosomiasis, and others as determined by one of ordinary skill
in the art.
[0160] Cancer therapies and their dosages, routes of administration
and recommended usage are known in the art and have been described
in such literature as the Physician's Desk Reference (PDR). The PDR
discloses dosages of the agents that have been used in treatment of
various cancers. The dosing regimen and dosages of these
aforementioned chemotherapeutic drugs that are therapeutically
effective will depend on the particular cancer being treated, the
extent of the disease and other factors familiar to the physician
of skill in the art and can be determined by the physician. The
contents of the PDR are expressly incorporated herein in its
entirety by reference. One of skill in the art can review the PDR,
using one or more of the following parameters, to determine dosing
regimen and dosages of the chemotherapeutic agents and conjugates
that can be used in accordance with the teachings of this
invention. These parameters include:
Comprehensive index
By Manufacturer
[0161] Products (by company's or trademarked drug name) Category
index Generic/chemical index (non-trademark common drug names)
Color images of medications Product information, consistent with
FDA labeling Chemical information
Function/action
Indications & Contraindications
[0162] Trial research, side effects, warnings
Analogues and Derivatives
[0163] One skilled in the art of cytotoxic agents will readily
understand that each of the cytotoxic agents described herein can
be modified in such a manner that the resulting compound still
retains the specificity and/or activity of the starting compound.
The skilled artisan will also understand that many of these
compounds can be used in place of the cytotoxic agents described
herein. Thus, the cytotoxic agents of the present invention include
analogues and derivatives of the compounds described herein.
[0164] All references cited herein and in the examples that follow
are expressly incorporated by reference in their entireties.
EXAMPLES
[0165] The invention will now be illustrated by reference to
non-limiting examples. Unless otherwise stated, all percents,
ratios, parts, etc. are by weight. All reagents were purchased from
the Aldrich Chemical Co., New Jersey, or other commercial sources.
Nuclear Magnetic Resonance (.sup.1H NMR) spectra were acquired on a
Bruker 400 MHz instrument and mass spectra were acquired on a
Bruker Daltonics Esquire 3000 instrument using electrospray
ionization.
Example 1
(2S)-1-[5-methoxy-2-nitro-4-(phenylmethoxy)-benzoyl]-2-indolinecarboxylic
acid methyl ester 5
##STR00113##
[0167] To a stirred solution of
4-benzyloxy-5-methoxy-2-nitrobenzoic acid 3 (7.01 g, 23.1 mmol) in
anhydrous dichloromethane (100 mL) and THF (10 mL) was added oxalyl
chloride (4.1 mL, 46.2 mmol) and DMF (30 .mu.L, 0.38 mmol) at room
temperature. Large amounts of bubbles formed after the addition of
the DMF. The mixture was stirred overnight (the reaction usually
finished within 3 hours) and then the solvents were removed by
rotary evaporation in vacuo. The residue was co-evaporated one more
time by addition of anhydrous dichloromethane and high vacuumed to
give the acetyl chloride 4 as a yellow solid, which was directly
used for the next step.
[0168] To a stirred solution of (s)-(-)-Indoline-2-carboxylic acid
1 (3.43 g, 21.0 mmol) in anhydrous methanol (42 mL) was added
thionyl chloride (3.1 mL, 42.0 mmol) dropwise at 0.degree. C. The
ice bath was removed after 30 minutes and the mixture continued to
be stirred at room temperature for 5 hours. The solvent was removed
under reduced pressure and the residue was further dried on high
vacuum to give methyl ester 2, which was dissolved in anhydrous THF
((70 mL) in a 500 mL round bottom flask. The solution was cooled to
0.degree. C. and triethylamine (9.7 mL, 69.3 mmol) was added,
followed quickly by addition of freshly prepared acetyl chloride 4
in anhydrous THF (70 mL) via canula at 0.degree. C. The mixture was
stirred at 0-5.degree. C. for another 1.5 hours then at room
temperature for 30 minutes. The reaction was quenched by addition
of cold 5% HCl and then diluted with ethyl acetate and water. The
aqueous layer was extracted with ethyl acetate three times. The
combined organic layers were washed subsequently with brine,
saturated sodium bicarbonate and brine, dried over anhydrous sodium
sulfate and filtered. The solvents were evaporated under reduced
pressure and the residue was purified via silica gel chromatography
(Hexanes/Ethyl acetate, 2:1, 1.5:1) to give
(2S)-1-[5-methoxy-2-nitro-4-(phenylmethoxy)-benzoyl]-2-indolinecarboxylic
acid methyl ester 5 as a yellow solid (9.1 g, y=94%). .sup.1H NMR
(400 Hz, CDCl.sub.3): the compound appears as three distinct
rotomers. .delta. 8.27 (d, J=8.4 Hz, 0.3H), 7.90 (s, 0.1H), 7.82
(s, 0.6H), 7.79 (s, 0.3H), 7.50-7.28 (m, 5.4H), 7.20-7.09 (m,
1.3H), 7.05 (s, 0.6H), 6.97-6.81 (m, 1.6H), 6.76 (s, 0.1H), 5.85
(d, J=8.0 Hz, 0.1H), 5.70 (d, J=8.0 Hz, 0.6H), 5.45-5.41 (m, 0.6H),
5.33-5.21 (m, 2.1H), 4.55 (dd, J.sub.1=10.8 Hz, J.sub.2=2.8 Hz,
0.3H), 3.98 (s, 1.8H), 3.94 (s, 0.9H), 3.83-3.81 (m, 2.4H), 3.62
(dd, J.sub.1=16.4 Hz, J.sub.2=11.4 Hz, 1H), 3.56 (s, 0.9H),
3.27-3.13 (m, 1H); .sup.13C NMR (400 Hz, CDCl.sub.3): 171.5, 164.7,
155.2, 154.4, 148.6, 148.3, 140.3, 137.4, 135.11, 135.05, 130.5,
129.2, 128.7, 128.4, 127.9, 127.6, 127.5, 126.7, 125.5, 124.8,
124.3, 123.9, 117.6, 112.4, 110.1, 109.2, 108.8, 71.3, 71.2, 61.5,
60.2, 60.1, 56.7, 56.5, 52.5, 52.4, 33.6, 31.4; HRMS(ESI, m/z):
calc. 463.1505 (M+H).sup.+, found 463.1516.
(2S)-1-[5-methoxy-2-nitro-4-(phenylmethoxy)-benzoyl]-2-indolinealdehyde
6
##STR00114##
[0170] To a stirred solution of the methyl ester 5 (4.4 g, 9.5
mmol) in anhydrous dichloromethane (11 mL) and toluene (33 mL) was
added dibal-H (19 mL, 1.0 M in toluene) dropwise via a syringe pump
in 30 minutes at -78.degree. C. The mixture continued to be stirred
at -78.degree. C. for 3 hours and TLC (hexanes/AcOEt, 1:1.5) showed
that the starting material was almost consumed. The reaction was
quenched with methanol (0.4 mL) and 5% HCl (30 mL) at -78.degree.
C. Ethyl acetate (100 mL) was added and the dry ice/acetone bath
was removed. The mixture was stirred at room temperature for 30
minutes and then transferred to a separatory funnel. The aqueous
layer was extracted with AcOEt twice and the combined organic
layers were washed with brine, saturated sodium bicarbonate and
brine, and dried over anhydrous sodium sulfate. It was filtered
through celite and the solvents were removed under reduced pressure
(temperature <35.degree. C.). The residue was purified by flash
chromatography (Hexanes/AcOEt, 1.5:1, 1:1, 1:1.5) to give the
aldehyde 6 as a yellow solid (2.85 g, y=69%). .sup.1H NMR (400 Hz,
CDCl.sub.3): the compound appears as three distinct rotomers.
.delta. 10.02 (s, 0.3H), 9.85 (s, 0.5H), 9.45 (s, 0.2H), 8.32-8.31
(m, 0.2H), 7.93 (s, 0.3H), 7.83 (s, 0.5H), 7.79 (s, 0.2H),
7.53-7.34 (m, 5.2H), 7.26-7.14 (m, 1.3H), 7.08 (s, 0.5H), 7.01-6.94
(m, 1H), 6.91-6.82 (m, 1H), 5.78 (d, J=8.4 Hz, 0.3H), 5.71 (d,
J=8.4 Hz, 0.5H), 5.52-5.48 (m, 0.5H), 5.35-5.21 (m, 2.3H),
4.53-4.50 (m, 0.2H), 4.06 (s, 1.5H), 3.98 (s, 0.6H), 3.94 (s,
0.9H), 3.63-3.17 (m, 2H); HRMS (ESI, m/z): calc. 433.1400
(M+H).sup.+, found 433.1387.
Compound 7:
##STR00115##
[0172] To a stirred solution of aldehyde 6 (2.16 g, 5 mmol) in THF
(230 mL) was added deioned water (150 mL) and sodium dithionite
(85%, 4.61 g, 22.5 mmol). The obtained slightly cloudy solution
became clear after addition of another 5 mL of deioned water. The
clear mixture was stirred at room temperature for 16 hours and 30
mL of MeOH was added. After stirring for another 2 hours, the
solvents were removed under reduced pressure (bath temperature
below 35.degree. C.). The residue was suspended in acetonitrile and
evaporated to help remove any remaining water. The obtained white
solid was further completely dried by leaving on a high vacuum for
a few hours. The residue was suspended in dichloromethane/methanol
(1:1) and filtered through celite. The flask and the solid were
thoroughly washed with dichloromethane/methanol (1:1). The filtrate
was stripped under reduced pressure. The residue was dissolved in
methanol (50 mL) followed by addition of acetyl chloride (1.8 mL,
25 mmol) dropwise. The mixture was stirred at room temperature for
30 minutes and concentrated under reduced pressure (bath
temperature below 35.degree. C.) to remove half of the methanol.
The remainder was quenched with saturated sodium bicarbonate
followed by addition of dichloromethane (150 mL) and water (100
mL). The aqueous layer was extracted with dichloromethane
(2.times.100 mL) and the combined organic layers were washed with
brine, dried over anhydrous sodium sulfate and filtered. The
solvents were removed under reduced pressure and the residue was
purified by silica gel chromatography (Hexanes/AcOEt, 1:1, 1:1.3,
1:1.5) to give compound 7 as a yellow solid (1.41 g, y=73%).
.sup.1H NMR (400 Hz, CDCl.sub.3): .delta. 8.26 (d, J=8.0 Hz, 1H),
7.83 (d, J=4.4 Hz, 1H), 7.57 (s, 1H), 7.46-7.23 (m, 7H), 7.11-7.08
(m, 1H), 6.86 (s, 1H), 5.23 (d, J=12 Hz, 1H), 5.18 (d, J=12 Hz,
1H), 4.44 (ddd, J.sub.1=11.2 Hz, J.sub.2=4.4 Hz, J.sub.3=4.0 Hz,
1H), 3.97 (s, 3H), 3.67 (dd, J.sub.1=16.4 Hz, J.sub.2=11.2 Hz, 1H),
3.46 (dd, J.sub.1=16.4 Hz, J.sub.2=4.0 Hz, 1H); .sup.13C NMR (400
Hz, CDCl.sub.3): .delta. 163.8, 163.0, 150.9, 148.3, 141.96,
139.97, 136.0, 129.4, 128.6, 128.1, 128.08, 127.3, 124.7, 124.69,
120.7, 116.8, 111.9, 111.3, 70.8, 56.2, 54.9, 32.5; HRMS(ESI, m/z):
calc. 385.1552 (M+H).sup.+, found 385.1592.
Indolinobenzodiazepine (IBD) Monomer 8:
##STR00116##
[0174] To a stirred solution of the starting material 7 (1.41 g,
3.67 mmol) in dichloromethane (26 mL) was added a freshly mixed
solution of methanesulfonic acid (26 mL) in dichloromethane (52 mL)
at room temperature. The mixture was stirred at room temperature
for 1.5 hours and diluted with dichloromethane (100 mL). The
mixture was poured on ice (.about.200 g)/MeOH (10 mL). The pH of
the obtained solution was adjusted to 7 with saturated NaHCO.sub.3,
solid NaHCO.sub.3 and water. The mixture was separated and the
dichloromethane layer was washed with brine. The combined aqueous
layers were extracted with ethyl acetate (3.times.80 mL). The ethyl
acetate layers were combined and washed with brine. The
dichloromethane and ethyl acetate were combined, dried over
anhydrous sodium sulfate and filtered. The solvents were removed
and the residue (1.26 g) was purified by silica gel chromatography
(CH.sub.2Cl.sub.2/MeOH, 20:1, 15:1) to give the IBD monomer 8 as a
yellow solid (1.02 g, y=95%). .sup.1H NMR (400 Hz, CDCl.sub.3):
.delta. 8.29 (d, J=8.0 Hz, 1H), 7.91 (d, J=4.8 Hz, 1H), 7.59 (s,
1H), 7.32-7.28 (m, 2H), 7.13 (t, J=7.2 Hz, 1H), 6.94 (s, 1H), 6.02
(s, --OH), 4.50 (dt, J.sub.1=10.8 Hz, J.sub.2=4.4 Hz, 1H), 4.02 (s,
3H), 3.73 (dd, J.sub.1=16.8 Hz, J.sub.2=10.8 Hz, 1H), 3.52 (dd,
J.sub.1=16.8 Hz, J.sub.2=3.6 Hz, 1H); HRMS (ESI, m/z): calc.
295.1083 (M+H).sup.+, found 295.1076.
Example 2
(s)-(-)-3-(Benzyloxycarbonyl)-4-oxazolidinecarboxylic methyl ester
10
##STR00117##
[0176] To a stirred solution of
(s)-(-)-3-(Benzyloxycarbonyl)-4-oxazolidinecarboxylic acid 9 (1.75
g, 6.96 mmol) in anhydrous methanol (15 mL) was added thionyl
chloride (1.02 mL, 13.9 mmol) at 0.degree. C. After 30 minutes, the
ice/water bath was removed and the reaction mixture continued to be
stirred at room temperature for 3.5 hours. The reaction was
quenched by addition of saturated sodium bicarbonate and diluted
with dichloromethane (100 mL) and water (50 mL). The mixture was
separated and the aqueous layer was extracted with dichloromethane
(2.times.50 mL). The combined organic layers were washed with
brine, dried over anhydrous sodium sulfate and filtered. The
solvents were removed under reduced pressure and the residue was
purified by silica gel chromatography (Hexanes/AcOEt, 1.5:1) to
give (s)-(-)-3-(Benzyloxycarbonyl)-4-oxazolidinecarboxylic methyl
ester 10 as colorless oil (1.84 g, y=99%). .sup.1H NMR (400 Hz,
CDCl.sub.3): the compound appears as a pair of distinct rotomers.
.delta. 7.35 (bs, 5H), 5.22-4.99 (m, 4H), 4.53-4.45 (m, 1H),
4.22-4.09 (m, 2H), 3.76 (s, 1.5H), 3.65 (s, 1.5H); MS (m/z): found
288.0 (M+Na).sup.+.
Compound 11:
##STR00118##
[0178] To a stirred solution of
(s)-(-)-3-(Benzyloxycarbonyl)-4-oxazolidinecarboxylic methyl ester
10 (1.04 g, 3.92 mmol) in ethyl acetate (16 mL) was added triethyl
amine (1.4 mL, 10 mmol) and palladium hydroxide on carbon (20%, 267
mg, 0.337 mmol). The air in the reaction flask was removed by
vacuum, then a hydrogen balloon was applied and the mixture was
stirred under hydrogen atmosphere at room temperature for 2 hours.
To a solution of acetyl chloride 4 (prepared from 1.3 g, 4.3 mmol
of 4-benzyloxy-5-methoxy-2-nitrobenzoic acid 2 following the
procedures described above) in anhydrous THF (15 mL) was added
triethyl amine (1.1 mL, 7.9 mmol) at 0.degree. C., followed by
addition of the above hydrogenation reaction mixture by filtration
through celite. The palladium catalyst/celite was washed with
anhydrous THF (15 mL). The obtained mixture was stirred at
0.degree. C. for 3 hours. It was diluted with ethyl acetate and
saturated ammonium chloride. The pH of the mixture was adjusted to
6.about.7 by addition of 5% hydrochloric acid. The mixture was
separated and the aqueous layer was extracted with ethyl acetate
(2.times.80 mL). The combined organic layers were washed with
brine, dried over anhydrous sodium sulfate and filtered. The
solvents were removed under reduced pressure and the residue was
purified by silica gel chromatography (Hexanes/AcOEt, 1:2, 1:3) to
give compound 11 as a pale yellow solid (1.49 g, y=91%). .sup.1H
NMR (400 Hz, CDCl.sub.3): the compound appears as a pair of
distinct rotomers. .delta. 7.78 (s, 0.5H), 7.75 (s, 0.5H),
7.48-7.37 (m, 5H), 6.97 (s, 0.5H), 6.91 (s, 0.5H), 5.39 (d, J=4.8
Hz, 0.5H), 5.26-5.23 (m, 2.5H), 4.95 (dd, J1=7.2 Hz, J2=4.4 Hz,
0.5H), 4.81 (d, J=3.6 Hz, 0.5H), 4.67 (d, J=3.6 Hz, 0.5H),
4.37-4.30 (m, 1H), 4.25-4.11 (m, 1.5H), 4.02 (s, 1.5H), 3.97 (s,
1.5H), 3.87 (s, 1.5H), 3.67 (s, 1.5H); HRMS (ESI, m/z): calc.
417.1298 (M+H).sup.+, found 417.1305.
Aldehyde 12:
##STR00119##
[0180] To a stirred solution of the methyl ester 11 (1.49 g, 3.6
mmol) in anhydrous dichloromethane (4 mL) and toluene (12 mL) was
added dibal-H (6.5 mL, 1.0 M in toluene) dropwise via a syringe
pump in 30 minutes at -78.degree. C. The mixture continued to be
stirred at -78.degree. C. for 2 hours. The reaction was quenched
with methanol (146 .mu.L, 3.6 mmol) and 5% HCl (30 mL) at
-78.degree. C. Ethyl acetate (100 mL) was added and the dry
ice/acetone bath was removed. The mixture was stirred at room
temperature for 30 minutes and then transferred to a separatory
funnel. The aqueous layer was extracted with AcOEt twice. All the
organic layers were combined, washed with brine, saturated sodium
bicarbonate and brine. It was dried over anhydrous sodium sulfate
and filtered through celite. The filtrate was evaporated under
reduced pressure and the residue was purified by silica gel
chromatography (Hexanes/AcOEt, 1:5, 1:10) to give the aldehyde 12
as a pale yellow solid (980 mg, y=70%). .sup.1H NMR (400 Hz,
CDCl.sub.3): the compound appears as a pair of distinct rotomers.
.delta. 9.83 (s, 0.67H), 9.45 (s, 0.33H), 7.77 (s, 0.67H), 7.72 (s,
0.33H), 7.45-7.37 (m, 5H), 6.90 (s, 1H), 5.31-5.19 (m, 3H), 4.77
(bs, 1H), 4.67-4.56 (m, 1H), 4.36-3.94 (m, 5H); HRMS (ESI, m/z):
calc. 387.1192 (M+H).sup.+, found 387.1184.
Compound 13:
##STR00120##
[0182] To a stirred solution of aldehyde 12 (154 mg, 0.4 mmol) in
THF (21 mL) was added deioned water (14 mL) and sodium dithionite
(85%, 369 mg, 1.8 mmol). The clear mixture was stirred at room
temperature for 16 hours and 5 mL of MeOH was added. After being
stirred another 2 hours, the solvents were removed under reduced
pressure (bath temperature below 35.degree. C.). The residue was
suspended in acetonitrile and evaporated to help remove the
remaining water. The obtained white solid was further completely
dried by leaving on a high vacuum for a few hours. The residue was
suspended in dichloromethane/methanol (2:1) and filtered through
celite. The flask and the solid were thoroughly washed with
dichloromethane/methanol (1:1). The filtrate was stripped under
reduced pressure. The residue was dissolved in methanol (5 mL) and
a freshly prepared acetyl chloride (0.15 mL)/MeOH (5 mL) solution
was added quickly. The mixture was stirred at room temperature for
30 minutes and quenched by addition of saturated sodium
bicarbonate. It was diluted with dichloromethane and water. The two
layers were separated and the aqueous layer was extracted with
dichloromethane. The combined dichloromethane layers were washed
with brine and dried over anhydrous sodium sulfate. The solvents
were removed under reduced pressure to give 127 mg crude product.
The aqueous layer and the washing solution were combined and
acidified to pH 2.about.3 with KHSO.sub.4. It was concentrated to
half under reduced pressure (temperature <40.degree. C.) and
extracted with dichloromethane. The combined dichloromethane was
washed with saturated sodium bicarbonate and brine, dried over
anhydrous sodium sulfate. It was filtered and the filtrate was
evaporated under reduced pressure. The residue was combined with
above 127 mg crude product and purified by silica gel
chromatography (Hexanes/AcOEt, 1:3, 1:5, 1:8) to give compound 13
as a colorless foam (80 mg, y=61%). .sup.1H NMR (400 Hz,
CDCl.sub.3): .delta. 7.77 (d, J=4.0 Hz, 1H), 7.52 (s, 1H),
7.46-7.28 (m, 5H), 6.88 (s, 1H), 5.28 (d, J=5.2 Hz, 1H), 5.23 (d,
J=12 Hz, 1H), 5.17 (d, J=12 Hz, 1H), 5.05 (d, J=5.2 Hz, 1H), 4.49
(dd, J1=9.6 Hz, J2=3.2 Hz, 1H), 4.33 (dd, J1=9.6 Hz, J2=6.4 Hz,
1H), 3.96 (s, 3H), 3.83 (dd, J1=6.4 Hz, J2=3.2 Hz, 1H); MS (m/z):
found 361.1 (M+Na).sup.+, 379.1 (M+H.sub.2O+Na).sup.+, 339.1
(M+H).sup.+.
Oxazolidinobenzodiazepine (OBD) Monomer 14:
##STR00121##
[0184] A solution of compound 13 (90 mg, 0.27 mmol) and Pd/C (10%,
90 mg) in absolute ethanol (1.5 mL) was bubbled with argon.
1,4-Cyclohexadiene (496 .mu.l, 5.3 mmol) was added and the argon
bubble was continued for 3 hours until the starting material
disappeared (TLC, dichloromethane/methanol 10:1). The mixture was
then filtered through celite and the celite was washed with
methanol. The filtrate was evaporated under reduced pressure to
give 63 mg of the crude product as colorless foam, which was
purified by silica gel chromatography (dichloromethane/methanol,
20:1) to give OBD monomer 14 (55 mg, y=82%) as a white solid.
.sup.1H NMR (400 Hz, CDCl.sub.3): it appears as a mixture of imine
and its methyl ethers, C11(R) and C11(S) (2:3:1). .delta. 7.71 (bs,
1H), 7.43 (s, 0.5H), 7.41 (s, 1H), 7.18 (s, 1.5H), 6.83 (s, 1H),
6.36 (s, 1.5H), 6.13 (s, 0.5H), 5.25 (d, J=4.8 Hz, 0.5H), 5.22-5.20
(m, 1H), 5.14 (d, J=5.2 Hz, 1.5H), 5.10 (d, J=4.8 Hz, 0.5H), 5.05
(d, J=5.2 Hz, 1.5H), 5.00-4.97 (m, 1H), 4.47 (d, J=8.8 Hz, 1.5H),
4.44-4.41 (m, 1H), 4.32 (apt, J=8.0 Hz, 0.5H), 4.28-4.25 (m, 1H),
4.18-4.00 (m, 2.times.1.5H+2.times.0.5H=4H), 3.84 (bs,
3.times.1H+0.5H=3.5H), 3.76 (bs, 3.times.1.5H+1H=5.5H), 3.73 (s,
3.times.0.5H=1.5H), 3.56 (dt, J1=8.8 Hz, J2=2.8 Hz, 1.5H), 3.34 (s,
3.times.1.5H=4.5H), 3.22 (s, 3.times.0.5H=1.5H); MS (m/z): found
303.1 (M+MeOH+Na).sup.+, 271.1 (M+Na).sup.+.
Example 3
Dimer 15 (IGN-09):
##STR00122##
[0186] To a solution of IBD monomer 8 (147 mg, 0.5 mmol) and
1,3-diiodopropane (23 .mu.l, 0.2 mmol) in anhydrous DMF (1.0 mL)
was added potassium carbonate (111 mg, 0.8 mmol). The mixture was
stirred at room temperature overnight (16 hours) and diluted with
dichloromethane. It was washed with saturated ammonium chloride and
brine, dried over anhydrous sodium sulfate and filtered. The
filtrate was evaporated under reduced pressure and the residue was
purified through preparative reverse phase HPLC (C18 column,
acetonitrile/water) to give dimer 15 (IGN-09) (18.9 mg, y=15%) as a
white solid. .sup.1H NMR (400 Hz, CDCl.sub.3): .delta. 8.26 (d,
J=8.0 Hz, 2H), 7.87 (d, J=4.4 Hz, 2H), 7.55 (s, 2H), 7.26 (s, 4H),
7.12-7.08 (m, 2H), 6.88 (s, 2H), 4.45 (ddd, J1=10.8 Hz, J2=4.4 Hz,
J3=4.0 Hz, 2H), 4.36-4.26 (m, 4H), 3.94 (s, 6H), 3.70 (dd, J1=16.8
Hz, J2=10.8 Hz, 2H), 3.50 (dd, J1=16.8 Hz, J2=4.0 Hz, 2H), 2.45 (p,
J=6.0 Hz, 2H); HRMS (ESI, m/z): calc. 629.2400 (M+H).sup.+, found
629.2400.
Example 4
Dimer 18 (IGN-01):
##STR00123##
[0188] To a stirred solution of 1,3-Benzenedimethanol 16 (11 mg,
0.08 mmol) in anhydrous dichloromethane (0.8 mL) was added
triethylamine (33 .mu.l, 0.24 mmol) then methanesulfonyl chloride
(16 .mu.L, 0.21 mmol) dropwise in 15 minutes at
-5.about.-10.degree. C. The solution was stirred at
-5.about.-10.degree. C. for another 60 minutes and was quenched
with ice/water, diluted with cold ethyl acetate. The mixture was
separated and the organic layer was washed with cold water, dried
over anhydrous sodium sulfate. It was filtered and the filtrate was
evaporated by rotary evaporation in vacuo (temperature
<35.degree. C.). The residue 17 was high vacuumed for a few
hours before being dissolved in anhydrous DMF (1.5 mL). IBD monomer
7 (94 mg, 0.32 mmol), anhydrous potassium carbonate (50 mg, 0.36
mmol) and potassium iodide (27 mg, 0.16 mmol) were added
subsequently. The mixture was stirred at room temperature for 17
hours (checked by mass spectrum) and diluted with dichloromethane.
It was washed with brine, dried over anhydrous sodium sulfate and
filtered. The filtrate was evaporated under reduced pressure and
the residue was purified by reverse phase HPLC (C18 column,
CH.sub.3CN/H.sub.2O, loaded column with CH.sub.3CN/H.sub.2O, 3:1,
stirred for 30 min and centrifuged before injection) to furnish
dimer 18 (IGN-01, 6.6 mg) as a white solid. .sup.1H NMR (400 Hz,
CDCl.sub.3): .delta. 8.21 (d, J=8.0 Hz, 2H), 7.79 (d, J=4.4 Hz,
2H), 7.51 (s, 2H), 7.46 (s, 1H), 7.36 (bs, 3H), 7.23-7.18 (m, 4H),
7.06-7.03 (m, 2H), 6.79 (s, 2H), 5.20 (d, J=12.4 Hz, 2H), 5.14 (d,
J=12.4 Hz, 2H), 4.41 (ddd, J1=10.8 Hz, J2=4.4 Hz, J3=4.0 Hz, 2H),
3.92 (s, 6H), 3.64 (dd, J1=17.2 Hz, J2=11.2 Hz, 2H), 3.42 (dd,
J1=16.8 Hz, J2=4.0 Hz, 2H); HRMS (ESI, m/z): calc. 691.2557
(M+H).sup.+, found 691.2570.
Example 5
Dimer 19 (IGN-02):
##STR00124##
[0190] To a stirred solution of 1,3-Benzenedimethanol 16 (10 mg,
0.074 mmol) in anhydrous dichloromethane (0.8 mL) was added
triethylamine (31 .mu.l, 0.22 mmol) then methanesulfonyl chloride
(15 .mu.L, 0.19 mmol) dropwise in 15 minutes at
-5.about.-10.degree. C. The solution was stirred at
-5.about.-10.degree. C. for another 60 minutes and was quenched
with ice/water, diluted with cold ethyl acetate. The mixture was
separated and the organic layer was washed with cold water, dried
over anhydrous sodium sulfate. It was filtered and the filtrate was
evaporated by rotary evaporation in vacuo (temperature
<35.degree. C.). The residue 17 was high vacuumed before
dissolving in anhydrous DMF (1.5 mL). OBD monomer 14 (70 mg, 0.28
mmol), anhydrous potassium carbonate (51 mg, 0.37 mmol) and
potassium iodide (25 mg, 0.15 mmol) were added subsequently. The
mixture was stirred at room temperature for 17 hours (checked by
mass spectrum) and diluted with dichloromethane. It was washed with
brine, dried over anhydrous sodium sulfate and filtered. The
filtrate was evaporated under reduced pressure and the residue was
purified by reverse phase HPLC (C18 column, CH.sub.3CN/H.sub.2O,
loaded column with CH.sub.3CN/H.sub.2O, 3:1, stirred for 30 min and
centrifuged before injection) to furnish dimer 19 (IGN-02, 10.0 mg)
as a white solid. .sup.1H NMR (400 Hz, CDCl.sub.3): .delta. 7.75
(d, J=4.0 Hz, 2H), 7.50-7.48 (bs, 3H), 7.38 (bs, 3H), 6.83 (s, 2H),
5.26 (d, J=5.2 Hz, 2H), 5.21 (d, J=14.4 Hz, 2H), 5.15 (d, J=14.0
Hz, 2H), 5.03 (d, J=5.6 Hz, 2H), 4.34-4.30 (m, 2H), 3.94 (s, 6H),
3.86-3.76 (m, 2H); HRMS (ESI, m/z): calc. 599.2142 (M+H).sup.+,
found 599.2184.
Example 6
Triol 21:
##STR00125##
[0192] To a stirred solution of dimethyl 5-hydroxyisophthalate 20
(2.1 g, 10 mmol) in anhydrous THF (50 mL) was added lithium
aluminum hydride (2.0 M in THF, 10 mL, 20 mmol) at
-20.about.-30.degree. C. via a syringe pump in 30 minutes. The
cooling bath was removed after 30 minutes and the mixture continued
to be stirred at room temperature for 4 hours. It was cooled to
0.about.-10.degree. C. and quenched with saturated sodium sulfate.
The mixture was diluted with acetonitrile and 5% hydrochloric acid
(20 mL) was added. It was stirred for 30 minutes and dried over
anhydrous sodium sulfate. The mixture was filtered through celite
and the filtrate was evaporated under reduced pressure. The residue
was purified through silica gel chromatography
(Dichloromethane/Methanol, 10:1, 8:1, 5:1) to give triol 21 (1.5 g,
y=99%) as a colorless oil which became white solid after stocking.
.sup.1H NMR (400 Hz, MeOD): .delta. 6.78, (s, 1H), 6.69 (s, 2H),
4.50 (s, 4H). .sup.13C NMR (400 Hz, MeOD): .delta. 158.7, 144.4,
117.8, 113.8, 65.2; MS (m/z): found 153.0 (M-H).sup.-.
Compound 22:
##STR00126##
[0194] To a solution of triol 21 (827 mg, 5.37 mmol) and methyl
5-bromovalerate (998 mg, 5.12 mmol) in acetonitrile (40 mL) was
added potassium carbonate (3.71 g, 26.9 mmol). The mixture was put
in a 86.degree. C. oil bath and refluxed for 6 hours. The reaction
mixture was removed from the oil bath, cooled to room temperature
and the solvents were evaporated under reduced pressure
(temperature <35.degree. C.). The residue was diluted with
dichloromethane and filtered. The filtrate was washed with brine,
dried over anhydrous sodium sulfate and filtered. The filtrate was
stripped under reduced pressure and the residue was purified
through silica gel chromatography (Hexanes/Ethyl acetate, 1:2, 1:3)
to give compound 22 (1.15 g, y=84%) as a white solid. .sup.1H NMR
(400 Hz, CDCl.sub.3): .delta. 6.89 (s, 1H), 6.80 (s, 2H), 4.62 (s,
4H), 3.98-3.95 (m, 2H), 3.67 (s, 3H), 2.41-2.37 (m, 2H), 2.23 (bs,
--OH.times.2), 1.84-1.78 (m, 4H); MS (m/z): found 291.1
(M+Na).sup.+.
Compound 23:
##STR00127##
[0196] Following the procedure to prepare compound 22, compound 23
(1.43 g, y=75%) was synthesized as a white solid from triol 21
(1.16 g, 7.53 mmol), methyl 4-bromobutyrate (1.52 g, 8.39 mmol) and
potassium carbonate (5.2 g, 37.6 mmol). .sup.1H NMR (400 Hz,
CDCl.sub.3): .delta. 6.90 (s, 1H), 6.80 (s, 2H), 4.62 (s, 4H), 4.00
(t, J=6.0 Hz, 2H), 3.68 (s, 3H), 2.51 (t, J=7.2 Hz, 2H), 2.19 (s,
--OH.times.2), 2.13-2.06 (m, 2H); MS (m/z): found 277.1
(M+Na).sup.+.
Compound 24:
##STR00128##
[0198] Following the procedure to prepare compound 22, compound 24
(515 mg, y=37%) was synthesized as a white sticky solid from triol
21 (953 mg, 6.19 mmol), methyl bromoacetate (587 .mu.l, 6.19 mmol)
and potassium carbonate (4.3 g, 31 mmol). .sup.1H NMR (400 Hz,
CDCl.sub.3): .delta. 6.95 (s, 1H), 6.81 (s, 2H), 4.64 (s,
--OH.times.2), 4.61 (s, 4H), 3.81 (s, 3H), 2.41 (s, 2H); .sup.13C
NMR (400 Hz, CDCl.sub.3): .delta. 169.4, 158.1, 143.0, 118.5,
112.1, 65.2, 64.8, 52.3; MS (m/z): found 249.0 (M+Na).sup.+.
Compound 27:
##STR00129##
[0200] To a solution of 5-nitro-m-xylene-.alpha.,.alpha.'-diol 25
(1.07 g, 5.84 mmol) in methanol (50 mL) was added Pd/C (10%, 311
mg, 0.29 mmol). Hydrogen was introduced to replace the air then the
mixture was hydrogenated (H.sub.2, 5 psi) for 2 hours at room
temperature. The solution was filtered through celite and the
filtrate was evaporated by rotary evaporation in vacuo to give
compound 26 as a white solid (900 mg, y=100%). .sup.1H NMR (400 Hz,
MeOD): .delta. 6.71 (s, 1H), 6.66 (s, 2H), 4.51 (s, 4H); .sup.13C
NMR (400 Hz, MeOD): .delta. 148.9, 143.8, 116.7, 114.3, 65.5; It
was dissolved in anhydrous acetonitrile (30 mL) and ethyl
bromoacetate (443 .mu.l, 4.67 mmol) and potassium carbonate (807
mg, 5.84 mmol) were added. The mixture was put in a 86.degree. C.
oil bath and refluxed for 17 hours. The reaction mixture was
removed from the oil bath, cooled to room temperature and diluted
with dichloromethane. It was filtered through celite and the solid
was washed with dichloromethane. White precipitate appeared in the
filtrate. It was collected by filtration to give compound 27 (414
mg, y=39%) as a white solid. .sup.1H NMR (400 Hz, MeOD): .delta.
6.67 (s, 1H), 6.53 (s, 2H), 4.51 (s, 4H), 3.94 (s, 2H), 3.73 (s,
3H); .sup.13C NMR (400 Hz, MeOD): .delta. 174.0, 149.7, 143.9,
116.2, 111.6, 65.6, 52.6, 46.5; MS (m/z): found 248.0
(M+Na).sup.+.
Compound 28:
##STR00130##
[0202] To a solution of 5-nitro-m-xylene-.alpha.,.alpha.'-diol 25
(564 mg, 3.08 mmol) in methanol (35 mL) was added Pd/C (10%, 164
mg, 0.154 mmol). Hydrogen was introduced to replace the air then
the mixture was hydrogenated (H.sub.2, 5 psi) for 2 hours at room
temperature. The solution was filtered through celite and the
filtrate was evaporated by rotary evaporation in vacuo to give
compound 26, which was dissolved in anhydrous acetonitrile (15 mL)
and methyl 4-bromobutyrate (557 mg, 3.08 mmol) and potassium
carbonate (426 mg, 3.08 mmol) were added. The mixture was put in a
86.degree. C. oil bath and refluxed for 18 hours. The reaction
mixture was removed from the oil bath, cooled to room temperature
and diluted with dichloromethane. It was filtered through celite
and the solid was washed with dichloromethane/acetonitrile (1:1).
The filtrate was evaporated under reduced pressure and the residue
was purified through silica gel chromatography (Combiflash,
dichloromethane/methanol) to give compound 28 (292 mg, y=37%) as a
white solid. .sup.1H NMR (400 Hz, MeOD): .delta. 6.62 (s, 1H), 6.55
(s, 2H), 4.50 (s, 4H), 3.65 (s, 3H), 3.13 (d, J=7.2 Hz, 2H), 2.43
(d, J=7.2 Hz, 2H), 1.89 (p, J=7.2 Hz, 2H); .sup.13C NMR (400 Hz,
MeOD): .delta. 175.9, 150.5, 143.7, 115.5, 111.7, 65.7, 52.2, 44.3,
32.5, 25.8; MS (m/z): found 276.0 (M+Na).sup.+.
Compound 29:
##STR00131##
[0204] To a solution of compound 27 (230 mg, 1.02 mmol) in
anhydrous acetonitrile (7 mL) was added methyl iodide (70 .mu.l,
1.12 mmol) and potassium carbonate (155 mg, 1.12 mmol). The mixture
was put in a 86.degree. C. oil bath and refluxed for 17 hours. The
reaction mixture was removed from the oil bath, cooled to room
temperature and diluted with dichloromethane. It was filtered
through celite and the solid was washed with
dichloromethane/methanol (10:1). The filtrate was evaporated under
reduced pressure and the residue was purified through silica gel
chromatography (Combiflash, dichloromethane/methanol) to give
compound 29 (98 mg, y=40%) as a white solid. .sup.1H NMR (400 Hz,
MeOD): .delta. 6.70 (s, 1H), 6.63 (s, 2H), 4.84 (s, 2.times.--OH),
4.54 (s, 4H), 4.16 (s, 2H), 3.69 (s, 3H), 3.05 (s, 3H); .sup.13C
NMR (400 Hz, MeOD): .delta. 173.6, 150.9, 143.8, 115.6, 111.0,
65.7, 54.9, 52.4, 39.8; MS (m/z): found 262.0 (M+Na).sup.+.
Compound 30:
##STR00132##
[0206] To a solution of compound 28 (151 mg, 0.597 mmol) in
anhydrous acetonitrile (4 mL) was added methyl iodide (74 .mu.l,
1.19 mmol) and potassium carbonate (99 mg, 0.716 mmol). The mixture
was put in an 86.degree. C. oil bath and refluxed for 17 hours. The
reaction mixture was removed from the oil bath, cooled to room
temperature and diluted with dichloromethane. It was filtered
through celite and the solid was washed with
dichloromethane/methanol (10:1). The filtrate was evaporated under
reduced pressure and the residue was purified through silica gel
chromatography (Combiflash, dichloromethane/methanol) to give
compound 30 (63 mg, y=39%) as a colorless oil. .sup.1H NMR (400 Hz,
MeOD): .delta. 6.67 (s, 2H), 6.65 (s, 1H), 4.54 (s, 4H), 3.65 (s,
3H), 3.36 (t, J=7.2 Hz, 2H), 2.92 (s, 3H), 2.36 (t, J=7.2 Hz, 1H),
1.87 (p, J=7.2 Hz, 2H); .sup.13C NMR (400 Hz, MeOD): .delta. 175.7,
151.3, 143.7, 115.0, 111.4, 65.9, 53.0, 52.2, 38.9, 32.2, 23.3; MS
(m/z): found 290.0 (M+Na).sup.+.
Compound 34 (IGN-03):
##STR00133##
[0208] To a stirred solution of compound 22 (80.4 mg, 0.3 mmol) in
anhydrous dichloromethane (2 mL) was added triethylamine (125
.mu.l, 0.9 mmol) then methanesulfonyl chloride (60 .mu.L, 0.78
mmol) dropwise in 15 minutes at -5.about.-10.degree. C. The
solution was stirred at -5.about.-10.degree. C. for another 60
minutes and was quenched with ice/water, diluted with cold ethyl
acetate. The mixture was separated and the organic layer was washed
with cold water, dried over anhydrous sodium sulfate. It was
filtered and the filtrate was evaporated by rotary evaporation in
vacuo (temperature <35.degree. C.). The residue 31 was high
vacuumed before dissolving in anhydrous DMF (3 mL). IBD monomer 7
(221 mg, 0.75 mmol) and anhydrous potassium carbonate (207 mg, 1.5
mmol) were added. The mixture was stirred at room temperature for
20 hours (checked by mass spectrum) and diluted with
dichloromethane. It was washed with water and brine, dried over
anhydrous sodium sulfate and filtered. The filtrate was evaporated
under reduced pressure and the residue was purified through silica
gel chromatography (hexanes/ethyl acetate, 1:3, 1:4, 1:6, 1:10,
then ethylacetate/methanol, 10:1) to give compound 34 (169 mg,
y=68%, 86% purity based on analytical reverse phase HPLC) as a
yellowish solid. Fractions that contained impurities and compound
34 were also collected and the solvents were evaporated to give 70
mg of yellowish solid. The two yellowish solids were combined and
further purified through reverse phase HPLC (C18 column,
CH.sub.3CN/H.sub.2O, loaded column with CH.sub.3CN/H.sub.2O, 3:1,
stirred for 30 min and centrifuged before injection) to furnish
dimer 34 (IGN-03, 103 mg, y=41%) as a white solid. .sup.1H NMR (400
Hz, CDCl.sub.3): .delta. 8.27 (d, J=8.0 Hz, 2H), 7.85 (d, J=3.2 Hz,
2H), 7.58 (s, 2H), 7.29-7.24 (m, 4H), 7.12-7.07 (m, 3H), 6.94 (s,
2H), 6.83 (s, 2H), 5.22 (d, J=12.8 Hz, 2H), 5.16 (d, J=12.8 Hz,
2H), 4.47 (dt, J1=11.2 Hz, J2=4.4 Hz, 2H), 3.98 (bs, 8H), 3.73-3.64
(m, 2H), 3.68 (s, 3H), 3.48 (dd, J1=16.8 Hz, J2=3.6 Hz, 2H),
2.42-2.38 (m, 2H), 1.83-1.80 (m, 4H); HRMS (ESI, m/z): calc.
821.3187 (M+H).sup.+, found 821.3188.
Compound 35 (IGN-04):
##STR00134##
[0210] Following the procedure to prepare compound 34, compound 35
(IGN-04) was synthesized (151 mg, y=62%, 88% purity based on
analytical reverse phase HPLC) as a yellowish solid. Part of it was
further purified by reverse phase HPLC for .sup.1H NMR analysis.
.sup.1H NMR (400 Hz, CDCl.sub.3): .delta. 8.17 (d, J=8.0 Hz, 2H),
7.74 (d, J=5.2 Hz, 2H), 7.48 (s, 2H), 7.20-7.15 (m, 4H), 7.03-6.99
(m, 3H), 6.85 (s, 2H), 6.75 (s, 2H), 5.12 (d, J=12.8 Hz, 2H), 5.06
(d, J=12.8 Hz, 2H), 4.37 (dt, J1=11.2 Hz, J2=4.4 Hz, 2H), 3.93 (t,
J=6.0 Hz, 2H), 3.86 (s, 6H), 3.64-3.57 (m, 2H), 3.60 (s, 3H), 3.39
(dd, J1=16.8 Hz, J2=3.6 Hz, 2H), 2.44 (t, J=7.2 Hz, 2H), 2.02 (p,
J=6.4 Hz, 2H); HRMS (ESI, m/z): calc. 807.3030 (M+H).sup.+, found
807.3008.
Compound 36 (IGN-05):
##STR00135##
[0212] Following the procedure to prepare compound 34, compound 36
(IGN-05) was synthesized (84.5 mg, y=18%) as a white solid after
preparative reverse phase HPLC. .sup.1H NMR (400 Hz, CDCl.sub.3):
.delta. 8.24 (d, J=8.0 Hz, 2H), 7.79 (d, J=4.4 Hz, 2H), 7.55 (s,
2H), 7.26-7.22 (m, 4H), 7.12-7.07 (m, 3H), 6.96 (s, 2H), 6.81 (s,
2H), 5.18 (d, J=12.8 Hz, 2H), 5.12 (d, J=12.8 Hz, 2H), 4.64 (s,
2H), 4.44 (dt, J1=10.8 Hz, J2=4.4 Hz, 2H), 3.95 (s, 6H), 3.77 (s,
3H), 3.73-3.62 (m, 2H), 3.44 (dd, J1=16.8 Hz, J2=3.6 Hz, 2H); HRMS
(ESI, m/z): calc. 779.2717 (M+H).sup.+, found 779.2703.
Compound 39 (IGN-06):
##STR00136##
[0214] Following the procedure to prepare compound 34, compound 39
(IGN-06) was synthesized in 6% yield as a white solid after
preparative reverse phase HPLC. .sup.1H NMR (400 Hz, CDCl.sub.3):
.delta. 8.28 (d, J=8.0 Hz, 2H), 7.86 (d, J=4.0 Hz, 2H), 7.58 (s,
2H), 7.31-7.26 (m, 4H), 7.12 (t, J=7.2 Hz, 2H), 6.90-6.86 (m, 3H),
6.72 (s, 2H), 5.22 (d, J=12.4 Hz, 2H), 5.13 (d, J=12.4 Hz, 2H),
4.51-4.46 (m, 2H), 3.99 (s, 6H), 3.74-3.68 (m, 2H), 3.71 (s, 3H),
3.49 (dd, J.sub.1=16.8 Hz, J.sub.2=3.6 Hz, 2H), 3.09 (s, 3H); HRMS
(ESI, m/z): calc. 792.3033 (M+H).sup.+, found 792.3013.
Compound 40 (IGN-07):
##STR00137##
[0216] Following the procedure to prepare compound 34, compound 40
(IGN-07) was synthesized in 21% yield as a white solid after
preparative reverse phase HPLC. .sup.1H NMR (400 Hz, CDCl.sub.3):
.delta. 8.27 (d, J=8.0 Hz, 2H), 7.84 (d, J=4.4 Hz, 2H), 7.58 (s,
2H), 7.30-7.23 (m, 4H), 7.21-7.02 (m, 3H), 6.88 (s, 2H), 6.74 (s,
2H), 5.23-5.13 (m, 4H), 4.50-4.42 (m, 2H), 3.99 (s, 6H), 3.74-3.70
(m, 2H), 3.67 (s, 3H), 3.51-3.33 (m, 4H), 2.92 (s, 3H), 2.36-2.30
(m, 2H), 1.93-1.84 (m, 2H); HRMS (ESI, m/z): calc. 820.3346
(M+H).sup.+, found 820.3329.
Example 7
Compound 41:
##STR00138##
[0218] To a solution of compound 34 (42 mg, 0.051 mmol) in
anhydrous 1,2-dichloroethane (1 mL) was added trimethyltin
hydroxide (139 mg, 0.77 mmol). The mixture was heated at
78-82.degree. C. (80.degree. C. oil bath) and stirred overnight.
The TLC (CH.sub.2Cl.sub.2/MeOH, 10:1) showed the disappearance of
the starting material. The reaction mixture was cooled to room
temperature and diluted with dichloromethane. It was washed with
drops of 5% hydrochloric acid in brine, saturated ammonium chloride
and brine, dried over anhydrous sodium sulfate, filtered and
evaporated. The residue was purified by silica gel chromatography
(combiflash, CH.sub.2Cl.sub.2/MeOH, from 1:0 to 5:1) to give IGN-03
acid 41 (33.8 mg, y=82%) as a yellowish solid. The residue can also
be used for next step without purification. MS (m/z): found 805.1
(M-H).sup.-, 823.0 (M+H.sub.2O--H).sup.-, 829.2 (M+Na).sup.+, 847.2
(M+H.sub.2O+Na).sup.+.
Compound 42:
##STR00139##
[0220] To a stirred solution of compound 35 (32 mg, 0.040 mmol) in
a mixture of THF (0.4 mL), methanol (0.1 mL) and deioned water (0.1
ml) was added freshly prepared 2N LiOH (24 .mu.l, 0.048 mmol) at
0.degree. C. The cooling bath was removed and the mixture was
stirred at room temperature for 8 hours. The reaction mixture was
diluted with ethyl acetate and water. The pH of the mixture was
adjusted to 4-5 with 5% hydrochloric acid. It was washed with
brine, dried over anhydrous sodium sulfate and filtered. The
filtrate was evaporated under reduced pressure and the residue was
purified by preparative reverse phase HPLC (C18 column,
acetonitrile/H.sub.2O) to give the IGN-04 acid 42 (4.2 mg, y=13%)
as a white solid. MS (m/z): found 791.0 (M-H).sup.-, 809.0
(M+H.sub.2O--H).sup.-, 815.2 (M+Na).sup.+, 833.1
(M+H.sub.2O+Na).sup.+.
Compound 43:
##STR00140##
[0222] To a stirred solution of IGN-03 acid 41 (8.9 mg, 0.011 mmol)
in anhydrous dichloromethane (0.2 mL) was added
N-hydroxysuccinimide (2.6 mg, 0.022 mmol),
N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (4.2
mg, 0.022 mmol) and a tiny particle of dimethylaminopyridine. The
mixture was stirred at room temperature overnight and diluted with
dichloromethane. It was washed with saturated ammonium chloride and
brine, dried over anhydrous sodium sulfate and filtered. The
filtrate was evaporated under reduced pressure. The residue was
purified through silica gel chromatography (Combiflash,
CH.sub.2Cl.sub.2/MeOH, from 1:0 to 10:1) to give IGN-03 NHS eater
43 (7.9 mg, y=79%) as a yellowish solid. Reverse phase preparative
HPLC (C18 column, CH.sub.3CN/H.sub.2O, extracted the product
fractions with dichloromethane) purification gave 3.2 mg white
solid for .sup.1H NMR analysis. .sup.1H NMR (400 Hz, CDCl.sub.3):
.delta. 8.28 (d, J=8.0 Hz, 2H), 7.87 (d, J=4.0 Hz, 2H), 7.59 (s,
2H), 7.31-7.27 (m, 4H), 7.15-7.10 (m, 3H), 6.97 (s, 2H), 6.86 (s,
2H), 5.25 (d, J=12.4 Hz, 2H), 5.18 (d, J=12.4 Hz, 2H), 4.49 (dt,
J.sub.1=10.8 Hz, J.sub.2=4.0 Hz, 2H), 4.04 (t, J=5.6 Hz, 2H), 4.01
(s, 6H), 3.72 (dd, J.sub.1=16.8 Hz, J.sub.2=10.8 Hz, 2H), 3.51 (dd,
J.sub.1=16.8 Hz, J.sub.2=4.0 Hz, 2H), 2.85 (bs, 4H), 2.72 (t, J=6.8
Hz, 2H), 1.99-1.91 (m, 4H); HRMS (ESI, m/z): calc. 904.3194
(M+H).sup.+, found 904.3182.
Compound 44:
##STR00141##
[0224] Following the procedure to prepare compound 43, compound 44
was synthesized in 86% yield as a yellowish solid. MS (m/z): found
944.2 (M+MeOH+Na).sup.+, 976.2 (M+2MeOH+Na).sup.+.
Compound 45 (IGN-07 acid):
##STR00142##
[0225] To a solution of compound 40 (14 mg, 0.017 mmol) in
anhydrous 1,2-dichloroethane (0.5 mL) was added trimethyltin
hydroxide (62 mg, 0.34 mmol). The mixture was heated at
78-82.degree. C. (80.degree. C. oil bath) and stirred overnight.
The TLC (CH.sub.2Cl.sub.2/MeOH, 10:1) showed the disappearance of
the starting material. The reaction mixture was cooled to room
temperature and diluted with dichloromethane. It was washed with
saturated ammonium chloride and brine, dried over anhydrous sodium
sulfate, filtered and evaporated to give IGN-07 acid 45 as a pale
yellowish solid (29.2 mg, contaminated with trimethyltin
hydroxide). MS (m/z): found 804.1 (M-H).sup.-, 822.1
(M+H.sub.2O-H).sup.-, 828.2 (M+Na).sup.+, 846.2
(M+H.sub.2O+Na).sup.+. It was used for next step without
purification.
Compound 46:
##STR00143##
[0227] To a stirred solution of IGN-07 acid 45 from above reaction
(0.017 mmol) in anhydrous dichloromethane (0.5 mL) was added
N-hydroxysuccinimide (6.1 mg, 0.051 mmol),
N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (9.8
mg, 0.051 mmol) and a tiny particle of dimethylaminopyridine. The
mixture was stirred at room temperature overnight and diluted with
dichloromethane. It was washed with saturated ammonium chloride and
brine, dried over anhydrous sodium sulfate and filtered. The
filtrate was evaporated under reduced pressure. The residue was
purified through silica gel chromatography (Combiflash,
CH.sub.2Cl.sub.2/MeOH, from 1:0 to 10:1) to give IGN-07 NHS eater
46 (9.1 mg, y=59% for two steps from IGN-07) as a yellowish solid.
.sup.1H NMR (400 Hz, CDCl.sub.3): .delta. 8.25 (d, J=7.6 Hz, 2H),
7.82 (d, J=4.4 Hz, 2H), 7.55 (s, 2H), 7.26-7.18 (m, 5H), 7.09 (t,
J=7.6 Hz, 2H), 6.84 (s, 2H), 6.74 (s, 2H), 5.21 (d, J=12.4 Hz, 2H),
5.15 (d, J=12.4 Hz, 2H), 4.46-4.42 (m, 2H), 3.98 (s, 6H), 3.72-3.64
(m, 2H), 3.44-3.37 (m, 4H), 2.95 (s, 3H), 2.74 (bs, 4H), 2.57 (t,
J=7.2 Hz, 2H), 1.95 (t, J=7.2 Hz, 2H); HRMS (ESI, m/z): calc.
903.3354 (M+H).sup.+, found 903.3347.
Example 8
Compound 47:
##STR00144##
[0229] To a stirred solution of cysteamine hydrochloride (568 mg, 5
mmol) in anhydrous methanol (15 mL) was added S-methyl
methanethiosulfonate (519 .mu.l, 5.5 mmol) at 0.degree. C. The
mixture was stirred at room temperature overnight. Triethylamine
(1.4 mL, 10 mmol) was added and the solvents were removed under
reduced pressure. The residue was dissolved in 50 mL of anhydrous
dichloromethane and gave a 0.1 M solution of compound 47 in
dichloromethane (assuming 100% yield). An aliquot of the solution
(0.2 mL) was used for next step reaction. The rest of the solution
was diluted with dichloromethane, washed with saturated sodium
bicarbonate and brine, dried over anhydrous sodium sulfate and
filtered. The filtrate was evaporated under reduced pressure and
the residue was purified through silica gel chromatography
(dichloromethane/methanol, 10:1 with 1% triethylamine) to give
compound 47 (82 mg, y=13%, product lost in the aqueous work up due
to its good water solubility) as a colorless oil. .sup.1H NMR (400
Hz, CDCl.sub.3): .delta. 3.02 (t, J=6.4 Hz, 2H), 2.77 (t, J=6.4 Hz,
2H), 2.41 (s, 3H), 1.34 (bs, 2H).
Compound 48 (IGN-08):
##STR00145##
[0231] To a flask containing IGN-03 acid 41 (8.1 mg, 0.01 mmol) was
added above 0.1 M solution of compound 47 in anhydrous
dichloromethane (0.2 mL).
N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (3.8
mg, 0.02 mmol), triethylamine (1.4 .mu.l, 0.01 mmol) and a tiny
particle of dimethylaminopyridine were added. The mixture was
stirred at room temperature overnight and diluted with
dichloromethane. It was washed with saturated ammonium chloride and
brine, dried over anhydrous sodium sulfate and filtered. The
filtrate was evaporated under reduced pressure and the residue was
purified through preparative reverse phase HPLC (C18 column,
acetonitrile/H.sub.2O) to give compound 48 (4.0 mg, y=44%) as a
white solid. .sup.1H NMR (400 Hz, CDCl.sub.3): .delta. 8.25 (d,
J=8.0 Hz, 2H), 7.84 (d, J=4.4 Hz, 2H), 7.57 (s, 2H), 7.29-7.24 (m,
4H), 7.10 (t, J=7.6 Hz, 2H), 7.06 (s, 1H), 6.92 (s, 2H), 6.82 (s,
2H), 5.22 (d, J=12.8 Hz, 2H), 5.17 (d, J=12.4 Hz, 2H), 4.46 (dt,
J.sub.1=11.2 Hz, J.sub.2=4.4 Hz, 2H), 3.98 (bs, 8H), 3.69 (dd,
J.sub.1=16.8 Hz, J.sub.2=10.8 Hz, 2H), 3.62 (d, J=6.4 Hz, 1H), 3.58
(d, J=6.0 Hz, 1H), 3.48 (dd, J.sub.1=17.2 Hz, J.sub.2=3.6 Hz, 2H),
2.82 (t, J=6.4 Hz, 2H), 2.39 (s, 3H), 2.23 (t, J=6.8 Hz, 2H),
1.80-1.78 (m, 4H); HRMS (ESI, m/z): calc. 912.3101 (M+H).sup.+,
found 912.3118.
Compound 49:
##STR00146##
[0233] To a suspension of tris(2-carboxyethyl) phosphine
hydrochloride (TCEP.HCl, 3.8 mg, 0.013 mmol) in a drop of deioned
water (.about.50 .mu.L) was added saturated sodium bicarbonate
dropwise (.about.25 .mu.L) to adjust the pH to about 6.about.7,
followed by addition of pH 6.5 buffer solution (0.1 M phosphate
buffer, 0.3 mL). The obtained mixture was added to the solution of
compound 48 (IGN-08, 4.0 mg, 0.0044 mmol) in methanol (1.0 mL) and
acetonitrile (1.0 mL). The solution was stirred at room temperature
for 1.5 hours and diluted with pH 6.5 buffer and dichloromethane
(the reaction was checked by mass spectra, which showed only the
product signals). It was separated and the organic layer was washed
with brine, dried over anhydrous sodium sulfate and filtered. The
filtrate was evaporated under reduced pressure and the residue was
purified by silica gel chromatography (Combiflash,
dichloromethane/MeOH) to give product 49 as a pale yellow solid
(2.7 mg, y=71%). MS (m/z): found 864.0 (M-H).sup.-, 932.0
(M+MeOH+2H.sub.2O-H).sup.-, 888.1 (M+Na).sup.+, 920.2
(M+MeOH+Na).sup.+, 952.2 (M+2MeOH+Na).sup.+.
Example 9
Compound 50:
##STR00147##
[0235] To a stirred solution of cysteamine hydrochloride (227 mg, 2
mmol) in anhydrous methanol (10 mL) was added aldrithiol (661 mg, 3
mmol). Reaction solution became clear yellow from clear colorless
after the addition of aldrithiol. The mixture was stirred at room
temperature for 21 hours. Triethylamine (279 .mu.l, 2 mmol) was
added and the solvents were removed under reduced pressure. The
residue was purified through silica gel chromatography (Combiflash,
dichloromethane/methanol, 1:0 to 15:1 with 0.1% triethylamine) to
give compound 50 (301 mg, y=81%) as a colorless oil. .sup.1H NMR
(400 Hz, CDCl.sub.3): .delta. 8.52-8.49 (m, 1H), 7.69-7.60 (m, 2H),
7.15-7.10 (m, 1H), 3.04 (t, J=6.0 Hz, 2H), 2.92 (t, J=6.0 Hz), 1.92
(bs, 2H).
Compound 51 (IGN-10):
##STR00148##
[0237] To a solution of IGN-03 acid 41 (from 0.05 mmol of IGN-03
without purification) in anhydrous dichloromethane (1 mL) was added
compound 50 (37 mg, 0.2 mmol),
N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (38
mg, 0.2 mmol) and a tiny particle of dimethylaminopyridine. The
mixture was stirred at room temperature overnight and diluted with
dichloromethane. It was washed with saturated ammonium chloride and
brine, dried over anhydrous sodium sulfate and filtered. The
filtrate was evaporated under reduced pressure. The residue was
purified through silica gel chromatography (Combiflash,
dichloromethane/methanol, 1:0 to 5:1) to give 51 mg of yellow foam,
which was further purified through preparative reverse phase HPLC
(C18 column, acetonitrile/H.sub.2O) to give compound 51 (7.4 mg,
y=15%) as a yellowish solid. .sup.1H NMR (400 Hz, CDCl.sub.3):
.delta. 8.50 (d, J=4.4 Hz, 1H), 8.28 (d, J=8.0 Hz, 2H), 7.87 (d,
J=4.4 Hz, 2H), 7.63-7.59 (m, 3H), 7.52 (d, J=8.0 Hz, 1H), 7.31-7.21
(m, 4H), 7.14-7.09 (m, 4H), 6.96 (s, 2H), 6.85 (s, 2H), 5.23 (d,
J=12.8 Hz, 2H), 5.18 (d, J=12.4 Hz, 2H), 4.49 (dt, J.sub.1=11.2 Hz,
J.sub.2=4.4 Hz, 2H), 4.03-4.00 (m, 8H), 3.72 (dd, J.sub.1=16.8 Hz,
J.sub.2=11.2 Hz, 2H), 3.60 (d, J=5.6 Hz, 1H), 3.57 (d, J=5.6 Hz,
1H), 3.50 (dd, J.sub.1=16.8 Hz, J.sub.2=3.6 Hz, 2H), 2.95 (t, J=5.6
Hz, 2H), 2.30 (t, J=6.4 Hz, 2H), 1.85-1.84 (m, 4H); HRMS (ESI,
m/z): calc. 975.3210 (M+H).sup.+, found 975.3190.
Compound 53:
##STR00149##
[0239] To a stirred solution of 4-benzyloxy-3-methoxybenzyl alcohol
52 (2.5 g, 10 mmol) in acetic anhydride (30 mL) was added
copper(II) nitrate hydrate (2.7 g, 11 mmol) slowly in portion at
0.degree. C. The obtained suspension continued to be stirred at
0.degree. C. for 1 hour and at room temperature for 3 hours. The
reaction mixture was poured on ice/water and stirred for 1 hour. It
was filtered to collect the yellow solid, which was subsequently
dissolved in MeOH/THF (1:1, V/V, 30 mL). Potassium carbonate (2.1
g, 15 mmol) was added and the obtained mixture was stirred at room
temperature for 3 hours. It was concentrated under reduced pressure
and the residue was diluted with dichloromethane, washed with water
and brine, dried over anhydrous sodium sulfate and filtered. The
filtrate was evaporated under reduced pressure and the residue was
purified through silica gel chromatography (CH.sub.2Cl.sub.2/MeOH,
20:1, 18:1, 15:1) to give compound 53 (1.50 g, y=52%) as yellow
solid. .sup.1H NMR (400 Hz, CDCl.sub.3): .delta. 7.78 (s, 1H),
7.48-7.33 (m, 5H), 7.20 (s, 1H), 5.18 (s, 2H), 4.96 (s, 2H), 4.01
(s, 3H).
Example 10
Compound 123:
##STR00150##
[0241] To a stirred solution of compound 122 (137 mg, 0.22 mmol) in
THF (1.5 mL) and MeOH (0.5 mL) was added a solution of lithium
hydroxide monohydrate (46 mg, 1.1 mmol) in deioned water (0.5 mL).
The mixture was stirred in a 60.degree. C. oil bath for 6 hours. It
was cooled to room temperature and diluted with ethyl acetate and
water. The pH was adjusted to 4-5 with 5% hydrochloric acid. The
aqueous layer was extracted with ethyl acetate. The combined
organic layers were washed with saturated sodium bicarbonate and
brine, dried over anhydrous sodium sulfate and filtered. The
filtrate was striped to give compound 123 (87.5 mg, y=65%). MS
(m/z): found 606.1 (M-H).sup.-.
Compound 124:
##STR00151##
[0243] To a solution of acid 123 (87.5 mg, 0.14 mmol) in anhydrous
DMF (1 mL) was added DMAP (21 mg, 0.17 mmol), methyl
5-aminovalerate hydrochloride (26 mg, 0.15 mmol) and EDC (40 mg,
0.21 mmol). The mixture was stirred at room temperature overnight
and diluted with ethyl acetate. It was washed with saturated
ammonium chloride, brine, saturated sodium bicarbonate and brine,
dried over anhydrous sodium sulfate and filtered. The filtrate was
striped and the residue was purified through silica gel
chromatography (Combiflash, dhchloromethane/MeOH) to give compound
124 (71 mg, y=70%) as a yellow foam. .sup.1H NMR (400 Hz,
CDCl.sub.3): .delta. 9.07 (s, 1H), 8.62 (s, 1H), 8.40 (s, 1H), 7.19
(s, 1H), 7.17 (s, 1H), 7.09 (s, 1H), 7.00 (s, 1H), 6.74 (s, 1H),
6.62 (s, 3H), 6.46 (s, 1H), 3.94 (s, 3H), 3.85 (bs, 12H), 3.34-3.31
(m, 2H), 2.32 (t, J=7.2 Hz, 2H), 1.68-1.55 (m, 4H), 1.48 (s, 9H);
MS (ESI, m/z): found 721.0 (M+H)+.
Compound 125:
##STR00152##
[0245] To a solution of IBD monomer 8 (118 mg, 0.4 mmol) and methyl
4-bromobutyrate (109 mg, 0.6 mmol) in anhydrous DMF (1.5 mL) was
added potassium carbonate (111 mg, 0.8 mmol). The mixture was
stirred at room temperature overnight and diluted with ethyl
acetate, washed with saturated ammonium chloride and brine. It was
dried over anhydrous sodium sulfate and filtered. The filtrate was
striped under reduced pressure to give compound 125 (146 mg, y=93%)
as a yellow foam. .sup.1H NMR (400 Hz, CDCl.sub.3): .delta. 8.25
(d, J=8.0 Hz, 1H), 7.84 (d, J=4.4 Hz, 1H), 7.52 (s, 1H), 7.26-7.22
(m, 2H), 7.10-7.06 (m, 1H), 6.81 (s, 1H), 4.44 (dt, J.sub.1=10.8
Hz, J.sub.2=4.0 Hz, 1H), 4.15-4.07 (m, 2H), 3.92 (s, 3H), 3.68 (s,
3H), 3.67-3.64 (m, 1H), 3.46-3.43 (m, 1H), 2.55 (t, J=7.2 Hz, 2H),
2.22-2.15 (m, 2H); MS (ESI, m/z): found 465.2 (M+MeOH+K).sup.+.
Compound 126:
##STR00153##
[0247] The mixture of compound 125 (146 mg, 0.37 mmol) and
trimethyltin hydroxide (669 mg, 3.7 mmol) in anhydrous
1,2-dichloroethane (2 mL) was heated to 80.degree. C. (oil bath
temperature) and stirred at that temperature for 18 hours. The oil
bath was removed and the mixture was diluted with dichloromethane,
washed with brine/5% HCl (0.5 mL), saturated sodium bicarbonate and
brine, dried over anhydrous sodium sulfate and filtered. The
filtrate was striped and the residue was purified through silica
gel chromatography (Combiflash, dichloromethane/MeOH) to give
compound 126 (90 mg, y=64%) as a yellow solid. .sup.1H NMR (400 Hz,
CDCl.sub.3): .delta. 8.26 (d, J=8.0 Hz, 1H), 7.83 (bs, 1H), 7.54
(s, 1H), 7.30-7.25 (m, 2H), 7.11 (t, J=7.6 Hz, 1H), 6.88 (s, 1H),
4.48 (dt, J.sub.1=11.2 Hz, J.sub.2=4.0 Hz, 1H), 4.16-4.13 (m, 2H),
3.94 (s, 3H), 3.71 (dd, J.sub.1=16 Hz, J.sub.2=11.2 Hz, 1H), 3.47
(d, J=16 Hz, 1H), 2.60 (t, J=6.4 Hz, 2H), 2.22-2.18 (m, 2H).
Compound 127 (IGN-11):
##STR00154##
[0249] To a flask containing compound 124 (71 mg, 0.099 mmol) was
added 4N HCl in dioxane (4 mL). The mixture was stirred at room
temperature for 2 hours and striped under reduced pressure. The
residue was dissolved in anhydrous dichloromethane (1.5 mL).
Compound 126 (42 mg, 0.11 mmol), triethylamine (14 .mu.l, 0.1
mmol), EDC (38 mg, 0.2 mmol) and DMAP (1 mg, 0.0099 mmol) were
added subsequently. The reaction mixture was stirred at room
temperature for 22 hours and diluted with dichloromethane, washed
with saturated ammonium chloride and brine. It was dried over
anhydrous sodium sulfate and filtered. The filtrate was striped
under reduced pressure and the residue was purified through silica
gel chromatography (Combiflash, dichloromethane/MeOH) to furnish
compound 127 (14 mg, y=49%) as a yellow solid. HRMS (ESI, m/z):
calc. 983.4164 (M+H).sup.+, found 983.4167.
Example 11
Preparation of IGN-03 NHS Ester (Compound 43) and IGN-07 NHS Ester
(Compound 46) Stock Solution:
[0250] Solutions of IGN-03 NHS ester and IGN-07 NHS ester are made
fresh to a 0.006 M stock based on a molecular weight of 903.93
g/mole (IGN-03 NHS ester) or 902.95 (IGN-07 NHS ester) in
dimethylacetamide (DMA). The stock solution is assayed
spectrophotometrically using a reference extinction coefficient
determined at 330 nm (.epsilon..sub.330 nm=15,231 M.sup.-1
cm.sup.-1).
Example 12
4-(tert-Butoxycarbonylamino)-1-methyl-1H-pyrrole-2-carboxylic
acid
##STR00155##
[0252] Methyl
4-(tert-butoxycarbonylamino)-1-methyl-1H-pyrrole-2-carboxylate
(Eldon E. Baird and Peter B. Dervan, J. Am. Chem. Soc. 1996, 118,
6141-6146) (5.0 g, 19.67 mmol) in 120 ml of 1:1 THF/H.sub.2O was
added 8 g of NaOH in 30 ml of water. The mixture was stirred
overnight, concentrated, diluted with water, extracted with
EtAc/Hexane (1:1). The aqueous solution was adjusted to pH 4.0 with
20% H.sub.3PO.sub.4 and extracted with EtAc (4.times.60 ml). The
organic solutions were combined, dried over MgSO.sub.4, filtered,
evaporated and crystallized with ethanol/EtAc/Hexane to afford 3.81
g (81%) of the title product. .sup.1H NMR (CD.sub.3OD) 12.79 (s,
1H), 10.48 (br, 1H), 7.51 (s, 1H), 6.99 (s, 1H), 3.78 (s, 3H), 1.49
(s, 9H); .sup.13C NMR 158.47, 153.82, 123.64, 121.56, 109.58,
79.52, 37.06, 28.42; MS m/z- 239.2 (M-H).
4-(tert-butoxycarbonylamino)-1-methyl-1H-imidazole-2-carboxylic
acid
##STR00156##
[0254] Methyl
4-(tert-butoxycarbonylamino)-1-methyl-1H-imidazole-2-carboxylate
(5.0 g, 19.59 mmol) in 120 ml of 1:1 THF/H.sub.2O was added 8 g of
NaOH in 30 ml of water. The mixture was stirred overnight,
concentrated, diluted with water, extracted with EtAc/Hexane (1:1).
The aqueous solution was adjusted to pH 4.0 with 20%
H.sub.3PO.sub.4 and extracted with EtAc (4.times.60 ml). The
organic solutions were combined, dried over MgSO.sub.4, filtered,
evaporated and crystallized with ethanol/EtAc/Hexane to afford 3.85
g (81%) of the title product. .sup.1H NMR (DMSO) 9.32 (s, 1H), 7.29
(s, 1H), 3.57 (s, 3H), 1.42 (s, 9H); .sup.13C NMR 172.45, 159.78,
136.93, 135.44, 132.85, 79.50, 35.57, 28.07; MS m/z- 240.8
(M-H).
1-Methyl-4-nitro-1H-pyrrole-2-carboxylic acid
##STR00157##
[0256] Methyl 1-methyl-4-nitro-1H-pyrrole-2-carboxylate (5.0 g,
27.17 mmol) in 120 ml of 1:1 THF/H.sub.2O was added 8 g of NaOH in
30 ml of water. The mixture was stirred overnight, concentrated,
diluted with water, extracted with EtAc/Hexane (1:1). The aqueous
solution was adjusted to pH 3.about.4 with 20% H.sub.3PO.sub.4 and
extracted with EtAc (4.times.60 ml). The organic solutions were
combined, dried over MgSO.sub.4, filtered, evaporated and
crystallized with ethanol/EtAc/Hexane to afford 4.06 g (88%) of the
title product. .sup.1H NMR (DMSO) 13.12 (s, 1H), 8.21 (s, 1H), 7.25
(s, 1H), 3.91 (s, 3H); .sup.13C NMR 160.97, 134.01, 129.16, 123.81,
111.38, 37.47; MS m/z- 169.1 (M-H).
Methyl
1-methyl-4-(1-methyl-4-nitro-1H-pyrrole-2-carboxamido)-1H-pyrrole-2-
-carboxylate
##STR00158##
[0258] In a hydrogenation bottle was added methyl
1-methyl-4-nitro-1H-pyrrole-2-carboxylate (3.0 g, 16.30 mmol), 80
ml of THF, 405 mg of 10% Pd/C and 1.3 ml of HCl (conc.). After
evacuation under vacuum the bottle was placed under 30 psi hydrogen
and shaken for 5 hours. The mixture was filtered through celites,
evaporated to dryness without further purification. To the dry
mixture was added 1-methyl-4-nitro-1H-pyrrole-2-carboxylic acid
(2.75 g, 16.18 mmol), 80 ml of DMA, EDC (8.51 g, 44.27 mmol) and
DIPEA (2.80 ml, 16.10 mmol). The mixture was stirred under Ar
overnight, concentrated, diluted with THF/EtAc (1:2, 150 ml), and
washed 1M NaH.sub.2PO.sub.4/NaCl (conc) and NaHCO.sub.3 (conc)
separately. The organic layer was separated and dried over
MgSO.sub.4, filtered concentrated and crystallized with
THF/H.sub.2O to afford 3.74 g (75%) of the title product. .sup.1H
NMR (DMSO) 10.25 (s, 1H), 8.17 (s, 1H), 7.25 (s, 1H), 6.52 (s, 1H),
6.08 (s, 1H), 3.90 (s, 3H), 3.78 (s, 3H), 3.56 (s, 3H); .sup.13C
NMR 157.87, 156.84, 133.76, 128.16, 123.39, 119.13, 118.18, 111.83,
107.50, 104.17, 51.55, 37.41, 36.03; MS m/z+ 329.1 (M+Na).
Methyl
4-(4-(tert-butoxycarbonylamino)-1-methyl-1H-pyrrole-2-carboxamido)--
1-methyl-1H-imidazole-2-carboxylate
##STR00159##
[0260] Methyl
4-(tert-butoxycarbonylamino)-1-methyl-1H-imidazole-2-carboxylate
(2.50 g, 9.80 mmol) in 30 ml of EtAc was added 6 ml of HCl (conc.).
After stirring for 45 min, the mixture was diluted with ethanol and
toluene, concentrated and co-evaporated with ethanol/toluene (1:1,
3.times.50 ml) to dryness without further purification. To the dry
compound was added
4-(tert-butoxycarbonylamino)-1-methyl-1H-pyrrole-2-carboxylic acid
(2.35 g, 9.8 mmol), EDC (5.60 g, 29.1 mmol), DIPEA (1.70 ml, 9.8
mmol) and 80 ml of DMA. The mixture was stirred under Ar overnight,
concentrated, diluted with THF/EtAc (1:2, 150 ml), and washed 1M
NaH.sub.2PO.sub.4/NaCl (conc) and NaHCO.sub.3 (conc) separately.
The organic solvent layer was separated and dried over MgSO.sub.4,
filtered, concentrated and purified on SiO2 chromatography eluted
with EtAc/DCM (1:25 to 1:15) to afford 2.72 g (73%) of the title
product. .sup.1H NMR (DMF-d7) 10.27 (s, 1H), 9.08 (s, 1H), 7.41 (s,
1H), 7.32 (s, 1H), 7.07 (s, 1H), 4.10 (s, 3H), 3.93 (s, 3H), 3.84
(s, 3H), 1.47 (s, 9H); .sup.13C NMR 162.62, 161.20, 153.82, 145.32,
144.12, 132.56, 128.46, 124.39, 119.83, 79.51, 52.75, 36.06, 35.83,
28.88; MS m/z+ 400.2 (M+Na).
Methyl
4-(4-(tert-butoxycarbonylamino)-1-methyl-1H-imidazole-2-carboxamido-
)-1-methyl-1H-imidazole-2-carboxylate
##STR00160##
[0262] Methyl
4-(tert-butoxycarbonylamino)-1-methyl-1H-imidazole-2-carboxylate
(2.50 g, 9.80 mmol) in 30 ml of EtAc was added 6 ml of HCl (conc.).
After stirred for 30 min, the mixture was diluted with ethanol and
toluene, concentrated and co-evaporated with ethanol/toluene (1:1,
3.times.50 ml) to dryness compound without further purification. To
the dryness compound was added
4-(tert-butoxycarbonylamino)-1-methyl-1H-imidazole-2-carboxylic
acid (2.36 g, 9.8 mmol), EDC (5.90 g, 30.7 mmol), DIPEA (1.70 ml,
9.8 mmol) and 80 ml of DMA. The mixture was stirred under Ar
overnight, concentrated, diluted with THF/EtAc (1:2, 150 ml), and
washed 1M NaH.sub.2PO.sub.4/NaCl (conc) and NaHCO.sub.3 (conc)
separately. The organic solvent layer was separated and dried over
MgSO.sub.4, filtered, concentrated and purified on SiO2
chromatography eluted with EtAc/DCM (1:25 to 1:15) to afford 2.65 g
(71.5%) of the title product. .sup.1H NMR (DMSO) 11.17 (s, 1H),
10.48 (s, 1H), 7.58 (s, 1H), 7.32 (s, 1H), 4.01 (s, 3H), 3.94 (s,
3H), 3.92 (s, 3H), 1.45 (s, 9H); .sup.13C NMR 160.60, 157.30,
135.92, 135.45, 132.86, 126.12, 114.83, 79.50, 52.70, 35.58, 34.92,
28.08; MS m/z+ 401.8 (M+Na).
1-Methyl-4-(1-methyl-4-nitro-1H-pyrrole-2-carboxamido)-1H-pyrrole-2-carbox-
ylic acid
##STR00161##
[0264] Methyl
1-methyl-4-(1-methyl-4-nitro-1H-pyrrole-2-carboxamido)-1H-pyrrole-2-carbo-
xylate (2.0 g, 6.53 mmol) in 50 ml of DMA was added 2 g of LiOH in
30 ml of water. The mixture was stirred overnight, concentrated,
diluted with water, extracted with EtAc/Hexane (1:1). The aqueous
solution was adjusted to pH 4.0 with 20% H.sub.3PO.sub.4 to form
precipitates. The precipitates were filtered, washed with water and
dried over P.sub.2O.sub.5 with vacuum to afford 1.4 g (73%) of the
title product. H NMR (DMF-d7) 10.34 (br, 1H), 8.17 (s, 1H), 7.62
(s, 1H), 7.51 (s, 1H), 7.00 (s, 1H), 4.09 (s, 1H), 3.91 (s, 1H);
.sup.13C NMR 158.47, 135.61, 129.11, 127.77, 123.65, 121.57,
121.50, 109.48, 108.52, 38.38, 37.05; MS m/z- 291.0 (M-H).
4-(4-(tert-Butoxycarbonylamino)-1-methyl-1H-pyrrole-2-carboxamido)-1-methy-
l-1H-imidazole-2-carboxylic acid
##STR00162##
[0266] Methyl
4-(4-(tert-butoxycarbonylamino)-1-methyl-1H-pyrrole-2-carboxamido)-1-meth-
yl-1H-imidazole-2-carboxylate (2.0 g, 5.30 mmol) in 50 ml of DMA
was added 2 g of LiOH in 30 ml of water. The mixture was stirred
overnight, concentrated, diluted with water, extracted with
EtAc/Hexane (1:1). The aqueous solution was adjusted to pH 4.0 with
20% H.sub.3PO.sub.4 to form precipitates. The precipitates were
filtered, washed with water and dried over P.sub.2O.sub.5 with
vacuum to afford 1.44 g (75%) of the title product. .sup.1H NMR
(DMSO) 10.41 (br, 1H), 9.07 (s, 1H), 7.48 (s, 1H), 6.97 (s, 1H),
6.88 (s, 1H), 3.92 (s, 1H), 3.81 (s, 1H), 1.47 (s, 9H); .sup.13C
NMR 160.46, 158.42, 152.85, 145.21, 135.81, 129.11, 127.77, 122.39,
121.57, 113.58, 79.81, 36.06, 35.25, 28.17; MS m/z- 362.1
(M-H).
Methyl
4-(4-(4-(4-(tert-butoxycarbonylamino)-1-methyl-1H-pyrrole-2-carboxa-
mido)-1-methyl-1H-imidazole-2-carboxamido)-1-methyl-1H-pyrrole-2-carboxami-
do)-1-methyl-1H-pyrrole-2-carboxylate
##STR00163##
[0268] In a hydrogenation bottle was added methyl
1-methyl-4-(1-methyl-4-nitro-1H-pyrrole-2-carboxamido)-1H-pyrrole-2-carbo-
xylate (1.0 g, 3.27 mmol), 20 ml of THF, 305 mg of 10% Pd/C (50%
wet) and 0.25 ml of HCl (conc.). After evacuation under vacuum the
bottle was placed under 50 psi hydrogen and shaken for 4 hours. The
mixture was filtered through celite, evaporated to dryness without
further purification. To the dried mixture was added
4-(4-(tert-butoxycarbonylamino)-1-methyl-1H-pyrrole-2-carboxamido)-1-meth-
yl-1H-imidazole-2-carboxylic acid (1.15 g, 3.16 mmol), 10 ml of
DMA, EDC (2.0 g, 10.4 mmol) and DIPEA (0.70 ml, 4.02 mmol). The
mixture was stirred under Ar overnight, concentrated, diluted with
Hexane/EtAc (1:1, 10 ml) and water 10 ml to form precipitates. The
precipitates were filtered, washed 1M NaH.sub.2PO.sub.4, 1 M
NaHCO.sub.3 and water, dried over P.sub.2O.sub.5 with vacuum to
afford 1.61 g (82%) of the title product. H NMR (DMF-d7) 10.29 (s,
1H), 10.20 (s, 1H), 10.12 (s, 1H), 9.08 (s, 1H), 7.58 (s, 1H), 7.47
(d, 1H, J=1.7 Hz), 7.26 (d, 1H, J=1.5 Hz), 7.15 (d, 1H, J=1.5 Hz),
6.98 (s, 1H), 6.91 (d, 1H, J=1.8 Hz), 6.86 (s, 1H), 3.97 (s, 3H),
3.82 (s, 3H), 3.73 (s, 3H), 3.56 (s, 3H), 1.45 (s, 9H); .sup.13C
NMR 162.16, 160.05, 159.90, 157.20, 154.31, 137.88, 135.35, 124.56,
124.39, 124.24, 123.09, 120.09, 119.82, 115.32, 105.58, 102.27,
79.31, 51.51, 38.13, 36.01, 35.80, 35.08, 28.79; MS m/z+ 644.2
(M+Na).
Methyl
1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-4-nitro-1H-pyrrole-2-c-
arboxamido)-1H-pyrrole-2-carboxamido)-1H-pyrrole-2-carboxamido)-1H-pyrrole-
-2-carboxylate
##STR00164##
[0270] In a hydrogenation bottle was added methyl
1-methyl-4-(1-methyl-4-nitro-1H-pyrrole-2-carboxamido)-1H-pyrrole-2-carbo-
xylate (2.0 g, 6.53 mmol), 80 ml of DMA, 500 mg of 10% Pd/C (50%
wet) and 0.4 ml of HCl (conc.). After evacuation under vacuum, the
bottle was placed under 50 psi hydrogen and shaken for 4 hours. The
mixture was filtered through celite, evaporated to dryness without
further purification. To the dry mixture was added
1-methyl-4-(1-methyl-4-nitro-1H-pyrrole-2-carboxamido)-1H-pyrrole-2-carbo-
xylic acid (1.49 g, 5.10 mmol), 30 ml of DMA, EDC (4.0 g, 20.8
mmol) and DIPEA (1.0 ml, 5.75 mmol). The mixture was stirred under
Ar overnight, concentrated, diluted with Hexane/EtAc (1:1, 10 ml)
and water 10 ml to form precipitates. The precipitates were
filtered, washed 1M NaH.sub.2PO.sub.4, 1 M NaHCO.sub.3 and water,
dried over P.sub.2O.sub.5 under vacuum to afford 2.13 g (76%) of
the title product. .sup.1H NMR (DMSO) 10.28 (s, 1H), 10.25 (s, 1H),
9.78 (s, 1H), 8.18 (s, 1H), 7.86 (s, 1H), 7.52 (s, 1H), 7.31 (d,
1H, J=1.7 Hz), 7.25 (s, 1H), 7.23 (s, 1H), 7.17 (d, 1H, J=1.5 Hz),
6.98 (s, 1H), 6.71 (s, 1H), 4.02 (s, 3H), 3.94 (s, 3H), 3.83 (s,
3H), 3.73 (s, 3H), 3.56 (s, 3H), 1.47 (s, 9H); .sup.13C NMR 160.78,
158.93, 158.06, 157.81, 135.25, 127.28, 126.36, 123.78, 122.57,
121.91, 121.40, 120.94, 119.65, 110.73, 108.39, 107.34, 103.75,
80.81, 51.57, 39.74, 38.52, 38.22, 37.08, 28.63; MS m/z+ 573.2
(M+Na).
4-(4-(4-(4-(tert-butoxycarbonylamino)-1-methyl-1H-pyrrole-2-carboxamido)-1-
-methyl-1H-imidazole-2-carboxamido)-1-methyl-1H-pyrrole-2-carboxamido)-1-m-
ethyl-1H-pyrrole-2-carboxylic acid
##STR00165##
[0272] Methyl
4-(4-(4-(4-(tert-butoxycarbonylamino)-1-methyl-1H-pyrrole-2-carboxamido)--
1-methyl-1H-imidazole-2-carboxamido)-1-methyl-1H-pyrrole-2-carboxamido)-1--
methyl-1H-pyrrole-2-carboxylate (510 mg, 0.82 mmol) in 10 ml of DMA
was added 0.8 g of LiOH in 10 ml of water. The mixture was stirred
overnight, concentrated, diluted with water, extracted with
EtAc/Hexane (1:1). The aqueous solution was adjusted to pH 4.0 with
20% H.sub.3PO.sub.4 to form precipitates. The precipitates were
filtered, washed with water and dried over P.sub.2O.sub.5 under
vacuum to afford 363 mg (73%) of the title product. .sup.1H NMR
(DMF-d7) 10.31 (s, 1H), 10.18 (s, 1H), 10.11 (s, 1H), 9.10 (s, 1H),
7.58 (s, 1H), 7.54 (s, 1H), 7.41 (s, 1H), 7.33 (s, 1H), 7.21 (s,
1H), 7.10 (s, 1H), 7.06 (s, 1H), 4.10 (s, 1H), 3.98 (s, 1H), 3.95
(s, 1H), 3.93 (s, 1H), 1.47 (s, 9H); .sup.13C NMR 162.16, 160.05,
159.90, 157.20, 154.31, 137.88, 135.35, 124.56, 124.39, 123.51,
123.09, 121.76, 120.09, 119.83, 118.96, 115.32, 109.53, 105.58,
102.27, 79.32, 38.13, 36.02, 35.81, 34.88, 28.79; MS m/z- 606.2
(M-H).
S-3-(Tert-Butoxycarbonylamino)Propyl Ethanethioate
##STR00166##
[0274] tert-Butyl 3-hydroxypropylcarbamate (3.22 g, 18.37 mmol) in
100 ml of DCM at 0.degree. C. was added thiolacetic acid (2.0 ml,
26.73 mmol) and triphenylphosphine (7.0 g, 26.73 mmol) under Ar.
After stirred at 0.degree. C. for 15 min, DIAD (6.0 ml, 28.93) was
added. The mixture was stirred at 0.degree. C. for 2 h then RT
overnight. The mixture was concentrated, diluted with 120 ml of
EtAc/Hexane (1:2), filtered through celite. The solution was washed
with NaHCO.sub.3 (conc.)/NaCl (conc.) and 1 M NaH.sub.2PO.sub.4
respectively, dried over MgSO.sub.4, filtered, evaporated and
purified on SiO.sub.2 chromatography eluted with EtAc/Hexane (1:7
to 1:6) to afford 3.22 g (75%) of the title compound. .sup.1H NMR
(CDCl.sub.3) 3.09 (t, 2H, J=6.5 Hz), 2.84 (t, 2H, J=6.9 Hz), 2.27
(s, 3H), 1.69 (dt, 2H, J=6.8, 13.5 Hz), 1.38 (s, 9H); .sup.13C NMR
196.35, 156.16, 79.50, 39.26, 30.79, 30.24, 28.61, 26.44; MS m/z+
256.0 (M+Na).
S-3-(Tert-Butoxycarbonyl(Methyl)Amino)Propyl Ethanethioate
##STR00167##
[0276] To a solution of NaH (0.57 g, 60%, 14.25 mmol) in 20 ml of
THF at 0.degree. C. was added S-3-(tert-butoxycarbonylamino)propyl
ethanethioate (1.25 g, 5.36 mmol) under Ar. After stirring at
0.degree. C. for 30 min, MeI (1.0 ml, 16.06 mmol) was added to the
mixture. Stirring was continued at 0.degree. C. for 2 h then RT
overnight. The mixture was concentrated, redisolved in 120 ml of
EtAc/Hexane (1:2), washed with 1 M NaH.sub.2PO.sub.4 NaCl (conc.),
dried over MgSO.sub.4, filtered, evaporated and purified on
SiO.sub.2 chromatography eluted with EtAc/Hexane (1:7) to afford
1.121 g (85%) of the title compound. .sup.1H NMR (CDCl.sub.3) 3.69
(t, 2H, J=7.3 Hz), 2.41 (t, 2H, J=7.3 Hz), 2.39 (s, 3H), 2.03 (s,
3H), 1.76 (m, 2H), 1.47 (s, 9H); .sup.13C NMR 173.21, 153.39,
83.28, 43.67, 31.84, 28.26, 28.19, 27.11, 15.65; MS m/z+ 270.0
(M+Na).
S-3-(Methylamino)Propyl Ethanethioate Hydrogen Chloride Salt
##STR00168##
[0278] S-3-(tert-Butoxycarbonyl(methyl)amino)propyl ethanethioate
(206 mg, 0.834 mmol) in 4 ml of EtAc was added 1.0 ml of HCl
(conc.) at RT. The mixture was stirred at RT for 1 h, diluted with
ethanol/toluene (6 ml, 1:1), evaporated and co-evaporated with
ethanol/toluene (3.times.10 ml), crystallized with
ethanol/EtAc/Hexane, filtered, and dried over a vacuum to afford
135 mg (88%) of the title compound. .sup.1H NMR (CDCl.sub.3) 9.70
(br, 1H), 8.56 (br, 1H), 3.42 (m, 2H), 2.52 (m, 2H), 2.35 (s, 3H),
2.05 (s, 3H), 1.88 (m, 2H); .sup.13C NMR 174.64, 40.57, 31.57,
27.69, 20.94, 15.62; MS m/z+ 170.0 (M+Na), 148.10 (M+H).
Tert-Butyl 2-(Pyridin-2-Yldisulfanyl)Ethylcarbamate (217)
##STR00169##
[0280] To the solution of 2,2'-dithiolpyridine (3.97 g, 18.02 mmol)
in 100 ml of methanol and 80 ml of 1 M NaH.sub.2PO.sub.4, pH 6.8
was added tert-Butyl 2-mercaptoethylcarbamate (1.00 g, 5.65 mmol)
in 50 ml of methanol. The mixture was stirred under Ar overnight,
concentrated, extracted with dichloromethane, dried over
MgSO.sub.4, filtered, evaporated and purified on SiO.sub.2
chromatography eluted with EtAc/Hexane (1:10 to 1:6) to afford
1.341 g (83%) of the title compound. .sup.1H NMR (CDCl.sub.3) 8.39
(m, 1H), 7.56 (m, 1H), 7.49 (m, 1H), 7.03 (m, 1H), 7.00 (m, 1H),
3.34 (m, 2H), 2.84 (m, 2H), 1.37 (s, 9H); .sup.13C NMR 160.05,
159.39, 159.07, 149.87, 137.21, 120.78, 79.48, 39.58, 38.96, 28.57;
MS m/z+ 309.2 (M+Na).
2-(pyridin-2-yldisulfanyl)ethanamine
##STR00170##
[0282] tert-Butyl 2-(pyridin-2-yldisulfanyl)ethylcarbamate (1.06 g,
3.70 mmol) in 16 ml of EtAc was added 4.0 ml of HCl (conc.) at RT.
The mixture was stirred at RT for 0.5 h, diluted with
ethanol/toluene (6 ml, 1:1), evaporated and co-evaporated with
ethanol/toluene (3.times.10 ml), crystallized with
ethanol/EtAc/Hexane, filtered, and dried over a vacuum to afford
135 mg (88%) of the title compound. .sup.1H NMR (CD.sub.3OD) 7.58
(m, 1H), 7.47 (m, 1H), 7.06 (m, 1H), 6.83 (m, 1H), 3.34 (m, 2H),
3.02 (m, 2H); .sup.13C NMR 158.69, 149.07, 137.81, 122.48, 120.98,
39.52, 36.94; MS m/z+ 187.10 (M+H).
Methyl 4-Bromobutanoate (223)
##STR00171##
[0284] 4-Bromobutanoyl chloride (3.1 ml, 25.28 mmol) was added to
15 ml of dry metanol at 0.degree. C. Stirring was continued at
0.degree. C. under Ar for 2 h then at RT overnight. The mixture was
evaporated, diluted with EtAc/Hexane (1:5), filtered through
SiO.sub.2 gel, and evaporated to afford 4.50 g (99%) of the title
compound. .sup.1H NMR (CDCl.sub.3) 3.65 (s, 3H), 3.43 (t, 2H, J=6.5
Hz), 2.47 (t, 2H, J=7.1 Hz), 2.13 (dt, 2H, J=6.7, 13.6 Hz);
.sup.13C NMR 173.08, 51.84, 32.82, 32.34, 27.89; MS m/z+ 203.0
(M+Na).
(Z)-methyl
4-(7-methoxy-2',3'-benzo[e]-5-oxo-5,11a-dihydro-1H-benzo[e]pyrr-
olo[1,2-a][1,4]diazepin-8-yloxy)butanoate
##STR00172##
[0286]
(Z)-2,3-Benzo-8-hydroxy-7-methoxy-1H-benzo[e]pyrrolo[1,2-a][1,4]dia-
zepin-5(11aH)-one (60 mg, 0.20 mmol) in 4 ml of acetone was added
Cs.sub.2CO.sub.3 (90 mg, 0.28 mmol), followed added methyl
4-bromobutanoate (50 mg, 0.27 mmol). The mixture was stirred under
Ar over night, evaporated, and purified on SiO.sub.2 chromatography
eluted with EtAc/DCM (1:5 to 1:3) to afford 50.1 mg (63%) of the
title compound. .sup.1H NMR (CDCl.sub.3) 8.19 (d, 1H, J=7.9 Hz),
7.80 (d, 1H, J=4.2 Hz), 7.48 (s, 1H), 7.19 (m, 2H), 7.03 (d, 1H,
J=7.4 Hz), 6.77 (s, 1H), 4.41 (m, 1H), 3.88 (s, 3H), 3.64 (m, 2H),
3.62 (s, 3H), 3.42 (dd, 1H, J=3.4, 13.7 Hz), 2.50 (t, 2H, J=7.2
Hz), 2.12 (t, 2H, J=6.8 Hz); .sup.13C NMR, 173.64, 164.12, 163.24,
152.25, 148.41, 142.28, 140.34, 129.69, 128.39, 124.97, 120.85,
117.15, 112.15, 110.68, 68.08, 56.40, 55.18, 51.90, 32.84, 30.64,
24.50; MS m/z+ 187.10 (M+H). MS m/z+ 417.2 (M+Na), 435.2
(M+Na+H.sub.2O).
4-(7-methoxy-2,3-benzo[e]-5-oxo-5,11a-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,-
4]diazepin-8-yloxy) butanoic acid
##STR00173##
[0288] (Z)-methyl
4-(7-methoxy-2',3'-benzo[e]-5-oxo-5,11a-dihydro-1H-benzo[e]pyrrolo[1,2-a]-
[1,4]diazepin-8-yloxy)butanoate (41 mg, 0.104 mmol) and
trimethyltin hydroxide (302 mg, 1.67 mmol) in 15 ml of
dichloroethane was refluxed at 85.degree. C. under Ar overnight.
The mixture was washed with 1 M NaH.sub.2PO.sub.4, pH 3.5, dried
over MgSO.sub.4, filtered, evaporated and purified on SiO.sub.2
chromatography eluted with EtAc/DCM/HCl (1:25:0.01%) to afford 30
mg (76%) of the title compound. .sup.1H NMR (CDCl.sub.3) 8.18 (d,
1H, J=7.9 Hz), 7.85 (m, 1H), 7.46 (s, 1H), 7.20 (m, 2H), 7.04 (d,
1H, J=7.4 Hz), 6.81 (s, 1H), 4.40 (m, 1H), 3.86 (s, 3H), 3.63 (m,
2H), 3.23 (dd, 1H, J=10.2, 16.3 Hz), 2.52 (t, 2H, J=7.2 Hz), 2.12
(t, 2H, J=6.8 Hz); .sup.13C NMR, 173.64, 164.12, 163.24, 152.25,
148.41, 142.28, 140.34, 129.69, 128.39, 125.10, 120.85, 117.19,
112.15, 110.68, 67.94, 56.43, 55.18, 31.81, 30.64, 24.21; MS m/z-
397.0 (M+H.sub.2O-H).
4-{[4-({4-[4-(4-(7-methoxy-2',3'-benzo[e]-5-oxo-5,11a-dihydro-1H-benzo[e]p-
yrrolo[1,2-a][1,4]diazepin-8-yloxy)butyrylamino]-1-methyl-1H-pyrrole-2-car-
bonyl}amino)-1-methyl-1H-imidazole-2-carbonyl]amino}-1-methyl-1H-pyrrole-2-
-carbonyl]-amino}-1-methyl-1H-pyrrole-2-carboxylic acid methyl
ester (226)
##STR00174##
[0290] To methyl
4-(4-(4-(4-(tert-butoxycarbonylamino)-1-methyl-1H-pyrrole-2-carboxamido)--
1-methyl-1H-imidazole-2-carboxamido)-1-methyl-1H-pyrrole-2-carboxamido)-1--
methyl-1H-pyrrole-2-carboxylate (15 mg, 0.024 mmol) in 4 ml of EtAc
was added 1.0 ml of HCl (conc.). The mixture was stirred at RT for
0.5 h, diluted with ethanol/toluene (6 ml, 1:1), evaporated and
co-evaporated with ethanol/toluene (3.times.10 ml), and dried over
a vacuum. The solid compound was used directly without further
purification. To the solid was added
4-(7-methoxy-2',3'-benzo[e]-5-oxo-5,11a-dihydro-1H-benzo[e]pyrrolo[-
1,2-a][1,4]diazepin-8-yloxy) butanoic acid (6 mg, 0.015 mmol), EDC
(40 mg, 0.21 mmol), DIPEA (4 ul, 0.023 mmol) and 1 ml of DMA. The
mixture was stirred under Ar over night, evaporated, and purified
on HPLC preparative C-18 column (.PHI.10 mm.times.200 mm column,
flow rate 9 mL/min and a gradient solvent system going from 75:25
solvent A:B at time 0-5 min to 40:60 A:B at 15 min then to 20:80
A:B at 25 min until to 10:90 A:B at 30 min. Solvent A--water,
solvent B--acetonitrile/dioxane (1:2)) and lyophilized to afford a
white solid (4.2 mg (30%) of the title compound). MS m/z- 900.3
(M+H.sub.2O-H).
S-3-(4-(4-(4-(4-(tert-butoxycarbonylamino)-1-methyl-1H-pyrrole-2-carboxami-
do)-1-methyl-1H-imidazole-2-carboxamido)-1-methyl-1H-pyrrole-2-carboxamido-
)-N,1-dimethyl-1H-pyrrole-2-carboxamido)propyl ethanethioate
(227)
##STR00175##
[0292]
4-(4-(4-(4-(tert-butoxycarbonylamino)-1-methyl-1H-pyrrole-2-carboxa-
mido)-1-methyl-1H-imidazole-2-carboxamido)-1-methyl-1H-pyrrole-2-carboxami-
do)-1-methyl-1H-pyrrole-2-carboxylic acid (256 mg, 0.42 mmol), NHS
(60 mg, 0.52 mmol) and EDC (500 mg, 2.60 mmol) in 4 ml of DMA were
stirred under Ar for 2 h, then S-3-(methylamino)propyl
ethanethioate hydrogen chloride salt (76.5 mg, 0.42 mmol) was added
and the mixture was kept stirring for 24 h, evaporated and purified
on SiO.sub.2 chromatography eluted with THF/DCM (1:5 to 1:4) to
afford 198 mg (64%) of the title compound. .sup.1H NMR (DMSO) 10.21
(s, 1H), 10.09 (s, 1H), 10.06 (s, 1H), 9.08 (s, 1H), 7.76 (d, 1H,
J=1.7 Hz), 7.52 (s, 1H), 7.28 (s, 1H), 7.21 (d, 1H, J=1.7 Hz), 6.97
(s, 1H), 6.87 (s, 1H), 3.98 (s, 1H), 3.86 (s, 3H), 3.75 (s, 3H),
3.73 (s, 3H), 3.66 (m, 2H), 2.85 (s, 3H), 2.60 (m, 2H), 2.01 (s,
3H), 1.45 (s, 9H); .sup.13C NMR 173.31, 162.16, 160.05, 159.90,
157.20, 154.31, 137.88, 135.35, 124.56, 124.39, 123.51, 123.09,
121.76, 120.09, 119.83, 118.96, 115.32, 109.53, 105.58, 102.27,
79.32, 43.67, 38.13, 36.02, 35.81, 34.88, 31.84, 28.79, 28.26,
28.21, 27.01; MS m/z+ 759.2 (M+Na).
(Z)--S-3-(4-(4-(4-(4-(4-(7-methoxy-2,3-benzo[e]-5-oxo-5,11a-dihydro-1H-ben-
zo[e]pyrrolo[1,2-a][1,4]diazepin-8-yloxy)butanamido)-1-methyl-1H-pyrrole-2-
-carboxamido)-1-methyl-1H-imidazole-2-carboxamido)-1-methyl-1H-pyrrole-2-c-
arboxamido)-N,1-dimethyl-1H-pyrrole-2-carboxamido)propyl
ethanethioate
##STR00176##
[0294]
S-3-(4-(4-(4-(4-(tert-butoxycarbonylamino)-1-methyl-1H-pyrrole-2-ca-
rboxamido)-1-methyl-1H-imidazole-2-carboxamido)-1-methyl-1H-pyrrole-2-carb-
oxamido)-N,1-dimethyl-1H-pyrrole-2-carboxamido)propyl ethanethioate
(227) (27 mg, 0.037 mmol) was stirred in 2 ml of dioxane and 0.5 ml
of HCl (conc) for 15 min, diluted with ethanol/toluene (6 ml, 1:1),
evaporated and co-evaporated with ethanol/toluene (4.times.10 ml),
crystallized with EtOH/DCM/Hexane and dried over a vacuum to afford
21 mg of solid. The solid compound was used directly without
further purification. To the solid was added
4-(7-methoxy-2,3-benzo[e]-5-oxo-5,11a-dihydro-1H-benzo[e]pyrrolo[1,2-a][1-
,4]diazepin-8-yloxy) butanoic acid (10 mg, 0.026 mmol), EDC (101
mg, 0.52 mmol), DIPEA (5 ul, 0.028 mmol) and 2 ml of DMA. The
mixture was stirred overnight, evaporated, diluted with DCM, washed
with 1 M NaH.sub.2PO.sub.4/NaCl (conc), pH 4.0, dried over
MgSO.sub.4, filtered, evaporated and purified on HPLC preparative
C-18 column (<10 mm.times.200 mm column, flow rate 9 mL/min and
a gradient solvent system going from 75:25 solvent A:B at time 0-5
min to 40:60 A:B at 15 min then to 20:80 A:B at 25 min until to
10:90 A:B at 30 min. Solvent A--water, solvent
B--acetonitrile/dioxane (1:2)) and lyophilized to afford a white
solid 8.2 mg (32%) of the title compound. MS m/z- 1015.1
(M+H.sub.2O-H), UV .epsilon..sub.(l=305 nm)=32800
M.sup.-1cm.sup.-1.
tert-Butyl
1-methyl-5-(1-methyl-2-(1-methyl-5-(1-methyl-5-(2-(pyridin-2-yl-
disulfanyl)ethylcarbamoyl)-1H-pyrrol-3-ylcarbamoyl)-1H-pyrrol-3-ylcarbamoy-
l)-1H-imidazol-4-ylcarbamoyl)-1H-pyrrol-3-ylcarbamate (229)
##STR00177##
[0296]
4-(4-(4-(4-(tert-butoxycarbonylamino)-1-methyl-1H-pyrrole-2-carboxa-
mido)-1-methyl-1H-imidazole-2-carboxamido)-1-methyl-1H-pyrrole-2-carboxami-
do)-1-methyl-1H-pyrrole-2-carboxylic acid (102 mg, 0.17 mmol),
2-(pyridin-2-yldisulfanyl)ethanamine hydrogen chloride salt (40 mg,
0.18 mmol), DIPEA (30 ul, 0.17 mmol) and EDC (200 mg, 1.04 mmol) in
2 ml of DMA were stirred under Ar for 24 h, evaporated and purified
on SiO.sub.2 chromatography eluted with THF/DCM (1:5 to 1:4) to
afford 90 mg (68%) of the title compound. .sup.1H NMR (DMSO) 10.93
(s, 1H), 10.19 (s, 1H), 10.06 (s, 1H), 9.03 (s, 1H), 8.81 (m 1H),
8.29 (m, 1H), 8.03 (m, 1H), 7.68 (s, 1H), 7.47 (s, 1H), 7.28 (s,
1H), 7.24 (s, 1H), 7.18 (m, 1H), 6.87 (s, 1H), 3.96 (s, 1H), 3.86
(s, 3H), 3.75 (s, 3H), 3.73 (s, 3H), 3.58 (m, 2H), 2.48 (m, 2H),
1.45 (s, 9H); MS m/z+ 798.0 (M+Na), 776.0 (M+H).
4-(4-(4-(7-methoxy-2,3-benzo[e]-1-5-oxo-5,11a-dihydro-1H-benzo[e]pyrrolo[1-
,2-a][1,4]diazepin-8-yloxy)butanamido)-1-methyl-1H-pyrrole-2-carboxamido)--
1-methyl-N-(1-methyl-5-(1-methyl-5-(methyl(2-(pyridin-2-yldisulfanyl)ethyl-
)carbamoyl)-1H-pyrrol-3-ylcarbamoyl)-1H-pyrrol-3-yl)-1H-imidazole-2-carbox-
amide
##STR00178##
[0298] tert-Butyl
1-methyl-5-(1-methyl-2-(1-methyl-5-(1-methyl-5-(2-(pyridin-2-yldisulfanyl-
)ethylcarbamoyl)-1H-pyrrol-3-ylcarbamoyl)-1H-pyrrol-3-ylcarbamoyl)-1H-imid-
azol-4-ylcarbamoyl)-1H-pyrrol-3-ylcarbamate (229) (30 mg, 0.038
mmol) was stirred in 2 ml of dioxane and 0.5 ml of HCl (conc) for
15 min, diluted with ethanol/toluene (6 ml, 1:1), evaporated and
co-evaporated with ethanol/toluene (4.times.10 ml), crystallized
with EtOH/DCM/Hexane and dried over vacuum to afford 19.5 mg of
solid. The solid compound was used directly without further
purification. To the solid was added
4-(7-methoxy-2,3-benzo[e]-5-oxo-5,11a-dihydro-1H-benzo[e]pyrrolo[1,2-a][1-
,4]diazepin-8-yloxy) butanoic acid (10 mg, 0.026 mmol), EDC (102
mg, 0.52 mmol), DIPEA (5 ul, 0.028 mmol) and 2 ml of DMA. The
mixture was stirred overnight, evaporated, diluted with DCM, washed
with 1 M NaH.sub.2PO.sub.4/NaCl (conc), pH 4.0, dried over
MgSO.sub.4, filtered, evaporated and purified on HPLC preparative
C-18 column (.PHI.10 mm.times.200 mm column, flow rate 9 mL/min and
a gradient solvent system going from 75:25 solvent A:B at time 0-5
min to 40:60 A:B at 15 min then to 20:80 A:B at 25 min until to
10:90 A:B at 30 min. Solvent A--water, solvent
B--acetonitrile/dioxane (1:2)) and lyophilized to afford a white
solid 7.5 mg (27%) of the title compound. MS m/z- 1050.0
(M+H.sub.2O-H), UV .epsilon..sub.(l=305 nm)=32855 M.sup.-1
cm.sup.-1.
1-(4-(2-Bromoethoxy)Phenyl)Ethanone
##STR00179##
[0300] 1-(4-hydroxyphenyl)ethanone (8.2 g, 60.2 mmol), potassium
carbonate (15.2 g, 110.1 mmol), and KI (1.0 g, 6.0 mmol) in 100 DMF
was stirred for 5 min, then 1,2-dibromoethane (60 ml, 696.2 mmol)
was added. The mixture was stirred overnight, evaporated, diluted
with EtAc/Hexane (1:1), washed with 0.1 M HCl/NaCl (conc), dried
over MgSO.sub.4, filtered, evaporated and purified by SiO.sub.2
chromatography eluted with EtAc/Hexane (1:3 to 2:3) to afford 12.41
g (85.2%) of the title compound. .sup.1H NMR (CDCl.sub.3) 7.87
(ddd, 2H, J=2.8, 4.9, 9.7 Hz), 6.88 (ddd, 2H, J=2.8, 4.9, 9.6 Hz),
4.29 (t, 2H, J=6.2 Hz), 3.59 (t, 2H, J=6.2 Hz); .sup.13C NMR
196.88, 162.11, 131.15, 130.54, 113.80, 68.06, 29.50, 26.62; MS
m/z+ 264.80 (M+Na), 266.80 (M+2+Na).
(5-Hydroxy-1,3-Phenylene)Dimethanol
##STR00180##
[0302] To a solution of 100 ml of 2.0 M LiAlH.sub.4 in THF at
0.degree. C. was added dimethyl 5-hydroxy isophthalate (12.3 g,
58.5 mmol) in 120 ml of THF in 15 min under Ar. The mixture was
stirred at 0.degree. C. for 30 min then at RT overnight. The
mixture was quenched with 20 ml of methanol at 0.degree. C., and
the mixture was adjusted to pH 5.0 with addition of
H.sub.3PO.sub.4, filtered through celite, evaporated and
crystallized with ether/hexane to afford 76.6 (85%) of the title
compound. .sup.1H NMR (DMSO) 6.68 (s, 1H), 6.61 (s, 2H), 4.69 (s,
4H); MS m/z+ 177.0 (M+Na).
1-(4-(2-(3,5-bis(hydroxymethyl)phenoxy)ethoxy)phenyl)ethanone
(235)
##STR00181##
[0304] To a stirred solution of (5-hydroxy-1,3-phenylene)dimethanol
(3.0, 20.0 mmol), sodium carbonate (2.5 g, 29.0 mmol) and sodium
iodide (0.45 g, 2.9 mmol) in 60 ml of DMA was added
1-(4-(2-bromoethoxy)phenyl)ethanone (5.0, 20.57 mmol). The mixture
was stirred overnight, evaporated and purified on SiO.sub.2
chromatography eluted with EtAc/Hexane (4:1 to 5:1) to afford 5.41
g (86%) of the title compound. .sup.1H NMR (CD.sub.3OD) 7.99 (ddd,
2H, J=2.8, 4.8, 9.8 Hz), 7.07 (ddd, 2H, J=2.8, 4.7, 9.8 Hz), 6.94
(s, 1H), 6.89 (s, 2H), 4.58 (s, 4H), 4.42 (dd, 2H, J=2.2, 6.1 Hz),
4.37 (m, 2H), 2.55 (s, 3H); .sup.13C NMR 199.55, 164.66, 160.59,
144.72, 132.03, 131.74, 119.16, 115.64, 113.11, 68.36, 67.87,
65.20, 26.53; MS m/z+ 339.2 (M+Na).
1-(4-(2-(3,5-bis(bromomethyl)phenoxy)ethoxy)phenyl)ethanone
(236)
##STR00182##
[0306]
1-(4-(2-(3,5-bis(hydroxymethyl)phenoxy)ethoxy)phenyl)ethanone
(0.216 g, 0.68 mmol), carbon tetrabromide (0.50 g, 1.50 mmol) and
PPh3 (0.40 g, 1.52 mmol) was stirred in 18 ml of THF under Ar
overnight and filtered. The solution was concentrated, purified on
SiO.sub.2 chromatography eluted with EtAc/Hexane (1:4) and
crystallized with ether/hexane to afford 277 mg (92%) of the title
compound. .sup.1H NMR (CDCl.sub.3) 7.94 (ddd, 2H, J=2.7, 4.6, 9.6
Hz), 7.02 (s, 1H), 6.98 (ddd, 2H, J=2.7, 4.6, 9.6 Hz), 6.91 (d, 2H,
J=1.2 Hz), 4.62 (s, 4H), 4.35 (m, 4H), 2.55 (s, 3H); .sup.13C NMR
197.05, 162.63, 159.14, 139.98, 130.96, 130.85, 122.57, 155.60,
114.52, 66.78, 66.73, 32.88, 26.57; MS m/z+ 462.9 (M+Na), 464.9
(M+2+Na).
(R)-Methyl Piperidine-2-Carboxylate (238)
##STR00183##
[0308] To (R)-Piperidine-2-carboxylic acid (5.00 g, 38.73) in 150
ml of dry methanol at 0.degree. C. was added thionyl chloride (5.2
ml, 71.28 mmol) under Ar. The mixture was stirred at 0.degree. C.
for 30 min, then at RT overnight, evaporated and crystallized with
EtOH/hexane to afford 4.96 g (92%) of the title product. .sup.1H
NMR (CD.sub.3OD) 3.67 (s, 3H), 3.57 (m, 1H), 2.79 (m, 1H), 2.69 (m,
1H), 2.01 (m, 1H), 1.98 (m, 1H), 1.73 (m, 1H), 1.55-1.45 (m, 4H);
.sup.13C NMR 171.22, 62.50, 51.35, 45.35, 29.52, 28.41, 23.82; MS
m/z+ 144.0 (M+H).
(R)-Methyl
1-(4-(benzyloxy)-5-methoxy-2-nitrobenzoyl)piperidine-2-carboxyl-
ate (239)
##STR00184##
[0310] 4-(benzoyloxy)-5-methoxy-2-nitrobenzoic acid (1.70 g, 5.61
mmol), (R)-methyl piperidine-2-carboxylate (1.05 g, 5.84 mmol), EDC
(3.90 g, 20.31 mmol) and DIPEA (1.0 ml, 5.75 mmol) was stirred in
20 ml of DMA over night. The mixture was evaporated, diluted with
DCM, washed with washed 1M NaH.sub.2PO.sub.4/NaCl (conc) and 0.1 M
NaHCO.sub.3/NaCl (conc) separately. The organic solvent layer was
separated and dried over MgSO.sub.4, filtered, concentrated and
purified on SiO.sub.2 chromatography eluted with EtAc/DCM (1:15) to
afford 1.772 g (74%) of the title product. .sup.1H NMR (CDCl.sub.3)
7.69 (s, 1H), 7.40-7.38 (m, 2H), 7.35-7.27 (m, 3H), 6.76 (d, 1H),
5.15 (s, 2H), 3.91 (s, 3H), 3.83 (s, 1H), 3.73 (s, 3H), 3.18 (m,
2H), 1.70 (m 2H), 1.47 (m, 4H); .sup.13C NMR 171.89, 171.33,
155.10, 154.78, 148.32, 135.59, 129.05, 128.74, 127.80, 109.66,
109.58, 109.41, 71.63, 56.92, 52.70, 52.19, 45.70, 39.92, 27.29,
26.35, 21.63; MS m/z+ 451.2 (M+Na).
(R)-1-(4-(benzyloxy)-5-methoxy-2-nitrobenzoyl)piperidine-2-carbaldehyde
##STR00185##
[0312] (R)-Methyl
1-(4-(benzoyloxy)-5-methoxy-2-nitrobenzoyl)piperidine-2-carboxylate
(1.50 g, 3.50 mmol) in 30 ml of 1:1 DCM/benzene at -78.degree. C.
was added 7.5 ml of 1.0 M DIBAL in toluene under Ar in 10 min. The
mixture was stirred at -78.degree. C. for 1 hr and the reaction was
quenched with 0.5 ml of methanol. The mixture was diluted with 150
ml of EtAc and 100 ml of 0.2 M HCl. The organic solvent layer was
separated and was separated and the aqueous layer was extracted
with EtOAc (3.times.80 ml). The organics were combined, dried over
MgSO.sub.4, filtered, concentrated and purified on SiO2
chromatography eluted with EtAc/hexane (3:2) to afford 1.52 g (90%)
of the title product. .sup.1H NMR (CDCl.sub.3), 9.60 (s, 1H), 7.70
(s, 1H), 7.65-7.28 (m, 5H), 6.78 (m, 1H), 5.16 (s, 2H), 3.92 (s,
3H), 3.22, (m, 1H), 3.01 (m, 1H), 2.20 (m, 1H), 1.84 (m, 1H),
1.65-1.40 (m, 4H); .sup.13C NMR 200.24, 171.31, 155.13, 154.78,
148.41, 146.20, 137.57, 135.47, 129.03, 128.73, 127.31, 109.83,
109.41, 71.61, 64.50, 56.96, 45.98, 25.25, 23.42, 18.70; MS m/z+
421.1 (M+Na).
(R,Z)-3-(benzyloxy)-2-methoxy-7,
8,9,10-tetrahydrobenzo[e]pyrido[1,2-a][1,4]diazepin-12(6aH)-one
##STR00186##
[0314] To
(R)-1-(4-(benzyloxy)-5-methoxy-2-nitrobenzoyl)piperidine-2-carba-
ldehyde (1.0 g, 2.51 mmol) in a mixture solution of 25 ml of THF
and 15 ml of water was added Na.sub.2S.sub.2O.sub.4 (3.0 g, 17.25
mmol). The mixture was stirred for 4 h, diluted with methanol and
dioxane, evaporated and co-evaporated with dioxane (3.times.60 ml)
to dryness. The solid was sonicated with a mixture of
CH.sub.3OH/CH.sub.2Cl.sub.2 (1:1, 80 ml), filtered and evaporated
to solid. The yield solid was dissolved in CH.sub.3OH (100 ml) and
0.4 ml of HCl (conc) was added. The mixture was stirred for 1 h,
neutralized to pH 3.0 with 0.1 M NaHCO.sub.3, concentrated, and
extracted with CH.sub.2Cl.sub.2 (4.times.60 ml), The organic layers
were combined, washed with 1M NaHCO.sub.3/NaCl (conc.), dried over
Na.sub.2SO.sub.4, filtered, evaporated and purified on SiO.sub.2
chromatography eluted with EtAc/CH.sub.2Cl.sub.2 (1:3) to afford
615 mg (70%) of the title product. .sup.1H NMR (CDCl.sub.3), 7.81
(d, 1H, J=5.7 Hz), 7.38-7.23 (m, 6H), 6.74 (s, 1H), 5.12 (dd, 2H,
J=2.3, 21.8 Hz), 4.18 (m, 1H), 3.88 (d, 3H), 3.69 (m, 1H), 3.15 (m,
1H), 1.99 (m, 1H), 1.87 (m, 1H), 1.79-1.65 (m, 4H); .sup.13C NMR
167.76, 163.31, 150.72, 148.48, 140.09, 136.46, 128.87, 128.28,
127.53, 121.77, 111.01, 71.02, 56.41, 49.84, 39.93, 24.76, 23.21,
18.62; MS m/z+ 373.2 (M+Na), 391.2 (M+Na+H.sub.2O), 405.3
(M+Na+CH.sub.3OH).
(R,Z)-3-Hydroxy-2-methoxy-7,8,9,10-tetrahydrobenzo[e]pyrido[1,2-a][1,4]dia-
zepin-12(6aH)-one (242)
##STR00187##
[0316] To
(R,Z)-3-(benzyloxy)-2-methoxy-7,8,9,10-tetrahydrobenzo[e]pyrido[-
1,2-a][1,4]diazepin-12(6aH)-one (241) (215 mg, 0.614 mmol) in 25 ml
of CH.sub.2Cl.sub.2 at 0.degree. C. was added 25 ml of
CH.sub.2SO.sub.3H. The mixture was stirred at 0.degree. C. for 10
min and then at RT for 2 h, diluted with CH.sub.2Cl.sub.2,
neutralized with cold 1.0 M NaHCO.sub.3, extracted with
CH.sub.2Cl.sub.2, dried over Na.sub.2SO.sub.4, filtered, evaporated
and purified on SiO.sub.2 chromatography eluted with
CH.sub.3OH/CH.sub.2Cl.sub.2 (1:15) to afford 122 mg (70%) of the
title product. .sup.1H NMR (CDCl.sub.3), 7.75 (d, 1H, J=5.7 Hz),
7.28 (s, 1H), 6.70 (s, 1H), 4.08 (m, 1H), 3.83 (d, 3H), 3.61 (m,
1H), 3.08 (m, 1H), 1.91 (m, 1H), 1.81 (m, 1H), 1.71.about.1.55 (m,
4H); .sup.13C NMR 167.81, 163.46, 148.53, 145.71, 140.84, 121.23,
111.89, 111.39, 56.45, 49.83, 39.96, 24.71, 23.22, 18.60; MS m/z+
283.7 (M+Na).
(5Z,5'Z,6aR,6a'R)-3,3'-(5-(2-(4-Acetylphenoxy)ethoxy)-1,3-phenylene)bis(me-
thylene)bis(oxy)bis(2-methoxy-7,
8,9,1-tetrahydrobenzo[e]pyrido[1,2-a][1,4]diazepin-12(6aH)-one)
(243)
##STR00188##
[0318] To a stirring solution of
(R,Z)-3-hydroxy-2-methoxy-7,8,9,10-tetrahydrobenzo[e]pyrido[1,2-a][1,4]di-
azepin-12(6aH)-one (242) (42 mg, 0.16 mmol), Cs.sub.2CO.sub.3 (100
mg, 0.307 mmol), KI (3.2 mg, 0.018 mmol) in 5 ml of acetone was
added 1-(4-(2-(3,5-bis(bromomethyl)phenoxy)ethoxy)phenyl)ethanone
(236) (36 mg, 0.081 mmol). The mixture was stirred over night,
evaporated and purified on HPLC preparative C-18 column ((10
mm.times.200 mm column, flow rate 9 mL/min and a gradient solvent
system going from 80:20 solvent A:B at time 0-5 min to 50:50 A:B at
15 min then to 30:70 A:B at 25 min until to 10:90 A:B at 30 min.
Solvent A--water, solvent B--dioxane) and lyophilized to afford a
white solid 39.1 mg (61%) of the title compound. .sup.1H NMR
(DMF-d.sub.7), 8.30 (m, 2H), 7.75 (d, 2H, J=5.7 Hz), 7.30 (s, 2H),
7.01 (m, 2H), 6.71 (s, 2H), 6.68 (s, 1H), 6.63 (s, 2H), 5.21 (s,
4H), 4.43 (m, 2H), 4.32 (m, 2H), 4.08 (m, 2H), 3.83 (s, 6H), 3.61
(m, 2H), 3.08 (m, 2H), 2.56 (s, 3H), 1.91 (m, 2H), 1.81 (m, 2H),
1.71.about.1.55 (m, 8H); MS m/z+ 823.2 (M+Na), 839.3 (M+K), 857.3
(M+K+H.sub.2O); MS m/z- 799.2 (M-H).
tert-Butyl
2-(4-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)butanoyl)hydrazineca-
rboxylate (245)
##STR00189##
[0320] 4-Maleimidobutyric acid (245 mg, 1.33 mmol), tert-butyl
hydrazinecarboxylate (201 mg, 1.52 mmol) and EDC (400 mg, 2.08
mmol) in 5 ml of CH.sub.2Cl.sub.2, were stirred overnight under Ar,
washed with 1 M NaH.sub.2PO.sub.4/NaCl (conc), dried over
MgSO.sub.4, filtered, evaporated and purified on SiO.sub.2
chromatography eluted with MeOH/DCM (1:25) to afford 335 mg (85%)
of the title compound. .sup.1H NMR (CDCl.sub.3), 7.83 (br, 1H),
6.65 (s, 2H), 6.50 (br, 1H), 3.58 (t, 2H, J=6.3 Hz), 2.15 (t, 2H,
J=7.0 Hz), 1.90 (dt, 2H, J=6.8, 13.4 Hz), 1.40 (s, 9H); .sup.13C
NMR 171.30, 155.61, 134.41, 82.00, 37.13, 31.38, 28.36, 24.95; MS
m/z+ 320.2 (M+Na).
4-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)butanehydrazide
trifluroacetic acid salt (246)
##STR00190##
[0322] To tert-Butyl
2-(4-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)butanoyl)-hydrazinecarboxylate
(245) (200 mg, 0.673 mmol) in 8 ml of DCM was added 2 ml of TFA.
The mixture was stirred for 45 min, diluted with ethanol/toluene (8
ml, 1:1), evaporated and co-evaporated with ethanol/toluene
(3.times.10 ml), crystallized with ethanol/EtAc/Hexane, filtered,
and dried under vacuum to afford 188 mg (90%) of the title
compound. .sup.1H NMR (CD.sub.3OD) 6.72 (s, 2H), 5.39 (s, 0.6H),
3.47 (t, 2H, J=6.6 Hz), 2.20 (m, 2H), 1.85 (m, 2H); .sup.13C NMR
172.72, 135.56, 54.93, 39.20, 37.99, 25.20; MS m/z+ 197.9
(M+H).
(E)-N'-(1-(4-(2-(3,5-bis(((S,Z)-2-methoxy-12-oxo-6a,7,8,9,10,12-hexahydrob-
enzo[e]pyrido[1,2-a][1,4]diazepin-3-yloxy)methyl)phenoxy)ethoxy)phenyl)eth-
ylidene)-4-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)butanehydrazide
(247)
##STR00191##
[0324] 4-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)butanehydrazide
trifluroacetic acid salt (246) (3 mg, 0.0096 mmol),
(5Z,5'Z,6aR,6a'R)-3,3'-(5-(2-(4-Acetylphenoxy)ethoxy)-1,3-phenylene)bis(m-
ethylene)bis(oxy)bis(2-methoxy-7,
8,9,10-tetrahydrobenzo[e]pyrido[1,2-a][1,4]diazepin-12(6aH)-one)
(243) (7.5 mg, 0.0093 mmol) and 50 mg 4 .ANG. molecular sieves was
stirred in 2 ml of dry 5% HAc in DCM (one day earlier dried by 4
.ANG. molecular sieves) for 2 h, neutralized with 0.5 ml of DIPEA,
evaporated and purified on HPLC preparative C-18 column (q) 10
mm.times.200 mm column, flow rate 9 mL/min and a gradient solvent
system going from 80:20 solvent A:B at time 0-5 min to 50:50 A:B at
15 min then to 30:70 A:B at 25 min until to 10:90 A:B at 30 min.
Solvent A--water, solvent B--methanol/dioxane (2:1)) and
lyophilized to afford a white solid 5.6 mg (61%) of the title
compound. MS m/z+ 1066.3 (M+2CH.sub.3OH+Na).
Example 13
[0325] Preparation of huN901-IGN-07 Conjugate:
[0326] huN901 antibody that binds to the CD56 antigen was selected
for conjugation of IGN derivatives. A solution of huN901 antibody
at a concentration of 3 mg/mL in an aqueous buffer containing 0.05
M N-(2-hydroxyethyl)-piperazine-N'-2-ethanesulfonic acid (HEPES)
and 2 mM ethylenediaminetetra-acetic acid (EDTA), pH 8 was treated
with a 20-fold molar excess of a solution of IGN-07 NHS ester in
dimethylacetamide (DMA) such that the final concentration of DMA in
the buffer was 10% v/v. The reaction mixture was stirred at room
temperature for 120 min and then loaded onto a Sephadex G25 gel
filtration column (HiPrep.TM. 26/10 Desalting Column GE#17-5087-01)
that has been previously equilibrated into an aqueous buffer
containing 0.01 M sodium citrate, 0.135 M sodium chloride, pH 5.5.
The conjugated antibody-containing fractions are collected and
pooled to yield product. The pooled sample was dialyzed overnight
against the same elution buffer (0.01 M sodium citrate, 0.135 M
sodium chloride, pH 5.5) to further purify the product.
[0327] The final conjugate was assayed spectrophotometrically using
the extinction coefficients that were determined for IGN-07
(.epsilon..sub.330 nm=15,231 M-1 cm-1 and .epsilon..sub.280
nm=26,864 M-1 cm-1) and huN901 antibody (.epsilon..sub.280
nm=225,000 M-1 cm-1). An average of 3.1 IGN molecules per molecule
of antibody were linked.
##STR00192##
Preparation of IGN-10 (Compound 51) Stock Solution:
[0328] A solution of IGN-10 was made fresh to a 0.004 M stock based
on a molecular weight of 975.14 g/mole in dimethylacetamide (DMA).
The stock solution was assayed spectrophotometrically using a
reference extinction coefficient determined at 330 nm
(.epsilon..sub.330 nm=15,500 M-1 cm-1).
Example 14
[0329] Preparation of muB38.1-IGN-10 Conjugate:
[0330] muB38.1 antibody that binds to the EpCAM antigen was
selected for conjugation of IGN derivatives through a disulfide
bond. A solution of muB38.1 antibody at a concentration of 2.5
mg/mL in an aqueous buffer containing phosphate buffered saline
(PBS) pH 7.4 was treated with 120 molar excess of 1-homocysteine
thiolactone for 12 hr at 37.degree. C. The reaction mixture was
loaded onto a Sephadex G25 gel filtration column (HiPrep.TM. 26/10
Desalting Column GE#17-5087-01) that was previously equilibrated in
PBS pH 7.4. Fractions containing antibody are collected and pooled
and assayed for reactive thiol content using the Ellman's assay.
The modified antibody was then treated with a 4-fold molar excess
of IGN-10 (in DMA) per free thiol and allowed to react at room
temperature for 8 hr. The reaction mixture was loaded onto a
Sephadex G25 gel filtration column (HiPrep.TM. 26/10 Desalting
Column GE#17-5087-01) that has been previously equilibrated into an
aqueous buffer containing 0.01 M sodium citrate, 0.135 M sodium
chloride, pH 5.5. The conjugated antibody-containing fractions are
collected and pooled to yield product. The pooled sample was
dialyzed overnight against the same elution buffer (0.01 M sodium
citrate, 0.135 M sodium chloride, pH 5.5) to further purify the
product.
[0331] The final conjugate was assayed spectrophotometrically using
the extinction coefficients that were determined for IGN-10
(.epsilon..sub.330 nm=15,500 M-1 cm-1 and .epsilon..sub.280
nm=26,864 M-1 cm-1) and muB38.1 antibody (.epsilon..sub.280
nm=215,525 M-1cm-1). An average of 0.7 IGN molecules per molecule
of antibody was linked.
##STR00193##
Example 15
[0332] DNA Probe Assay for Measuring IGN Dimer Binding and
Alkylation to Double Stranded DNA (dsDNA):
[0333] Reaction conditions: dsDNA (25 .mu.M final concentration) in
100 mM TRIS, 1 mM EDTA, pH 8 was mixed with 3.7 molar equivalents
of IGN-01 (compound 18), IGN-02 (compound 19), or IGN-09 (compound
15) dissolved in acetonitrile (final acetonitrile concentration
<2% by volume). The reaction was incubated at 15.degree. C.
(below TM of the dsDNA) and 10 .mu.l aliquots are injected on
reverse phase-HPLC at various time points after mixing
[0334] HPLC conditions: Waters Xbridge C8 2.1.times.50 mm column,
Buffer A: 100 mM hexafluoroisopropanol, 16.3 mM triethylamine, in
water, Buffer B: Methanol; 98% A.fwdarw.100% B over 32 min, 0.25
ml/min flow, 60.degree. C. column heat, 260 nm detection. Areas
under the curve (AUC) for the probe DNA peak and the resulting
IGN/DNA adduct peak are used to determine the % crosslinking at
each time point of incubation.
[0335] DNA annealing: single stranded DNA (Invitrogen) was annealed
into dsDNA using a Peltier thermal cycler (PTC-200, MJ Research). 1
mM DNA in 100 mM TRIS, 1 mM EDTA pH 8 was heated to 80.degree. C.
and then gradually cooled to 4.degree. C. over 90 min in 15 degree
steps. The resulting dsDNA was kept at 4.degree. C. until used in
the assay. IGN-01, IGN-02, and IGN-09 did not form covalent adducts
with single stranded DNA (ssDNA) in control experiments.
Example 16
##STR00194##
[0336] 2-(2-(2-methoxyethoxy)ethoxy)ethyl
4-methylbenzenesulfonate
[0337] To a stirred solution of
2-(2-(2-methoxyethoxy)ethoxy)ethanol (1.64 g, 10 mmol) in anhydrous
dichloromethane (30 mL) was added triethylamine (2.53 g, 25 mmol),
tosyl chloride (3.81 g, 20 mmol) and DMAP (0.061 g, 0.5 mmol)
subsequently at room temperature. The mixture continued to be
stirred overnight and worked up by diluted with ethyl acetate and
filtered to remove the triethylamine hydrochloride solid. The solid
was washed with ethyl acetate and the filtrate was evaporated. The
residue was diluted with ethyl acetate and filtered to remove the
additional precipitate. The filtrate was evaporated to give the
crude product as liquid. It was purified by silica gel
chromatography (dichloromethane/methanol) to give compound 249a as
an oil (3.16 g, yield=99%). .sup.1H NMR (400 Hz, CDCl.sub.3):
.delta. 7.81 (d, J=8.0 Hz, 2H), 7.35 (d, J=8.0 Hz, 2H), 4.17 (t,
J=3.2 Hz, 2H), 3.70 (t, J=4.8 Hz, 2H), 3.64-3.60 (m, 6H), 3.54 (t,
J=4.8 Hz, 2H), 3.38 (s, 3H), 2.46 (s, 3H); .sup.13C NMR (400 Hz,
CDCl.sub.3): .delta. 144.7, 133.0, 129.8, 127.9, 71.9, 70.7, 70.52,
70.50, 69.2, 68.6, 59.0, 21.6; MS (m/z): found 341.1
(M+Na).sup.+.
##STR00195##
(5-(2-(2-(2-methoxyethoxy)ethoxy)ethylamino)-1,3-phenylene)dimethanol
[0338] To the mixture of the tosylate 249a (1.85 g, 5.81 mmol) and
aniline compound 26 (1.78 g, 11.6 mmol) in anhydrous DMF (9 mL) was
added anhydrous potassium carbonate (1.61 g, 11.6 mmol). The
mixture was heated to 85.degree. C. and stirred at that temperature
overnight. The solution was cooled to room temperature and diluted
with dichloromethane. It was filtered through celite and the solid
was washed with dichloromethane. The filtrate was evaporated and
the residue was diluted with dichloromethane and filtered again to
remove the additional solid. The filtrate was evaporated and the
residue was purified by silica gel chromatography
(dichloromethane/methanol) to give compound 249b as a light
yellowish oil (835 mg, yield=48%). .sup.1H NMR (400 Hz,
CDCl.sub.3): .delta. 6.60 (s, 1H), 6.47 (s, 2H), 4.48 (s, 4H), 4.31
(bs, 1H), 3.66-3.59 (m, 8H), 3.55-3.52 (m, 2H), 3.36 (s, 3H), 3.24
(t, J=4.8 Hz, 2H); .sup.13C NMR (400 Hz, CDCl.sub.3): .delta.
148.5, 142.4, 114.6, 110.7, 71.8, 70.4, 70.3, 70.1, 69.4, 64.9,
58.9, 43.5; MS (m/z): found 322.2 (M+Na).sup.+.
##STR00196##
Compound 249c (IGN-14 Linker):
[0339] To the solution of compound 249b (319 mg, 1.07 mmol) and
methyl 4-bromobutyrate (248 mg, 1.37 mmol) in anhydrous
acetonitrile (5 mL) was added anhydrous potassium carbonate (177
mg, 1.28 mmol). The mixture was stirred and heated at reflux
(86.degree. C. oil bath) overnight. It was cooled to room
temperature and diluted with dichloromethane. The mixture was
filtered through celite and the filtrate was evaporated. The
residue was purified by silica gel chromatography
(dichloromethane/methanol) to give compound 249c (IGN-14 linker) as
colorless oil (246 mg, yield=58%). .sup.1H NMR (400 Hz,
CDCl.sub.3): .delta. 6.69 (s, 2H), 6.66 (s, 1H), 4.64 (s, 4H), 3.71
(s, 3H), 3.64-3.62 (m, 8H), 3.57-3.54 (m, 4H), 3.40-3.38 (m, 5H),
2.38 (t, J=7.2 Hz, 2H), 1.93 (p, J=7.2 Hz, 2H); MS (m/z): found
422.3 (M+Na).sup.+.
##STR00197##
Compound 249d (IGN-14-OMe):
[0340] To a stirred solution of compound 249c (120 mg, 0.3 mmol) in
anhydrous dichloromethane (3 mL) was added triethylamine (146
.mu.l, 1.05 mmol). The mixture was cooled to -10.degree. C. and
methanesulfonyl chloride (70 .mu.l, 0.9 mmol) was added slowly in
15 minutes. The solution continued to be stirred between
-10.degree. C. to -5.degree. C. for 60 minutes and quenched by
addition of ice/water. It was diluted with ethyl acetate and washed
with cold water. The organic layer was dried over anhydrous sodium
sulfate, filtered, evaporated and high vacuumed to give the
mesylate as colorless oil. The mesylate was transferred to a 10 mL
round bottom flask with ethyl acetate, evaporated and high
vacuumed. Compound 8 (221 mg, 0.75 mmol) was added followed by
addition of anhydrous DMF (2 mL) and anhydrous potassium carbonate
(207 mg, 1.5 mmol). The mixture was stirred at room temperature
overnight. It was diluted with dichloromethane and washed with
brine. The organic layer was dried over anhydrous sodium sulfate,
filtered and evaporated. The residue was purified by preparative
reverse phase HPLC (C18 column, eluted with CH.sub.3CN/H.sub.2O) to
give compound 249d (IGN-14-OMe) as a light yellowish solid (98 mg,
yield=34%). .sup.1H NMR (400 Hz, CDCl.sub.3): .delta. 8.29 (d,
J=8.0 Hz, 2H), 7.86 (d, J=4.4 Hz, 2H), 7.58 (s, 2H), 7.31-7.26 (m,
4H), 7.12 (t, J=8.0 Hz, 2H), 6.88 (s, 2H), 6.83 (s, 1H), 6.76 (s,
2H), 5.18 (dd, J.sub.1=23.2 Hz, J.sub.2=12.4 Hz, 4H), 4.49 (dt,
J.sub.1=10.8 Hz, J.sub.2=4.4 Hz, 2H), 3.99 (s, 6H), 3.73-3.52 (m,
19H), 3.40-3.37 (m, 5H), 2.35 (t, J=7.2 Hz, 2H), 1.90 (p, J=7.2 Hz,
2H); .sup.13C NMR (400 Hz, CDCl.sub.3): .delta. 173.7, 164.9,
163.2, 151.1, 148.5, 148.4, 142.1, 140.2, 137.8, 129.7, 128.2,
124.9, 120.7, 117.0, 113.8, 112.0, 111.4, 110.4, 72.0, 71.3, 70.7,
70.6, 68.6, 59.1, 56.3, 55.0, 51.7, 50.7, 32.7, 31.3, 22.4; MS
(m/z): found 974.6 (M+Na).sup.+, 992.7 (M+H.sub.2O+Na).sup.+,
1010.7 (M+2H.sub.2O+Na).sup.+, 950.3 (M-H).sup.-, 1022.3
(M+4H.sub.2O-H).sup.-.
##STR00198##
Compound 249f (IGN-14-NHS):
[0341] To the solution of compound 249d (105 mg, 0.11 mmol) in
anhydrous 1,2 dichloroethane (2 mL) was added trimethyltin
hydroxide (299 mg, 1.65 mmol). The mixture was heated to 80.degree.
C. and stirred overnight. It was cooled to room temperature,
diluted with dichloromethane and washed with mixed solution of
saturated sodium chloride and 5% hydrochloric acid (.about.1 mL),
then brine. The organic layer was dried over anhydrous sodium
sulfate, filtered and evaporated. The residue was passed a short
silica gel column and eluted with dichloromethane/methanol to
remove the extra trimethyltin hydroxide. The product fractions were
evaporated and high vacuumed to give the acid 249e as a yellowish
solid (102 mg, yield=99%). MS (m/z): found 936.1 (M-H).sup.-, 960.3
(M+Na).sup.+. Compound 249e was then dissolved in anhydrous
dichloromethane (1 mL). N-hydroxysuccinimide (NHS, 37.5 mg, 0.326
mmol) and N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide
hydrochloride (EDC, 62.5 mg, 0.326 mmol) was added subsequently.
The mixture was stirred at room temperature overnight and diluted
with dichloromethane, washed with brine and dried over anhydrous
sodium sulfate. It was filtered, evaporated and the residue was
purified by preparative reverse phase HPLC (C18 column, eluted with
acetonitrile/water). The product fractions were combined and
extracted with dichloromethane. The organic layers were dried over
anhydrous sodium sulfate, filtered, evaporated and high vacuumed to
give compound 249f (IGN-14-NHS) as a light yellowish solid (57.8
mg, yield=51%). .sup.1H NMR (400 Hz, CDCl.sub.3): .delta. 8.28 (d,
J=7.6 Hz, 2H), 7.86 (d, J=4.4 Hz, 2H), 7.58 (s, 2H), 7.31-7.27 (m,
4H), 7.12 (t, J=7.6 Hz, 2H), 6.87 (s, 2H), 6.81 (s, 1H), 6.74 (s,
2H), 5.23 (dd, J.sub.1=26.4 Hz, J.sub.2=12.4 Hz, 4H), 4.49 (dt,
J.sub.1=10.8 Hz, J.sub.2=4.4 Hz, 2H), 4.00 (s, 6H), 3.73-3.47 (m,
18H), 3.37 (s, 3H), 2.79-2.74 (m, 4H), 2.59 (t, J=7.2 Hz, 2H), 1.97
(p, J=7.2 Hz, 2H); MS (m/z): found 1057.4 (M+Na).sup.+.
Example 17
##STR00199##
[0342] Compounds 250a (IGN-16-OMe) and 250b (IGN-18-OMe):
[0343] To a stirred solution of compound 34 (111 mg, 0.135 mmol) in
absolute ethanol (1.0 mL) and anhydrous dichloromethane (0.5 mL)
was added sodium borohydride (1.0 mg, 0.027 mmol) at 0.degree. C.
After 30 minutes, the ice/water bath was removed and the reaction
mixture continued to be stirred at room temperature for 3 hours.
The reaction was quenched by addition of saturated ammonium
chloride and diluted with dichloromethane. The mixture was
separated and the organic layer was washed with brine, dried over
anhydrous sodium sulfate and filtered. The solvents were removed
under reduced pressure and the residue was purified by preparative
reverse phase HPLC (C18 column, eluted with acetonitrile/water) to
give compounds 250a (IGN-16-OMe, 6.6 mg) and 250b (8.0 mg) as white
solid. 250a: MS (m/z), found 845.3 (M+Na).sup.+, 863.3
(M+H.sub.2O+Na).sup.+. 250b: .sup.1H NMR (400 Hz, CDCl.sub.3),
.delta. 8.34 (d, J=8.0 Hz, 2H), 7.49 (s, 2H), 7.27-7.03 (m, 6H),
6.89-6.87 (m, 3H), 6.05 (s, 2H), 4.96 (dd, J.sub.1=20.8 Hz,
J.sub.2=12.8 Hz, 4H), 4.40-4.34 (m, 2H), 3.94-3.91 (m, 2H), 3.87
(s, 6H), 3.67 (s, 3H), 3.53-3.42 (m, 6H), 2.78 (dd, J.sub.1=16.8
Hz, J.sub.2=4.0 Hz, 2H), 2.38-2.37 (m, 2H), 1.79-1.77 (m, 4H); MS
(m/z), found 847.3 (M+Na).sup.+.
Example 18
##STR00200##
[0344] Compound 251a:
[0345] To a stirred solution of compound 5 (840 mg, 1.82 mmol) in
ethyl acetate (10 mL) was added palladium on charcoal (10%, 193 mg,
0.182 mmol). The flask was briefly vacuumed and replaced with
H.sub.2 in a balloon. The mixture continued to be hydrogenated for
overnight and filtered through celite. The solid was washed with
methanol and the filtrate was treated with 5% hydrochloric acid
(0.1 mL). The solution was stripped under reduce pressure and the
residue was purified by silica gel chromatography
(dichloromethane/methanol) to give compound 251a as a white solid
(512 mg, yield=91%). .sup.1H NMR (400 Hz, CDCl.sub.3), .delta. 8.21
(d, J=8.0 Hz, 1H), 8.09 (bs, NH), 7.53 (s, 1H), 7.31-7.25 (m, 2H),
7.12 (t, J=7.6 Hz, 1H), 6.61 (s, 1H), 6.22 (bs, 1H), 4.73 (dd,
J.sub.1=10.4 Hz, J.sub.2=2.8 Hz, 1H), 4.07 (dd, J.sub.1=16.4 Hz,
J.sub.2=2.4 Hz, 1H), 3.98 (s, 3H), 3.34 (dd, J.sub.1=16.4 Hz,
J.sub.2=10.4 Hz, 1H); MS (m/z), found 333.1 (M+Na).sup.+, 308.9
(M-H).sup.-
##STR00201##
Compound 251b (IGN-17-OMe):
[0346] To a solution of compound 38 (0.165 mmol, prepared from 44
mg of compound 30 following the procedure described in example 6)
and 251a (128 mg, 0.413 mmol) in anhydrous DMF (1.5 mL) was added
anhydrous potassium carbonate (114 mg, 0.825 mmol). The mixture was
stirred at room temperature overnight and diluted with
dichloromethane, washed with brine and dried over anhydrous sodium
sulfate and magnesium sulfate. It was filtered, evaporated and part
of the residue was purified by preparative reverse phase HPLC (C18
column, eluted with acetonitrile/water) to give 1.9 mg of compound
251b as a white solid. The rest of the residue was purified by
preparative thin layer chromatography (dichloromethane/methanol,
12:1) to give 36.8 mg of product as a white solid. Total 38.7 mg of
compound 251b (IGN-17-OMe) was isolated (yield=28%). .sup.1H NMR
(400 Hz, CDCl.sub.3): .delta. 8.61 (s, 2H), 8.15 (d, J=8.0 Hz, 2H),
7.48 (s, 2H), 7.25 (d, J=7.6 Hz, 2H), 7.20 (t, J=7.6 Hz, 2H), 7.07
(t, J=7.6 Hz, 2H), 6.73 (s, 1H), 6.69 (s, 2H), 6.58 (s, 2H), 5.02
(dd, J.sub.1=17.6 Hz, J.sub.2=13.2 Hz, 4H), 4.66 (dd, J.sub.1=10.4
Hz, J.sub.2=2.8 Hz, 2H), 4.00 (dd, J.sub.1=16.4 Hz, J.sub.2=2.4 Hz,
2H), 3.90 (s, 6H), 3.68 (s, 3H), 3.39-3.23 (m, 4H), 2.89 (s, 3H),
2.44-2.30 (m, 2H), 1.91-1.92 (m, 2H); .sup.13C NMR (400 Hz,
CDCl.sub.3): .delta. 174.5, 169.1, 164.2, 151.6, 149.6, 146.9,
141.2, 137.3, 130.6, 129.4, 127.5, 124.9, 124.8, 119.6, 117.1,
114.2, 112.5, 110.9, 106.0, 71.4, 58.0, 56.2, 51.9, 51.7, 38.3,
31.1, 28.2, 21.8; MS (m/z), found 874.3 (M+Na).sup.+, 850.2
(M-H).sup.-.
Example 19
##STR00202##
[0347] Compound 252a:
[0348] The mixture of 1,3-dibromoaceton (0.863 g, purity 75%, 3.0
mmol) and methyl (triphenylphosphoranylidene)acetate (1.505 g, 4.5
mmol) in anhydrous THF (15 mL) was heated to reflux for 4.5 hours.
The solution was cooled to room temperature and evaporated. The
residue was purified by silica gel chromatography (hexanes/ethyl
acetate) to give compound 252a as colorless liquid (485 mg,
yield=60%). .sup.1H NMR (400 Hz, CDCl.sub.3): .delta. 6.06 (s, 1H),
4.76 (s, 2H), 4.19 (s, 2H), 3.79 (s, 3H); .sup.13C NMR (400 Hz,
CDCl.sub.3): .delta. 165.1, 150.4, 121.3, 51.8, 33.6, 25.5.
##STR00203##
Compound 252b (IGN-19-OMe):
[0349] The mixture of compound 252a (32 mg, 0.118 mmol), monomer 8
(87 mg, 0.294 mmol) and anhydrous potassium carbonate (49 mg, 0.353
mmol) in anhydrous DMF (1 mL) was stirred at room temperature
overnight. It was diluted with dichloromethane, washed with brine
and dried over anhydrous sodium sulfate. The solution was filtered,
evaporated and purified by silica gel chromatography
(dichloromethane/methanol) to give 105 mg of compound 252b mixed
with side products as yellowish foam. Part of the products was
further purified by preparative reverse phase HPLC (C18 column,
eluted with acetonitrile/water) to give 10 mg of compound 252b
(IGN-19-OMe) as a white solid. MS (m/z): found 721.2 (M+Na), 739.2
(M+H.sub.2O+Na).sup.+, 757.2 (M+2H.sub.2O+Na), 697.1 (M-H).sup.-,
769.1 (M+4H.sub.2O-H).sup.-.
Example 20
##STR00204##
[0350] Compound 253a:
[0351] To a solution of 2-(methyldithio)-isobutyraldehyde (690 mg,
4.59 mmol) in absolute ethanol (15 mL) was added methylamine (629
.mu.l, 33% wt, 5.05 mmol). The mixture was stirred at room
temperature for four hours and cooled to 0.degree. C. followed by
addition of sodium borohydride (174 mg, 4.59 mmol). After one hour,
the reaction was quenched with a few drops of cold 5% hydrochloric
acid and then basified with saturated sodium bicarbonate. The
mixture was diluted with dichloromethane and washed with brine. The
organic layer was dried over anhydrous sodium sulfate, filtered and
evaporated under reduce pressure. The residue was purified by
silica gel chromatography (0.2% triethylamine in
dichloromethane/methanol) to give volatile compound 253a as light
yellowish liquid (491 mg, yield=65%). .sup.1H NMR (400 Hz,
CDCl.sub.3): .delta. 2.61 (s, 2H), 2.45 (s, 3H), 2.39 (s, 3H), 1.32
(s, 6H), 1.20 (s, NH); .sup.13C NMR (400 Hz, CDCl.sub.3): .delta.
61.2, 51.7, 37.2, 26.5, 25.3; MS (m/z): found 166.0
(M+H).sup.+.
##STR00205##
Compound 253b:
[0352] The mixture of compound 249c (117 mg, 0.293 mmol) and
trimethyltin hydroxide (794 mg, 4.39 mmol) in anhydrous
1,2-dichloroethane (1.5 mL) was heated to 80.degree. C. and stirred
overnight. It was cooled to room temperature, diluted with
dichloromethane and washed with mixed solution of saturated sodium
chloride and 5% hydrochloric acid (.about.1 mL), then brine. The
organic layer was dried over anhydrous sodium sulfate, filtered and
evaporated. The residue was purified by silica gel chromatography
(dichloromethane/methanol) to give the acid 253b as a colorless oil
(93.9 mg, yield=99%). .sup.1H NMR (400 Hz, CDCl.sub.3): .delta.
6.62 (s, 2H), 6.57 (s, 1H), 4.50 (s, 4H), 3.63-3.54 (m, 8H),
3.53-3.46 (m, 4H), 3.36-3.31 (m, 5H), 2.29 (t, J=6.8 Hz, 2H), 1.83
(p, J=6.8 Hz, 2H); .sup.13C NMR (400 Hz, CDCl.sub.3): .delta.
177.0, 148.2, 142.4, 113.8, 110.1, 71.9, 70.7, 70.6, 70.4, 68.8,
65.2, 59.0, 50.8, 50.7, 31.4, 22.3; MS (m/z): found 384.2
(M-H).sup.-, 408.4 (M+Na).sup.+.
##STR00206##
Compound 253c:
[0353] To a solution of amine 253a (44.3 mg, 0.268 mmol) and
carboxylic acid 253b (93.3, 0.244 mmol) in anhydrous
dichloromethane (1.5 mL) was added N-hydroxysuccinimide (NHS, 70.1
mg, 0.365 mmol) and DMAP (5.95 mg, 0.049 mmol). The mixture was
stirred at room temperature overnight and diluted with
dichloromethane, washed with saturated ammonium chloride and brine,
dried over anhydrous sodium sulfate, filtered and evaporated. The
residue was purified by silica gel chromatography
(dichloromethane/methanol) to give compound 253c as colorless oil
(69.1 mg, yield=53%). .sup.1H NMR (400 Hz, CDCl.sub.3): .delta.
6.71 (s, 2H), 6.64 (s, 1H), 4.57 (s, 4H), 3.63-3.59 (m, 8H+20H),
3.54-3.51 (m, 4H), 3.38-3.34 (m, 5H), 3.08 (s, 2.35H), 3.00 (s,
0.65H), 2.86 (bs, 2H), 2.43 (s, 3H), 2.34 (t, J=6.8 Hz, 2H),
1.95-1.88 (m, 2H), 1.36 (s, 1.3H), 1.31 (s, 4.7H); .sup.13C NMR
(400 Hz, CDCl.sub.3): .delta. 173.7, 148.5, 142.7, 113.2, 109.8,
72.0, 70.8, 70.7, 70.6, 68.9, 65.6, 59.1, 56.5, 53.0, 52.2, 51.0,
50.8, 38.8, 30.6, 26.6, 25.6, 22.3; MS (m/z): found 555.5
(M+Na).sup.+.
##STR00207##
Compound 253d:
[0354] To a stirred solution of compound 253c (69.1 mg, 0.13 mmol)
in anhydrous dichloromethane (1.5 mL) was added triethylamine (63
.mu.l, 0.454 mmol). The mixture was cooled to -10.degree. C. and
methanesulfonyl chloride (30 .mu.l, 0.389 mmol) was added slowly in
15 minutes. The solution continued to be stirred between
-10.degree. C. to -5.degree. C. for 60 minutes and quenched by
addition of ice/water. It was diluted with ethyl acetate and washed
with cold water. The organic layer was dried over anhydrous sodium
sulfate, filtered, evaporated and high vacuumed to give the
mesylate as colorless oil. The mesylate was transferred to a 10 mL
round bottom flask with ethyl acetate, evaporated and high
vacuumed. Compound 8 (99 mg, 0.338 mmol) was added followed by
addition of anhydrous DMF (1 mL) and anhydrous potassium carbonate
(90 mg, 0.65 mmol). The mixture was stirred at room temperature
overnight. It was diluted with dichloromethane and washed with
brine. The organic layer was dried over anhydrous sodium sulfate,
filtered and evaporated. The residue was purified by silica gel
chromatography (dichloromethane/methanol) to give 150 mg yellowish
foam, which was further purified by preparative reverse phase HPLC
(C18 column, eluted with CH.sub.3CN/H.sub.2O) to give compound 253d
as a light yellowish solid (50.7 mg, yield=36%). MS (m/z): found
1107.7 (M+Na).sup.+, 1125.7 (M+H.sub.2O+Na).sup.+, 1143.7
(M+2H.sub.2O+Na).sup.+, 1083.4 (M-H).sup.-, 1155.5
(M+4H.sub.2O-H).sup.-.
##STR00208##
Compound 253e:
[0355] To a small vial containing tris(2-carboxyethyl)phosphine
hydrochloride (TCEP, 19.1 mg, 0.067 mmol) was added a few drops of
deioned water. Saturated sodium bicarbonate was added dropwise
until pH is about 7 indicated by a pH test paper. It was then
diluted with pH 6.5 phosphate buffer (0.4 mL) to give a fresh TCEP
solution. To a stirred solution of compound 253d (24.1 mg, 0.022
mmol) in methanol (3 mL) and acetonitrile (1 mL) was added the TCEP
solution and stirred at room temperature for 1.5 hours. It was
diluted with dichloromethane and washed with brine, dried over
anhydrous sodium sulfate, filtered and evaporated to give the thiol
as a yellowish solid (21.9 mg) which was directly used for next
step (the thiol is not able to be purified due to aggregation). To
a solution of the thiol (21.9 mg, 0.021 mmol) in anhydrous
dichloromethane (0.1 mL) and methanol (0.4 mL) was added
4-(2-pyridyldithio)butanoic acid (24.2 mg, 0.105 mmol) and triethyl
amine (29 .mu.l, 0.211 mmol). The mixture was stirred at room
temperature for five hours and quenched by saturated ammonium
chloride. It was diluted with dichloromethane, separated and the
organic layer was washed with brine, dried over anhydrous sodium
sulfate, filtered and evaporated. The residue was purified by
preparative reverse phase HPLC (C18 column, eluted with
acetonitrile/water) to give compound 253e as a white solid (7.3 mg,
yield=30%). .sup.1H NMR (400 Hz, CDCl.sub.3): .delta. 8.28 (d,
J=7.6 Hz, 2H), 7.89 (bs, 2H), 7.60 (bs, 2H), 7.31-7.26 (m, 4H),
7.12 (t, J=7.6 Hz, 2H), 6.91-6.78 (m, 5H), 5.22-5.13 (m, 4H),
4.54-4.49 (m, 2H), 3.99 (s, 6H), 3.68-3.41 (m, 20H), 3.38 (s, 3H),
3.07 (s, 3H), 2.78-2.77 (m, 2H), 2.47 (bs, 2H), 2.35 (bs, 2H),
2.01-1.95 (m, 4H), 1.31 (s, 6H); MS (m/z): found 1179.7
(M+Na).sup.+, 1197.7 (M+H.sub.2O+Na).sup.+, 1073.6
(M+H.sub.2O--H).sup.-, 1191.5 (M+2H.sub.2O-H).sup.-.
##STR00209##
Compound 253f:
[0356] To a solution of compound 253e (9.0 mg, 0.00778 mmol) in
anhydrous dichloromethane (0.5 mL) was added N-hydroxysuccinimide
(NHS, 2.68 mg, 0.023 mmol) and
N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDC,
4.47 mg, 0.023 mmol) subsequently. The mixture was stirred at room
temperature overnight and diluted with dichloromethane, washed with
brine and dried over anhydrous sodium sulfate. It was filtered,
evaporated and the residue was purified by preparative reverse
phase HPLC (C18 column, eluted with acetonitrile/water). The
product fractions were combined and extracted with dichloromethane.
The organic layers were dried over anhydrous sodium sulfate,
filtered, evaporated and high vacuumed to give compound 253f
(IGN-20-NHS) as a yellowish foam (4.4 mg, yield=45%). MS (m/z):
found 1276.7 (M+Na).sup.+.
Example 21
##STR00210##
[0357] Compound 254a (IGN-23-OMe) and 254b (IGN-24-OMe):
[0358] To a stirred solution of compound 249d (91.8 mg, 0.103 mmol)
in absolute ethanol (1.0 mL) and anhydrous dichloromethane (0.4 mL)
was added sodium borohydride (0.4 mg, 0.0106 mmol) at 0.degree. C.
After 30 minutes, the ice/water bath was removed and the reaction
mixture continued to be stirred at room temperature for 3 hours.
The reaction was quenched by addition of saturated sodium ammonium
chloride and diluted with dichloromethane. The mixture was
separated and the organic layer was washed with brine, dried over
anhydrous sodium sulfate and filtered. The solvents were removed
under reduced pressure and the residue was purified by preparative
reverse phase HPLC (C18 column, eluted with acetonitrile/water) to
give compounds 254a (IGN-23-OMe, 24.2 mg, yield=24.5%) and 254b
(IGN-24-OMe, 26.3 mg, yield=26.6%) as a yellowish solid. 254a:
.sup.1H NMR (400 Hz, CDCl.sub.3): .delta. 8.34 (d, J=8.0 Hz, 1H),
8.27 (d, J=7.6 Hz, 1H), 7.83 (d, J=4.4 Hz, 1H), 7.57 (s, 1H), 7.46
(s, 1H), 7.29-7.02 (m, 6H), 6.87 (s, 1H), 6.75 (s, 1H), 6.70-6.66
(m, 2H), 6.10 (s, 1H), 5.21-5.02 (m, 4H), 4.49-4.39 (m, 2H), 3.99
(s, 3H), 3.89 (s, 3H), 3.66 (s, 3H), 3.64-3.41 (m, 19H), 3.39-3.34
(m, 4H), 2.78 (dd, J.sub.1=16.4 Hz, J.sub.2=3.6 Hz, 1H), 2.33 (t,
J=7.2 Hz, 2H), 1.90-1.84 (m, 2H); .sup.13C NMR (400 Hz,
CDCl.sub.3): .delta. 173.8, 166.8, 164.0, 163.5, 152.3, 151.2,
148.7, 148.5, 143.0, 142.1, 140.7, 140.2, 138.5, 137.8, 129.8,
129.7, 128.3, 127.9, 125.0, 124.7, 123.9, 120.9, 117.5, 117.0,
114.6, 113.4, 113.2, 112.1, 111.6, 110.2, 110.1, 104.2, 72.1, 71.4,
71.2, 70.80, 70.76, 70.70, 68.7, 59.2, 57.3, 56.5, 56.4, 55.1,
54.8, 51.8, 50.9, 50.7, 33.3, 32.7, 31.3, 22.4; MS (m/z), found
976.7 (M+Na).sup.+, 994.6 (M+H.sub.2O+Na).sup.+; 254b: MS (m/z),
found 978.7 (M+Na).sup.+.
##STR00211##
Compound 254c and 254d (IGN-23-NHS):
[0359] To the solution of compound 254a (31.8 mg, 0.033 mmol) in
anhydrous 1,2 dichloroethane (1 mL) was added trimethyltin
hydroxide (90 mg, 0.5 mmol). The mixture was heated to 80.degree.
C. and stirred overnight. It was cooled to room temperature,
diluted with dichloromethane and washed with mixed solution of
saturated sodium chloride and 5% hydrochloric acid (.about.1 mL),
then brine. The organic layer was dried over anhydrous sodium
sulfate, filtered and evaporated. The residue was passed a short
silica gel column and eluted with dichloromethane/methanol to
remove the extra trimethyltin hydroxide. The product fractions were
evaporated and high vacuumed to give the acid 254c as a yellowish
solid (20.8 mg, yield=66%). MS (m/z): found 938.2 (M-H).sup.-,
962.3 (M+Na).sup.+. Compound 254c (20.8 mg, 0.022 mmol) was then
dissolved in anhydrous dichloromethane (1 mL). The reaction flask
was briefly vacuumed and replaced with argon. N-hydroxysuccinimide
(NHS, 5.09 mg, 0.044 mmol) and
N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDC,
8.48 mg, 0.044 mmol) was added subsequently. The mixture was
stirred at room temperature overnight and diluted with
dichloromethane, washed with brine and dried over anhydrous sodium
sulfate. It was filtered, evaporated and the residue was purified
by preparative reverse phase HPLC (C18 column, eluted with
acetonitrile/water). The product fractions were combined and
extracted with dichloromethane. The organic layers were dried over
anhydrous sodium sulfate, filtered, evaporated and high vacuumed to
give compound 254d (IGN-23-NHS) as a light yellowish solid (9.8 mg,
yield=43%). MS (m/z): found 1059.6 (M+Na).sup.+, 1077.6
(M+H.sub.2O+Na).sup.+.
##STR00212##
Compound 254e and 254f (IGN-24-NHS):
[0360] To the solution of compound 254b (26.3 mg, 0.028 mmol) in
anhydrous 1,2 dichloroethane (1 mL) was added trimethyltin
hydroxide (74.6 mg, 0.413 mmol). The mixture was heated to
80.degree. C. and stirred overnight. It was cooled to room
temperature, diluted with dichloromethane and washed with mixed
solution of saturated sodium chloride and 5% hydrochloric acid
(.about.1 mL), then brine. The organic layer was dried over
anhydrous sodium sulfate, filtered and evaporated. The residue was
passed a short silica gel column and eluted with
dichloromethane/methanol to remove the extra trimethyltin
hydroxide. The product fractions were evaporated and high vacuumed
to give the acid 254e as a yellowish solid (26 mg, yield=100%). MS
(m/z): found 940.5 (M-H).sup.-, 964.6 (M+Na).sup.+. Compound 2542
(26 mg, 0.028 mmol) was then dissolved in anhydrous dichloromethane
(1 mL). N-hydroxysuccinimide (NHS, 9.57 mg, 0.083 mmol),
N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDC,
15.9 mg, 0.083 mmol) and DMAP (0.34 mg, 0.0028 mmol) was added
subsequently. The mixture was stirred at room temperature overnight
and diluted with dichloromethane, washed with saturated ammonium
chloride and brine, dried over anhydrous sodium sulfate. It was
filtered, evaporated and the residue was purified by preparative
reverse phase HPLC (C18 column, eluted with acetonitrile/water).
The product fractions were combined and extracted with
dichloromethane. The organic layers were dried over anhydrous
sodium sulfate, filtered, evaporated and high vacuumed to give
compound 254f (IGN-24-NHS) as a light yellowish solid (3.0 mg,
yield=10%). MS (m/z): found 1061.7 (M+Na).sup.+. Note: DMAP should
not have been added and it may be the cause of the low yield.
Example 22
##STR00213##
[0361] Compound 255a:
[0362] To a stirred solution of O-methyl-undecaethylene glycol (500
mg, 0.968 mmol) in anhydrous dichloromethane (3 mL) was added
triethylamine (270 .mu.l, 1.94 mmol), tosyl chloride (277 mg, 1.45
mmol) and DMAP (5.91 mg, 0.048 mmol) subsequently at room
temperature. The mixture continued to be stirred overnight and
worked up by diluted with ethyl acetate and filtered to remove the
triethylamine hydrochloride solid. The solid was washed with ethyl
acetate and the filtrate was evaporated. The residue was diluted
with ethyl acetate and filtered to remove the additional
precipitate. The filtrate was evaporated to give the crude product
as liquid. It was purified by silica gel chromatography
(dichloromethane/methanol) to give compound 255a as a light
yellowish oil (630 mg, yield=97%). .sup.1H NMR (400 Hz,
CDCl.sub.3): .delta. 7.81 (d, J=8.0 Hz, 2H), 7.35 (d, J=8.0 Hz,
2H), 4.17 (t, J=4.8 Hz, 2H), 3.72-3.54 (m, 42H), 3.39 (s, 3H), 2.46
(s, 3H); MS (m/z): found 693.6 (M+Na).sup.+.
##STR00214##
Compound 255b:
[0363] To the mixture of the tosylate 255a (630 mg, 0.939 mmol) and
aniline 28 (238 mg, 0.939 mmol) in anhydrous DMF (3 mL) was added
anhydrous potassium carbonate (195 mg, 1.409 mmol) and potassium
iodide (31.2 mg, 0.188 mmol). The mixture was heated to 85.degree.
C. and stirred at that temperature overnight. The solution was
cooled to room temperature and diluted with dichloromethane. It was
filtered through celite and the solid was washed with
dichloromethane. The filtrate was evaporated and the residue was
diluted with dichloromethane and filtered again to remove the
additional solid. The filtrate was evaporated and the residue was
purified by silica gel chromatography (hexanes/10% methanol in THF)
to give compound 255b as a colorless oil (41.8 mg, yield=5.9%).
.sup.1H NMR (400 Hz, CDCl.sub.3): .delta. 6.66 (s, 2H), 6.65 (s,
1H), 4.60 (s, 4H), 3.69 (s, 3H), 3.66-3.58 (m, 42H), 3.56-3.53 (m,
2H), 3.39-3.36 (m, 5H), 2.52 (broad s, 20H), 2.36 (t, J=7.2 Hz,
2H), 1.91 (p, J=7.2 Hz, 2H); .sup.13C NMR (400 Hz, CDCl.sub.3):
.delta. 173.9, 148.5, 142.8, 113.4, 109.9, 72.1, 70.8, 70.7, 68.9,
65.7, 59.2, 51.8, 50.9, 50.7, 31.3, 22.4; MS (m/z): found 774.3
(M+Na).sup.+.
##STR00215##
Compound 255c (IGN-26-OMe):
[0364] To a stirred solution of compound 255b (41.8 mg, 0.056 mmol)
in anhydrous dichloromethane (1 mL) was added triethylamine (27
.mu.l, 0.196 mmol). The mixture was cooled to -10.degree. C. and
methanesulfonyl chloride (12.9 .mu.l, 0.167 mmol) was added slowly
in 15 minutes. The solution continued to be stirred between
-10.degree. C. to -5.degree. C. for 60 minutes and quenched by
addition of ice/water. It was diluted with ethyl acetate and washed
with cold water. The organic layer was dried over anhydrous sodium
sulfate, filtered, evaporated and high vacuumed to give the
mesylates as colorless oil. MS (m/z): found 930.3 (M+Na).sup.+. The
mesylates (30 mg, 0.033 mmol) was transferred to a 5 mL round
bottom flask with ethyl acetate, evaporated and high vacuumed.
Compound 8 (29.2 mg, 0.099 mmol) was added followed by addition of
anhydrous DMF (0.5 mL), anhydrous potassium carbonate (22.8 mg,
0.165 mmol) and potassium iodide (5.5 mg, 0.033 mmol). The mixture
was stirred at room temperature overnight. It was diluted with
dichloromethane and washed with brine. The organic layer was dried
over anhydrous sodium sulfate, filtered and evaporated. The residue
was purified by silica gel chromatography (hexanes/10% methanol in
THF) to give 20.5 mg of a mixture which contained compound 255c. It
was dissolved in anhydrous dichloromethane (0.3 mL). Triethylamine
(4 .mu.l, 0.03 mmol), tosyl chloride (3.8 mg, 0.02 mmol) and DMAP
(0.2 mg, 0.002 mmol) were added subsequently at room temperature.
The mixture continued to be stirred at room temperature overnight
and then was evaporated. The residue was purified by silica gel
chromatography (dichloromethane/methanol) to give 11 mg of light
yellowish foam. It was further purified by preparative reverse
phase HPLC (C18 column, eluted with CH.sub.3CN/H.sub.2O) to give
compound 255c (IGN-26-OMe) as colorless foam (1.6 mg, yield=2.2%).
MS (m/z): found 1326.5 (M+Na).sup.+, 1344.6 (M+H.sub.2O+Na).sup.+,
1362.5 (M+2H.sub.2O+Na).sup.+.
Example 23
##STR00216##
[0365] Compound 256a:
[0366] To a stirred solution of compound 7 (384 mg, 1.0 mmol) in
absolute ethanol (6 mL) and anhydrous dichloromethane (2 mL) was
added sodium borohydride (37.8 mg, 1.0 mmol) at 0.degree. C. After
30 minutes, the ice/water bath was removed and the reaction mixture
continued to be stirred at room temperature overnight. The reaction
was quenched by addition of saturated ammonium chloride and diluted
with dichloromethane. The mixture was separated and the organic
layer was washed with brine, dried over anhydrous sodium sulfate
and filtered. The solvents were removed under reduced pressure to
give compound 256a as a white solid (369 mg, yield=96%). .sup.1H
NMR (400 Hz, CDCl.sub.3): .delta. 8.37 (d, J=8.0 Hz, 1H), 7.50 (s,
1H), 7.40-7.24 (m, 6H), 7.18 (d, J=7.2 Hz, 1H), 7.05 (t, J=7.2 Hz,
1H), 6.12 (s, 1H), 5.06 (s, 2H), 4.40 (tt, J.sub.1=10.0 Hz,
J.sub.2=3.6 Hz, 1H), 3.87 (s, 3H), 3.52-3.41 (m, 3H), 2.78 (dd,
J.sub.1=16.8 Hz, J.sub.2=3.6 Hz, 1H); .sup.13C NMR (400 Hz,
CDCl.sub.3): .delta. 166.5, 152.1, 142.73, 142.70, 140.4, 136.3,
129.5, 128.5, 127.9, 127.7, 127.1, 124.5, 123.8, 117.2, 114.5,
112.7, 103.4, 70.5, 57.1, 56.2, 54.5, 33.1; MS (m/z), found 409.2
(M+Na).sup.+.
##STR00217##
Compound 256b:
[0367] To a solution of compound 256a (369 mg, 0.955 mmol) in
anhydrous acetonitrile (9 mL) was added iodomethane (65 .mu.l, 1.05
mmol) and potassium carbonate (158 mg, 1.15 mmol). The mixture was
stirred, heated to 82.degree. C. and refluxed overnight. The
reaction mixture was removed from the oil bath, cooled to room
temperature and diluted with dichloromethane. It was filtered
through celite and the filtrate was evaporated under reduced
pressure. The residue was purified through silica gel
chromatography (hexanes/ethyl acetate) to give compound 256b as a
colorless foam (195 mg, yield=51%). Also 123 mg of starting
material 256a was recovered. .sup.1H NMR (400 Hz, CDCl.sub.3):
.delta. 8.29 (d, J=8.0 Hz, 1H), 7.46 (s, 1H), 7.44 (s, 1H),
7.39-7.24 (m, 5H), 7.16 (d, J=7.2 Hz, 1H), 7.04 (t, J=7.6 Hz, 1H),
6.46 (s, 1H), 5.19 (dd, J.sub.1=15.2 Hz, J.sub.2=12.4 Hz, 2H),
4.36-4.29 (m, 1H), 3.89 (s, 3H), 3.38-3.31 (m, 2H), 3.02 (dd,
J.sub.1=10.8 Hz, J.sub.2=4.0 Hz, 1H), 2.70 (dd, J.sub.1=16.8 Hz,
J.sub.2=2.8 Hz, 1H), 2.65 (s, 3H); .sup.13C NMR (400 Hz,
CDCl.sub.3): .delta. 166.9, 151.2, 144.2, 142.1, 141.9, 136.7,
129.8, 128.6, 128.0, 127.8, 127.3, 125.1, 123.9, 121.7, 117.1,
113.5, 104.7, 71.1, 64.2, 57.2, 56.3, 40.2, 32.0; MS (m/z): found
423.2 (M+Na).sup.+.
##STR00218##
Compound 256c:
[0368] To a stirred solution of compound 256b (195 mg, 0.487 mmol)
in ethyl acetate (2.5 mL) was added palladium on charcoal (10%,
25.9 mg, 0.024 mmol). The flask was briefly vacuumed and replaced
with H.sub.2 in a balloon. The mixture continued to be hydrogenated
for overnight and filtered through celite. The filtrate was
stripped under reduce pressure and the residue was purified by
silica gel chromatography (dichloromethane/methanol) to give
compound 256c as a white solid (126 mg, yield=83%). .sup.1H NMR
(400 Hz, MeOD): .delta. 8.14 (d, J=8.0 Hz, 1H), 7.30-7.23 (m, 2H),
7.22 (s, 1H), 7.10 (t, J=7.6 Hz, 1H), 6.56 (s, 1H), 4.46-4.38 (m,
1H), 3.88 (s, 3H), 3.48-3.37 (m, 2H), 3.12 (dd, J.sub.1=10.8 Hz,
J.sub.2=4.4 Hz, 1H), 2.84 (dd, J.sub.1=16.8 Hz, J.sub.2=2.8 Hz,
1H), 2.80 (s, 3H).
##STR00219##
Compound 256d (IGN-29-OMe):
[0369] To a stirred solution of compound 249c (136 mg, 0.34 mmol)
in anhydrous dichloromethane (2 mL) was added triethylamine (142
.mu.l, 1.02 mmol). The mixture was cooled to -10.degree. C. and
methanesulfonyl chloride (66 .mu.l, 0.85 mmol) was added slowly in
15 minutes. The solution continued to be stirred between
-10.degree. C. to -5.degree. C. for 60 minutes and quenched by
addition of ice/water. It was diluted with ethyl acetate and washed
with cold water. The organic layer was dried over anhydrous sodium
sulfate, filtered, evaporated and high vacuumed to give the
mesylate as colorless oil. The mesylate was transferred to a 10 mL
round bottom flask with ethyl acetate, evaporated and high
vacuumed. Compound 8 (120 mg, 0.41 mmol) and 256c (106 mg, 0.34
mmol) were added to it followed by addition of anhydrous DMF (1.5
mL), anhydrous potassium carbonate (235 mg, 1.7 mmol). The mixture
was stirred at room temperature overnight. It was diluted with
dichloromethane and washed with brine. The organic layer was dried
over anhydrous sodium sulfate, filtered and evaporated. The residue
was purified by preparative reverse phase HPLC (C18 column, eluted
with CH.sub.3CN/H.sub.2O) to give compound 256d (IGN-29-OMe) as a
light yellowish solid (46 mg, yield=14%) and compound 256e. 256d:
.sup.1H NMR (400 Hz, CDCl.sub.3), .delta. 8.27 (d, J=8.0 Hz, 2H),
7.84 (d, J=4.8 Hz, 1H), 7.57 (s, 1H), 7.32-7.04 (m, 7H), 6.87 (s,
1H), 6.82 (s, 1H), 6.76-6.70 (m, 2H), 6.50 (s, 1H) 5.18-5.12) m,
4H), 4.49-4.43 (m, 1H), 4.40-4.35 (m, 1H), 3.98 (s, 3H), 3.89 (s,
3H), 3.68-3.52 (m, 18H), 3.41-3.36 (m, 6H), 3.08 (dd, J.sub.1=10.8
Hz, J.sub.2=4.4 Hz, 1H), 2.56 (dd, J.sub.1=16.8 Hz, J.sub.2=2.8 Hz,
1H), 2.70 (s, 3H), 2.34 (t, J=7.2 Hz, 2H), 1.92-1.85 (m, 2H); MS
(m/z): found 990.6 (M+Na).sup.+, 1008.6 (M+H.sub.2O+Na).sup.+.
256e: MS (m/z): found 1006.6 (M+Na).sup.+.
##STR00220##
Compound 256f and Compound 256g (IGN-29-NHS):
[0370] To the solution of compound 256d (46 mg, 0.048 mmol) in
anhydrous 1,2 dichloroethane (1.5 mL) was added trimethyltin
hydroxide (129 mg, 0.71 mmol). The mixture was heated to 80.degree.
C. and stirred overnight. It was cooled to room temperature,
diluted with dichloromethane and washed with mixed solution of
saturated sodium chloride and 5% hydrochloric acid (.about.1 mL),
then brine. The organic layer was dried over anhydrous sodium
sulfate, filtered and evaporated. The residue was passed a short
silica gel column and eluted with dichloromethane/methanol to
remove the extra trimethyltin hydroxide. The product fractions were
evaporated and high vacuumed to give the acid 256f as a yellowish
solid (36.9 mg, yield=81%). MS (m/z): found 952.8 (M-H).sup.-.
Compound 256f (36.9 mg, 0.039 mmol) was then dissolved in anhydrous
dichloromethane (0.8 mL). N-hydroxysuccinimide (NHS, 13.4 mg, 0.12
mmol) and N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide
hydrochloride (EDC, 22.2 mg, 0.12 mmol) was added subsequently. The
mixture was stirred at room temperature overnight and diluted with
dichloromethane, washed with brine and dried over anhydrous sodium
sulfate. It was filtered, evaporated and the residue was purified
by preparative reverse phase HPLC (C18 column, eluted with
acetonitrile/water). The fractions containing product were combined
and extracted with dichloromethane. The organic layers were dried
over anhydrous sodium sulfate, filtered, evaporated and high
vacuumed to give compound 256g (IGN-29-NHS) as a light yellowish
solid (25.4 mg, yield=62%). MS (m/z): found 1073.4 (M+Na).sup.+,
1091.4 (M+H.sub.2O+Na).sup.+, 1103.3 (M+3H.sub.2O-H).sup.-.
Example 24
##STR00221##
[0371] methyl
1-(4-(benzyloxy)-5-methoxy-2-nitrobenzoyl)-6-nitroindoline-2-carboxylate
(258b)
[0372] Methyl 6-nitroindoline-2-carboxylate (258a) (0.233 g, 1.048
mmol) was dissolved in anhydrous tetrahydrofuran (4 ml) in a
separate flask and cooled to 0.degree. C. an ice bath. In another
flask 4-(benzyloxy)-5-methoxy-2-nitrobenzoyl chloride (4) (0.371 g,
1.153 mmol) was dissolved in anhydrous tetrahydrofuran (4 ml) and
cooled to 0.degree. C. in an ice bath. To the flask containing the
indoline was added triethylamine (0.438 ml, 3.15 mmol) via syringe
and the acetyl chloride 4 was added quickly to the reaction mixture
via cannula at 0.degree. C. The reaction was stirred for 90 minutes
at 0.degree. C. and then at room temperature for an additional 1
hour. The reaction was then quenched with 5% HCl and extracted with
ethyl acetate (3.times.). The combined organic layers were washed
with brine, dried over anhydrous sodium sulfate, and concentrated
in vacuo. The residue was purified by silica gel chromatography
using 30% Acetone in hexane to give methyl
1-(4-(benzyloxy)-5-methoxy-2-nitrobenzoyl)-6-nitroindoline-2-carboxylate
(258b) (0.220 g, 0.434 mmol, 41.4% yield) as a yellowish foam.
.sup.1H NMR (400 Hz, CDCl.sub.3): .delta. 3.30 (m, 1H), 3.60 (s,
3H), 3.69 (m, 1H), 3.86 (s, 3H), 4.64 (dd, 1H, J=2.4 Hz, 10.8),
5.23 (s, 2H), 7.31 (m, 1H), 7.46 (m, 6H), 7.99 (dd, 1H, J=2.0, 8.0
Hz), 9.04 (d, 1H, J=2.0 Hz). MS (m/z), found 530.1
([M].sup.++Na).
##STR00222##
1-(4-(benzyloxy)-5-methoxy-2-nitrobenzoyl)-6-nitroindoline-2-carbaldehyde
(258c)
[0373] Methyl
1-(4-(benzyloxy)-5-methoxy-2-nitrobenzoyl)-6-nitroindoline-2-carboxylate
(258b) (1.023 g, 2.016 mmol) was dissolved in a mixture of
anhydrous dichloromethane (2.5 mL) and toluene (7.5 mL) and cooled
to -78.degree. C. in a dry ice and acetone bath. After 15 minutes
DIBAL-H (1.0M in THF) (4.03 mL, 4.03 mmol) was added via a syringe
pump over about a 20 minute period. The resulting solution was
stirred for 2 hrs at -78.degree. C. after which methanol (1 ml) was
added dropwise to quench the reaction at -78.degree. C. The
reaction was then diluted with 5% HCl and ethyl acetate and warmed
to room temperature. The aqueous layer was washed with additional
ethyl acetate and the combined organic layers were washed with
brine and dried over anhydrous sodium sulfate. The reaction mixture
was passed through a layer of celite and concentrated in vacuo. The
crude residue was purified by silica gel chromatography using 40%
acetone in hexane to give
1-(4-(benzyloxy)-5-methoxy-2-nitrobenzoyl)-6-nitroindoline-2-carbaldehyde
(258c) (621 mg, 1.301 mmol, 64.5% yield). .sup.1H NMR (400 Hz,
CDCl.sub.3): .delta. 3.15-3.60 (m, 2H), 3.90 (s, 0.6H), 3.92 (s,
1.2H), 3.97 (s, 1.2H), 4.57 (d, 0.2H, J=4.8 Hz), 5.21 (m, 2.4H),
5.5 (m, 0.4H), 6.39 (s, 0.4H), 6.46 (s, 0.2H), 6.76 (s, 0.2H), 6.89
(s, 0.4H), 7.01 (s, 0.4H), 7.19-7.41 (m, 5.6H), 7.60-7.77 (m,
1.6H), 7.86-7.91 (m, 0.8H), 8.94 (s, 0.4H), 9.34 (s, 0.4H), 9.74
(s, 0.4H), 9.90 (s, 0.2H). MS (m/z), found 500.1
([M].sup.++Na).
##STR00223##
Compound 258e:
[0374]
1-(4-(benzyloxy)-5-methoxy-2-nitrobenzoyl)-6-nitroindoline-2-carbal-
dehyde (258c) (0.125 g, 0.262 mmol) was dissolved in
tetrahydrofuran (8 mL) and water (5.33 mL). To this solution was
added sodium hydrosulfite (0.456 g, 2.62 mmol) and the reaction was
capped with a septa and vented with a needle (no nitrogen/argon
needed) and stirred overnight. Methanol was added to the reaction
mixture and stirred an additional 30 minutes at which point the
reaction was concentrated in vacuo to remove all solvents. The
residue was dissolved in a 1:1 mixture of methanol and
dichloromethane (20 mL) which left a residue which did not
dissolve. The mixture was passed through a short pad of silica on
top of a short pad of celite and rinsed thoroughly with the 1:1
mixture of methanol and dichloromethane. The filtrate was filtered
again through celite and then a solution of HCl in dioxane (4M) was
added with stirring until a pH of .about.3-4 was obtained. The
reaction was then stirred for an additional 30 minutes and then
aqueous sodium bicarbonate was added until the reaction became
basic (.about.pH 8-9) at which time additional dichloromethane was
added and the organic layer removed. The aqueous layer was washed
with additional dichloromethane and the resulting organic layers
were combined and washed with brine, dried over anhydrous sodium
sulfate and concentrated in vacuo. The residue containing compound
258d (0.105 g, 0.263 mmol, 100% yield) was used in the next step
without further treatment. MS (m/z), found 454.2
([M].sup.++Na+CH3OH).
[0375] To a small vial containing
4-methyl-4-(methyldisulfanyl)pentanoic acid (0.061 g, 0.313 mmol),
EDC (0.060 g, 0.313 mmol), and DMAP (0.038 g, 0.313 mmol) were
dissolved in dichloromethane (1 mL) with stirring. To this mixture
compound 258d (0.125 g, 0.313 mmol) dissolved in dichloromethane
(1.5 mL) was added and the mixture was stirred at room temperature
overnight. Water was added and the layers were separated. The
organic layer was washed with brine, dried over anhydrous sodium
sulfate, and concentrated in vacuo. The residue was purified on a
silica gel column using 50% ethyl acetate in hexane to give
compound 258e (0.037 g, 0.064 mmol, 20.54% yield). .sup.1H NMR (400
Hz, CDCl.sub.3): .delta. 1.27 (s, 6H), 1.97 (t, 2H, J=8.0 Hz), 2.06
(t, 2H, J=8.0 Hz), 2.45 (s, 3H), 3.48 (m, 1H), 3.67 (m, 1H), 3.99
(s, 3H), 4.49 (m, 1H), 5.24 (q, 2H, J=8.4 Hz), 6.90 (s, 1H), 7.22
(d, 1H, J=8.0 Hz), 7.39 (m, 5H), 7.55 (s, 1H), 7.82 (d, 1H, J=8.0
Hz), 7.87 (d, 1H, J=4.0 Hz), 8.07 (s, 1H). MS (m/z), found 630.3
([M].sup.++Na+MeOH).
##STR00224##
Compound 258f:
[0376] Compound 258e (0.0185 g, 0.032 mmol) was dissolved in
anhydrous dichloromethane (0.5 ml) and to this solution was added
methanesulfonic acid (0.021 ml, 0.321 mmol) dissolved in anhydrous
dichloromethane (0.500 ml) and the resulting mixture was stirred at
room temperature for three hours. The reaction was poured over a
mixture of ice and methanol and neutralized to pH 7 with aqueous
sodium bicarbonate. The reaction was then diluted with
dichloromethane and the layers were separated. The organic layer
was washed with brine, dried over anhydrous sodium sulfate, and
concentrated in vacuo. The residue was purified by silica ptlc
using 3% methanol in dichloromethane to give
NH(4-methyl-4-methyldithio-pentanoate)-indole IGN monomer (0.007 g,
0.014 mmol, 44.9% yield). MS (m/z), found 484.0 ([M]-1).
##STR00225##
Compound 258g:
[0377] In a small vial dissolved Compound 8 (0.033 g, 0.112 mmol)
in DMF (1.5 ml) with stirring at room temperature.
1,3-diiodopropane (0.065 ml, 0.561 mmol) was added followed by the
addition of potassium carbonate (0.023 g, 0.168 mmol). The reaction
was covered in foil and stirred at room temperature overnight. The
reaction was diluted with dichloromethane and washed with aqueous
ammonium chloride and brine. The organic layer was dried over
anhydrous sodium sulfate, filtered, and concentrated in vacuo. The
residue was purified by silica ptlc using 50% ethyl acetate in
hexane to give Compound 258g (0.018 g, 0.039 mmol, 34.7% yield). MS
(m/z), found 533.0 ([M].sup.++K).sup.+.
##STR00226##
Compound 258 h (IGN-15-SMe):
[0378] In a small vial dissolved Compound 258f (0.007 g, 0.014
mmol) in dimethylformamide (1 ml) with stirring at room
temperature. Compound 8 (6.66 mg, 0.014 mmol) was added followed by
the addition of potassium carbonate (1.992 mg, 0.014 mmol). The
reaction was covered in foil and stirred at room temperature
overnight. Reaction was diluted with dichloromethane and washed
with aqueous ammonium chloride and brine. The organic layer was
dried over anhydrous sodium sulfate, filtered, and concentrated in
vacuo. The residue was purified by silica ptlc plate in 5% methanol
in dichloromethane to give Compound 258h (IGN-15-SMe) (0.005 g,
7.32 .mu.mol, 50.8% yield). MS (m/z), found 906.3
([M].sup.++Na+2CH3OH).
Example 25
##STR00227##
[0379] Compound 259a:
[0380] In a small vial dissolved Compound 8 (0.100 g, 0.340 mmol)
in DMF (5 ml) with stirring at room temperature. 1,5-diiodopentane
(0.506 ml, 3.40 mmol) was added followed by the addition of
potassium carbonate (0.070 g, 0.510 mmol). The reaction was covered
in foil and stirred at room temperature overnight. The reaction was
diluted with dichloromethane and washed with aqueous ammonium
chloride and brine. The organic layer was dried over anhydrous
sodium sulfate, filtered, and concentrated in vacuo. The residue
was purified by silica ptlc using 50% ethyl acetate in hexane to
give Compound 259a (0.045 g, 7.32 .mu.mol, 27% yield). .sup.1H NMR
(400 Hz, CDCl.sub.3): .delta. 1.64 (m, 2H), 1.94 (M, 4H), 3.24 (t,
2H, J=6.5 Hz), 3.52 (dd, 1H, J=4.0, 16.6 Hz), 3.73 (dd, 1H, J=10.5,
16.6 Hz), 3.98 (s, 3H), 4.12 (m, 2H), 4.50 (dt, 1H, J=4.0, 11.2
Hz), 6.84 (s, 1H), 7.13 (t, 1H, J=6.0 Hz), 7.29 (m, 2H), 7.57 (s,
1H), 7.90 (d, 1H, J=4.4 Hz), 8.29 (d, 1H, J=8.0 Hz). MS (m/z),
found 533.3 ([M].sup.++K).sup.+.
##STR00228##
Compound 259b (IGN-21-SMe):
[0381] In a small vial dissolved Compound 258f (15 mg, 0.031 mmol)
in dimethylformamide (1 ml) with stirring at room temperature.
Compound 259a (17.42 mg, 0.036 mmol) was added followed by the
addition of potassium carbonate (4.27 mg, 0.031 mmol). The reaction
was covered in foil and stirred at room temperature overnight.
Reaction was diluted with dichloromethane and washed with aqueous
ammonium chloride and brine. The organic layer was dried over
anhydrous sodium sulfate, filtered, and concentrated in vacuo. The
residue was purified by silica ptlc plate in 5% methanol in
dichloromethane to give Compound 259a (IGN-15-SMe) (0.006 g, 7.32
.mu.mol, 22% yield). MS (m/z), found 934.1
([M].sup.++Na+2CH3OH).
Example 26
##STR00229##
[0382] Compound 260a:
[0383] Compound 256a (55 mg, 0.142 mmol) was dissolved in anhydrous
dichloromethane and then 4-methoxy-4-oxobutanoic acid (76 mg, 0.575
mmol), EDC (70 mg, 0.365 mmol), and DMAP (8.69 mg, 0.071 mmol) were
added sequentially. The mixture was stirred overnight at room
temperature and was checked by TLC to ensure no starting material
remained. The reaction was then diluted with water and ethyl
acetate. After further extraction with ethyl acetate, the organic
was washed with brine, dried over sodium sulfate, filtered and
concentrated in vacuo. The crude residue was purified by silica gel
chromatography using 50% ethyl acetate in hexane to give compound
260a (54 mg, yield=76%). .sup.1H NMR (400 Hz, CDCl.sub.3): .delta.
8.21 (d, J=8.0 Hz, 1H), 7.45-7.25 (m, 7H), 7.20 (d, J=7.2 Hz, 1H),
7.08 (t, J=7.4 Hz, 1H), 6.825 (s, 1H), 5.27 (q, J=15.1 Hz, 2H),
4.56 (t, J=12.6 Hz, 1H), 4.35-4.29 (m, 1H), 3.99 (s, 3H), 3.65 (s,
3H), 3.44-3.38 (m, 2H), 2.88 (dd, J.sub.1=16.4 Hz, J.sub.2=2 Hz,
1H), 2.58-2.50 (m, 1H), 2.40-2.33 (m, 1H), 2.26-2.18 (m, 1H),
1.99-1.92 (m, 1H); MS (m/z), found 523.1 (M+Na).sup.+.
##STR00230##
Compound 260b:
[0384] To a solution of compound 260a (50 mg, 0.100 mmol) in
anhydrous dichloromethane (11.5 ml) was added drop wise
methanesulfonic acid (0.389 ml, 5.99 mmol) resulting in a yellow
solution. The reaction stirred at room temperature and was
monitored by TLC until completion beginning at 30 minutes. It was
diluted with water and methanol then neutralized to pH 7 using
saturated sodium bicarbonate. The aqueous layer was extracted with
dichloromethane and the organic layer dried over sodium sulfate.
The crude product was purified by silica gel chromatography using
6% methanol in dichloromethane to give compound 260b (40 mg,
yield=98%). .sup.1H NMR (400 Hz, CDCl.sub.3): .delta. 8.22 (d,
J=8.0 Hz, 1H), 7.35 (s, 1H), 7.28 (t, J=7.8 Hz, 1H), 7.22 (d, J=7.2
Hz, 1H), 7.09 (t, J=7.4 Hz, 1H), 6.90 (s, 1H), 6.06 (s, 1H), 4.63
(t, J=12.6 Hz, 1H), 4.38-4.30 (m, 1H), 4.00 (s, 3H), 3.66 (s, 3H),
3.47-3.39 (m, 2H), 2.90 (dd, J.sub.1=16.2 Hz, J.sub.2=2.2 Hz, 1H),
2.69-2.59 (m, 2H), 2.52-2.45 (m, 1H), 2.22-2.14 (m, 1H); MS (m/z),
found 433 (M+Na).sup.+.
##STR00231##
Compound 260c:
[0385] Compound 260b (20 mg, 0.049 mmol) and compound 259a (30 mg,
0.061 mmol) were dissolved in anhydrous N,N-dimethylformamide (1
ml). Potassium carbonate (20.20 mg, 0.146 mmol) was added and the
reaction stirred overnight at room temperature. It was quenched
with water and extracted with dichloromethane. The organic was
washed with brine and dried over sodium sulfate. The crude product
was purified by silica gel chromatography using 5% methanol in
dichloromethane to give compound 260c (25 mg, yield=66%). MS (m/z),
found 813.5 (M+Na+H.sub.2O).sup.+.
Example 27
##STR00232##
[0386] Compound 261a:
[0387] The commercially available starting material,
thiazolidine-4-carboxylic acid (1.3 g, 9.59 mmol) was dissolved in
anhydrous methanol (19.18 mL) and cooled to 0.degree. C. in an ice
bath. Thionyl chloride (1.40 mL, 19.18 mmol) was added drop wise
and the reaction stirred for 30 minutes. The ice bath was removed
and stirring continued either for 4-5 hours or overnight. The
solvent was stripped and the product placed on the high vacuum to
give 4-(methoxycarbonyl)thiazolidin-3-ium chloride. Without further
purification and assuming 100% yield, the
4-(methoxycarbonyl)thiazolidin-3-ium chloride (1.761 g, 9.59 mmol)
and compound 4 (3.39 g, 10.55 mmol) were each dissolved separately
in tetrahydrofuran (32.0 mL) and cooled to 0.degree. C.
Triethylamine (4.41 mL, 31.6 mmol) was added to the solution with
4-(methoxycarbonyl)thiazolidin-3-ium chloride and then compound 4
was added quickly via canula. After 20 minutes, the pH of the
solution was checked to ensure it was basic. The reaction stirred
at 0.degree. C. for 1.5 hours and then at room temperature for 30
minutes and was checked by MS. It was quenched with cold 5%
hydrochloric acid and diluted with cold ethyl acetate and water.
The solution was extracted with ethyl acetate three times and the
combined organic washed with brine, saturated sodium bicarbonate
and then brine again. It was dried over sodium sulfate, filtered
and stripped. The crude material was purified by silica gel
chromatography using a gradient of 50% to 75% ethyl acetate in
hexanes to give compound 261a (4.1 g, yield=99%). .sup.1H NMR (400
Hz, CDCl.sub.3): the compound appears as a pair of distinct
rotomers. .delta. 7.78 (s, 0.6H), 7.74 (s, 0.4H), 7.48-7.35 (m,
5H), 6.96 (s, 0.4H), 6.92 (s, 0.6H), 5.40 (dd, J.sub.1=7.0 Hz,
J.sub.2=3.4 Hz, 0.6H), 5.31-5.22 (m, 2H), 5.13 (d, 9.6 Hz, 0.4H),
4.60 (d, J=9.6 Hz, 0.4H), 4.46 (dd, J.sub.1=4.4 Hz, J.sub.2=3.2 Hz,
0.4H), 4.36 (d, J=8.4 Hz, 0.6H), 4.26 (d, J=8.4 Hz, 0.6H), 4.02 (s,
1.8H), 3.96 (s, 1.2H), 3.86 (s, 1.8H), 3.71 (s, 1.2H), 3.48-3.43
(m, 0.6H), 3.36-3.29 (m, 1.4H); MS (m/z), found 455.3
(M+Na).sup.+.
##STR00233##
Compound 261b:
[0388] Compound 261a (4.1 g, 9.48 mmol) was dissolved in
dichloromethane (11 mL) and toluene (33 mL) then cooled to
-78.degree. C. in an acetone/dry ice bath. Diisobutylaluminium
hydride (18.96 mL, 18.96 mmol) was added very slowly, over at least
30 minutes, using a syringe pump. The reaction stirred at
-78.degree. C. for 3 hours and was quenched with methanol (0.4 mL)
and then 5% hydrochloric acid (30 mL). Ethyl acetate (100 ml) was
added and the ice bath removed. The mixture continued to stir at
room temperature for 30 minutes. It was extracted using ethyl
acetate and the combined organic washed with brine, saturated
sodium bicarbonate, and then brine again. It was dried over
anhydrous sodium sulfate and filtered through celite. The crude
material was purified by silica gel chromatography using 75% ethyl
acetate in hexanes to give compound 261b (2.3 g, yield=60%).
.sup.1H NMR (400 Hz, CDCl.sub.3): the compound appears as a pair of
rotomers. .delta. 9.80 (s, 0.8H), 9.41 (s, 0.2H), 7.80 (s, 0.8H),
7.73 (s, 0.2H), 7.49-7.36 (m, 5H), 6.91 (s, 0.2H), 6.84 (s, 0.8H),
5.25-5.22 (m, 2H), 4.85-4.73 (m, 1H), 4.35-4.30 (m, 1H), 4.22-4.17
(m, 1H), 4.04-3.97 (m, 3H), 3.40-3.26 (m, 2H); MS (m/z), found
425.0 (M+Na).sup.+.
##STR00234##
Compound 261c:
[0389] Compound 261b was dissolved in tetrahydrofuran (230 mL) then
water (150 mL). Sodium hydrosulfite (5.27 g, 25.7 mmol) was added
slowly, in small portions. If the solution remained cloudy,
additional water was added drop wise until the solution cleared.
The reaction was capped with a septa and needle to allow release of
the SO.sub.2 gas and was stirred overnight. The solution changed
from a yellow to very pale, almost colorless solution. The
following morning, water was added until the solution cleared and
then methanol (30 mL) was added. It stirred for an additional 2
hours and the solvents were then evaporated and the residue
re-evaporated with acetonitrile at least twice. The white residue
was placed on the high vacuum for a few hours. It was re-dissolved
in methanol:dichloromethane [1:1], filtered through celite, and
stripped. The filter step was repeated until dilution in methanol
appeared clear with no particles. The intermediate was placed on
the high vacuum until completely dry then dissolved in anhydrous
methanol (50 ml). Acetyl chloride (1.9 ml, 26.7 mmol) was added
drop wise at room temperature, causing a yellow precipitate to
form. It stirred at room temperature for 30 minutes and was
quenched with saturated sodium bicarbonate. The mixture was diluted
with dichloromethane and water (130 mL/85 mL) and extracted with
dichloromethane. The aqueous layer was acidified with sodium
hydrogensulfate, concentrated to a reduced volume, and then
re-extracted. The combined organic was washed with saturated sodium
bicarbonate and brine and dried over sodium sulfate. The stripped
residue was purified by silica gel chromatography using 60% ethyl
acetate in hexanes to give compound 261c (1.2 g, yield=59%).
.sup.1H NMR (400 Hz, CDCl.sub.3): .delta. 7.69 (d, J=4.4 Hz, 1H),
7.52-7.28 (m, 6H), 6.87 (s, 1H), 5.22 (q, J=12.3 Hz, 2H), 4.85, (d,
J=10.4 Hz, 1H), 4.58 (d, J=10.4 Hz, 1H), 4.03-4.02 (m, 1H), 3.98
(s, 3H), 3.51-3.47 (m, 1H), 3.45-3.23 (m, 1H); MS (m/z), found
377.3 (M+Na).sup.+.
##STR00235##
Compound 261d:
[0390] Compound 261c (75 mg, 0.212 mmol) was dissolved in neat
trifluoroacetic acid (0.4 ml, 5.19 mmol). It refluxed for
approximately 1 hour at 50.degree. C. and then the temperature was
increased to 80.degree. C. After 3 hours total, the solvent was
evaporated. The residue was directly purified by PTLC using 5%
methanol in dichloromethane to give compound 261d (19.4 mg, 35%).
.sup.1H NMR (400 Hz, CDCl.sub.3): .delta. 7.72 (d, J=4.4 Hz, 1H),
7.51 (s, 1H), 6.91 (s, 1H), 6.18 (s, 1H), 4.85 (d, J=10.4 Hz, 1H),
4.58 (J=10.4 Hz, 1H), 4.05-4.02 (m, 1H), 3.99 (s, 3H), 3.50 (dd,
J.sub.1=12.4 Hz, J.sub.2=6 Hz, 1H), 3.32, (dd, J.sub.1=12.4H,
J.sub.2=2 Hz, 1H); MS (m/z), found 319.0 (M+Na+MeOH)+.
Example 28
##STR00236##
[0391] Compound 262:
[0392] Compound 249c (18 mg, 0.045 mmol) was dissolved in anhydrous
dichloromethane (0.45 mL) and then cooled in an ice/brine bath.
First, triethylamine (0.022 ml, 0.158 mmol) and then
methanesulfonyl chloride (10.46 .mu.l, 0.135 mmol) were added; the
second very slowly. The mixture continued to stir in the bath for 1
hour. The reaction was quenched with ice/water and diluted with
cold ethyl acetate. After separation, the organic layer was washed
again with cold water and dried over sodium sulfate. It was
filtered and evaporated under reduced pressure, keeping the
temperature below 20.degree. C., and then placed on the high vacuum
to be used directly. Once completely dry, the product, and compound
261d (28.5 mg, 0.108 mmol) were dissolved in anhydrous
N,N-dimethylformamide (350 .mu.L). Potassium carbonate (29.8 mg,
0.216 mmol) was added. After stirring overnight at room
temperature, the reaction was diluted with dichloromethane, washed
with brine, dried over sodium sulfate, filtered and stripped. The
crude product was first purified by silica gel chromatography using
4% methanol in dichloromethane to remove baseline residue. The
recovered material was then purified using reverse phase HPLC (C18
column, CH.sub.3CN/H.sub.2O, loaded column with 3:1, centrifuged
before injection) to give compound 262 as a solid. .sup.1H NMR (400
Hz, CDCl.sub.3): .delta. 7.68 (dd, J.sub.1=4.4 Hz, J.sub.2=1.6 Hz,
2H), 7.51 (s, 2H), 6.86 (s, 2H), 6.78 (s, 1H), 6.71 (s, 2H), 5.16
(dq, J.sub.1=8.4 Hz, J.sub.2=2.2, 4H), 4.85 (d, J=10.4 Hz, 2H),
4.58 (J=10.4 Hz, 2H), 4.04-3.97 (m, 7H), 3.68-3.38 (m, 18H),
3.40-3.29 (m. 7H), 2.33 (t, 7.2 Hz, 2H), 1.89-1.35 (m, 2H) MS
(m/z), found 914.1 (M+Na).sup.+.
Example 29 (IGN-13)
##STR00237##
[0393] methyl
3-(2-(2-(2-(3,5-bis(hydroxymethyl)phenoxy)ethoxy)ethoxy)ethoxy)
propanoate (263b)
[0394] To a stirred mixture of methyl
3-(2-(2-(2-(tosyloxy)ethoxy)ethoxy)ethoxy)propanoate (263a) (1.504
g, 3.85 mmol) and (5-hydroxy-1,3-phenylene)dimethanol (21) (0.54 g,
3.50 mmol) in anhydrous DMF (7.8 ml) was added potassium carbonate
(0.726 g, 5.25 mmol). The reaction was stirred at room temperature
for 18 hours at 75.degree. C. The mixture was allowed to cool to
room temperature, quenched with water, and extracted with ethyl
acetate. The organic extracts were washed with brine, dried over
anhydrous magnesium sulfate, filtered and concentrated.
Purification by silica gel chromatography (5%
MeOH/CH.sub.2Cl.sub.2) yielded methyl
3-(2-(2-(2-(3,5-bis(hydroxymethyl)phenoxy)ethoxy)
ethoxy)ethoxy)propanoate (263b) (340 mg, 26%). .sup.1H NMR (400 Hz,
CDCl.sub.3): .delta. 6.83 (s, 1H), 6.75 (s, 2H), 4.52 (s, 4H), 4.05
(t, J=4.8 Hz, 2H), 3.79 (t, J=4.8 Hz, 2H), 3.70 (t, J=6.4 Hz, 2H),
3.65 (s, 3H), 3.70-3.56 (m, 8H), 3.26 (s, 2H), 2.55 (t, J=6.4 Hz,
2H); .sup.13C NMR (400 Hz, CDCl.sub.3): .delta. 172.31, 159.1,
143.0, 117.7, 112.1, 70.8, 70.7, 70.5, 70.4, 69.8, 67.5, 66.6,
64.7, 51.8, 34.9; MS (m/z), found 395.2 (M+Na).sup.+.
##STR00238##
Compound 263c:
[0395] To a stirred solution of methyl
3-(2-(2-(2-(3,5-bis(hydroxymethyl)phenoxy)ethoxy)
ethoxy)ethoxy)propanoate (263b) (145 mg, 0.389 mmol) in anhydrous
dichloromethane (5.5 ml) was added triethylamine (0.163 ml, 1.168
mmol). The mixture was cooled to -5.degree. C. and methanesulfonyl
chloride (0.076 ml, 0.973 mmol) was added slowly. After stirring
for one hour at -5.degree. C. the reaction was quenched with cold
water and extracted with cold ethyl acetate. The organic extracts
were washed with cold water, dried over anhydrous sodium sulfate,
filtered and concentrated under reduced pressure to give methyl
3-(2-(2-(2-(3,5-bis((methylsulfonyloxy)methyl)
phenoxy)ethoxy)ethoxy)ethoxy) propanoate. MS (m/z), found 551.1
(M+Na).sup.+. To a stirred mixture of methyl
3-(2-(2-(2-(3,5-bis((methylsulfonyloxy)methyl)
phenoxy)ethoxy)ethoxy)ethoxy)propanoate (206 mg, 0.390 mmol) and
compound 8 (287 mg, 0.974 mmol) in anhydrous DMF (3.9 ml) was added
potassium carbonate (269 mg, 1.949 mmol). The reaction was allowed
to stir at room temperature for 18 hours. The mixture was quenched
with water and extracted three times with dichloromethane. The
organic extracts were washed with water and brine, dried over
anhydrous sodium sulfate, filtered and concentrated in vacuo.
Purification by flash silica gel chromatography (5%
MeOH/CH.sub.2Cl.sub.2) followed by preparative reverse phase HPLC
(C18 column, eluted with CH.sub.3CN/H.sub.2O) gave compound 263c
(110 mg, 30%) as a white solid. .sup.1H NMR (400 Hz, CDCl.sub.3):
.delta. 8.18 (d, J=8.0 Hz, 2H), 7.77 (m, 2H), 7.49 (s, 2H), 7.19
(m, 4H), 7.02 (m, 2H), 6.89 (s, 2H), 6.87 (s, 1H), 6.75 (s, 2H),
5.10 (m, 4H), 4.39 (m, 2H), 4.05 (m, 2H), 3.90 (s, 6H), 3.77 (m,
2H), 3.67 (t, J=6.4 Hz, 2H), 3.64 (m, 2H), 3.59 (s, 3H), 3.70-3.54
(m, 8H), 3.40 (m, 2H), 2.51 (t, J=6.4 Hz, 2H); MS (m/z), found
965.3 (M+H.sub.2O+Na).sup.+, 983.3 (M+2H.sub.2O+Na).sup.+.
##STR00239##
Compound 263d:
[0396] To a solution of compound 263c (51 mg, 0.055 mmol) in
1,2-Dichloroethane (2.2 ml) was added trimethyl tin hydroxide (199
mg, 1.103 mmol). The reaction was stirred for 18 hours at
80.degree. C., then cooled to room temperature, and quenched with
saturated ammonium chloride. The mixture was extracted with
dichloromethane. The organic layer was washed with brine, dried
over anhydrous sodium sulfate, filtered and concentrated.
Purification by silica gel chromatography (10%
MeOH/CH.sub.2Cl.sub.2) yielded compound 263d (35 mg, 70%). .sup.1H
NMR (400 Hz, CDCl.sub.3): .delta. 8.26 (d, J=8.0 Hz, 2H), 7.88 (m,
2H), 7.58 (s, 2H), 7.28 (m, 4H), 7.11 (m, 3H), 7.00 (s, 2H), 6.88
(s, 2H), 5.21 (m, 4H), 4.49 (m, 2H), 4.18 (m, 2H), 4.00 (s, 6H),
3.89 (m, 2H), 3.79 (m, 2H), 3.70 (m, 10OH), 3.51 (m, 2H), 2.62 (m,
2H); MS (m/z), found 909.2 (M-1).sup.-, 927.2 (M-1+H.sub.2O).sup.-,
945.2 (M-1+2H.sub.2O).sup.-.
##STR00240##
Compound 263e:
[0397] To a solution of compound 263d (30 mg, 0.033 mmol) in
anhydrous dichloromethane (2.5 mL) was added N-hydroxy succinimide
(9.77 mg, 0.082 mmol), EDC (15.78 mg, 0.082 mmol), and DMAP (0.406
mg, 3.29 .mu.mol). The reaction was stirred for 18 hours at room
temperature and then diluted with dichloromethane. The mixture was
washed with saturated ammonium chloride and brine. The organic
layer was dried over anhydrous sodium sulfate, filtered and
concentrated in vacuo. The crude material was purified by
preparative reverse phase HPLC (C18 column, eluted with
CH.sub.3CN/H.sub.2O). Fractions containing product were extracted
with dichloromethane, dried over anhydrous sodium sulfate, filtered
and co-evaporated with acetonitrile under reduced pressure to give
compound 263e (4.5 mg, 13%) as a white solid; MS (m/z), found
1030.4 (M+Na).sup.+, 1046.3 (M+K).sup.+.
Example 30 (IGN-27)
##STR00241##
[0398] methyl
3-(2-(2-(2-(3,5-bis(hydroxymethyl)phenylamino)ethoxy)ethoxy)
ethoxy)propanoate (264a)
[0399] To a mixture of methyl
3-(2-(2-(2-(tosyloxy)ethoxy)ethoxy)ethoxy)propanoate (263a) (250
mg, 0.640 mmol) and (5-amino-1,3-phenylene)dimethanol (26) (108 mg,
0.704 mmol) in anhydrous DMF (1.4 ml) was added potassium carbonate
(133 mg, 0.960 mmol). The reaction stirred for 18 hours at
80.degree. C. and then was allowed to cool to room temperature. The
mixture was quenched with water and extracted two times with ethyl
acetate. The organic extracts were washed with brine, dried over
anhydrous magnesium sulfate, filtered and concentrated.
Purification by silica gel chromatography (5% Methanol/methylene
chloride) yielded methyl
3-(2-(2-(2-(3,5-bis(hydroxymethyl)phenylamino)ethoxy)ethoxy)
ethoxy)propanoate (264a) (61 mg, 25%); .sup.1H NMR (400 Hz,
CDCl.sub.3): .delta. 6.58 (s, 1H), 6.47 (s, 2H), 4.49 (s, 4H), 3.67
(t, J=6.4 Hz, 2H), 3.62 (s, 3H), 3.64-3.54 (m, 10H), 3.21 (t, J=5.2
Hz, 2H), 2.51 (t, J=6.4 Hz, 2H); MS (m/z), found 394.3
(M+Na).sup.+.
##STR00242##
Compound 264b:
[0400] To a solution of methyl
3-(2-(2-(2-(3,5-bis(hydroxymethyl)phenylamino)ethoxy)
ethoxy)ethoxy)propanoate (264a) (60 mg, 0.162 mmol) in acetonitrile
(1.6 ml) was added iodomethane (0.013 ml, 0.210 mmol) and potassium
carbonate (26.8 mg, 0.194 mmol). The reaction stirred at 82.degree.
C. for 18 hours. The mixture was cooled to room temperature and
then the solvent was removed under reduced pressure. The crude
material was diluted with 3:1 CH.sub.2Cl.sub.2/MeOH and filtered
through Celite. The filtrate was concentrated and purified by
silica gel chromatography eluting with 5% Methanol/dichloromethane
to give Compound 264b (35 mg, 56%). .sup.1H NMR (400 Hz,
CDCl.sub.3): .delta. 6.58 (s, 3H), 4.52 (s, 4H), 3.64 (t, J=6.4 Hz,
2H), 3.60 (s, 3H), 3.53 (m, 12H), 2.91 (s, 3H), 2.51 (t, J=6.4 Hz,
2H), 2.28 (s, 2H); .sup.13C NMR (400 Hz, CDCl.sub.3): .delta.
172.1, 149.8, 142.4, 113.4, 109.9, 70.7, 70.6, 70.4, 70.3, 68.6,
66.5, 65.6, 52.3, 51.7, 38.9, 34.8; MS (m/z), found 408.4
(M+Na).sup.+.
##STR00243##
Compound 264c:
[0401] To a stirred solution of compound 246b (60 mg, 0.156 mmol)
in anhydrous dichloromethane (2.8 mL) was added triethylamine
(0.065 mL, 0.467 mmol). The mixture was cooled to -5.degree. C. and
methanesulfonyl chloride (0.030 mL, 0.389 mmol) was added slowly.
After stirring for one hour at -5.degree. C. the reaction was
quenched with cold water and extracted with cold ethyl acetate. The
organic layer was washed with cold water, dried over anhydrous
sodium sulfate, filtered and concentrated under reduced pressure to
give the dimesylate intermediate. MS (m/z), found 564.0
(M+Na).sup.+. To a mixture of the dimesylate linker (49 mg, 0.090
mmol) and compound 8 (66.6 mg, 0.226 mmol) in anhydrous DMF (0.9
mL) was added potassium carbonate (62.5 mg, 0.452 mmol). The
reaction was stirred for 18 hours at room temperature, quenched
reaction with water and extracted three times with dichloromethane.
The organic extracts were washed with water and brine, dried over
anhydrous sodium sulfate, filtered and concentrated in vacuo.
Purification by flash silica gel chromatography (5%
MeOH/CH.sub.2Cl.sub.2) followed by preparative reverse phase HPLC
(C18 column, eluted with CH.sub.3CN/H.sub.2O) gave compound 264c
(16 mg, 19%) as a white solid. .sup.1H NMR (400 Hz, CDCl.sub.3):
.delta. 8.18 (d, J=8.0 Hz, 2H), 7.76 (m, 2H), 7.48 (s, 2H), 7.18
(m, 4H), 7.02 (t, J=7.2 Hz, 2H), 6.79 (m, 2H), 6.74 (s, 1H), 6.65
(s, 2H), 5.08 (m, 4H), 4.39 (m, 2H), 3.89 (s, 6H), 3.66 (t, J=6.4
Hz, 2H), 3.62 (m, 2H), 3.60 (s, 3H), 3.53 (m, 12H), 3.40 (m, 2H),
2.91 (s, 3H), 2.51 (t, J=6.4 Hz, 2H); MS (m/z), found 978.3
(M+H.sub.2O+Na).sup.+, 996.3 (M+2H.sub.2O+Na).sup.+.
##STR00244##
Compound 264d:
[0402] To a solution of Compound 264c (26 mg, 0.028 mmol) in
anhydrous 1,2-Dichloroethane (1.1 ml) was added trimethyl tin
hydroxide (100 mg, 0.554 mmol). The reaction was stirred for 18
hours at 80.degree. C. The mixture was allowed to cool to room
temperature and extracted with dichloromethane and saturated
ammonium chloride. The organic extracts were washed with brine,
dried over anhydrous sodium sulfate, filtered and concentrated in
vacuo. Purification by preparative TLC in 5% Methanol/methylene
chloride yielded compound 264d (14 mg, 55%). MS (m/z), found 922.1
(M-1).sup.-, 940.0 (M-1+H.sub.2O).sup.-, 958.1
(M-1+2H.sub.2O).sup.-.
##STR00245##
Compound 264e:
[0403] To a stirred solution of compound 264d (13 mg, 0.014 mmol)
in anhydrous dichloromethane (1.0 mL) was added
N-hydroxysuccinimide (5.01 mg, 0.042 mmol), EDC (8.09 mg, 0.042
mmol), and DMAP (0.172 mg, 1.407 .mu.mol). The reaction stirred for
18 hours at room temperature. The mixture was extracted with
dichloromethane and saturated ammonium chloride. The organic layer
was washed with brine, dried over anhydrous sodium sulfate,
filtered and concentrated in vacuo. The crude material was purified
by preparative reverse phase HPLC (C18 column, eluted with
CH.sub.3CN/H.sub.2O). Fractions containing product were combined
and extracted with dichloromethane, dried over anhydrous sodium
sulfate, filtered and co-evaporated with acetonitrile under reduced
pressure to obtain compound 264e (4.1 mg, 29%). MS (m/z), found
1021.3 (M+H).sup.+, 1043.2 (M+Na).sup.+, 1061.2
(M+H.sub.2O+Na).sup.+, 1079.2 (M+2H.sub.2O+Na).sup.+.
Example 31 (IGN-28)
##STR00246##
[0404] methyl
1-(tosyloxy)-3,6,9,12,15,18,21,24,27,30,33,36-dodecaoxanonatriacontan-39--
oate (265b):
[0405] To a stirred solution of methyl
1-hydroxy-3,6,9,12,15,18,21,24,27,30,33,36-dodecaoxanonatriacontan-39-oat-
e (265a) (1.2 g, 1.897 mmol) in dichloromethane (9.48 mL) at
0.degree. C. was added triethylamine (0.529 mL, 3.79 mmol), toluene
sulfonylchloride (0.542 g, 2.84 mmol) and DMAP (0.023 g, 0.190
mmol). The mixture was stirred for one hour at 0.degree. C. and
then three hours at ambient temperature, after which it was
quenched with water and extracted twice with dichloromethane. The
organic extracts were washed with brine, dried over anhydrous
magnesium sulfate, filtered and concentrated in vacuo. Purification
by silica gel chromatography (5% MeOH/CH.sub.2Cl.sub.2) gave methyl
1-(tosyloxy)-3,6,9,12,15,18,21,24,27,30,33,36-dodecaoxanonatriacon-
tan-39-oate (265b) (1.0 g, 67%) as a light yellow oil. .sup.1H NMR
(400 Hz, CDCl.sub.3): .delta. 7.80 (d, J=8.4 Hz, 2H), 7.35 (d,
J=8.0 Hz, 2H), 4.16 (t, J=4.8 Hz, 2H), 3.75 (t, J=6.4 Hz, 2H), 3.69
(s, 3H), 3.64 (m, 46H), 2.60 (t, J=6.4 Hz, 2H), 2.45 (s, 3H).
##STR00247##
methyl
1-(3,5-bis(hydroxymethyl)phenylamino)-3,6,9,12,15,18,21,24,27,30,3-
3,36-dodecaoxanonatriacontan-39-oate (265c)
[0406] To a stirred mixture of methyl
1-(tosyloxy)-3,6,9,12,15,18,21,24,27,30,33,36-dodecaoxanonatriacontan-39--
oate (265b) (700 mg, 0.890 mmol) and
(5-amino-1,3-phenylene)dimethanol (26) (150 mg, 0.978 mmol) in
anhydrous DMF (2.0 ml) was added potassium carbonate (184 mg, 1.334
mmol). The reaction was stirred at 80.degree. C. overnight. The
mixture was cooled to room temperature, quenched with water and
extracted with 10% Methanol/Methylene chloride. The organic layer
was washed with brine, dried over anhydrous magnesium sulfate,
filtered and concentrated in vacuo. The crude product was purified
by silica gel chromatography (eluted with 5.fwdarw.15% MeOH/CH2Cl2)
to give methyl 1-(3,5-bis(hydroxymethyl)
phenylamino)-3,6,9,12,15,18,21,24,27,30,33,36-dodecaoxanonatriacontan-39--
oate (265c) (285 mg, 42%). .sup.1H NMR (400 Hz, CDCl.sub.3):
.delta. 6.62 (s, 1H), 6.51 (s, 2H), 4.52 (s, 4H), 3.72 (t, J=6.4
Hz, 2H), 3.65 (s, 3H), 3.61 (m, 48H), 2.94 (s, 2H), 2.63 (s, 1H),
2.57 (t, J=6.4 Hz, 2H); MS (m/z), found 790.4 (M+Na).sup.+.
##STR00248##
methyl
2-(3,5-bis(hydroxymethyl)phenyl)-5,8,11,14,17,20,23,26,29,32,35,38-
-dodecaoxa-2-azahentetracontan-41-oate (265d)
[0407] To a stirred solution of methyl
1-(3,5-bis(hydroxymethyl)phenylamino)-3,6,9,12,15,18,21,24,27,30,33,36-do-
decaoxanonatriacontan-39-oate (265c) (67 mg, 0.087 mmol) in
anhydrous DMF (1.0 ml) was added iodomethane (7.06 .mu.l, 0.113
mmol) and potassium carbonate (14.47 mg, 0.105 mmol). The reaction
was stirred at 82.degree. C. for 18 hours. The mixture was cooled
to room temperature, diluted with water and extracted with
dichloromethane. The organic layer was dried over anhydrous sodium
sulfate, filtered and concentrated in vacuo. Purification by
preparative TLC (10% MeOH/CH.sub.2Cl.sub.2) gave methyl
2-(3,5-bis(hydroxymethyl)phenyl)-5,8,11,14,17,20,23,26,29,32,35,38-dodeca-
oxa-2-azahentetracontan-41-oate (265d) (62 mg, 92%). .sup.1H NMR
(400 Hz, CDCl.sub.3): .delta. 6.65 (s, 3H), 4.59 (d, J=5.6 Hz, 4H),
3.74 (t, J=6.4 Hz, 2H), 3.67 (s, 3H), 3.61 (m, 46H), 3.54 (t, J=6.0
Hz, 2H) 2.98 (s, 3H), 2.59 (t, J=6.4 Hz, 2H), 2.55 (m, 2H); MS
(m/z), found 820.5 (M+K).sup.+.
##STR00249##
Compound 265e:
[0408] To a stirred solution of methyl
2-(3,5-bis(hydroxymethyl)phenyl)-5,8,11,14,17,20,23,
26,29,32,35,38-dodecaoxa-2-azahentetracontan-41-oate (265d) (71 mg,
0.091 mmol) in anhydrous dichloromethane (1.4 mL) was added
triethylamine (0.038 mL, 0.272 mmol). The mixture was cooled to
-5.degree. C. and methanesulfonyl chloride (0.018 mL, 0.227 mmol)
was added slowly. After stirring for one hour at -5.degree. C. the
reaction was quenched with cold water and extracted with cold ethyl
acetate. The organic extracts were washed with cold water, dried
over anhydrous sodium sulfate, filtered and concentrated under
reduced pressure to give methyl
2-(3,5-bis((methylsulfonyloxy)methyl)
phenyl)-5,8,11,14,17,20,23,26,29,32,35,38-dodecaoxa-2-azahentetracontan-4-
1-oate. MS (m/z), found 960.2 (M+Na).sup.+. To a mixture of methyl
2-(3,5-bis((methylsulfonyloxy)methyl)phenyl)-5,8,11,14,17,20,23,26,29,32,-
35,38-dodecaoxa-2-azahentetracontan-41-oate (69 mg, 0.074 mmol) and
compound 8 (54.1 mg, 0.184 mmol) in anhydrous DMF (0.8 mL) was
added potassium carbonate (50.8 mg, 0.368 mmol). The reaction was
allowed to stir for 18 hours at room temperature. The reaction was
quenched with water and extracted twice with dichloromethane. The
remaining aqueous layer was extracted twice with 50%
MeOH/CH.sub.2Cl.sub.2. The combined organic extracts were washed
with brine, dried over anhydrous sodium sulfate, filtered and
concentrated in vacuo. Purification by flash silica gel
chromatography (5% MeOH/CH.sub.2Cl.sub.2) followed by preparative
reverse phase HPLC (C18 column, eluted with CH.sub.3CN/H.sub.2O)
gave compound 265e (23 mg, 23%). MS (m/z), found 1375.4
(M+Na+H.sub.2O).sup.+, 1393.4 (M+Na+2H.sub.2O).sup.+.
##STR00250##
Compound 265f:
[0409] To a stirred solution of compound 265e (22 mg, 0.016 mmol)
in anhydrous 1,2-dichloroethane (300 .mu.L) was added trimethyl tin
hydroxide (44.7 mg, 0.247 mmol). The reaction stirred at 90.degree.
C. for 18 hours. The mixture was allowed to cool to room
temperature and then diluted with dichloromethane. The organic
layer was washed with brine containing a few drops 5% concentrated
hydrochloric acid and then with brine alone, dried over anhydrous
sodium sulfate, filtered and concentrated in vacuo. Purification by
preparative TLC (2.times.5% MeOH/CH2Cl2) gave compound 265f (7.5
mg, 34%). MS (m/z), found 1318.4 (M-1).sup.-, 1336.4
(M-1+H.sub.2O).sup.-, 1354.4 (M-1+2H.sub.2O).sup.-.
##STR00251##
Compound 265g:
[0410] To a stirred solution of compound 265f (7.5 mg, 5.68
.mu.mol) in anhydrous dichloromethane (400 .mu.L) was added
N-hydroxy succinimide (1.961 mg, 0.017 mmol), EDC (3.27 mg, 0.017
mmol), and DMAP (0.069 mg, 0.568 .mu.mol). The reaction stirred for
18 hours at room temperature. The mixture was extracted with
dichloromethane and saturated ammonium chloride. The organic layer
was washed with brine, dried over anhydrous sodium sulfate,
filtered and the solvent was removed under reduced pressure. The
crude material was purified by preparative reverse phase HPLC (C18
column, eluted with CH.sub.3CN/H.sub.2O). Fractions containing
product were extracted with dichloromethane, dried over anhydrous
sodium sulfate, filtered and co-evaporated with acetonitrile to
give compound 265g (1.5 mg, 19%). MS (m/z), found 1439.9
(M+Na).sup.+, 1457.9 (M+Na+H.sub.2O).
Example 32 (IGN-22)
##STR00252##
[0411] Compound 266a:
[0412] To a solution of compound 258d (20 mg, 0.050 mmol) in
dichloromethane (1.0 mL) was added mono-methyl succinate (13.23 mg,
0.100 mmol), EDC (19.20 mg, 0.100 mmol), and DMAP (3.06 mg, 0.025
mmol) was added. The reaction stirred at room temperature for 18
hours. The mixture was diluted with water and extracted with ethyl
acetate. The organic extracts were washed with brine, filtered and
concentrated under reduced pressure. Purification by silica gel
chromatography (3% MeOH/CH.sub.2Cl.sub.2) gave compound 266a (15
mg, 58%). MS (m/z), found 568.4 (M+Na+MeOH).sup.+.
##STR00253##
Compound 266b:
[0413] To a solution of compound 266a (15 mg, 0.029 mmol) in
dichloromethane (3.5 ml) was added methanesulfonic acid (0.114 ml,
1.753 mmol). The reaction was stirred for one hour at room
temperature then diluted with methanol and water. The mixture was
neutralized with saturated sodium bicarbonate to pH=7 and extracted
three times with dichloromethane. The organic layer was dried over
anhydrous sodium sulfate, filtered and concentrated in vacuo.
Purification by preparative TLC (2.times.5% MeOH/CH.sub.2Cl.sub.2)
gave compound 266b (11.5 mg, 93%). MS (m/z), found 446.4
(M+Na).sup.+, 478.4 (M+Na+MeOH).sup.+.
##STR00254##
Compound 266c:
[0414] To a mixture of compound 266b (11.5 mg, 0.027 mmol) and
compound 259a (19.98 mg, 0.041 mmol) in anhydrous DMF (0.5 ml) was
added potassium carbonate (11.26 mg, 0.081 mmol). The reaction was
stirred for 18 hours at room temperature. The mixture was quenched
with water and extracted three times with dichloromethane. The
organic layer was washed with brine, dried over anhydrous sodium
sulfate, filtered and concentrated under reduced pressure.
Purification by preparative TLC (5% MeOH/CH.sub.2Cl.sub.2) followed
by preparative reverse phase HPLC (C18 column, eluted with
CH.sub.3CN, H.sub.2O) yielded compound 266c (4 mg, 18%). .sup.1H
NMR (400 Hz, CDCl.sub.3): .delta. 8.27 (d, J=8.0 Hz, 1H), 8.06 (s,
1H), 7.87 (m, 2H), 7.74 (m, 1H), 7.55 (s, 1H), 7.52 (s, 1H), 7.49
(m, 1H), 7.26 (m, 1H) 7.19 (d, J=8.8 Hz, 1H), 7.10 (m, 1H), 6.82
(m, 2H), 4.49 (m, 2H), 4.12 (m, 4H), 3.95 (s, 6H), 3.71 (s, 3H),
3.48 (m, 4H), 2.75 (m, 2H), 2.66 (m, 2H), 1.98 (m, 4H), 1.70 (m,
2H); MS (m/z), found 824.1 (M+K).sup.+.
Example 33 (IGN-31)
##STR00255##
[0415]
3,5-bis((tert-butyldimethylsilyloxy)methyl)-N-(2-(2-(2-methoxyethox-
y)ethoxy) ethyl)aniline (267a)
[0416] To a solution of
(5-(2-(2-(2-methoxyethoxy)ethoxy)ethylamino)-1,3-phenylene)dimethanol
(249b) (0.4 g, 1.336 mmol) in dichloromethane (6.68 mL) was added
t-butyldimethylsilyl chloride (0.604 g, 4.01 mmol) and imidazole
(0.318 g, 4.68 mmol). The reaction stirred at room temperature for
90 minutes. The mixture was diluted with dichloromethane and
filtered through Celite. The filtrated was concentrated and
purified by silica gel chromatography eluting with 20% Ethyl
acetate/Hexanes to yield
3,5-bis((tert-butyldimethylsilyloxy)methyl)-N-(2-(2-(2-methoxyethoxy)etho-
xy)ethyl) aniline (267a) (600 mg, 85%). MS (m/z), found 550.3
(M+Na).sup.+.
##STR00256##
N-(3,5-bis((tert-butyldimethylsilyloxy)methyl)phenyl)-N-(2-(2-(2-methoxye-
thoxy)ethoxy)ethyl)-4-methyl-4-(methyldisulfanyl)pentanamide
(267b)
[0417] To a mixture of
3,5-bis((tert-butyldimethylsilyloxy)methyl)-N-(2-(2-(2-methoxyethoxy)etho-
xy)ethyl)aniline (267a) (525 mg, 0.995 mmol) and
4-methyl-4-(methyldisulfanyl)pentanoic acid (232 mg, 1.193 mmol) in
anhydrous dichloromethane (9.0 mL) was added EDC (229 mg, 1.193
mmol) and DMAP (12.15 mg, 0.099 mmol). The reaction was stirred at
room temperature for five hours. The mixture was diluted with
dichloromethane and water. The organic layer was washed with brine,
dried over anhydrous sodium sulfate, filtered and concentrated
under reduced pressure. Purification by silica gel chromatography
(30% Ethyl acetate/Hexanes) gave
N-(3,5-bis((tert-butyldimethylsilyloxy)
methyl)phenyl)-N-(2-(2-(2-methoxyethoxy)ethoxy)ethyl)-4-methyl-4-(methyld-
isulfanyl)pentanamide (267b) (335 mg, 48%).
##STR00257##
N-(3,5-bis(hydroxymethyl)phenyl)-N-(2-(2-(2-methoxyethoxy)ethoxy)ethyl)-4-
-methyl-4-(methyldisulfanyl)pentanamide (267c)
[0418] To a stirred solution of
N-(3,5-bis((tert-butyldimethylsilyloxy)methyl)phenyl)-N-(2-(2-(2-methoxye-
thoxy)ethoxy)ethyl)-4-methyl-4-(methyldisulfanyl)pentanamide (267b)
(315 mg, 0.447 mmol) in anhydrous acetonitrile (7.0 mL) at
0.degree. C. was added anhydrous pyridine (7.00 mL) followed by
dropwise addition of HF.Pyridine (3.1 mL, 1 mL/100 mg). The
reaction stirred at 0.degree. C. for two hours. It was diluted with
ethyl acetate and slowly quenched with saturated sodium
bicarbonate. The mixture was extracted three times with ethyl
acetate. The organic layer was washed with water and brine, dried
over sodium sulfate, filtered and concentrated. Purification by
silica gel chromatography, eluting with 5% MeOH/CH.sub.2Cl.sub.2,
yielded
N-(3,5-bis(hydroxymethyl)phenyl)-N-(2-(2-(2-methoxyethoxy)ethoxy)ethyl)-4-
-methyl-4-(methyldisulfanyl)pentanamide (267c) (190 mg, 89%).
.sup.1H NMR (400 Hz, CDCl.sub.3): .delta. 7.21 (s, 1H), 7.16 (s,
2H), 4.63 (s, 4H), 3.79 (t, J=5.2, 5.6 Hz, 2H), 3.53 (m, 6H), 3.48
(m, 4H), 3.29 (s, 3H), 2.53 (s, 2H), 2.27 (s, 3H), 2.07 (m, 2H),
1.84 (m, 2H), 1.08 (s, 6H); MS (m/z), found 498.2 (M+Na).sup.+.
##STR00258##
Compound 267d:
[0419] To a stirred solution of
N-(3,5-bis(hydroxymethyl)phenyl)-N-(2-(2-(2-methoxyethoxy)ethoxy)ethyl)-4-
-methyl-4-(methyldisulfanyl)pentanamide (267c) (72 mg, 0.151 mmol)
in anhydrous dichloromethane (3.0 mL) was added triethylamine
(0.063 mL, 0.454 mmol). The mixture was cooled to -5.degree. C. and
methanesulfonyl chloride (0.029 mL, 0.378 mmol) was added slowly.
After stirring for one hour at -5.degree. C. the reaction was
quenched with cold water and extracted with cold ethyl acetate. The
organic layer was washed with cold water, dried over anhydrous
sodium sulfate, filtered and concentrated under reduced pressure to
give (5-(N-(2-(2-(2-methoxyethoxy)ethoxy)
ethyl)-4-methyl-4-(methyldisulfanyl)pentanamido)-1,3-phenylene)bis(methyl-
ene) dimethanesulfonate. MS (m/z), found 654.1 (M+Na). To a mixture
of
(5-(N-(2-(2-(2-methoxyethoxy)ethoxy)ethyl)-4-methyl-4-(methyldisulfanyl)p-
entanamido)-1,3-phenylene)bis(methylene) dimethanesulfonate (89 mg,
0.141 mmol) and compound 8 (83 mg, 0.282 mmol) in anhydrous DMF
(1.5 mL) was added potassium carbonate (97 mg, 0.704 mmol). The
reaction stirred for 18 hours at room temperature. The mixture was
quenched with water and extracted twice with dichloromethane. The
organic layer was washed with brine, dried over anhydrous sodium
sulfate, filtered and concentrated in vacuo. Purification by silica
gel chromatography (5% MeOH/CH.sub.2Cl.sub.2) and preparative
reverse phase HPLC (C18 column, eluted with CH.sub.3CN/H.sub.2O)
yielded compound 267d (27 mg, 18%). .sup.1H NMR (400 Hz,
CDCl.sub.3): .delta. 8.28 (d, J=4.8 Hz, 2H), 7.87 (m, 2H), 7.61 (s,
2H), 7.37-7.27 (m, 7H), 7.13 (t, J=7.2, 7.6 Hz, 2H), 6.88 (s, 2H),
5.25 (m, 4H), 4.50 (m, 2H), 4.00 (s, 6H), 3.90 (m, 2H), 3.73 (m,
2H), 3.60 (m, 6H), 3.51 (m, 6H), 3.30 (s, 3H), 2.32 (s, 3H), 2.15
(m, 2H), 1.90 (m, 2H), 1.13 (s, 6H); MS (m/z), found 1050.3
(M+Na).sup.+, 1068.3 (M+H.sub.2O+Na).sup.+, 1086.3
(M+2H.sub.2O+Na).sup.+.
Example 34 (IGN-32)
##STR00259##
[0420] Compound 268a:
[0421] To a mixture of compound 253b (150 mg, 0.389 mmol) and
tert-butyl 3-(2-(2-(2-aminoacetamido)acetamido)acetamido)propanoate
(148 mg, 0.467 mmol) in anhydrous DMF (1.5 ml) was added EDC (90
mg, 0.467 mmol) and DMAP (4.75 mg, 0.039 mmol). The reaction
stirred for 18 hours at room temperature. The mixture was directly
purified by preparative reverse phase HPLC (C18 column, eluted with
CH.sub.3CN/H.sub.2O+0.1% formic acid). Further purification by
preparative TLC (15% MeOH/CH.sub.2Cl.sub.2) yielded compound 268a
(170 mg, 64%). .sup.1H NMR (400 Hz, CDCl.sub.3): .delta. 7.62 (m,
1H), 7.56 (m, 1H), 7.38 (m, 1H), 7.11 (m, 1H), 6.55 (s, 2H), 6.52
(s, 1H), 4.45 (s, 4H), 4.17 (s, 2H), 3.63 (m, 6H), 3.55-3.40 (m,
12H), 3.28 (m, 7H), 2.33 (t, J=6.4 Hz, 2H), 2.16 (m, 2H), 1.79 (m,
2H), 1.36 (s, 9H); MS (m/z), found 706.3 (M+Na).sup.+.
##STR00260##
Compound 268b:
[0422] To a stirred solution of compound 268a (59 mg, 0.086 mmol)
in anhydrous dichloromethane (1.75 ml) was added triethylamine
(0.036 ml, 0.259 mmol). The mixture was cooled to -5.degree. C. and
methanesulfonyl chloride (0.017 ml, 0.216 mmol) was added slowly.
After stirring for one hour at -5.degree. C. the reaction was
quenched with cold water and extracted with cold ethyl acetate. The
organic extracts were washed with cold water, dried over anhydrous
sodium sulfate, filtered and concentrated under reduced pressure to
give the desired dimesylate intermediate. MS (m/z), found 862.3
(M+Na).sup.+.
[0423] To a solution of the dimesylate intermediate (65 mg, 0.077
mmol) and compound 8 (114 mg, 0.387 mmol) in anhydrous DMF (1.0 mL)
was added potassium carbonate (86 mg, 0.619 mmol). The reaction was
stirred for 18 hours at room temperature, then quenched with water
and extracted three times with dichloromethane. The organic layer
was washed with brine, dried over anhydrous sodium sulfate,
filtered and concentrated under reduced pressure. Purification by
silica gel chromatography (2%.fwdarw.10% MeOH/CH.sub.2Cl.sub.2)
yielded compound 268b (22 mg, 21%). .sup.1H NMR (400 Hz,
CDCl.sub.3): .delta. 8.26 (d, J=8.0 Hz, 2H), 7.88 (m, 2H), 7.58 (s,
2H), 7.28 (m, 4H), 7.13 (t, J=7.2 Hz, 2H), 6.89 (s, 2H), 6.81 (s,
1H), 6.73 (s, 2H), 5.19 (m, 4H), 4.48 m, 2H), 3.99 (s, 6H), 3.7-3.4
(m, 26H), 3.34 (s, 3H), 2.45 (t, J=6.4 Hz, 2H), 2.30 (m, 2H), 1.81
(m, 2H), 1.44 (s, 9H).
Example 35
[0424] Preparation of chB38.1-IGN14 Conjugate:
[0425] A solution of chB38.1 antibody at a concentration of 2 mg/mL
in an aqueous buffer containing 0.05 M
N-(2-hydroxyethyl)-piperazine-N'-2-ethanesulfonic acid (HEPES) and
2 mM ethylenediaminetetra-acetic acid (EDTA), pH 8 was treated with
a 10-fold molar excess of a solution of IGN14-NHS in
dimethylacetamide (DMA) such that the final concentration of DMA in
the buffer was 10% v/v. The reaction mixture was stirred at room
temperature for 120 min and then loaded onto a Sephadex G25 gel
filtration column (HiPrep.TM. 26/10 Desalting Column GE#17-5087-01)
that had been previously equilibrated into an aqueous buffer
containing 10 mM histidine, 250 mM glycine, 1% sucrose pH 5.5. The
conjugated antibody-containing fractions were collected and pooled
to yield product. The pooled sample was dialyzed overnight against
the same elution buffer to further purify the product. The final
conjugate was assayed spectrophotometrically using the extinction
coefficients that were determined for IGN-14
(.epsilon..sub.330=15,231 M.sup.-1 cm.sup.-1 and
.epsilon..sub.280=26,864 M.sup.-1 cm.sup.-1) and chB38.1 antibody
(.epsilon..sub.280nm=204,000 M.sup.-1 cm.sup.-1). An average of 3.3
IGN14 molecules per molecule of antibody were linked.
Example 36
[0426] Preparation of huMy9-6-IGN23 Conjugate
[0427] A solution of huMy9-6 antibody at a concentration of 2 mg/mL
in an aqueous buffer containing 0.05 M
N-(2-hydroxyethyl)-piperazine-N'-2-ethanesulfonic acid (HEPES) and
2 mM ethylenediaminetetra-acetic acid (EDTA), pH 8.5 was treated
with a 12.5-fold molar excess of a solution of IGN23-NHS in
dimethylacetamide (DMA), glycerol, and sucrose. The final
concentration of DMA, glycerol and sucrose in the buffer was 15%,
5% and 5% (v/v) respectively. The reaction mixture was stirred at
room temperature for 120 min and then loaded onto a Sephadex G25
gel filtration column (HiPrep.TM. 26/10 Desalting Column
GE#17-5087-01) that had been previously equilibrated into an
aqueous buffer containing 10 mM histidine, 250 mM glycine, 1%
sucrose, pH 5.5. The conjugated antibody-containing fractions were
collected and pooled to yield product. The pooled sample was
concentrated using Millipore centrifugal filter devices, and then
dialyzed overnight against the same elution buffer to further
purify the product.
[0428] The final conjugate was assayed spectrophotometrically using
the extinction coefficients that were determined for IGN-23
(.epsilon..sub.330=15,231 M.sup.-1 cm.sup.-1 and
.epsilon..sub.280=26,864 M.sup.-1 cm.sup.-1) and huMy9-6
(.epsilon..sub.280 nm=206,460 M-1cm-1). An average of 2.2 IGN23
molecules per molecule of antibody were linked.
Example 37
[0429] Preparation of chB38.1-IGN27 Conjugate
[0430] A solution of chB38.1 antibody at a concentration of 2 mg/mL
in an aqueous buffer containing 0.05 M
N-(2-hydroxyethyl)-piperazine-N'-2-ethanesulfonic acid (HEPES) and
2 mM ethylenediaminetetra-acetic acid (EDTA), pH 8.5 was treated
with a 12-fold molar excess of a solution of IGN27-NHS in
dimethylacetamide (DMA, 5 mM stock) such that the final
concentration of DMA in the buffer was 15% v/v. The reaction
mixture was stirred at room temperature for 4 hr and then loaded on
to a Sephadex G25 gel filtration column (HiPrep.TM. 26/10 Desalting
Column GE#17-5087-01) that had been previously equilibrated into an
aqueous buffer containing PBS pH 7.4. The conjugated
antibody-containing fractions were collected and pooled to yield
product. The pooled sample was dialyzed overnight against the same
elution buffer to further purify the product.
[0431] The final conjugate was assayed spectrophotometrically using
the extinction coefficients that were determined for IGN-27
(.epsilon..sub.330=15,231 M.sup.-1 cm.sup.-1 and
.epsilon..sub.280=26,864 M.sup.-1 cm.sup.-1) and chB38.1 antibody
(.epsilon..sub.280 nm=204,000 M-1cm-1). An average of 2.9 IGN27
molecules per molecule of antibody were linked.
Example 38
In Vitro Potency IGN Free Drugs and IGN Conjugates:
[0432] General Procedure Used: Samples of IGN Free Drugs or IGN
Conjugates were added to 96-well flat bottomed tissue culture
plates and titrated using serial dilutions to cover the desired
molar range. Antigen positive (Ag+) or Antigen negative (Ag-) cells
were added to the wells in specific cell densities in such a way
that there were triplicate samples for each drug concentration for
each corresponding cell line. The plates were then incubated at
37.degree. C. in an atmosphere of 5% CO.sub.2 for 4-5 days
depending on the cell line. COLO 205 (1,000 cells/well), Namalwa
(3,000 cells/well)--4 days; RH30(1,000 cells/well), Ramos (10,000
cells/well), KB (1,000 cells/well)--5 days)
[0433] At the end of the incubation period cytotoxic potencies were
then assessed using a WST-based cell viability assay and surviving
cells were measured by developing with WST (2-7 hours). The
absorbance in each well was measured and the surviving fraction of
cells at each concentration was plotted to reveal the cytotoxicity
and antigen specificity (of the conjugates).
[0434] The cytotoxicity of the IGN Free Drugs and the potency and
specificity of the IGN conjugates were measured against a panel of
human cancer cell lines selected from COLO 205, NB-4, LOVO,
Namalwa, RH30, Ramos, KB, and/or LOVO. Results are illustrated in
FIGS. 51-58.
[0435] FIG. 51: Table which demonstrates the high potency (in nM)
of the IGN Free Drugs against multiple cell lines. In general the
IGN Free Drugs are found to be potent in the low picomolar range
against this panel of cell lines.
[0436] FIG. 52: (A) chB38.1-IGN13 conjugate (3.8 IGN/Ab) was found
to be potent at sub-picomolar levels against COLO 205 (Ag+) cells
and the activity was significantly diminished (0.26 nM) when the
antigen binding sites were blocked with 1 .mu.M unconjugated
chB38.1 antibody indicating the high specificity of this conjugate
(>260 fold). (B) chB38.1-IGN13 conjugate (3.8 IGN/Ab) was found
to be potent picomolar levels (0.002 pM) against LOVO (Ag+) cells
in a clonogenic assay.
[0437] FIG. 53: huMy9-6-IGN13 conjugate (3.4 IGN/Ab) was found to
be potent at picomolar levels against NB-4 (Ag+) cells (0.077 nM)
and the activity was significantly diminished (1.0 nM) when the
antigen binding sites were blocked with 1 .mu.M huMy9-6 antibody
indicating that this conjugate is specific.
[0438] FIG. 54: (A) chB38.1-IGN14 conjugate (3.1 IGN/Ab) was found
to be potent at sub-picomolar levels against COLO 205 (Ag+) cells
and the activity was significantly less towards Namalwa (Ag-) cells
(0.9 nM) indicating the high specificity of this conjugate (>900
fold). (B) chB38.1-IGN14 conjugate (2.6 IGN/Ab) was found to be
very potent towards LOVO (Ag+) cells (0.012 nM) and the activity
was significantly less towards Namalwa (Ag-) cells (>3.0 nM)
indicating the high specificity of this conjugate (>250
fold).
[0439] FIG. 55: huMy9-6-IGN14 conjugate (3.3 IGN/Ab) was found to
be highly potent against NB-4 (Ag+) cells (0.033 nM) and the
activity was significantly less towards Namalwa (Ag-) cells (0.6
nM) indicating the high specificity of this conjugate.
[0440] FIG. 56: (A) chB38.1-IGN23 conjugate (2.5 IGN/Ab) was found
to be potent at picomolar levels against LOVO (Ag+) cells (0.063
nM) and the activity was significantly less towards Namalwa (Ag-)
cells (>3.0 nM) indicating the high specificity of this
conjugate. (B) chB38.1-IGN23 conjugate (2.0 IGN/Ab) was found to be
potent at picomolar levels against COLO 205 (Ag+) cells (0.006 nM)
and the activity was significantly diminished (2.5 nM) when the
antigen binding sites were blocked with 1 .mu.M chB38.1 indicating
that this conjugate is specific.
[0441] FIG. 57: chB38.1-IGN29 conjugate (2.8 IGN/Ab) was found to
be potent at sub-nanomolar levels against COLO 205 (Ag+) cells
(0.410 nM) and the activity was significantly diminished (18 nM)
when the antigen binding sites were blocked with 1 .mu.M chB38.1
indicating that this conjugate is specific.
Example 39
[0442] In Vivo Efficacy of chB38.1-IGN14 Conjugate in COLO 205
Tumor Bearing Nude Mice:
[0443] In this study, the anti-tumor activity of chB38.1-IGN14 was
investigated in female nude mice bearing COLO 205 tumors, a human
colon carcinoma model. COLO 205 tumor cells, 2.times.10.sup.6
cells/mouse were subcutaneously inoculated at a volume of 0.1
mL/mouse in the area over the right shoulder of female athymic nude
mice, 5 weeks of age. Eight days after tumor cell inoculation mice
were randomized into groups (n=6 per group) by tumor volume.
Treatment was initiated the day of randomization, and groups
included a control group dosed with PBS (200 .mu.L/injection),
naked chB38.1 antibody (2.8 mg/kg), non-targeting chKTI-IGN14 (50
.mu.g/kg) conjugate and chB38.1-IGN14 (50 .mu.g/kg IGN14 dose; 2.5
mg/kg antibody dose). All treatments were administered twice on a
weekly schedule (day 8 and 15, post-cell inoculation). Arrows
indicate dosing times post inoculation. All treatments were well
tolerated with the mean body weight losses comparable to loss seen
in PBS control mice. Median tumor volume vs time is shown (FIG. 58)
with the data demonstrating the anti-tumor activity of the
chB38.1-IGN14 conjugate. Both the non-targeting and the naked
antibody show no activity beyond that seen with the vehicle
control, suggesting that the anti-tumor activity observed with the
chB38.1-IGN-14 conjugate is antigen-specific.
Example 40
[0444] FIG. 59 shows the mass spectrum of chB38.1-IGN14
(deglycosylated antibody). Peaks are labeled D1-D7 to indicate the
number of IGN14 molecules attached per antibody. The average number
of IGN14 molecules per antibody was calculated to be 3.5 (matching
drug load calculated by UV-vis).
* * * * *